10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

0001193125-14-199057.txt : 20140514 0001193125-14-199057.hdr.sgml : 20140514 20140514161044 ACCESSION NUMBER: 0001193125-14-199057 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20140514 DATE AS OF CHANGE: 20140514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MELA SCIENCES, INC. /NY CENTRAL INDEX KEY: 0001051514 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133986004 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51481 FILM NUMBER: 14841623 BUSINESS ADDRESS: STREET 1: 50 SOUTH BUCKHOUT STREET STREET 2: SUITE 1 CITY: IRVINGTON STATE: NY ZIP: 10533 BUSINESS PHONE: 914-591-3783 MAIL ADDRESS: STREET 1: 50 SOUTH BUCKHOUT STREET STREET 2: SUITE 1 CITY: IRVINGTON STATE: NY ZIP: 10533 FORMER COMPANY: FORMER CONFORMED NAME: ELECTRO OPTICAL SCIENCES INC /NY DATE OF NAME CHANGE: 19971216 10-Q 1 d720781d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000 — 51481

MELA SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware

13-3986004

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

50 South Buckhout Street, Suite 1

Irvington, New York

10533

(Address of Principal Executive offices)

(Zip Code)

Registrant’s Telephone Number, including area code:

(914) 591-3783

(Former name if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “accelerated filer” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of April 30, 2014: 52,107,465 shares of the Registrant’s common stock were outstanding.

MELA Sciences, Inc.

Table of Contents


	Page
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
Condensed Balance Sheets as of March 31, 2014 (unaudited) and December 31, 2013		1
Condensed Statements of Operations (unaudited) for the three month periods ended March 31, 2014 and 2013		2
Condensed Statements of Cash Flows (unaudited) for the three month periods ended March 31, 2014 and 2013		3
Notes to Condensed Financial Statements (unaudited)		4
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		11
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk		17
ITEM 4. Controls and Procedures		17
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings		17
ITEM 1A. Risk Factors		18
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds		18
ITEM 3. Defaults Upon Senior Securities		18
ITEM 4. Mine Safety Disclosures		18
ITEM 5. Other Information		18
ITEM 6. Exhibits		18
SIGNATURE		19
EXHIBIT INDEX		20

MELA SCIENCES, INC.

BALANCE SHEETS


	March 31, 2014			December 31, 2013
	(unaudited)			*
ASSETS
Current Assets:
Cash and cash equivalents	$	8,122,709		$	3,782,881
Accounts receivable (net of allowance of $43,080 and $46,130 as of March 31, 2014 and December 31, 2013, respectively)		34,121			57,151
Inventory (net of reserve of $325,000 as of March 31, 2014 and December 31, 2013)		5,648,020			5,631,205
Prepaid expenses and other current assets		465,140			879,698

Total Current Assets		14,269,990			10,350,935
Property and equipment, net		2,995,253			3,690,784
Patents and trademarks, net		40,526			41,795
Other assets		48,000			48,000

Total Assets	$	17,353,769		$	14,131,514


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable (includes related parties of $85,972 and $32,902 as of March 31, 2014 and December 31, 2013, respectively)	$	1,311,174		$	1,478,995
Accrued expenses (includes related parties of $23,129 and $48,000 as of March 31, 2014 and December 31, 2013, respectively)		819,851			844,131
Deferred placement revenue		201,864			243,605
Warrant liability		8,464,865			3,017,142
Other current liabilities		61,815			67,934

Total Current Liabilities		10,859,569			5,651,807

Long Term Liabilities:
Deferred placement revenue		28,834			63,754
Deferred rent		110,111			120,120

Total Long Term Liabilities		138,945			183,874

Total Liabilities		10,998,514			5,835,681


COMMITMENTS AND CONTINGENCIES

Stockholders’ Equity:
Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 12,300 at March 31, 2014 and 0 at December 31, 2013		1,230			—
Common stock - $0.001 par value; authorized 95,000,000 shares:
Issued and outstanding 52,107,465 shares at March 31, 2014 and 47,501,596 at December 31, 2013		52,108			47,502
Additional paid-in capital		182,430,391			176,396,209
Accumulated deficit		(176,128,474	)		(168,147,878	)

Total Stockholders’ Equity		6,355,255			8,295,833

Total Liabilities and Stockholders’ Equity	$	17,353,769		$	14,131,514

*	Derived from the audited balance sheet as of December 31, 2013

The accompanying notes are an integral part of these financial statements

MELA SCIENCES, INC.

STATEMENTS OF OPERATIONS

(unaudited)


	Three months ended March 31,
	2014			2013
Net revenues	$	97,638		$	144,100
Cost of revenue		918,523			1,080,263

Gross profit		(820,885	)		(936,163	)

Operating expenses:
Research and development		707,824			1,262,001
Selling, general and administrative		3,203,533			4,287,228

Total operating expenses		3,911,357			5,549,229

Operating loss		(4,732,242	)		(6,485,392	)

Other income (expenses):
Interest income		618			2,105
Interest expense		(1,199	)		(48,763	)
Change in fair value of warrant liability		137,142			15,433
Registration rights liquidated damages		(3,389,940	)		—
Other income, net		5,025			5,000

		(3,248,354	)		(26,225	)



Net loss	$	(7,980,596	)	$	(6,511,617	)


Basic and diluted net loss per common share	$	(0.16	)	$	(0.17	)


Basic and diluted weighted average number of common shares outstanding		48,926,409			39,233,943

The accompanying notes are an integral part of these financial statements

MELA SCIENCES, INC.

STATEMENTS OF CASH FLOWS

(unaudited)


	Three Months Ended March 31,
	2014			2013
Cash flows from operating activities:
Net loss	$	(7,980,596	)	$	(6,511,617	)
Adjustments to reconcile net loss:
Depreciation and amortization		696,800			496,733
Bad debt expense		700			40,000
Non-cash interest expense		—			14,101
Write-off of unamortized financing costs		—			41,166
Stock-based compensation		164,168			268,381
Change in fair value of warrant liability		(137,142	)		(15,433	)
Changes in operating assets and liabilities:
Accounts receivable		22,330			(29,447	)
Inventory		(16,815	)		238,642
Prepaid expenses and other current assets		414,558			89,173
Accounts payable and accrued expenses		(192,101	)		(834,292	)
Other current liabilities		(6,119	)		19,785
Deferred rent		(10,009	)		(5,913	)
Deferred revenue		(76,661	)		88,873
Long-term interest payable		—			7,417

Net cash used in operating activities		(7,120,887	)		(6,092,431	)
Cash flows from investing activities:
Purchases of property and equipment		—			(1,641,297	)

Net cash used in investing activities		—			(1,641,297	)
Cash flows from financing activities:
Net proceeds from private placements/public offerings		11,460,715			15,746,549
Net proceeds from long term debt		—			6,000,000
Expenses related to borrowings and issuance of warrant		—			(245,358	)
Proceeds from exercise of stock options		—			18,059

Net cash provided by financing activities		11,460,715			21,519,250

Net increase in cash and cash equivalents		4,339,828			13,785,522

Cash and cash equivalents at beginning of period		3,782,881			7,861,524

Cash and cash equivalents at end of period	$	8,122,709		$	21,647,046


Supplemental Schedule of Noncash Investing and Financing Activities:
Amortization of deferred financing costs	$	—		$	41,166

The accompanying notes are an integral part of these financial statements

MELA SCIENCES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

1. ORGANIZATION AND BASIS OF PRESENTATION

MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company primarily focused on the commercialization of its flagship product, the MelaFind^® system, and the further design and development of MelaFind^® and its technology. The MelaFind^® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. The MelaFind^® system features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been ‘trained’ and blind tested on the Company’s proprietary database of melanomas and benign lesions. The MelaFind^® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.

The components of the MelaFind^® system include:

•

a hand-held component, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);

•

a proprietary database of pigmented skin lesions, believed to be the largest positive prospective database to date in the US; and

•

lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.

In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind^® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, the Company installed the first commercial MelaFind^® systems, and proceeded with the commercial launch of MelaFind^®. The Company is currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using the MelaFind^® system to their performance if MelaFind^® was not available.

In 2012 the Company evolved from a research and development company to a commercial enterprise. The launch of MelaFind^® in 2012 and the subsequent commercialization activities supporting the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013.

In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, the Company appointed a new CEO and adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. As part of this strategy, in late December 2013, the Company changed its business model for the MelaFind^® system from a rental-based to a sales-based model. The Company has reduced its costs, added more experience to its management team, and reorganized its sales and marketing activities to better support the commercialization of the MelaFind^® system. The Company is also seeking a coverage determination from the Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, as a prerequisite to obtain reimbursement by Medicare for use of the MelaFind^® system. This process could take up to two years. Once a coverage determination has been made, the Company plans to seek reimbursement by Medicaid, Medicare and other third-party payers.

On August 22, 2013, the Company received a notice from The NASDAQ Stock Market that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. The Company was granted an automatic 180 grace period by NASDAQ in which to regain compliance. On February 19, 2014, the Company was notified by NASDAQ that the Company was eligible for an additional 180 day grace period and has until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement or risk delisting.

On October 17, 2013, the FDA notified the Company that its report with respect to the PAS was inadequate to allow the agency to complete its review, and as a result revised the PAS status on the FDA website to “Progress Inadequate.” In January 2014, the Company’s revised enrollment plan and schedule was approved by the FDA and the interactive review process was closed. On April 2, 2014, the FDA updated the study status to “Progress Adequate” and approved our new study timeline. The Company currently targets submission of the PAS report the FDA by year-end 2017.

In February 2014, the Company sold to two investors (the “Purchasers”) (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, (the “Series A Preferred Stock”), convertible into 14,642,857 shares of common stock at an initial conversion price of

$0.84, and (ii) warrants to purchase up to 13,297,297 shares of the Company’s common stock, for net proceeds of approximately $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. The number of shares issuable upon conversion of the Series A Preferred Stock and exercise of the warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions. The Purchasers have been granted rights of participation in future offerings of our securities for one year. In addition, as a condition of the financing, the Company’s directors purchased an aggregate of 202,703 shares of common stock at a price of $0.74 per share, for aggregate gross proceeds of $150,000.

The warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative.

In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature.

Liquidity

The Company has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. In February 2014, as noted above, the Company raised net proceeds of approximately $11.5 million from the sale of Series A Preferred Stock, common stock and warrants to strengthen the Company’s financial position.

The Company’s net losses have had a significant negative impact on working capital and its financial position and may impact the Company’s future ability to meet its obligations in the ordinary course of business. As a result, management believes that there is significant doubt about the Company’s ability to continue as a going concern. The Company continues to assess the effects of its previously announced cost reduction plan and is prepared to reduce various operational costs as necessary. Although the Company has no specific arrangements or plans, additional capital will be needed during the upcoming months, which may take the form of equity, equity-linked or debt financing. In addition, the Company anticipates that long-term it will need to raise funds to support further advances in the technology and clinical trials. The timing and amount of any additional funding the Company may require will be affected by numerous factors, many of which are not in the control of the Company including the market acceptance of the MelaFind^® system.

There can be no assurances that the Company will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms or at all and there can be no assurance that any additional funding the Company obtains will be sufficient to meet the Company’s financing needs. Any additional funding that the Company may obtain in the future could be dilutive to common stockholders, provide new investors with rights and preferences senior to common stockholders and provide for restrictive covenants that could limit the Company’s ability to take certain actions. Unless the Company is able to generate sufficient revenues or to raise additional capital near-term, the Company’s operations will be scaled back to maintain only vital activities, or discontinued.

2. USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements, the use of estimates to determine the elements of our revenue and deferred revenue, accrued expenses, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates.

3. RECENT ACCOUNTING PRONOUNCEMENTS

The Financial Accounting Standards Board has issued a number of new accounting standards that require future adoption. Based on the Company’s initial review of these new standards, none are expected to have a material impact on the Company’s financial statements.

4. INVENTORIES

Inventories currently consist of MelaFind^® systems and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind^® systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices.

In December 2013, the Company changed its business model for the MelaFind^® system from a rental-based model to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind^® systems from property and equipment into inventory at December 31, 2013.

Inventory consists of the following:


	March 31,			December 31,
	2014			2013
MelaFind^® Systems	$	5,401,866		$	5,401,866
Mela record cards		324,685			327,900
Accessories		246,469			226,439

		5,973,020			5,956,205
Reserve for obsolete inventory		(325,000	)		(325,000	)

	$	5,648,020		$	5,631,205

5. FIXED ASSETS

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition exceeds its carrying amount. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value.

In December 2013, the Company changed its business model for the MelaFind^® system from a rental-based to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind^® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent new and unused systems. Systems that have been leased under the rental-based model remain in property and equipment.

Property and equipment, at cost, consists of the following:


	March 31,			December 31,			Estimated
	2014			2013			Useful Life	Useful Life

Leasehold improvements	$	905,888		$	905,888		Lease Term	Lease Term
Laboratory and research equipment		1,083,661			1,083,661		3-5 years	3-5 years
Office furniture and equipment		2,022,833			2,022,833		3-5 years	3-5 years
MelaFind^® Systems		5,081,816			5,081,816		3 years	3 years

		9,094,198			9,094,198
Accumulated depreciation and amortization		(6,098,945	)		(5,403,414	)

	$	2,995,253		$	3,690,784

6. NET LOSS PER COMMON SHARE

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of March 31, 2014 and March 31, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:


	March 31,
	2014		2013

Common stock equivalents of convertible preferred stock		14,642,857		—
Common stock options		2,907,574		1,435,314
Common stock purchase warrants		21,047,641		200,000
Restricted stock awards		65,050		—

Total		38,663,122		1,635,314

7. COMPREHENSIVE LOSS

For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts.

8. STOCK-BASED COMPENSATION

Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.

The fair value of each option award granted is estimated on the date of grant using the Black-Sholes option valuation model and assumptions as noted in the following table:


	March 31,
	2014	2013

Expected life	6.5 years	6.5 years
Expected volatility	75.51%	76.83%
Risk-free interest rate	2.14-2.45%	1.25-1.38%
Dividend yield	—	—

9. DEBT

On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc., a venture capital lender, whereby the Company borrowed $6 million (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6.4 million, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000.

Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 693,202 shares of common stock at an exercise price of approximately $1.12 per share. The warrant expires on April 26, 2018.

For financial reporting purposes, the $6 million funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5.3 million. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of approximately $15,000 are included in operating results for the three months ended March 31, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $1.16 to $1.18 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $1.15 to $1.16 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value.

The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders equity.

As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were approximately $1.0 million.

10. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors.

As discussed in detail in Note 1, on February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share, convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of common stock for net proceeds of $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014, and will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on March 31, 2014 was equivalent to the fair value on February 5, 2014, and therefore no change in fair value has been recorded for the three months ended March 31, 2014.

Common Stock

The Company is authorized to issue 95,000,000 shares of common stock with a par value of $0.001 per share.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6.0 million registered offering of 4,228,181 shares of the Company’s common stock, fully paid prefunded warrants (“Series B Warrants”) to purchase up to 4,343,247 shares of its common stock and additional warrants (“Series A Warrants”) to purchase up to 6,857,142 shares of its common stock. The Series A Warrants are exercisable beginning on May 1, 2014 at a price of $0.85 per share and expire on May 1, 2019. The Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013.

The holders exercised 2,000,000 and 2,343,247 on March 5, 2014 and March 7, 2014, respectively, of the Series B Warrants. There were no warrant exercises in the first quarter of 2013.

The Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The change in fair value of the warrant liability for the three months ended March 31, 2014, was $137,000.

On February 12, 2013 the Company entered into an underwriting agreement with Cowen and Company, LLC, relating to the public offering of 6.1 million shares of the Company’s common stock, at a price to the public of $1.30 per share less underwriting discounts and commissions. The gross proceeds to the Company from the sale of the Common Stock totaled $7.9 million. After deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by the Company, net proceeds were approximately $7.3 million. The offering closed on February 15, 2013.

In June 2012, the Company entered into a sales agreement with Cowen and Company, LLC, to sell shares of the Company’s common stock through an “at-the-market” equity offering program (the “ATM Program”), which was terminated on February 15, 2013. During the three months ended March 31, 2013, and in connection with its termination, the Company sold approximately 4.7 million shares under the ATM Program for gross and net proceeds of approximately $8.8 million and $8.5 million, respectively. During the term of the ATM Program, the Company sold a total of approximately 6.6 million shares for aggregate gross and net proceeds of approximately $14.4 million and $13.8 million, respectively.

Outstanding common stock warrants consist of the following:


Issue Date	Expiration Date		Total Warrants		Ex. Price
5/7/2009		5/7/2014		200,000	$	11.35
4/26/2013		4/26/2018		693,202	$	1.12
10/31/2013		10/31/2018		6,857,142	$	0.85
2/5/2014		2/5/2019		13,297,297	$	0.74

				21,047,641

During the three months ended March 31, 2014, the number of outstanding shares of the Company’s common stock increased from 47,501,596 to 52,107,465.

11. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

•

Level 1: Observable inputs such as quoted prices in active markets;

•

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2014 and December 31, 2013 is as follows:


	March 31, 2014	December 31, 2013

Stock Price	$0.62	$	0.64
Risk-free Rate (5-year U.S. Treasury Yield)	1.73%		1.75	%
Volatility (Annual)	93.46%		93.43	%
Time to Maturity (Years)	4.85-5.08		5.33

Derivative warrant liabilities consist of the following:


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Warrant Derivative Liabilities
Beginning balance at January 1, 2014	$	3,017,142
Issuance of warrants with derivative liabilities		5,584,865
Changes in estimated fair value		(137,142	)

Ending balance at March 31, 2014	$	8,464,865

ITEM 2.

MELA SCIENCES, INC.

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations is intended to provide information to help you better understand and evaluate our financial condition and results of operations. We recommend that you read this section in conjunction with our unaudited condensed financial statements and accompanying notes included under Part I, Item 1 of this Quarterly Report and our financial statements and accompanying notes in our Annual Report on Form 10-K for the year ended December 31, 2013. We have experienced and expect to continue to experience volatility in our operating loss resulting from the MelaFind^® system activities that can vary significantly period-to-period. Therefore we believe that period-to-period comparisons of our historical results of operations may not be meaningful and should not be relied on as indicative of our future performance.

This quarterly report on Form 10-Q, including the following discussion and analysis of financial condition and results of operations, contains forward-looking statements that you should read in conjunction with the financial statements and notes to financial statements that we have included elsewhere in this report. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as “believe”, “anticipate,” “expect,” “intend,” “plan,” “will,” “may” “should,” “estimate,” “predict,” “potential,” “continue,” or the negative of such terms or other similar expressions, identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. Factors that might cause such a difference include those discussed below under the heading “Risk Factors,” as well as those discussed elsewhere in this quarterly report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2013. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Overview

We are a medical device company primarily focused on the commercialization of our flagship product, the MelaFind^® system, and the further design and development of the MelaFind^® system and our technology. The MelaFind^® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. The MelaFind^® system features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been ‘trained’ and blind tested on our proprietary database of melanomas and benign lesions. The MelaFind^® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.

The components of the MelaFind^® system include:

•

a hand-held component, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);

•

a proprietary database of pigmented skin lesions, believed to be the largest positive prospective database to date in the US; and

•

lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.

In November 2011, we received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind^® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, we installed the first commercial MelaFind^® system, and proceeded with the commercial launch of MelaFind^®. We are evolving from a research and development company to a commercial stage enterprise. The launch of MelaFind^® in 2012 and the subsequent commercialization activities supporting the launch did not meet our initial goals and objectives. Revenues have been lower than forecasted while expenses increased throughout 2012 and into 2013. In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, we appointed a new CEO and adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. As part of this strategy, in late December 2013, we changed our business model for the MelaFind^® system from a rental-based to a sales-based model. We reduced costs, added more experience to our management team, and reorganized our sales and marketing activities to better support the commercialization of the MelaFind^® system. We are also seeking a coverage determination from the Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, as a prerequisite to obtain reimbursement by Medicare for use of the MelaFind^® system. This process could take up to two years. Once a coverage determination has been made, we plan to seek reimbursement by Medicaid, Medicare and other third-party payers.

The historical placement rate of MelaFind^® systems varied from month to month and was not directly related to the number of potential customers we may have at any one time. Our placement rate to date has not met the level we initially estimated, due to a number of factors, including the time it takes to properly train doctors and staff for correct use, our limited marketing to date, and general awareness as to the potential benefits of MelaFind^®. We can give no assurances that customer returns will not increase or that all our customers will continue to use the MelaFind^® system in the future. Until the results of our sales-based model becomes more apparent, our revenues will be dependent on the amount of usage generated from our leased systems, which is out of our control as usage (i.e. the number of patients used on and the amount of lesions per patient) ultimately will be determined between the doctor and the individual patients. Our financial success will depend on a number of factors, primary among which is our ability to sell MelaFind^® systems, increase the penetration with dermatologists, encourage the usage of these systems, and control our costs. Currently, we cannot determine when we will have sufficient revenues to cover our continuing developmental costs, manufacturing, marketing and other operational expenses.

We are committed to enhancing the capabilities of the MelaFind^® system. Based on the insights from our key opinion leaders and feedback from our users, we are transitioning MelaFind^® from a melanoma scoring technology to a dermal imaging and metrics clinical tool. We are also considering the broadening of our target market beyond clinical dermatologists. Our long term goal is to enable the Company to be an information exchange company, with a focus on optically gathering data that can improve the diagnosis of various cancers, enable better patient care, improve efficiency and reduce costs. The scope and the speed of implementing these new strategies will depend on our financial and human resources and ultimately the acceptance of our products in the marketplace.

We are currently conducting a Post-Approval Study, (a “PAS”) evaluating the sensitivity and physician’s rate of false positive readings after using the MelaFind^® system. On October 17, 2013, the FDA notified us that our report with respect to the PAS was inadequate to allow the agency to complete its review, and as a result the FDA revised the PAS status on its website to “Progress Inadequate.” In January 2014, a revised enrollment plan and schedule was approved by the FDA and the interactive review process was closed. On April 2, 2014, the FDA updated the study status to “Progress Adequate” and approved our new study timeline. We currently target submission of the PAS report to the FDA by year-end 2017.

On August 22, 2013, we received a notice from The NASDAQ Stock Market that, for the previous 30 consecutive business days, we were not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. We were granted an automatic 180 grace period by NASDAQ in which to regain compliance. On February 19, 2014, we were notified by NASDAQ that we were eligible for an additional 180 day grace period. We have until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement or risk delisting.

Liquidity and Capital Resources

Since our inception, we have generated significant losses. As of March 31, 2014, we had an accumulated deficit of approximately $176 million. We expect to continue to invest in the further development of the MelaFind^® system, clinical trials and medical conferences. We anticipate that we will continue to incur net losses for the foreseeable future as the commercial launch of the MelaFind^® continues and as we conduct the PAS.

In February 2014, we sold to two investors (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, (the “Series A Preferred Stock”), convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of the Company’s common stock, for net proceeds of $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. The number of shares issuable upon conversion of the Series A Preferred Stock and exercise of the warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions. These investors have been granted rights of participation in future offerings of our securities for one year. In addition, as a condition of the financing, our directors purchased an aggregate of 202,703 shares of common stock, at a price of $0.74 per share, for aggregate gross proceeds of $150,000.

In connection with this financing, we also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

We have experienced recurring losses and negative cash flow from operations. We expect these conditions to continue for the foreseeable future. As the result of these factors, we have been and continue to be dependent on raising capital from the sale of securities in order to continue to operate and to meet our obligations in the ordinary course of business. We believe that our existing cash on hand and the actions we have taken to reduce expenses will support the Company’s operations into the fourth quarter of 2014. We continue to assess the effects of our previously announced cost reduction plan and are prepared to reduce various costs as necessary. Although we have no specific arrangements or plans, we will need to raise additional capital during the upcoming months, which may take the form of equity, equity linked, or debt financing. In addition, we anticipate that long-term we will need to raise funds to support further advances in the technology and to support clinical trials. The timing and amount of any additional funding we may seek will be affected by numerous factors, many of which are not in our control, including market acceptance of the MelaFind^® system.

There can be no assurances that we will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms or at all and there can be no assurance that any additional funding that we may obtain will be sufficient to meet our financing needs. Any additional funding that we may obtain in the future could be dilutive to common stockholders, provide new investors with rights and preferences senior to common stockholders and provide for restrictive covenants that could limit our ability to take certain actions. Unless we are able to generate sufficient revenues or are able to raise additional capital in the near term, our operations will be scaled back to maintain only vital activities, or discontinued altogether.

Results of Operations

Three Months Ended March 31, 2014 Compared with Three Months Ended March 31, 2013

Revenue

Revenue decreased to approximately $98,000 in the three months ended March 31, 2014 compared with approximately $144,000 in the three months ended March 31, 2013. The decrease of approximately $46,000 is the direct result of our change in business strategy from a lease-based model to a sales-based model, which resulted in a decrease in placements of the MelaFind^® system quarter to quarter. No revenue was recorded during the first quarter of 2014 from the sales of MelaFind^® units, although we received sales orders in the quarter that have been completed in the second quarter. Under our previous lease-based model, which was in force during the first quarter of 2013, we typically signed a user agreement with our customers that included an installation fee for the placement of the MelaFind^® system and billed for usage based on the number of patient sessions or lesions examined, or a fixed monthly rental fee. In addition, the user agreement provided for the sale of consumables needed to operate the system that were recognized on completion of the agreement. Deferred revenue was booked that primarily reflected the timed recognition of the installation fee revenue over the term of the user agreement, which is generally two years.

Cost of Revenue

Costs of revenue decreased to approximately $919,000 in the three months ended March 31, 2014, as compared with approximately $1,080,000 in the three months ended March 31, 2013. This decrease is also the result of our change in business strategy from a lease-based model to a sales-based model, which resulted in a decrease in placements of the MelaFind^® system quarter to quarter. Cost of revenue during the quarter consisted of direct costs associated with the placement of the MelaFind^® system in the doctor’s office, the cost of consumables, technical support costs and depreciation expense of the MelaFind^® systems placed with the customer, which remain the property of the Company.

Research and Development Expense

Research and development (“R&D”) expenses decreased to approximately $708,000 in the three months ended March 31, 2014 compared with approximately $1,262,000 in the three months ended March 31, 2013. The decrease of approximately $554,000 is the result of salary and headcount reductions in accordance with the cost reduction plan initiated in August 2013. Ongoing R&D efforts are for product enhancements and are expected to trend upward over the next several quarters.

Selling, General and Administrative Expense

Selling, general and administrative expenses (“SG&A”) decreased to approximately $3,204,000 in the three months ended March 31, 2014 from approximately $4,287,000 in the three months ended March 31, 2013. The decrease of approximately $1,083,000 is the result of salary and headcount decreases and a reduction in marketing expenses in accordance with the cost reduction plan initiated in August 2013. We plan to institute further actions during 2014 that may further reduce our quarterly levels of SG&A expense.

Interest Income

Interest income decreased to approximately $1,000 for the three months ended March 3, 2014 from approximately $2,000 in the three months ended March 31, 2013. The decrease is primarily the result of smaller cash balances available to invest during 2014.

Interest Expense

Interest expense for the three months ended March 31, 2014 was $1,000 as compared to $49,000 in the three months ended March 31, 2013 which represents interest expense on the Loan entered into in March 2013 and paid in full on September 10, 2013 (See Footnote 9 “Debt”).

Other Income

Other income for the three month periods ended March 31, 2014 and 2013 was the approximate $5,000 minimum royalty we earn each quarter from Kavo Dental GmbH on the sale/licensing of our DIFOTI product.

Change in Fair Value of Warrant Liability

The change in fair value of our warrant liability increased to a benefit of $137,000 for the three months ended March 31, 2014 from a benefit of $15,000 for the three months ended March 31, 2013, and in each period represents warrants accounted for as derivatives in separate transactions.

In October 2013, we entered into a securities purchase agreement with certain accredited investors in connection with a $6.0 million registered offering of 4,228,181 shares of the Company’s common stock, fully paid prefunded warrants (“Series B Warrants”) to purchase up to 4,343,247 shares of its common stock and additional warrants (“Series A Warrants”) to purchase up to 6,857,142 shares of its common stock. The Series A Warrants are exercisable beginning on May 1, 2014 at a price of $0.85 per share and expire on May 1, 2019. The Series B Warrants were exercisable immediately for no additional consideration. The Series B Warrants were completely exercised in March 2014. The Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value as of the inception date, and will be recorded at their respective fair values at each subsequent balance sheet date. The fair value of these warrants on March 31, 2014 was $2.9 million. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge or credit in the Statements of Operations. The change in fair value of the warrant liability for the three months ended March 31, 2014, was a benefit of approximately $137,000.

In February 2014, we sold (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of common stock. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date, and will be recorded at their respective fair values at each subsequent balance sheet date. The fair value of these warrants on March 31, 2014 was $5.6 million. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge or credit in the Statements of Operations. The change in fair value of this warrant liability for the three months ended March 31, 2014 was $0.

In connection with the loan agreement entered into in March 2013 with Hercules Technology Growth Capital Inc., we were obligated to issue a common stock purchase warrant to Hercules when the stockholders of the Company approved an increase in the authorized shares of the Company’s common stock. The stockholders approved the increase in April 2013 at which time the warrant was issued. For financial reporting purposes, during the period from the date the loan agreement was signed until the date the warrant was issued, the obligation to issue the warrant was accounted for as a derivative. The change in fair value of the derivative is included in operating results. The change in fair value was a benefit of approximately $15,000 for the three months ended March 31, 2013.

Registration Rights Liquidated Damages

In connection with the February 2014 financing (see above), we also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. In addition to the registration rights, the Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. We were unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million.

Summary of Cash Flow Activities

Our cash and cash equivalents at March 31, 2014 are liquid investments in money market accounts and deposits with commercial banks, which are held in amounts that substantially exceed FDIC limits.

Cash Flows from Operating Activities

Net cash used in operations was approximately $7.1 million for the three months ended March 31, 2014. For the corresponding period in 2013, net cash used in operations was approximately $6.1 million. In both periods, cash used in operations was attributable to net losses after an adjustment for non-cash charges, principally related to depreciation/amortization and share-based compensation, and other changes in operating assets and liabilities. Net cash used in operations for the period ended March 31, 2014 includes $3.4 million in liquidating damages that were paid to the Purchasers in our February 2014 financing.

Cash Flows from Investing Activities

For the three months ended March 31, 2014 and 2013, there was approximately $0.0 and $1.6 million respectively of net cash used in our investing activities for the purchase of fixed assets, which consist mainly of the MelaFind^® systems.

Cash Flows from Financing Activities

For the three months ended March 31, 2014, there was approximately $11.5 million provided by our financing activities representing the net proceeds from our February 2014 financing. For the three months ended March 31, 2013, there was approximately $15.7 million provided by the net proceeds from our public offering and approximately $5.8 million in net proceeds after expenses from borrowings.

Because of the numerous risks and uncertainties associated with the commercialization of medical devices such as MelaFind^®, our future development plans, and the costs of operating our Company, we are unable to estimate the exact amounts of future capital outlays and operating expenditures. Our future funding requirements will depend on many factors, including, but not limited to:

•

the cost of commercialization activities, including medical, marketing and sales expenses, contract manufacturing and inventory expenses and support of the current domestic direct sales force and conducting activities in Germany;

•

the cost of transitioning our operations and implementing a refocused marketing strategy;

•

sales of MelaFind^® units;

•

the amount of direct payments we are able to obtain from physicians utilizing MelaFind^®;

•

the costs of maintaining regulatory approval;

•

reimbursement amounts for the use of MelaFind^® that physicians are able to obtain from Medicare and third party payers;

•

the success of our research and development efforts in product development and enhancement, and meeting competitive services and technologies;

•

the schedule, costs, and results of our clinical trials and studies, including the Post-Approval Study;

•

the costs of maintaining or potentially building our inventory and other manufacturing expenses;

•

our ability to establish and maintain any collaborative, licensing or other arrangements, and the terms and timing of any such arrangements;

•

the costs involved in defending any patent infringement actions or other litigation claims brought against us by third parties; and

•

the costs of filing, prosecuting, defending and enforcing any patent claims or other rights.

Contractual Obligations

The following table summarizes our outstanding contractual obligations as of March 31, 2014, and the effect those obligations are expected to have on our liquidity and cash flows in future periods:


	Total		Less than 1 year		1-3 years
Operating leases	$	1,314,179	$	477,883	$	836,296

Our long-term operating lease obligations represent a non-cancelable operating lease for our laboratory, assembly, and office space. The lease on approximately 21,700 square feet of space expires in December 2016.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our judgments related to accounting estimates. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 1 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013, we believe that the following accounting policies and significant judgments and estimates relating to revenue recognition, stock-based compensation charges, and fair value of warrants are most critical to aid you in fully understanding and evaluating our reported financial results.

Revenue Recognition

We consider revenue to be earned when all of the following criteria are met: persuasive evidence a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. Our agreements with dermatologists regarding the MelaFind^® system combine the elements noted above with a future service obligation. Under our leased-based model, while the Company is required to place the MelaFind^® systems with dermatologists for their exclusive use, ownership of the MelaFind^® systems remained with the Company.

During 2013 and the first quarter of 2014, under the old leased-based method, we generated revenue from usage based on the number of patient sessions and lesions examined. Electronic record cards activate the MelaFind^® system, capture data and store the data. Additionally, we typically charged an initial installation fee for each MelaFind^® system which covered training, delivery, initial supplies, maintenance and the right to use the MelaFind^® system. In accordance with the accounting guidance regarding multiple-element arrangements, we allocated total contract consideration to each element based upon the relative standalone selling prices of each element, and recognized the associated revenue for each element as delivery occurred or over the related service period, generally expected to be two years. Revenues associated with undelivered elements were deferred until delivery occurred or services are rendered. The significant judgments we made related to allocation of the contract consideration to each element whereby changes in the standalone selling price could impact the amount of revenue recognized in a specific period and estimates of uncollectible accounts receivables.

Under the old leased-based method, costs of revenue are associated with: the placement of the MelaFind^® system in the doctor’s office, the cost of consumables delivered at installation, the cost of the electronic record cards, technical support costs and depreciation expense of the MelaFind^® system placed with the customer which remains the property of the Company.

In December 2013, we changed our business model from a leased-based model, to a sales-based model for the MelaFind^® system. No revenue was recorded during the fourth quarter of 2013 or the first quarter of 2014 from the sales of MelaFind units, although we received sales orders in the quarter that have been completed in the second quarter.

Stock-Based Compensation

We record compensation expense associated with stock options, restricted stock awards and other forms of equity compensation in accordance with FASB ASC 718, Compensation-Stock Compensation. The fair value of an equity award is determined at the date of grant using the Black-Sholes Model and the fair value of the equity award is expensed over the service period. The most significant inputs used to value an equity award include current stock price, the amount the employee must pay to acquire the equity award, volatility rate, interest rate and estimated term. For equity awards that vest upon achieving a defined milestone, the underlying compensation charge is recorded, when it is probable that the milestone will be achieved. It is then amortized over the estimated period to satisfy vesting requirements. The probability of vesting is updated at each reporting period and compensation is adjusted accordingly. The significant judgments relate to the assumptions used in the valuation model to determine the fair value of the equity instrument including the volatility rate, term and interest rate. Any increases (decreases) in either of the volatility rate, the term or the interest rate would increase (decrease) the value of the equity instrument and the corresponding compensation expense recognized each period. Estimates of performance based awards vesting can also have a significant impact on recognized stock compensation as the likelihood of a performance based award vesting can change from period-to-period with changes in estimates included in current period operations.

Fair Value Measurements

We make fair value measurements for financial instruments in accordance with the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures”. This standard defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 permits an entity to measure certain financial assets and financial liabilities at fair value with changes in fair value recognized in earnings each period.

ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are directly or indirectly observable for the asset or liability. Such inputs include quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, or inputs derived principally from or corroborated by observable market data by correlation or other means. Level 3 inputs are unobservable inputs for the asset or liability. Such inputs are used to measure fair value when observable inputs are not available.

Warrant Liability

We account for the 6,857,142 common stock Series A warrants issued in connection with the October 31, 2013 financing and the 13,297,297 common stock warrants issued in connection with the February 5, 2014 financing in accordance with the guidance contained in ASC 815-40-15-7D, “Contracts in Entity’s Own Equity” whereby under that provision they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, we classified the warrant instrument as a liability at its fair value and adjust the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of warrants issued by the Company in connection with the transaction has been estimated using a Black-Sholes valuation. We also accounted for

693,202 common stock warrants that were issued in connection with our debt financing during the three months ended March 31, 2013, as a liability until we increased our authorized number of shares at the 2013 Annual Meeting of Stockholders and then reclassified the warrants into equity.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.

Recent Accounting Pronouncements

ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Our exposure to market risk is confined to our cash, cash equivalents, and short-term investments. We invest in high-quality financial instruments, primarily money market funds, with the average effective duration of the portfolio within one year which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. Due to the short-term nature of our investments, we do not believe that we have any material exposure to interest rate risk arising from our investments. The Company is exposed to credit risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.

ITEM 4.

Controls and Procedures

Evaluation of disclosure controls and procedures

Based on their evaluation as of March 31, 2014, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, were effective to ensure that the information required to be disclosed by us in this Quarterly Report on Form 10-Q was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and Form l0-Q, and that such information was accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Change in internal control over financial reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the effectiveness of controls

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material in which case we will make separate disclosure as required.

Item 1A.

Risk Factors

Our business and operations entail a variety of serious risks and uncertainties, including those described in Item 1A of our Form 10-K for the year ended December 31, 2013. In addition, the following risk factors have materially changed during the three months ended March 31, 2014:

We have incurred losses for a number of years, and anticipate that we will incur continued losses for the foreseeable future.

Since 1999, we have primarily financed our operations through the sale of our equity securities and have devoted substantially all of our resources to research, development and commercialization of the MelaFind^® system. Our net loss for the three months ended March 31, 2014 was approximately $8.0 million, and as of March 31, 2014, we had an accumulated deficit of approximately $176 million. Our expenses will increase in connection with our continued commercialization and development activities related to MelaFind^®. Having commenced commercialization in March 2012, we expect to incur additional medical, marketing and sales expenses in the near future and to incur additional contract manufacturing and inventory expenses in the future which will require additional funding. Furthermore, having recently commenced a refocused marketing strategy focusing on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma, we expect to incur additional expenses continuing to transition our operations and implementing our refocused marketing strategy. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future and cannot determine at this time when we will generate any significant revenues. These losses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity.

We may be unable to continue commercialization of MelaFind^® or other products without additional funding

As of March 31, 2014 the Company had approximately $8.1 million in cash and cash equivalents and cash used in operations for the three months ended March 31, 2014 was approximately $7.1 million. Our total liabilities at March 31, 2014 were approximately $11.0 million. We expect to incur significant losses for the foreseeable future and may not achieve operating profits or positive cash flows from operations. Furthermore, under the terms of the securities purchase agreement entered into in connection with our February 2014 financing, we are prohibited from issuing (or entering into any agreement to issue) any equity securities in connection with a financing until August 2014. The Company’s ability to fund its operations is not assured and will be impacted by market acceptance of the MelaFind^® system and the related growth in revenues, cost cutting measures that are in place currently or may be put into place in the future and our ability to raise capital. We anticipate that long-term we will need to raise substantial funds to broaden the commercialization and awareness of the MelaFind^® system, including implementing our refocused marketing strategy focusing on the key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. The timing and amount of any additional funding the Company may require will be affected by the commercial success of its MelaFind^® product. For example, the funding, if available, could be in the form of either additional equity, equity-linked or debt financing. There can be no assurances that we will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that we do obtain will be sufficient to meet the Company’s needs in the long term. Any additional funding that we may obtain in the future could be dilutive to common stockholders and could provide new investors with rights and preferences senior to common stockholders. In the event that we are unable to achieve profitable operations and/or raise additional funds, we would need to further reduce current operations and expansion plans would be cancelled or ultimately we may need to terminate operations. Failure to fund operations will have a material adverse effect on our business and our stock price.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults Upon Senior Securities

Not applicable

Item 4.

Mine Safety Disclosures

Not applicable

Item 5.

Other Information

(a)

Not applicable

(b)

Not applicable

Item 6.

Exhibits


Exhibit Number		Exhibit Title

31.1#		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2#		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1#		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.1#		Interactive Data File

#	Filed herewith

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


MELA SCIENCES, INC.

By:		/s/ Robert W. Cook
		Robert W. Cook
		Chief Financial Officer (Principal Financial Officer)

Date: May 14, 2014

EXHIBIT INDEX


Exhibit No.		Description

31.1		Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.1		Interactive Data File

EX-31.1 2 d720781dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION BY THE INTERIM CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A) or

RULE 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Rose Crane, certify that:

1.	I have reviewed this report on Form 10-Q of MELA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operations of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 14, 2014

/s/ Rose Crane

Rose Crane

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d720781dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) or

RULE 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Robert W. Cook, certify that:

1.	I have reviewed this report on Form 10-Q of MELA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 14, 2014

/s/ Robert W. Cook

Robert W. Cook

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 d720781dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

MELA SCIENCES, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned officers of MELA Sciences, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s quarterly report on Form 10-Q for the period ended March 31, 2014 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Rose Crane

Rose Crane

Chief Executive Officer

(Principal Executive Officer)

May 14, 2014

/s/ Robert W. Cook

Robert W. Cook

Chief Financial Officer

(Principal Financial Officer)

May 14, 2014

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to MELA Sciences, Inc. and will be retained by MELA Sciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This written statement accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and will not be incorporated by reference into any filing of MELA Sciences, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 mela-20140331.xml XBRL INSTANCE DOCUMENT 6100000 1.30 7300000 7900000 1.00

12300

0.74

13297297 1000 0.10 0.84 202703 0.74

12300

0.74

13297297 0.84

5300000

563000

0.1045

1.12

6000000

693202 2000000 2343247 52107465

21647046

425000

6400000

4228181

4343247

0.85

6857142

52107465

12300

21047641

10000000

95000000

0.001

0.62

0.10

12300

1230

819851

6098945

1311174

10859569

8464865

85972

6355255

182430391

43080

23129

-176128474

201864

110111

52108

17353769

325000

10998514

138945

61815

28834

14269990

40526

48000

17353769

8122709

34121

5648020

9094198

727000

5973020

465140

2995253

200000

11.35

2014-05-07 2009-05-07

693202

1.12

2018-04-26 2013-04-26

6857142

0.85

2018-10-31 2013-10-31

13297297

0.74

2019-02-05 2014-02-05 2013-10-31

1.18

1.16

1.15

3017142

8464865

5081816

2022833

905888

1083661

246469

5401866

324685

7861524

47501596

10000000

95000000

0.001

0.64

0.10

844131

5403414

1478995

5651807

3017142

32902

8295833

176396209

46130

48000

-168147878

243605

120120

47502

14131514

325000

5835681

183874

67934

63754

10350935

41795

48000

14131514

3782881

57151

5631205

9094198

5956205

879698

3690784

5081816

2022833

905888

1083661

226439

5401866

327900

P180D P30D

14642857

11400000

P5Y P180D P42M 6000000 P1Y 150000

14642857

11400000

2 P5Y 500000

1000000

P5Y3M29D

0.9343

0.0175

0.7683

P6Y6M

39233943

-6092431

-0.17

0.0125

1635314

0.0138

-89173

-936163

5000

2105

15433

-6485392

29447

-26225

-6511617

-238642

144100

1641297

6000000

-834292

-5913

4287228

21519250

88873

268381

496733

13785522

41166

-1641297

48763

15746549

1080263

1262001

19785

18059

41166

7417

5549229

245358 40000 14101 13800000 14400000 6600000 2013-02-15 8500000 8800000 4700000

15000

1435314

200000

MELA MELA SCIENCES, INC. /NY false Smaller Reporting Company 2014 10-Q 2014-03-31 0001051514 --12-31 Q1

<div> 8. STOCK-BASED COMPENSATION Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant. The fair value of each option award granted is estimated on the date of grant using the Black-Sholes option valuation model and assumptions as noted in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center">March 31,</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2014</td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2013</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected life </td> <td valign="bottom">  </td> <td valign="bottom" align="center">6.5 years</td> <td valign="bottom"> </td> <td valign="bottom" align="center">6.5 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom" align="center">75.51%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">76.83%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2.14-2.45%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.25-1.38%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap" align="center"> —  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center"> —  </td> </tr> </table> </div>

<div> A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2014 and December 31, 2013 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="12%"></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Stock Price </td> <td valign="bottom">  </td> <td valign="bottom" align="center">$0.62</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.64</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Risk-free Rate (5-year U.S. Treasury Yield) </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.73%</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.75</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Volatility (Annual) </td> <td valign="bottom">  </td> <td valign="bottom" align="center">93.46%</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93.43</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Time to Maturity (Years) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap" align="center">4.85-5.08</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000

0.9346

<div> Outstanding common stock warrants consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Issue Date </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Expiration Date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total Warrants</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Ex. Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5/7/2009 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5/7/2014</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.35</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4/26/2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4/26/2018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">693,202</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.12</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 10/31/2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10/31/2018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,857,142</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.85</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2/5/2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2/5/2019</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,297,297</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.74</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,047,641</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

0.7551

<div> Property and equipment, at cost, consists of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Estimated</td> <td valign="bottom">  </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Useful Life</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Useful Life</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="2"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">905,888</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">905,888</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Lease Term</td> <td valign="bottom">  </td> <td valign="bottom" align="center">Lease Term</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Laboratory and research equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,083,661</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,083,661</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-5 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Office furniture and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,022,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,022,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-5 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> MelaFind® Systems </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,081,816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,081,816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">3 years</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">  </td> <td valign="bottom">   </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,094,198</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,094,198</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,098,945</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,403,414</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,995,253</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,690,784</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> </table> </div>

<div> 9. DEBT On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc., a venture capital lender, whereby the Company borrowed $6 million (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6.4 million, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000. Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 693,202 shares of common stock at an exercise price of approximately $1.12 per share. The warrant expires on April 26, 2018.   For financial reporting purposes, the $6 million funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5.3 million. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of approximately $15,000 are included in operating results for the three months ended March 31, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $1.16 to $1.18 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $1.15 to $1.16 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value. The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders equity. As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were approximately $1.0 million. </div>

<div> 11. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 1: Observable inputs such as quoted prices in active markets;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</td> </tr> </table> The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.   A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2014 and December 31, 2013 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="12%"></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Stock Price </td> <td valign="bottom">  </td> <td valign="bottom" align="center">$0.62</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.64</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Risk-free Rate (5-year U.S. Treasury Yield) </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.73%</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.75</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Volatility (Annual) </td> <td valign="bottom">  </td> <td valign="bottom" align="center">93.46%</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93.43</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Time to Maturity (Years) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap" align="center">4.85-5.08</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> Derivative warrant liabilities consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Warrant Derivative Liabilities</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance at January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,017,142</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issuance of warrants with derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,584,865</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Changes in estimated fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(137,142</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance at March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,464,865</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P6Y6M

<div> The fair value of each option award granted is estimated on the date of grant using the Black-Sholes option valuation model and assumptions as noted in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center">March 31,</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2014</td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2013</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected life </td> <td valign="bottom">  </td> <td valign="bottom" align="center">6.5 years</td> <td valign="bottom"> </td> <td valign="bottom" align="center">6.5 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom" align="center">75.51%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">76.83%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2.14-2.45%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.25-1.38%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap" align="center"> —  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center"> —  </td> </tr> </table> </div>

2014-02-05

<div> 3. RECENT ACCOUNTING PRONOUNCEMENTS The Financial Accounting Standards Board has issued a number of new accounting standards that require future adoption. Based on the Company’s initial review of these new standards, none are expected to have a material impact on the Company’s financial statements. </div>

<div> 4. INVENTORIES Inventories currently consist of MelaFind® systems and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind® systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices. In December 2013, the Company changed its business model for the MelaFind® system from a rental-based model to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind® systems from property and equipment into inventory at December 31, 2013. Inventory consists of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> MelaFind® Systems </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,401,866</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,401,866</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Mela record cards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">324,685</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">327,900</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accessories </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246,469</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">226,439</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,973,020</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,956,205</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Reserve for obsolete inventory </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(325,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(325,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,648,020</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,631,205</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

48926409

<div> 10. STOCKHOLDERS’ EQUITY  Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. As discussed in detail in Note 1, on February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share, convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of common stock for net proceeds of $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014, and will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on March 31, 2014 was equivalent to the fair value on February 5, 2014, and therefore no change in fair value has been recorded for the three months ended March 31, 2014. In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000. Common Stock The Company is authorized to issue 95,000,000 shares of common stock with a par value of $0.001 per share. On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6.0 million registered offering of 4,228,181 shares of the Company’s common stock, fully paid prefunded warrants (“Series B Warrants”) to purchase up to 4,343,247 shares of its common stock and additional warrants (“Series A Warrants”) to purchase up to 6,857,142 shares of its common stock. The Series A Warrants are exercisable beginning on May 1, 2014 at a price of $0.85 per share and expire on May 1, 2019. The Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013. The holders exercised 2,000,000 and 2,343,247 on March 5, 2014 and March 7, 2014, respectively, of the Series B Warrants. There were no warrant exercises in the first quarter of 2013. The Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The change in fair value of the warrant liability for the three months ended March 31, 2014, was $137,000.   On February 12, 2013 the Company entered into an underwriting agreement with Cowen and Company, LLC, relating to the public offering of 6.1 million shares of the Company’s common stock, at a price to the public of $1.30 per share less underwriting discounts and commissions. The gross proceeds to the Company from the sale of the Common Stock totaled $7.9 million. After deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by the Company, net proceeds were approximately $7.3 million. The offering closed on February 15, 2013. In June 2012, the Company entered into a sales agreement with Cowen and Company, LLC, to sell shares of the Company’s common stock through an “at-the-market” equity offering program (the “ATM Program”), which was terminated on February 15, 2013. During the three months ended March 31, 2013, and in connection with its termination, the Company sold approximately 4.7 million shares under the ATM Program for gross and net proceeds of approximately $8.8 million and $8.5 million, respectively. During the term of the ATM Program, the Company sold a total of approximately 6.6 million shares for aggregate gross and net proceeds of approximately $14.4 million and $13.8 million, respectively. Outstanding common stock warrants consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Issue Date </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Expiration Date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total Warrants</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Ex. Price</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5/7/2009 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5/7/2014</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.35</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4/26/2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4/26/2018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">693,202</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.12</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 10/31/2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10/31/2018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,857,142</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.85</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2/5/2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2/5/2019</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,297,297</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.74</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,047,641</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> During the three months ended March 31, 2014, the number of outstanding shares of the Company’s common stock increased from 47,501,596 to 52,107,465. </div>

-7120887

<div> Inventory consists of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> MelaFind® Systems </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,401,866</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,401,866</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Mela record cards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">324,685</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">327,900</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accessories </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246,469</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">226,439</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,973,020</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,956,205</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Reserve for obsolete inventory </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(325,000</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(325,000</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,648,020</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,631,205</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Derivative warrant liabilities consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Warrant Derivative Liabilities</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance at January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,017,142</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issuance of warrants with derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,584,865</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Changes in estimated fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(137,142</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance at March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,464,865</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.0173

<div> 7. COMPREHENSIVE LOSS For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts. </div>

-0.16

0.0214

<div> 6. NET LOSS PER COMMON SHARE Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of March 31, 2014 and March 31, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock equivalents of convertible preferred stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,642,857</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Common stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,907,574</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,435,314</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock purchase warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,047,641</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,663,122</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,635,314</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

38663122

<div> 1. ORGANIZATION AND BASIS OF PRESENTATION  MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company primarily focused on the commercialization of its flagship product, the MelaFind® system, and the further design and development of MelaFind® and its technology. The MelaFind® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. The MelaFind® system features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been ‘trained’ and blind tested on the Company’s proprietary database of melanomas and benign lesions. The MelaFind® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion. The components of the MelaFind® system include:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">a hand-held component, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">a proprietary database of pigmented skin lesions, believed to be the largest positive prospective database to date in the US; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.</td> </tr> </table> In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, the Company installed the first commercial MelaFind® systems, and proceeded with the commercial launch of MelaFind®. The Company is currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using the MelaFind® system to their performance if MelaFind® was not available. In 2012 the Company evolved from a research and development company to a commercial enterprise. The launch of MelaFind® in 2012 and the subsequent commercialization activities supporting the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013. In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, the Company appointed a new CEO and adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. As part of this strategy, in late December 2013, the Company changed its business model for the MelaFind® system from a rental-based to a sales-based model. The Company has reduced its costs, added more experience to its management team, and reorganized its sales and marketing activities to better support the commercialization of the MelaFind® system. The Company is also seeking a coverage determination from the Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, as a prerequisite to obtain reimbursement by Medicare for use of the MelaFind® system. This process could take up to two years. Once a coverage determination has been made, the Company plans to seek reimbursement by Medicaid, Medicare and other third-party payers. On August 22, 2013, the Company received a notice from The NASDAQ Stock Market that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. The Company was granted an automatic 180 grace period by NASDAQ in which to regain compliance. On February 19, 2014, the Company was notified by NASDAQ that the Company was eligible for an additional 180 day grace period and has until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement or risk delisting. On October 17, 2013, the FDA notified the Company that its report with respect to the PAS was inadequate to allow the agency to complete its review, and as a result revised the PAS status on the FDA website to “Progress Inadequate.” In January 2014, the Company’s revised enrollment plan and schedule was approved by the FDA and the interactive review process was closed. On April 2, 2014, the FDA updated the study status to “Progress Adequate” and approved our new study timeline. The Company currently targets submission of the PAS report the FDA by year-end 2017. In February 2014, the Company sold to two investors (the “Purchasers”) (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, (the “Series A Preferred Stock”), convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of the Company’s common stock, for net proceeds of approximately $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. The number of shares issuable upon conversion of the Series A Preferred Stock and exercise of the warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions. The Purchasers have been granted rights of participation in future offerings of our securities for one year. In addition, as a condition of the financing, the Company’s directors purchased an aggregate of 202,703 shares of common stock at a price of $0.74 per share, for aggregate gross proceeds of $150,000. The warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative. In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000. The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature. Liquidity The Company has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. In February 2014, as noted above, the Company raised net proceeds of approximately $11.5 million from the sale of Series A Preferred Stock, common stock and warrants to strengthen the Company’s financial position. The Company’s net losses have had a significant negative impact on working capital and its financial position and may impact the Company’s future ability to meet its obligations in the ordinary course of business. As a result, management believes that there is significant doubt about the Company’s ability to continue as a going concern. The Company continues to assess the effects of its previously announced cost reduction plan and is prepared to reduce various operational costs as necessary. Although the Company has no specific arrangements or plans, additional capital will be needed during the upcoming months, which may take the form of equity, equity-linked or debt financing. In addition, the Company anticipates that long-term it will need to raise funds to support further advances in the technology and clinical trials. The timing and amount of any additional funding the Company may require will be affected by numerous factors, many of which are not in the control of the Company including the market acceptance of the MelaFind® system. There can be no assurances that the Company will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms or at all and there can be no assurance that any additional funding the Company obtains will be sufficient to meet the Company’s financing needs. Any additional funding that the Company may obtain in the future could be dilutive to common stockholders, provide new investors with rights and preferences senior to common stockholders and provide for restrictive covenants that could limit the Company’s ability to take certain actions. Unless the Company is able to generate sufficient revenues or to raise additional capital near-term, the Company’s operations will be scaled back to maintain only vital activities, or discontinued. </div>

0.0245

-414558

-820885

5025

618

137142

-4732242

-22330

-3248354

-7980596

16815

97638

-192101

137000

-10009

3203533

11460715

-76661

164168

696800

4339828

1199

11460715

918523

707824

-6119

3911357

700 <div> Potential common stock equivalents outstanding as of March 31, 2014 and March 31, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock equivalents of convertible preferred stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,642,857</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Common stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,907,574</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,435,314</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock purchase warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,047,641</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,663,122</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,635,314</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> 2. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements, the use of estimates to determine the elements of our revenue and deferred revenue, accrued expenses, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates. </div> <div> 5. FIXED ASSETS The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition exceeds its carrying amount. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value. In December 2013, the Company changed its business model for the MelaFind® system from a rental-based to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent new and unused systems. Systems that have been leased under the rental-based model remain in property and equipment. Property and equipment, at cost, consists of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Estimated</td> <td valign="bottom">  </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Useful Life</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Useful Life</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="2"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">905,888</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">905,888</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Lease Term</td> <td valign="bottom">  </td> <td valign="bottom" align="center">Lease Term</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Laboratory and research equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,083,661</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,083,661</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-5 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Office furniture and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,022,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,022,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-5 years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> MelaFind® Systems </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,081,816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,081,816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3 years</td> <td valign="bottom">  </td> <td valign="bottom" align="center">3 years</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">  </td> <td valign="bottom">   </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,094,198</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,094,198</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,098,945</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,403,414</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,995,253</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,690,784</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> </tr> </table> </div> P10Y 3389940

2014-05-01

2019-05-01

P5Y

0.77

0.0084

0.10

P5Y29D

52107465

P5Y

P4Y10M6D

47501596

P3Y

-137142

5584865

14642857

65050

2907574

21047641

3 years

P3Y

3-5 years

Lease Term

3-5 years

2018-04-26 First 12 months 2013-04-25 180000 0001051514 mela:HerculesTechnologyGrowthCapitalIncMember 2014-01-01 2014-03-31 0001051514 us-gaap:EquipmentMember 2014-01-01 2014-03-31 0001051514 us-gaap:LeaseholdImprovementsMember 2014-01-01 2014-03-31 0001051514 us-gaap:OfficeEquipmentMember 2014-01-01 2014-03-31 0001051514 mela:MelaFindSystemsMember 2014-01-01 2014-03-31 0001051514 us-gaap:WarrantMember 2014-01-01 2014-03-31 0001051514 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001051514 us-gaap:RestrictedStockMember 2014-01-01 2014-03-31 0001051514 mela:SeriesAConvertiblePreferredStockMember 2014-01-01 2014-03-31 0001051514 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2014-01-01 2014-03-31 0001051514 us-gaap:EquipmentMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0001051514 us-gaap:OfficeEquipmentMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0001051514 us-gaap:MinimumMember 2014-01-01 2014-03-31 0001051514 us-gaap:EquipmentMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0001051514 us-gaap:OfficeEquipmentMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0001051514 us-gaap:MaximumMember 2014-01-01 2014-03-31 0001051514 mela:WarrantObligationMember 2014-01-01 2014-03-31 0001051514 mela:SeriesAWarrantsMember 2014-01-01 2014-03-31 0001051514 2014-01-01 2014-03-31 0001051514 us-gaap:WarrantMember 2013-01-01 2013-03-31 0001051514 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-03-31 0001051514 mela:WarrantObligationMember 2013-01-01 2013-03-31 0001051514 us-gaap:MinimumMembermela:AtmProgramMember 2013-01-01 2013-03-31 0001051514 us-gaap:MaximumMembermela:AtmProgramMember 2013-01-01 2013-03-31 0001051514 2013-01-01 2013-03-31 0001051514 2013-01-01 2013-12-31 0001051514 2013-09-08 2013-09-10 0001051514 us-gaap:SubsequentEventMember 2014-04-01 2014-04-03 0001051514 mela:SeriesAConvertiblePreferredStockMember 2014-02-06 2014-02-28 0001051514 2014-02-06 2014-02-28 0001051514 mela:SeriesAWarrantsMember 2013-10-28 2013-10-29 0001051514 mela:HerculesTechnologyGrowthCapitalIncMember 2013-03-14 2013-03-15 0001051514 2014-02-18 2014-02-19 0001051514 mela:SeriesAConvertiblePreferredStockMember 2014-02-04 2014-02-05 0001051514 2013-08-21 2013-08-22 0001051514 mela:MelaRecordCardsMember 2013-12-31 0001051514 mela:MelaFindSystemsMember 2013-12-31 0001051514 mela:AccessoriesMember 2013-12-31 0001051514 us-gaap:EquipmentMember 2013-12-31 0001051514 us-gaap:LeaseholdImprovementsMember 2013-12-31 0001051514 us-gaap:OfficeEquipmentMember 2013-12-31 0001051514 mela:MelaFindSystemsMember 2013-12-31 0001051514 2013-12-31 0001051514 2012-12-31 0001051514 mela:MelaRecordCardsMember 2014-03-31 0001051514 mela:MelaFindSystemsMember 2014-03-31 0001051514 mela:AccessoriesMember 2014-03-31 0001051514 us-gaap:EquipmentMember 2014-03-31 0001051514 us-gaap:LeaseholdImprovementsMember 2014-03-31 0001051514 us-gaap:OfficeEquipmentMember 2014-03-31 0001051514 mela:MelaFindSystemsMember 2014-03-31 0001051514 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2014-03-31 0001051514 mela:WarrantObligationMemberus-gaap:MinimumMember 2014-03-31 0001051514 mela:WarrantObligationMemberus-gaap:MaximumMember 2014-03-31 0001051514 mela:SecuritiesPurchaseAgreementMember 2014-03-31 0001051514 mela:CommonStockWarrantsWithExercisePriceZeroPointSevenFourMember 2014-03-31 0001051514 mela:CommonStockWarrantsWithExercisePriceZeroPointEightFiveMember 2014-03-31 0001051514 mela:CommonStockWarrantsWithExercisePriceOnePointOneTwoMember 2014-03-31 0001051514 mela:CommonStockWarrantsWithExercisePriceElevenPointThreeFiveMember 2014-03-31 0001051514 2014-03-31 0001051514 mela:SeriesAWarrantsMember 2013-10-29 0001051514 mela:SeriesBWarrantsMember 2013-10-29 0001051514 2013-10-29 0001051514 mela:HerculesTechnologyGrowthCapitalIncMember 2013-09-10 0001051514 mela:SeriesBWarrantsMember 2013-03-31 0001051514 2013-03-31 0001051514 2014-04-30 0001051514 mela:SeriesBWarrantsMember 2014-03-07 0001051514 mela:SeriesBWarrantsMember 2014-03-05 0001051514 mela:HerculesTechnologyGrowthCapitalIncMember 2013-03-15 0001051514 2013-03-15 0001051514 mela:SeriesAConvertiblePreferredStockMember 2014-02-28 0001051514 2014-02-28 0001051514 mela:SeriesAConvertiblePreferredStockMember 2014-02-05 0001051514 2013-08-22 0001051514 mela:ShelfRegistrationStatementMember 2013-02-12 shares iso4217:USD shares iso4217:USD iso4217:USD mela:Warrant pure mela:Investor Derived from the audited balance sheet as of December 31, 2013

EX-101.SCH 6 mela-20140331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Organization and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Use of Estimates link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Fixed Assets link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Net Loss Per Common Share link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Fixed Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Net Loss Per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Inventories - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Inventories - Schedule of Inventory (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Fixed Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Fixed Assets - Summary of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Net Loss Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Comprehensive Loss - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 mela-20140331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mela-20140331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mela-20140331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accessories [Member] Accessories [Member] Accessories [Member] Accounting Changes And Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Changes And Error Corrections [Text Block] Recent Accounting Pronouncements Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable Current Accounts payable (includes related parties of $85,972 and $32,902 as of March 31, 2014 and December 31, 2013, respectively) Accounts Payable Related Parties Current Accounts payable, related parties Accounts Receivable Net Current Accounts receivable (net of allowance of $43,080 and $46,130 as of March 31, 2014 and December 31, 2013, respectively) Accrued Liabilities Current Accrued expenses (includes related parties of $23,129 and $48,000 as of March 31, 2014 and December 31, 2013, respectively) Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Accumulated depreciation and amortization Additional Liquidation Damages Payable Additional Liquidation Damages Payable Additional liquidated damages payable Additional Paid In Capital Common Stock Additional paid-in capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss: Aggregate consideration receivable for warrants to be issued. Aggregate Consideration Receivable For Warrants To Be Issued Warrants issued to purchase common stock Agreed Amount to Waive Prepayment Penalty on Term Loan Agreed Amount To Waive Prepayment Penalty On Term Loan Prepayment penalty Allowance For Doubtful Accounts Receivable Current Allowance for accounts receivable, current Amendment Flag Amendment Flag Amortization Of Financing Costs Amortization of deferred financing costs Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Potential common stock equivalents Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Assets Total Assets Assets [Abstract] ASSETS Assets Current Total Current Assets Assets Current [Abstract] Current Assets: ATM Program [Member] Atm Program [Member] ATM Program [Member] Award Type [Axis] Award Type [Axis] Bad Debt Expense Bad Debt Expense Bad debt expense Borrowed Funds Loan payable Borrowed funds maturity period. Borrowed Funds Maturity Period Maturity period of loan Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Net increase in cash and cash equivalents Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Supplemental Schedule of Noncash Investing and Financing Activities: Class Of Stock [Domain] Class of Stock [Domain] Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Warrants exercisable date Class Of Warrant Or Right [Axis] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Class Of Warrant Or Right Exercisable Term Class Of Warrant Or Right Exercisable Term Warrants issued, exercisable term Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Warrants issued, exercise price Ex. Price Warrants issued to purchase common stock, exercise price Class Of Warrant Or Right [Line Items] Class of Warrant or Right [Line Items] Class Of Warrant Or Right Outstanding Total Warrants Class Of Warrant Or Rights Number Of Warrants Or Rights Exercised Class Of Warrant Or Rights Number Of Warrants Or Rights Exercised Warrants exercised Class Of Warrant Or Rights Warrants Or Rights Expiration Date Class Of Warrant Or Rights Warrants Or Rights Expiration Date Warrants expiry date Class Of Warrant Or Right [Table] Class of Warrant or Right [Table] Class of warrants or rights issuance date. Class Of Warrants Or Rights Issuance Date Warrant issuance date Commitments And Contingencies COMMITMENTS AND CONTINGENCIES Common Stock Issued Common Stock Issued Number of common stock issued through company ATM program Common Stock Minimum Bid Price Common Stock Minimum Bid Price Minimum bid price Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Purchase Agreement Aggregate Gross Proceeds Common Stock Purchase Agreement Aggregate Gross Proceeds Proceeds from common stock purchased Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Shares Purchased Common Stock Shares Purchased Common stock purchased, shares Common Stock Shares Purchased Share Price Common Stock Shares Purchased Share Price Common stock purchased, share price Common Stock Value Common stock - $0.001 par value; authorized 95,000,000 shares: Issued and outstanding 52,107,465 shares at March 31, 2014 and 47,501,596 at December 31, 2013 Common Stock Warrants With Exercise Price Eleven Point Three Five [Member] Common Stock Warrants With Exercise Price Eleven Point Three Five [Member] Ex. Price $ 11.35 [Member] Common Stock Warrants With Exercise Price One Point One Two [Member] Common Stock Warrants With Exercise Price One Point One Two [Member] Ex. Price $ 1.12 [Member] Common Stock Warrants With Exercise Price Zero Point Eight Five [Member] Common Stock Warrants With Exercise Price Zero Point Eight Five [Member] Ex. Price $ 0.85 [Member] Common Stock Warrants With Exercise Price Zero Point Seven Four [Member] Common Stock Warrants With Exercise Price Zero Point Seven Four [Member] Ex. Price $ 0.74 [Member] Comprehensive Income Net Of Tax Comprehensive income (loss) Comprehensive Income Note [Text Block] Comprehensive Loss Condensed Financial Statements Captions [Line Items] Condensed Financial Statements, Captions [Line Items] Convertible Preferred Stock Initial Conversion Price Convertible Preferred Stock Initial Conversion Price Preferred stock converted to common stock, conversion price Cost Of Revenue Cost of revenue Counterparty Name [Axis] Counterparty Name [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument Carrying Amount Initial carrying value of the loan Debt Instrument Fee Amount Term fee Debt Instrument Interest Rate Stated Percentage Accrued interest rate Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Debt instrument period of initial interest payment. Debt Instrument Period Of Initial Interest Payment Time period of interest payment Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument Unamortized Discount Initial loan discount amount Deferred Rent Credit Noncurrent Deferred rent Deferred Revenue Current Deferred placement revenue Deferred Revenue Noncurrent Deferred placement revenue Depreciation And Amortization Depreciation and amortization Derivative Inception Dates Derivative fair value inception date Derivative Liabilities Ending balance at March 31, 2014 Derivative Liabilities Current Warrant liability Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Due To Related Parties Current Accrued expenses, related parties Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic And Diluted Basic and diluted net loss per common share Earnings Per Share [Text Block] Net Loss Per Common Share Employee Stock Option [Member] Common Stock Options [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equipment [Member] Laboratory and Research Equipment [Member] Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Fair Value Adjustment Of Warrants Change in fair value of warrant liability Changes in fair value of warrants Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Assumptions Exercise Price Exercise prices Stock Price Fair Value Assumptions Expected Term Maturity period Time to maturity (Years) Fair Value Assumptions Expected Volatility Rate Volatility Volatility (Annual) Fair Value Assumptions Risk Free Interest Rate Risk free interest rate of return Risk-free Rate Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value Inputs Level 3 [Member] Significant Unobservable Inputs (Level 3) [Member] Fair Value Inputs Liabilities Quantitative Information Table [Text Block] Schedule of Fair Value Hierarchy Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss Change in fair value of warrant liability Change in fair value of warrant liability Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues Issuance of warrants with derivative liabilities Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease Changes in estimated fair value Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Beginning balance at January 1, 2014 Fair Value Of Warrant Obligation Fair Value Of Warrant Obligation Fair value of warrant obligation Fixed Assets Disclosure [Text Block] Fixed Assets Disclosure [Text Block] Fixed Assets Gains Losses On Extinguishment Of Debt Loss on early extinguishment of debt General And Administrative Expense Selling, general and administrative Gross Proceeds From Issuance Of Common Stock Gross Proceeds From Issuance Of Common Stock Gross proceeds from sale of common stock Gross Profit Gross profit Hercules Technology Growth Capital Inc. [Member] Hercules Technology Growth Capital Inc [Member] Hercules Technology Growth Capital Inc. [Member] Income Statement [Abstract] Income Statement [Abstract] Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable and accrued expenses Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Deferred Liabilities Deferred rent Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Interest Payable Net Long-term interest payable Increase Decrease In Inventories Inventory Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Operating Liabilities Other current liabilities Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Intangible Assets Net Excluding Goodwill Patents and trademarks, net Interest Expense Interest expense Inventory Current [Table] Inventory, Current [Table] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventories Inventory Gross Inventory, Gross Inventory [Line Items] Inventory [Line Items] Inventory Net Inventory (net of reserve of $325,000 as of March 31, 2014 and December 31, 2013) Inventory, Net Inventory Valuation Reserves Inventory reserves Reserve for obsolete inventory Investment Income Interest Interest income Investment Warrants Expiration Date Expiry date for warrant outstanding Leasehold Improvements [Member] Leasehold Improvements [Member] Liabilities Total Liabilities Liabilities And Stockholders Equity Total Liabilities and Stockholders' Equity Liabilities Current Total Current Liabilities Liabilities Current [Abstract] Current Liabilities: Liabilities Noncurrent Total Long Term Liabilities Liabilities Noncurrent [Abstract] Long Term Liabilities: Maximum [Member] Maximum [Member] MelaFind systems. Mela Find Systems [Member] MelaFind Systems [Member] Mela Record Cards [Member] Mela Record Cards [Member] Mela Record Cards [Member] Minimum [Member] Minimum [Member] Nasdaq Minimum Price Bid Requirement Additional Grace Period Nasdaq Minimum Price Bid Requirement Additional Grace Period Additional grace period Nasdaq Minimum Price Bid Requirement Grace Period Nasdaq Minimum Price Bid Requirement Grace Period Grace period granted by NASDAQ to regain compliance Net Cash Provided By Used In Financing Activities Continuing Operations Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Cash flows from financing activities: Net Cash Provided By Used In Investing Activities Continuing Operations Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Cash flows from investing activities: Net Cash Provided By Used In Operating Activities Continuing Operations Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Cash flows from operating activities: Net Income Loss Net loss Net loss Net Income Loss [Abstract] Net Income (Loss) Attributable to Parent [Abstract] Net Proceeds From Issuance Of Common Stock Net Proceeds From Issuance Of Common Stock Net proceeds from sale of common stock Net proceeds from sale of common stock. Net Proceeds From Sale Of Common Stock Net proceeds from sale of common stock Non cash interest expense. Noncash Interest Expense Non-cash interest expense Nonoperating Income Expense Non operating income and expense Nonoperating Income Expense [Abstract] Other income (expenses): Number Of Consecutive Business Days Not complied With Minimum Bid Price Number Of Consecutive Business Days Not Complied With Minimum Bid Price Number of consecutive business days, non-compliance of minimum bid price Number Of Outstanding Common Stock Shares Increased Number Of Outstanding Common Stock Shares Increased Number of outstanding common stock shares increased Number Of Purchasers Number Of Purchasers Number of purchasers of preferred stock and warrants Office Equipment [Member] Office Furniture and Equipment [Member] Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income Loss Operating loss Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Organization and Basis of Presentation Other Assets Noncurrent Other assets Other Liabilities Current Other current liabilities Other Nonoperating Income Expense Other income, net Payments for borrowings and warrant exercises. Payments For Borrowings And Warrant Exercises Expenses related to borrowings and issuance of warrant Payments To Acquire Property Plant And Equipment Purchases of property and equipment Percentage Of Change In Unobservable Input Percentage Of Change In Unobservable Input Change in underlying unobservable inputs Period Of Grant Period Of Grant Purchasers granted rights Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Par Value Per Share Preferred Stock Par Value Per Share Preferred stock, par value EX-101.PRE 10 mela-20140331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!,"'?^XP$``$,7```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F,U.XS`4A?=(O$/D+6I< M._S-J"D+?I:`!#R`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```/__`P!02P,$%``&``@````A`+55,"/U````3`(```L` M"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7 M^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X M8<'%#U1?````__\#`%!+`P04``8`"````"$`+K7Y<_$!```Z%@``&@`(`7AL M+U]R96QS+W=ON_#^$T5`VTTXNP%P%U.?IH[M:?/]T^^KU+^4>QVXVQRKOT ML39=2N-7:V/3^8.+BV'T?;ZS&<+!I;P,6SNZYL5MO>7EU4-; MF_#0DICJ^3CF1_]_\V&SV37^?FA>#[Y/?WF&_3F$E]AYG_*F+FQ]JDTI17NZ M0[+(FHW]AYSLAZZ<:R2'5\IR>(7DR,V<&G961&J8YU90Y MF924TN_184)RY$)9CEP@.5?*:JZ0&&)E-<10CK8Y!-WA2V5W^!*Y(]J1+#"2 M9=9(CNFXSXPK>'A?(SNT1Q=/KC80"`*!\_N$*BYY"5LU*Y]*_$_34DH?1+A! M=EO9TA2W21B0D M)&FK(2B'M8'-$-@\*[!+Y$XS4TH?*0S/4**=?(*C3QN9!)%)VL@DB$S1!H/` MU-'F`L2"=J=@HTC;&H+>L#8R&2*39T5FR3L0@?"`*=J9(S!S1!N?`O&IC2M, MJ]QCS<^AA>3V[(OO^@T``/__`P!02P,$%``&``@````A`&U_1A^1`P``4`L` M``\```!X;"]W;W)K8F]O:RYX;6R4EEEOXC`0Q]]7VN\0Y7V;"WJI4/4`+=*J M14N/1\M-#+&:V*SM%-A/OQ-'A`FFJ/L$3C)_S_&;L:^NUV7A?3"EN10#/SH) M?8^)5&9<+`;^\]/XQ[GO:4-%1@LIV,#?,.U?#[]_NUI)]?XFY;L'`D(/_-R8 MY640Z#1G)=4G7RP=:@M_KPO<*JLTHXX9E M`[\/2[EBG0>J6MY6O("W%TF8^,&P#7*JO(S-:568)PAOJP[YBGMQ?%I_6:?B MA;.5WAG52V_]RD4F5_6GD-I-NTK`@95]]NL3R"RR/?4)8<_:I)%M>-8Y986 M5*2,S.JO-;**D55\W(I,J8+2Y,SPE$+2VYT3I&&3BW>>&6H@L<)H(N?D<!_6F<% M[W^!9,[W92;B`V2DXIVM>T!>N_7%OLV8KUE&;K3NEKS7(27F(#N`%V^6RR&"LD-&?"MH+&Y^B_$8.6V/*%7FA1679 M&',!/<9I`?VIC:JP#F8KS`W]\:4U>E6XX`&AB]VX#M>%-B_G5M]3&+LD'A\R._X%N.Z)P[0 MA[IK5W[D3Q_7/7%X/J2SXQ'I))AG6.SEYWBG0I>WG5K?J=IS#A;_)01=OA/J M1&8'<6!?PJT++C4I7`?KG_H^9&PO=V]R:W-H965T&ULE)A; M;ZLX$,??5]KO@'A/P.9FHB1'A:J[1]HCK59[>2;$25`!1T";]MOOF'$`.Z<1 M>6D#_!C_Y^*9..MO'U5IO?.F+42]LYV)?U,>-_<_?+PMF6VV7U?NL M%#7?V)^\M;]M?_UE?1'-:WOBO+/`0MUN[%/7G5>.T^8G7F7M4IQY#4\.HJFR M#BZ;H].>&Y[M^Y>JTJ&N&SI55M0V6E@U=VBDX676@?[V M5)S;J[4JGV.NRIK7M_,B%]493.R*LN@^>Z.V5>6K[\=:--FN!+\_B)_E5]O] MQ8WYJL@;T8I#MP1S#@J]]3EV8@.H@W0%X)!U;[3^?>9M#1,',D@;24BY*$`!_K:J0I0$1R3[Z_Y=B MWYTVMA\3UQT`31>4]WQ=$C9T&>LFB(2HB["`>L.Z&+$I0%SF MTG`D-&7A(\HD;"B+]8431%#9@E&7,3.9&A%[(?E*&FRD^4&3L%YG;,P%UADB MD+(AWZ:T>X06-3G1)OWB_F:4L!XU9FSZ!!&,6N1&C!I](YT"A(8P^$83FK+X M$642-I09;2%!!)5YU/4";RPD++4IX5,643I6JR:-P,"9'[6>-L092R>*4>IB M0KS`V,&IA@2!'U,ZEJPN3W;>V4DEV*>GW8,924L4HS:#'WF4^D9\4YT)?19X M\"8G'BE+*-,!G,#F&-JEK>V@P MR.]:YGXU@I(H!K41+R*W%:?-AL"?;&A=VT.C@=S.!F:$)5&,BIOGL3CVC2:= M*@8"^),NK>M[:#X0[.W3O,;&VHEB4%_@TK&@5%K1QO7Y5\.>/#0=>EKO<_'8 MV_N%$\5<`T=]Y@5<EU!D;$1+X>MX=&!+F=$9/^I.0A@U^3%E',W"`V]G*J M["@F#`@)R;BO-('4F!/RV[@']^Y/V?XM(X[CKD.ABH&>)CO*PET24^8M\95( M8UK,%'D[-6(CD0E%!I/MLYB&OFOL)'G*DYT`&1@8GA?[H[,833S&X3&GXLV1 MI[PL6RL7;_*()D,PW!V.CT]4'AF,^PD<*_LSF#,\@%/=.3OR'UES+.K6*OD! M3+K+"%I+@^="O.C$N3]<[40'Y[G^XPG.[QR.).X2X(,0W?5"'GB&7P2V_P,` M`/__`P!02P,$%``&``@````A`(9YIQT&`P``IP@``!D```!X;"]W;W)K&ULE)9=;YLP%(;O)^T_6+XOGX%\**1JTW6KU$G3M(]K M!TRP"AC93M/^^YV#$PIDS;)<)-B\?GG.\>$XR^N7JB3/7&DAZX3ZCD<)KU.9 MB7J;T)\_[J]FE&C#ZHR5LN8)?>6:7J\^?ECNI7K2!>>&@$.M$UH8TRQ<5Z<% MKYAV9,-KN)-+53$#0[5U=:,XR]I%5>D&GA>[%1,UM0X+=8F'S'.1\CN9[BI> M&VNB>,D,\.M"-/KH5J67V%5,/>V:JU16#5AL1"G,:VM*294N'K:U5&Q30MPO M_H2E1^]V<&)?B51)+7/C@)UK04]CGKMS%YQ6RTQ`!)AVHGB>T!M_L9Y1=[5L M\_-+\+WN71-=R/UG);)'47-(-FP3;L!&RB>4/F0X!8O=D]7W[09\4R3C.=N5 MYKOL=URDD%&R<($*G5)8``-^D$E@9D!#VTO[N16:* MA(:Q$TV]T`"%K%^IQBP`@F?<;S M;"A.*"3@+3G>=,1F-7VV,!IIUNM'7G.=,H\N;] MSU"^'LOC6=!7SSKY@#K^'VH4#ZG#Z,W7[KC5'*@#QP_[$//YIZMQE0X6^-!H MO/['[R\8D,-;>7F^43PF'^?;:CKRR1D06[J#!;X3SMYEQ?.RUXW.URZ*AZR! M/WZOK*9?N]&XZYR5V$S:@\'VS8JK+5_SLM0DE3ML^@$47C?;G4[&W!.-&S+OS*U%;4F)<_!$JN8$F5/&CLPLFF[]48:."':RP+^$'!H M<9X#XEQ*&PO=V]R:W-H965T& MFC\<5$MV8*S474&3**8$.J%+V=4%_?EC=7-'B76\*WFK.RCH$2Q]6'S\,-]K ML[$-@"-(Z&Q!&^?Z&6-6-*"XC70/'7ZIM%'#EL4BU+X_B6*2X[ M&@@S>[]D]0])B7DITX,M. M#%0%72:SQPEEB_E0GU\2]O;BF=A&[S\;67Z5'6"QL4V^`6NM-U[Z7/I7N)F] MV;T:&O#-D!(JOFW==[W_`K)N''8[1T/>UZP\/H$56%#$1&GN24*WF`!>B9)^ M,K`@_##<][)T34&SVRB?QEF"4M`I M)>C"8GMVBRS/YFR'-14GS6/0X'74)*."839C2IC&94KO%_D'$9)GT_3/9W&.\\P\GX?SB_"747)M+XM=&@F5QH\O:.$NMX6_!&MY#3-[#T8?[QPVRGS=K6`(X@H;4YK9WKIHQ9 M48/B-M(=M/BFU$9QATM3,=L9X$5_2#4LC>-;IKAL:2!,S34,7992P),6&P6M M"Q`##7?HW]:RLT>:$M?@%#?K374S6=]?GY* MV-F39V)KO?MD9/%%MH#)QC+Y`JRT7GOI2^&W\#"[./W<%^"K(064?-.X;WKW M&615.ZQVA@'YN*;%VQ-8@0E%3)1FGB1T@P;PERCI.P,3PO?]_TX6KL[IZ#;* M)O$H03E9@77/TB,I$1OKM/H51,D!%2#I`3)"]X?WZ;40%@SU\3UQQ^P:OM!WW'9A,$7P,+-@80OU7I!BBASQZ2DXGE&`0%JNSG8^R>,:VF%)QT"PN M-X-'#/S4X]^3?K3BQ=Z*+X+WM@@;R!Z\I6?W7BHFV2!YYP0S M=+T3+\9"GUP\RLY"7@3-^$3SY^;>_O)_BG?>$'*]-R_.*08^)&64G:5E$31W M?3G/BHFSYL^?OPM^PA2%+E-@*EA"TU@B],9/2(J\87<8WL?4%^QL?X%#W8\` M&U[@4'6\@E=N*ME:TD")R#B:X!29,)9AX737]_9*.QRG_K'&KR=@0\01BDNM MW7'AVVWX'L]_`P``__\#`%!+`P04``8`"````"$`&`1CB\$#``"%#0``&0`` M`'AL+W=OD&6FUVLLSAK;="M"(;L?)W\\Y')M`D[3)@V.@NJA3U9?CU;?7LG!> M>*.$K-8NF_FNPZM,YJ(ZK-U__WGZ>N2H[\C)5,UGS"I[L95.F&BZ;@Z?JAJ=Y.Z@LO,#W$Z], M1>42P[*9PB'W>Y'Q1YF=2EYI(FEXD6K0KXZB5E>V,IM"5Z;-\ZG^FLFR!HJ= M*(1^:TE=I\R6/PZ5;-)=`76_LBC-KMSMQ8B^%%DCE=SK&=!Y)'1<\\);>,"T M6>4"*D#;G8;OU^X]6VY9XGJ;56O0?X*?5>^[HX[R_&%XV812MO!>P-+M@'L88-D1LKPA,`N1U&J'POL:/ M3;]*03!*P1!0VP/=`.Y.6V"\=XR8QQUDH`0VDC3`)Q7J7)#!I30?[$):$ M<TQ^(`[.FBT.P*6YNB",,O+\KP#3.AAAH2X;:IH6+@VZ%2QB;1AMBH!&6 MV'3_$&SZ9X9+&`HW6/CS>/Z>7!O_MH]@D25;/.R,K22$K<0^`7&0J?'.R)@P M-O]LB(%_B['&VPL8!]W*F#`VC3;$0",#T_I&V@ULT::#9LH7T"5FYD?S)!KM MOOA:V/W;=0[]!?QU.0SUX3[="_J&/MK5AUO,HF.F+881R&:?%3+4A_MY3]^T MA052?Q?`P9ZL0MO:?SAH]T``Q]'.5,(,HPB?WX/4):S(P`4]0! MIJ\.7;R]G!F.&L[&8!&::1/H8Q$7G3;(T$7C2)F8-IT*X$9W;HP/9>SPH!BK M3AMDJ-,X7FZD32?"C;0)1&FS*(F"N]@X'[$K_KP&$DA=+W6%)6\.?,N+0CF9 M/&%'&\!^T-WMNNW[`!LLX_X#=N%XW^L>0!-A.:FA_VZ]'^+G#H8'S9P#>2ZFO%_B"[@?4YC<```#__P,`4$L# M!!0`!@`(````(0"O(#XA<`8``/\>```9````>&PO=V]R:W-H965T7QX.7[Q&^*GCU^KL_6E:-JRONQL;^7:5G')ZWUY M.>[LO_[\]"&RK;;++OOL7%^*G?VM:.V/SS_^\/1>-Y_;4U%T%E2XM#O[U'77 MK>.T^:FHLG957XL+_.=0-U76PWZ(:^K*Y1X+<]E]ZTO M:EM5OOWE>*F;[/4,U_W5"[)\K-U_T,I79=[4;7WH5E#.0:'Z-<=.[$"EYZ=] M"5<@VFXUQ6%GOWA;SB+;>7[J&_1W6;RWRGNK/=7O/S7E_M?R4D"W89[$#+S6 M]6>!_K(7AV"PHXW^U,_`[XVU+P[9V[G[HW[_N2B/IPZF.X0K$A>VW7_C19M# M1Z',R@]%I;P^@P#X:U6EL`9T)/O:O[Z7^^ZTL]EZ%6YA"MJKYEPN+>%8F/?L(+LY'\U$CHH MBKR(*CM[8UO0HQ9F_\LS\^,GYPO,6#XP"3+P5S+>E$C'*F)Z1%FN''!`KQ0- M7?T?1(LJ0O1XN@0/J`I]HG`<5^'(=^R*:J4I5@Z]C=1%0W M$K$ZK;=9G5@<[G]U`N;=(F`JG]QN"3(PW])1M.]&@H\$M;9(?K+PF=TB!IGN M1V3F1!L)/A)4-,R"*GJ^PP*F';[-7+_")LB@06(WC")Z.YH`CH!N:P\6M^5: M>YJ*)5Y-!DAM+6/$KND=B)B&2X2VUQ.!HYABOK\]3363&['UFBSFJ1GA`W+G;A3IH_3: MH!BS:NH.[6X<`^W68\;(MZ%4?`>':Y^Q$)>(UF61/(KFA<[&O)IJ)ZM:XB$T M(RLU(UPBFG(1.H\KQZ@R.'O,LUO7-6<;$>Z-B*9<)(^BW.`3S*EIKS5G(S1\ M"7%]/V+$2JEG1/B`W'&V"*#EBC&NIHJ)G,0;,^W6XSO.UB$R$5S6H5WV'\K& MGB;KAT^_*@W0G*/-")>(II@DX[)[T<=CK*(IA[E>[@]?T*37 MVD/,`.%33.A&7N21Z$S-"!\0W=&^"*_%CNYIJI@Z>H#4'C-&'M#3.Q!UM$2T M+D/I!S0+FFHFYTI\A`R:=8C4X;*.IIEDXD)/W\G&@*YYXNEM/O92,\(EHBG_ MKF3T,?0,=Z,Y&8(30C*S4C7"*:\N]*3(9A:/").3&'.C,7QR6B*2>).?]"W+:B#/^[IAU+]$)\ M"QMVFE'%T_J#FT-]&>)<^H5I8,2O7/)GG5"[Z3`M`1HO4>PIBKL"#Z%XW"/$ M3:ZJ:(Y%6IS/K977;V+_+X1?\>51N3?YXHN2Y'@*>Y;]J>AQ?PN[/#K_PC:P MR=GO)Y$1"8O&[4]'_@NV'Z_9L?@M:X[EI;7.Q0'DN2NQ\=?@!B9^Z.IKOTWW M6G>P\=B_/<%&OG?P$``/__`P!02P,$%``&``@` M```A`&>S9OZ&`@``+@<``!D```!X;"]W;W)K&UL ME%7;;N(P%'Q?:?_!\GOC)#2!(D)50.Q6VDJKU5Z>C>,0JW$;2O]_C&%H" M54I?2!SF3.;,'#N3^[VLT)9K(U2=X2@(,>(U4[FHUQG^\WMY,\+(6%KGM%(U MS_`+-_A^^O7+9*?TLRDYMP@8:I/ATMIF3(AA)9?4!*KA-?Q3*"VIA:5>$]-H M3O.V2%8D#L.42"IJ[!G&^AH.512"\85B&\EKZTDTKZ@%_:84C3FR278-G:3Z M>=/<,"4;H%B)2MB7EA0CR<:/ZUIINJJ@[WUT2]F1NUU`:3K)!73@;$>:%QE^B,;S%)/II/7GK^`[2#< M--3-<30&9F?/`$Q^WQ[PQ=4\N**V%-`&(MU.!_%P0K:0`SM@9I>8N(N8OX-X M(R&@[U4D^/9YD:X(FL'H1.2H*V'F,;,6GN3N^$@C,,N8MY%P!B$;^H[VJ#!Z[4Y\+FVL^AF'M/G6Q^BHPUV MT:FVZP;0%7V4KQ#=#2F78W]V3KPN7_GV7K,(=O;,!JEZ5FV?0BOS1]Y M?C,W=,V?J%Z+VJ"*%S!583"$]K0_\/S"JJ;=M"MEX:!J;TOX+G'8T6$`X$(I M>URX(_7U2S?]#P``__\#`%!+`P04``8`"````"$`)$>JFRL$```<#P``&0`` M`'AL+W=OZ56JJI^/!/B)&@!1YAL=O]]9SS`@KD7Z'T)P1P?GSD>>^SME_[G3;L'2-E2D_9>5EI__]U\M3J&NB3LI3DO.2[?0/)O0O^Y]_VCYX]2JN MC-4:,)1BIU_K^K8Q39%>69$(@]]8"5_.O"J2&EZKBREN%4M.LE.1FXYE!6:1 M9*5.#)MJ"0<_G[.4Q3R]%ZRLB:1B>5*#?G'-;J)E*](E=$52O=YO3RDO;D!Q MS/*L_I"DNE:DFZ^7DE?),8>XWVTO25MN^3*B+[*TXH*?:P/H3!(ZCGEMKDU@ MVF]/&42`MFL5.^_T9WL3VX%N[K?2H'\R]A"]_YJX\LU[_R1^_LNQRK6&Z?8@(`]N6:P-<.S)1OV1(J6OI7=2\ M^)=`=D-%)$Y#`L^&Q`F-T/>](%P!RT1/M^D)S[:G9SBA;_L!CC_1TVMZPK/I MZ4\.:5+@TLNX6_,-IBYM,(+A;!.QVH.B&N8P^E'`@32N/] M]76=Q8LZ(N5";+"U?2=1=::C/V&NNT@5'03)I"Z MGUS'MRQE&J)91$R(==^?3Y)!CH#D'XH$^PTC<1U/B80P%(D?>.%X!H8(V&!& M,T"()9$$PTBFLQW!JGQEY1T(`U9V2::D1S2+B%N$FNVPGONV3XM%\-S2),R4 MV%E$W")4L7@PZ&V'TV(1K#JK+DW"-(GA6788!,/4B681,2'&2Q-29;E8!*MB ME4D^$&;*V5E$W")49VTH[LO52O1<(C2@*;WSD+B#C!1CL5F<##:5INF-N@%1 M.L`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`0L;T>&O_KR&"'!*_RG9=Y[K-Y9Z$OV>'\\\6:CIZ&/]DAN)'&%H;] M>S7F?**:5=,8JG":PIH2X]:&'[=\]3PQ<+]Z9!&_%O4B`1T(:=&H'KAM#RD: MUZ(NFM0#MT4:NR!M&E(VJP4K.V33>)U+EA!E+MM/9O64<,*P+;V%115^4\Q(FH(F(6L;0A%!$4.1-$5C M@].F(>N:-<7]_"A)8%<4)0G\J+;864R?"+Z4D@@ZL*(##AUPZ8`G!NXGTIJ. MR50^8((V0^8[?,!$;6:JKD_\@$G:#`EZ^H#)]$:9579Z5F95/YM<*[-)!U9T MP*$#+AWPQ("XC>%G5I\.!'0@K`=N1W(C`%%MZG-17`]H%DIJ4R^4TH'L;D#9 MD>S:W6%'%`X4+A0>%#$4`10A%!$4.1 M0)%"D>F$$@EVZ]HA$EP_]]D)^3K=UG1!(B&,+A)0.%"X4'A0^%`$4(101%#$ M4"1"S*L;S.FH^E#W>@IK9#JA1(+=+G:(!-WE;&%TD MH'"@<*'PH/"A"*`(H8B@B*%(FL*:D9OIM&E(;#*=4$+!>@P=0L$U#05Y^+&% MT84""@<*%PH/"A^*`(H0B@B*&(H$BK0IK!EY4LF:YA8;)12\>=0A%16GL;B5 MKKH8MD2Z7&#B8.)BXF'B8Q)@$F(281)CDF"28I)),A6W*&/U%D5-"&_C/'XQ MX5W$QHF#/+C:$FD3(NIHB(.KN)AXF/B8!)B$F$28Q)@DF*289)*(A+!N/XO( M]1Y6#0AO^'0(B.@/*0\E,]*1L`V!-+._PL3!Q,7$P\3'),`DQ"3"),8DP225 M1,R^,>?GA^OL5V?Y3%M$#0CO'=T'Y+$VGR%:3DI01HUKC4#:H$#BR!^EJ>)B MXF'B8Q)@$F(281)CDD@BKQ(+RQS1^U-<)-,2-2AL`OY*4/AB]*:$=K[X+XT8 MTDSQ"A,'$Q<3#Q,?DP"3$),(DQB3Y$KXK]2,@<'^3.#N@SQ,IE=]ZTN1XSK3 M$C4TO'=V?W;1/^SRWYXWPD)[8A)IPZ)KV55G2`=7<3'Q,/$Q"3`),8DPB3%) M,$DEF52WIV/+-,@=9*:MH>:#-](ZY$/TW92KSIQ<^VQ#UYRK)G^%B8.)BXF' MB8])@$F(281)C$F"22J)S(=AS`B(:<&A!R MVV0;NJZ=#`@D#J[B2B(#PO-!;^0]7,7'),`DQ"3"),8DP23%)-,2-2&\W=8A M(:([IR:$]E8-70M/)D00^8QFS1I3Z^`B+B8>)KXD+D<69.&KRV1+H[5$P<3%Q,/$Q\3`),0DE8YT$^9DP6 MRH?:H8APQ;A1D3PV)KA&BDFF)6I6NG5;S99N*_UC15LB;59$G>NO)Q?66-VW MZJYU9,E[+ZXMU05F1-L$+EX%CY:D/4$?UP@P"3&),(DQ23!),X\& M](]VG08@%ST7_Q`/$Q^3`)-0DMNU:*QK1Q9]+8$OQV]?9B-)5R\ M&IY:=#ZPU+68N-_(#;R/BP:8A)A$F,28))BDF&1:HL:)MFT?^Z40?T.G$2N2 M`%LB;:QP^Q97<3'Q)+G>*9%#P,VNV=&\7 MY,BT)=+&0]01S[,SL^71&A=Q,?$P\3$),`DQB3"),4DP23')M$0-2+?V+7M9 MLWG^(/<9MD3B[W<-<>E0'X!6DF@RY&#B8N)AXF,28!)B$F$28Y)@DF+"W[KE M$]D^`2(AXJU:\1KA(3^_YZM\OR][F^*3OS'+C^WKZ/5MWN]C_J(9&?>,)7O/ MKCENFTN[S:_,)7MII>D=<\G>76F.N^:2O<+"QH?7'\Q>XCVMW_-T?7[?' M/G]CJSP:\-^%A?V^F[UY0=[73MG[[R,!@R_%<6E_H;_ M@.L+X"]_`@``__\#`%!+`P04``8`"````"$`5LXN0YP/``"8>0``&0```'AL M+W=O$%_(A6IZ M:F+C^'[?W>R9!E)1O_`U%0W??+3L6,?*[+EX*]__/W\ M=/9KLS]L=R\WY];%Y/QL\W*WN]^^_+@Y_T\;?)F?GQV.ZY?[]=/N97-S_L_F M/Q^/K]>7EX>YQ\[P^7.Q>-R_DE8?= M_GE])/_<_[@\O.XWZ_NNT?/3I3V93"^?U]N7G]*CMW#P_9NX^_N?CYO M7HXLR7[SM#Z2]3\\;E\/?;;GNU/2/:_W?_U\_7*W>WXE*;YOG[;'?[JDYV?/ M=]?1CY?=?OW]B;SOORUW?=?G[OZAI7_>WNUWA]W#\8*DNV0KJK_GQ>7BDF3Z M]O5^2]X!W>QG^\W#S?F?UG7K6N>7W[YV&^B_V\WOPYN?SPZ/N]^K_?8^W;YL MR-8F^XGN@>^[W5^41ORNZ_( M.Z)O[/K^'W]SN"-;E*2YL*]HIKO=$UD!\N?9\Y:6!MDBZ[]OSFVRX.W]\?'F MW)E>7,TFCD7XV??-X1AL:]()'%X$O(W3V)-+BQW,OU` M#I?G('_S'/:'UX.LI#W=>*;F/+&"]'X$UO"(CNP6P7Z0_\^9A_= M%E:_5ZQABWYF9?IM:@T;U5I\>*O2KU6]8^D._6Q87\ZLK M=SJ?D92GYIGUJT%^Z#?M!U:#]'CL79`?>///;%-2'ET:^\T.GI[\;B[9X=<= MS?[ZN/[V=;_[?4:Z2++'#Z]KVN%:US1U?QRSHTX\=V.2(IEG^I&ENSLD& M(L?L@?1&O[XYBZNOE[](#W+'S9(9\J=%A;_K$D1J(^X!A24EO^BRI&LC40,X";[>ML'AJS.0MG)`3/D?8H*M!>VG'@U8N8+V80C1A:1+IS%7#:Q;NS% M1#:);MR)8M(QH[RK3#JP;>S%T"UTOG>C&G2@F/<%D)YA<-\Y4J>3B!%..&:6[J$XPM6ZT]]Z, M&5?>IZW92-5*!E52M9JKE&JI2M6`IP9\-7"K!@(6&#Y?5FH@5`.1&HC50*(& M4C60J8%<#11]8.CAW8ER^)2]Z3\ZJCY@:%3WIF_4J('V34#:762D*>VNTSH7 MVHIT0F\^JMR)4N=+9LARQ<>9(CPH_%[T[^NV#[R;-(!B!44(101%#$4"10I% M!D4.10%%"44%10U%`T5K$E)5DW,JK:JM&3W7!Y^:M&%WVB^*=JI\+BT9F7:G M$=:$_2=WEQXF/B/DM$DLR%%&3K>,&`Z@`(H5%"$4$10Q%`D4*109%#D4!10E M%!44-10-%*U)2+5.3LX^5^NTH5+KRAACR8AE=\5.+EXI=6Y^V6B@**$HH*BAJ*!HC4)J<;I=7GM.M`I_3EMJ-2X M"SUXP5WC'W0@R] M^\#[AY\6*Y@@A"*"(H8B@2*%(H,BAZ*`HH2B@J*&HH&B-0FIDNG\S@=* MN>-R+9/I,;F/77)DJF9,?$%$/8O(^P7-R5R,]>556^$4(281)C$F"28I)ADF M.28%)B4F%28U)@TFK9'(]4UG(=2!"+X62V(+,A0[S!OP1N0O.A$\ MN9@KZ[9"(!2+'=ZA,J:/,(DQ23!),JH#*'Q!=9AC*'C0+>B/?ICKV8D?_5\0M+8S*A6+BAV.': MQ#A+@DF*289)CDF!28E)A4F-28-):R1RL9,>5RIV\[DFO45*&[AH`W2&C'TY M)#Y?E"ONQ+@5D7/IPB3&),$DQ23#),5CCHQMEDDE39$ZVR33-.W:TT'KU7U5S\OB!#9<-&@6@TO'%GHMSK MLSH%A2-(VW^=Q8!C.^((,16Z:RNH.GD`T&HI<*:+A:N,B3UNC#7>3U\--=Y'WBW@`.==81)B$F$28Y)@DF*289)C4F!28E)A M4F/28-(:B5SC=/;H;8UW7^)8D,$J&+2P62>YV+5S3WUJRK&4+M^S=*0<-+X@ M0[7#1H%H].X!L<(DQ"3"),8DP23%),,DQZ3`I,2DPJ3&I,&D-1*IVNFWE*1J M-Q=YQ^494,=21^8<&7IK#Q-?$%'B(O)N_0:8K#`),8DPB3EA'VQ7(Y=Z$IPD MQ23#),>DP*3$I,*DQJ3!I#42N<+'YD!/NKG6UJ=!9\HMA4MNV$Y>L+VLCEY. M,#XWI!-_,PLE7QF\Y<9P7`68K#`),8DPB3%),$DQR3#),2DP*3&I,*DQ:3!I MC40^`,B01.KBNP'-*72>W]&^,<>1H=X\3'Q!AG$^6[@A;R`:#8>G[PI?+N,G1K7)!WL3RAU-@TI]_3*9,Z2?A///)/D8>(+,I0ZS!N(1H92AUE"G"7"),8DP23% M),,DQZ3`I,2DPJ3&I.&$'0W3[FJ`,I1NC5GD4J=SE&]+'5RU85.:4HE;RM*7 M-ISW]##Q!1E*'.8-1"-#B<,L(V0FU5*&QTN.#,,*#Q-?D*'`\5RJ:&0H<)@EQ%DB3&), M$DQ23#),#$Q)@DF*289)CDF!28E)A4F M-28-)JV1R`5.YR,_4."4RR>J4S&!J296%!W`Z`\&Y&+%]_=(@4F)285)C4F#2:MD4C% M3<\J/U#<'9>+>ZY.FG+#]ICES+0;PSTN#-7O"R)*6T3>W4L!)BM,0DPB3&), M$DQ23#),) M+\A0ZFSAAKR!:/3NT;#"),0DXH2?[;-?NR3WGS'.DF"28I)ADF-28%)B4F%2 M8])@TAJ)7.ID4/V1OIQRN2]WM7L:'88,I>AAX@LRE#C,&XA&AA*'64*<)>*D MG_B]4`9K,4Z18))BDF&28U)@4F)285)CTF#2&HE4Q$%]D&4H=-@I$ M(T.IPRPASA)QPDN=_&HQ[20DQED23%),,DQR3`I,2DPJ3&I,&DQ:(Y%+G4[Y MG7YYQ6$SA.2#?[B=1;MOER-#_7J8^((,)0ZG)P/1:%@_=3X?DQ"3"),8DP23 M%),,DQR3`I,2DXJ3_M*K8P\3,]U'?8US-)BT1B(7.)WP>UO@)_;E;)Y0+G1U M-M^!DXD>)KX@0Z'#O(%H9"ATF"7$62),8DP23%),,DQR3`I.V*>32R^0J;\[ MH<19*BG+E$W$RV?F-<[28-(:B5SJZF3GB:4^-NFIC=#AM*+G0.(+,I0Z;!2( M1H92AUE"G"7"),8DP23%),,DQZ3@A)7Z?#Y:ZG#355(6RQW[;2,U7ID&D]9( MY%JGLX"?Z-;9Y*'D'Y^,W>E?X#2EE.;* M'OM20873U)@TF+1&(A6[^[$IT8Z3Q^1US\5D%Q/UD*>'?#UTJX<"/;320Z$> MBO10K(<2/93JH4P/Y7JHT$.E'JKT4*V'&CW42B%YCXW-\='?Z?/!IQ62!Z.J ME\_49X,LN:&_S%-<@+A23LN\`?7=D:^';O50H(=6>BC40Y$>BO50HH=2/93I MH5P/%7JHU$.5'JKU4*.'Z$-JZ;X@VYEL0K:WV4-GV6,JGS?['QMO\_1T.+O; M_:0/E*4?NR+*'W;K3LC3;KL#4WF%[,;^.;C**^0!N7]VOPI/B7O6M=^MBQ+/ MK>MJ++ZTKY>C>>QK\B`M\IZ4/+?V-7F>%GVOX@7R7-S7]8]-MM[_V+XJ?SM_P```/__`P!02P,$%``&``@````A`"55FX?R`P``-Q```!D```!X M;"]W;W)K&ULE%==;Z,X%'U?:?X#XKV`#8$2)1FU MJKH[TJXT6NW,/!-P$E3`"+M-^^_W^H,`)IGBJ&I">WR/[[DG![SY^EY7SAOI M6$F;K8N\P'5(D].B;(Y;]\=_SW?WKL-XUA1911NR=3$<[_NOORQ.=/NA9T( MX0Y4:-C6/7'>KGV?Y2=29\RC+6G@/P?:U1F'R^[HL[8C62$7U96/@R#VZZQL M7%5AW2VI00^',B=/-'^M2<-5D8Y4&8?]LU/9LKY:G2\I5V?=RVM[E].ZA1+[ MLBKYARSJ.G6^_G9L:)?M*^C['459WM>6%[/R=9EWE-$#]Z"B4HYK6`#\-NI2V$-4"1[E^_GLN"GK1O&WBH)0@1P9T\8?RY%2=?)7QFG M]2\%0KJ4*H)U$7C711!>6L17&Y+]/64\VVTZ>G;`-$#)VDQ8$*VAL&@LNMD8 M="36/(A%68!!/-<9 M,0]UY>X>%28:85;7F:',\0<7NHJ9H6)I2(8!5$21X,LDZ9A=\NI M!=BDC@QJA5G0-`QW.;,`?R:WPBQ@CFV8!7C:,PZ',2JY%68EY0[3-`HNFDRT M3FQX!7C*&V&35V$4;X22.+[.*$_]-7ZO;$%V.0U[:4PVEZ!>%TG3FV(!=@D M'AI20BM,)(5&R!L-8B(T@EQ=WK%$F\S)I2/%K$$+W(6,)/N]W!+]F;,U:`FY M58@AE5#C+)F;6X-ZEX7IC6$CJQ23:%-TT]\:I*E#C`8_3.<-REC,6Z!-:M/B M2(&4Q^,TQ,&0[E-NJQP3]^H9]]"5]EJ?9.*&ACP$SUBCUXT@1U:I)M&F!O>F MYU6N+;&=5;0AE5O@E]$M;)!7BZ!`2\BM\@W-`^Z*YQ6H]_PJ&:29#M\JX="U MB)MY7H%ZST?!<(.=4&.KC)-H<]ZFYS5(>_Y^E:!HF,J4W"KCL'H$&\=,A$W3 M:Y#*]L"['W29,EL%')X'7(13P^8:M,!IV"KB)/JS:->@)>2`61YR6*"G`Y_; M7(-ZF\?)+=&M,DZ<)`SJ^:.+!O4V7P4W8@U;Q9I$3[N.\,SF*M:4S5&(TP1^ M+IZ8NLTJU^#@-V]\YO,^UT2X!UYB?KW5T4\=C=KL2/[)NF/9,*41:$\Y'-CDQQ,7\ACI:7(__N?P```/__`P!0 M2P,$%``&``@````A`+Q34PBF!@``11T``!@```!X;"]W;W)K]]K=JN;HXKGRT"WZN.9;.N MC]N5_\_?GS\DOM?UQ7%=[)MCM?*_5YW_\>GGGQY?F_9+MZNJW@,/QV[E[_K^ M]+!<=N6N.A3=HCE51WBR:=I#TCPW[)@R!:'HKZZ*.'A];% M1[/9U&6EFO+E4!U[=-)6^Z*'\7>[^M2=O1U*%W>'HOWRX?RX;?ML6F+YSWP_L;"HCS['K[,W!_JLFVZ9M,OP-T2!SKGG"[3)7AZ M>ES7P$"'W6NKSZ7?/Z2UNO?Z^/%40;YDG/ MP'/3?-'0W];Z)S!>SJP_#S/P9^NMJTWQLN__:EY_K>KMKH?IEL!($WM8?U=5 M5T)$P>JZ[_7&N7 MOE>^='US^`]!S+A")]PX@4_CA,=O3JX8"F,(GV?#Z.J;0F,`G\9`7GO1$MD. MP5-%7SP]MLVK!QD)?+I3H?.;/8"O<]1PJ&,^].8EMB#I#="(`@9$%Q'O*XO*KP3"[T_I6E*B5B00,@@%70Z$.)"12\H:$=UH:+M"!4R MB`PA2(6GJ>22S%D^18@H#>*$A$,APH4(8.XBHNT($2H&"#&I%4@J%KGUG,4I M"83"Y_!W[(7O-2D&E7`7B\&0T"!RE!F,X9$$`4VL6P!E`$Y,M/C=DU@,57.J M'()4:F8PIDIB(44<4>VP,2$3T'II=AF,$Q\MD!,^UW6#H9R".KU-.1E@9C#0 M_T<,29S\-D2-$"K<3$OC9,!:N6\+WF!EYQ%MI)G!F.@+QEA,`IO;D#!.H/SM M1J<,Q"GV6B-_G`HJZS210B*^&4,,4DE8FE!YSFU$J/.($D$?3D2T3!(B3L*A MMP:D2X54Q@T&N?"`)=%L5J8ZSD,1S63<^'#BHN7R+BZHL]:\$&'(F"76(2Q* M(I(_N041`8M!+>G,N"LZTXIY%QN46HL-B7LV.(?J&]:($4O8C,M4TJ,X%<2# M,AZT[`X"N^4CB1+VLQ@K&*?)1KZN891QH\3'R+R MUSN6/DDA'4O.JAXQU@!IL=R$*/.F<#B7M(ZC+BCY[94BG\LXW=]E!F.2B4\: M#9XKF.=7B*D1,NNS%Q0[ABC<"/=F2);,R$"[Y$6XZ/X!+K5&RK/XIV6Q\[;U]MX'7!0G?N M%J_!\$O?G(8KFN>FA^NKX=\=7%=6<'\3+`"\:9K^_$63&B]`G_X'``#__P,` M4$L#!!0`!@`(````(0!R1++/0P0```\0```8````>&PO=V]R:W-H965T&ULG%==CZM&#'VOU/^`>%]@($"(DEPMT&VO="M553^>"9DD:(&) M&++9_?>U,2"8;#:4?5C"^-CC8WO&>/WMO5KJFJR3M2*>8*Y+J]7)^2D5Q!A.[+,_JC\:HKA7IZONQ%%6R MRX'W.ULD:6>[>;DQ7V1I):0XU`:8,\G16\Z!&9A@:;O>9\``PZY5_+#1G]DJ M9IYN;M=-@/[)^%4.?FOR)*Z_5MG^1U9RB#;D"3.P$^(5H=_WN`3*YHWV2Y.! M/RIMSP_)):__%-??>'8\U9!N%Q@AL=7^(^8RA8B"&<-VT5(JF^GC>YXANM;#@.XMN.R?LG0I*ZE%UF+XE\"L=84&;%;(_!LC=B! ML;!=?]E8^4+3:37AV6DZAL^LP/%A^R\4%ZTB/%M%[S.\272;Z,5)G6S7E;AJ M4))`2)X3+'"V`AM=V&C'/I#WX@@!1"//:*6Q!2&2D/RWK6>MS3?(5]I"PEN( M/49$A/!UK3=B^V-(W$&P$H!`SP("KK)PH(0^3W[G-"I!F@?[>6R\7T@0B$OO MDCM&1`\1<8=0?8:-_[_/J+31P63OD*>$,23(LLG"PK&62B*BD=QCCB*/21X, MMAA`1E&'N*@,F(_'ZT'@44\AX8S#&A+$:T@XMFM9BI?1(T!,@"DTP-]9-%!/ MH;%0:!"$:"S=P%=R%0WECAU8BCPF^102<.IGD4`]A812XB%!J*!LN`^#,D&'7+8;/P ME8()6TQ[+M@O3\I%'#T"Q"U@$A-LA;.84`\=,5%.<`@4L.PH'P%VC-OC,0$3 MMYA)?+!5SN)#/7;$1[GZ0T88XN/:S/(7GG(S1R/,PGWF$E\L&?. MXD/-=L1'*:20#3OV/3Y#S#T^A)G$!]OG@,_7GX,X+4`!PAV M*1XMC3Z08.`9.3#WZYHZZ#"\@RNO=94P>!K[>]%5[JRH\0U(=LU)J.3_`=I:!`U!%`QV]U.+#-@8YE M`/@@1-V]X$=W/\IO_P,``/__`P!02P,$%``&``@````A`*R!AO;P.@``7LD` M`!0```!X;"]S:&%R9613=')I;F=S+GAM;.R=VVXYK==!_$H9&+>8A99XD MO_^W#K5J536ET?8V]HX,)-LC=M4Z?.=S??U//UZ-B[?5;#Z:3KZYM[F^<:^H M)H/I<#2Y^.;>F],7:T_N%?-%.1F6X^FD^N;>;36_]T_/_O-_^GH^7Q2\.YE_ M<^]RL;C^ZLLOYX/+ZJJ5OON3SO;3^\]^WH^>O;UXMGS MZ6!Y54T6!>*V.)RX#3CWUU\NGGW]I1YUCV\7KZ:3Q>6<1X?5,/_U M53E;+[8W>\76QN9._N/>M7[B&Q?-RL?JY M%Z/YH!P7?ZC*6?$"H,];^W0!+6[C7_>[=2_PV\U\S=-9*7(K^K=79]-Q_NN# M5PAHXJ2Y&@CB4\;J\:EW+7BWZ^X<'K_O'EZS^L6&T? M"IMQ^T.HYL?B-]5M_MR#C8V-S8W=S=TVW>PO9S,1:`K`5=!^L+:VN;6VW8*# MO]2+T;B:%?N@Z6(Z:Y^A?U6.]G5=3EI/>F7X]>KZ:3H+Z:# M'WI%_[*<5?/B:+DPIN;U_)+?EN-R,JAX$F:=%P_?])\7][_(GWI>#2(3;><_ M!F#LS>V?C MJG@XJ1;%]+P`+M,;.SO_N+^SW=MXLF'[W-]YU-O@S^'UQ&`6`/<)OJ MZ@R@>K&PW6/]^74U6(S>5N/;UNT/)V\Y+]B)>_-X-7M;:?W[VUN[/2CE%VS7 MVN!X5EV7HV%1_8@LG8,P";[IXI(C#CREE0;<'+:GTP44W$1`_LSQ#`D]0X1J M48'_6F*E5P#&UJ-0(8BQ)^&-(?)]]L.\\]$C.]U=IW+DD&\1SOIR5)Z-QJ/% MJ&I33,3Z=7GK4#Z:#,;+(8"956/.."RN2YB!?PL!3W9[3Q]OV:%!1N_I!O_] MMT(]1YDMV2]BYN&=1]G:[FUN/75'V7GR"\GB`U3XO#JOD#KO3_O%WNOGQ?[1Z]/#U]^A&`X/^OG# M#]Z_>_\N_Z,)T,OI>(BM]*`X@&T6MZW[P+<>)W/)VV*MN+^QOKDAZBP06 M#,LOX!5!?)BMVMWN;&X][.H]W"W6'%&7<>]W8W-GN[ M3Q_I@0\>=F\X1!1,)P@S"<*UT:08E-;5T0F!8G8\&HQ6$U(7` M?#%/GYKQZ^70!Z^?*^%CM#86 M;;4889Y]L4HI]Q>(0I,#1^=8(A-TX0@`'D_G!LL[[-.]J#HQJHNRK61[0>_D M$*M5H5>!+9&1"V])M8;,SI?,1>P'7\BXKE<3=;YTZ\E`LY$I/_8-QZ@?^_2T MYN7\E90M[SAY\[$/'KOS\>XS=SYZQX$CE9E*/<*4*,6I*TW%U-_:SF]_B*]Y MA;$9*7>U#_4:*\_KMQ:-[4_Q1E']*_3?=[/I?%Y'@+X"V"BJ])=5/ M,.[,:)18'J)BQU,SF?++]*OQ&(NZ5UQ4$Z`R-N%1#J]&$_-29$SFKSB!(WL, M("9GR)^K3SGF*JU?S?;"$!$L'X9[?-&ZR.%D4<&FB\(]FB\3?_8KY+_O7Y:3 MBXJ7B_-RY!6:H'[S(?,B^&FBDV(VNKC$I!SCZX^&9KL-RZORHFUK.*/$';73 MY'S-:C7H_/7-J'5F"Y? MLOWJ3:7[28<35>%:Q61IK@5P2A>">5;+A,@.QF+[X-NL9#%[XMR>,/U3 M`X5@Q.CM"J-Z^*?E?"%U,2\64UAG,$5?X$^%R[?(YWEUS5,C8W='VU=R0?]B M?VA#1KQRM@ALE?\.\M;,`1P%HEQ!=;^?H4?7IN?G(K7EI'1[2M4Z#0?7#&#_ M%E.8UEX[*^<\"N3E2'4>U%'U7&2=P,V\*[MD8@VW(!)U6^V.YO>,"C+_(;X; MG!I1;IFY%_E+B<'<:>G+6EZ#R:^XCN=UOWR^DIC!X+\4@)J7CT23OY03V@A' M>&Z"ZPY".U[B<(,&(V:$<(?SF>_3.ES71OE+^>%J^KCC<-J),PVJ:CAWQMLU MAAQBJ?:JYE]>+\_&2`AH$"MO"`_Z4%PZX,E!/^=36>S MZ8U6-ZJ3K@ZQ#"]?\U7PXY-C5S]6L\%H;B$(9^-/KTTOYZ]%V'+MMZ,AR#^[ M37BIAE77BPA9(KGL8@;Y1\9Q##&B;J.W).`C5^",&-YD(MT'>T,:Q"GSC>]\ MGZCHZC?[R^OKL9G$:.,^\>GA$@''1D@?.XRXTQ,PZWB;F;/L119H\WPB]+04 M3H=SPVMZZY1'1[.+Z>'1Z_-U?UVKW_8+XY>%,*9@NR*LP*C$>'_ M:DZP=#)8[Q4EKMJXA``K9.B,B*,3_@_EX?S\T__:=Z''GW_ZWU_T\%UY_*H: MRD>1F30BBBC!2VP2%AL1.AJ-H32%E2$Z=+<6D4X4X9;C`!I`.D(EG1/EGE^. MKL6=P^6`^)0>?\5IP)(G$>KF_OWOORV=>#Z1A/AE>N M2%ILZB^S%R0%W$.GHRO`^+JZ*4ZF5^5$OYZ75SJ=K6&/?VG++IZ]_[\.5AU[ M;6[\+7=2-N6K^36AG&_NH6/4@0GH4Q`X7\[XGQD`GH\N)O;G MQ"0507Y^,!)L1#.+:G`Y`?$7M^O%Z6=,+<:*,F;94"$4:E8O;:Y.FUZ,+&>J(S?D/X&<,[^-Q.VS8FQ+08$WRH!S?*KBX7!!- M_XOTQGQZ?0EF64@+#,;".W$R)\G+,5FFT>+RBE.)*"XY)CJ9E7[^Z7\2\A]- MJN'//_W5Y`Q&D(00"K.6WU$#_-4<;.1\M2A)C.A4LKT%A$`]SK(YJR827(T[ M?'XBRXEUAS-OB.&"F!]LL)Z>_&UI]B)A!,AF3EZ]MB>`%02V_%"(=!F M@=;$M[58XQ"74.2(9B=T>#?%8B18XD9D.:H3^`5,<[XE;=B@5"$UN+9SS_] MG[8=V&V&E$4$MPPA65PCK*9@=?UM+:%G'<*UM?V_T=:]XN9R1'ZXNKH>3V_G MQ262'!,TT+BI5"?'2#HL1FO&-HKUC<;C)9$^;Q_;C]?X&F:'&ADZG5#3_T1% M%C#!K%PCB??%K^,-(X9$S_\>T('T:,GU>-I`#O\V^.B^OI1*MTKLH;O&(T*T MZ"F$ABG%8ES.""_BYULB!.G)A:*XBXJ*Y_EO\VPE,=[TR=4ECD8#*\^<]HK* M%/'Y=P+(LT"@TOA-S8X1IP(L9_/E>KWZ$64^(*IIID/A+9F&$)85[:V#6__< M?)64/9S@0K]U11.4!%%-)9AY8Z!PT3!P<(-I005!45Y+`\$E,3WV9KV_3HD1 M14G:]OELB<^=1,I1)P_Q+U\\WY-O::KE\Q3CQ`;6R*#\0)AJ+P!1D#E^Y2`# M9(D*>%M.;A"E/M4U'J/*6829&AG[4].X1%.+@Z7"<-5D0KI`;OR!05G[1%2M M$P'PR6:6V6HB>#3!BJ`,R;NDHQG<57ORGZVVG3LW'5I78$[TCV5MG)$`9UPN M)RB8_[\=]6?.-PD"`2_2%Y?@U9!G4$!'-F"IY/1B+5)V?[$<4E0E^M[K&TU6 M*IN`O'E8`H`XF9+9I#1<^=*YRAYKP4YXRCR.Q'(MSPG#8F"&%3Y;2Q#]!@3) MVQ%DM=)95?F-/L=PT0W58),I`9"WY6BL>K([M)QD7T.W56^GXUCH42)=NW/# MYH,H\@G8RU0VRHV?84[-*\.B0(;4N&89,4JD6^,6F=TF1Q>5LNKRX)+-;WXL\W%3_ MVKZ#R'2)Q>5H-BS^O*2.D2U>8U!!T>(M2'QB(J%H+F;E%;$E M@B]L:GM9-:!I[]1"8RGM$@0R9L-4&4*N1;[WIM@_.+(+ED,\'/LKE6P^4H\T M_FZZMIAZ.P2QK/`"DO;"9/D`=/GJ!8[T0W7+,8@V+0A`$:/J$84$]OPRI@,` M.]FVX3_2D./-);()$(([L0R7UUFO$?NLS1N$I>2&P30_F"D8`DKKQ1X7!V+N M%;1,.)@"#=`%VB#66CEXID`@*TD]@PL=GTE#5&3\KZ;#"CO5)0\^6TO&&>H2 M;^2EQCZ+;J)L3JWVW/_!8-74]"1Z'8%ZN%HJ##(>RAPB6ZIM5[]_]E_+J M^M?^WPCA/J7P)/_@?7';.9:P%4-1%350!$^I!^_J::FP#$3"<9!IB&!*@S#S MC$"F9PN"T-#4Z.IL.9N[F",9Z_":'87X89`:GS-FP:?Y'H@QVB3(32S*'ZIB M>2WN6-Q,BUM"3FB[(_'>2ER+@RT!<(6\;FH-5`NQ8!83P:Q"R6C8JY$CI3F% M"J1.T6]K$M9D@\M;,-^A$!?/CB;%WO)B.5^\?[>%T]D6VC&V@.*:$NN`P%1R M>PJEO=[K/]_[K6MUD>LJIUGDUHOB'.)Z.YHNY[1X287/JP%:2@F/(/V'Y:TG MVZ`I@[$(#2)-<+:M*B,Z=BKNNUI>$9^F#G^FXQCUSAR=(FWNTU-'`;@$DVJ\ M[2BU]3!68@;.0S^*5_P-]EVIL[]#DV=U'I2^T]U$5I8+\G)*[6W2[<(/G,!5 M4:BLPZ_'V5U4$]3-J@OQ4WT7T4/QHCJ;87K?0`-,V<[H-D=O#WIU2V#@.!HL)@2-`$"CU.Z(P1EA&8W3Z]J=Y?ZHE<' M8]0="7=`>11C.,""%VO&&7'A(4)-]@C7(7(RO3%\DT,QF4@^4+2%S#6%*"JM M;EPPP80BRQ)M9J>W^`VPM5^:(,P"8O;$HY/>5&=!<,J)EGTHH^8P[K\N\^UP M4OQS.1&^Q6`[#50;.,-&U60V'8\MS2/>-_6K-D\KHQ%-8$<2V',TH5/I#,&: MMPHTL]K%%+I1E$YZ=4"!934TZJ/K3S5=SLR\=2\O*/L@A>D=KT"R=6""Q.4%#6M8$&=7U%_):/7F@O#H MT1QN"1-(G*ZI_@@@/FZ1%$`.7-6&,J%;B6C M+]Z_$_@O0.>%J(AS^980DRJ68$#MJCIH#V:DJHG"3/'@<>Q(L7K(7MPB/IT] MH0VI]D^6,*\"*GFTL]5[LOLX]'EP!(A6O86NW$QJ?8+9[?PLMX#!T(E%B<*- M]2<0FS#T<*0K^<(V4RG7ODK0JRM\GZVGC_7_D_T2]C,R3?=W0GZ"R#<5J'(^ MMC1*^)&\ZH(^/F3QYOI.0:'/&-PZL1J/8(EO+A#KZ-)C/]ZI)3@70(R/*%NB M1,*6]:]89YH39JB4DD0Y99B4WBD+@CVN+-:/R%K2=;2@SZEOE6H M,DC&\[*3X!,OI%.65N-K!T/FZV@A!\P=`>^:S M609(?U1=;SX"@N2N\/HHJ35/=.Z`69-M4D<0E)6O^^:8,@+(*\N_X[X<['QI MJ>I87RFHB76EG\D@B*JE2TCI&AS-N0U:Q9N-T)OK&-*[NFBLQFM+M^$((X+V M33G-KC05D9%QU];&5N_QQG9"?"FQR265J2I]SWX0=I-"3/-%9KT([0>N7%,O M;.Y:WU=+:(@^/`:+*?46,+M@=$YG@2D8C\7Y@/"]=D[*`_O6I3^#[O=IWX\% M'D\V=R4KGR,<*&N%%!':(/'[:DC=Y84DIL*M>_W]@B=-VNAG(*@``"0D6':< MR(2_ZQ-"0-M]9;UCZOMM6E=#'H*D"9#7C;P!A<7:C2CGF`3:D:#D'`E]H=9P M1!'*K@/J/<.)!QYC2\Z9^T&R1VMKM.:BE9]W0'"-N$ MY#FJ5JTT&&")BKDRY;&=ZHXWHAPCFHAZ8>9.Y#& M1%$PA$/B5YQ'A0P2F--(NJV'8&U?K[=WV"DC(X*`1;M>'` MZKH!$+Z+`%\O+>ZVT`TF+UJ$?"Z,''TG2M50&>@#^4Y%X]%]& M?+>8,VO8$J3+G/?2A-6-G?Z,_,_2ZJ+,BJ[=B@Y$@S[G]V9(W'4-MRWI=`KR MH$#?M"EMHL;[V&12CE&1G@]4#67=Y[@M2$E`51?-7:MQ7XB)$9.SZ?0'1Y\H MG:G$,T<3IO9#:311C524S"A1#R]<+,>F`.)+_5HCBH,/?AQ8#%.+!9-5XKQ_ ML&^B7)AS=JO`#%V\8"@+'@[S11P#ID586A"7VHK+9)POD:'\@4BM:A'CG;DO M,M0Y*UYV-Z$38<"3]+-PY]IE]IUQJFT<#)2GA@.<%M$!4:BT(+%T+#A[@SG) M,^@VR@Y-4WVWMW=L=ZN!7F-+1L*52@YPQA.PSI?P42=<`Q1@XM%54$7-Z\P= MZT!\1*@MPR8,Y=N<\NNQ:O_,6 MS3/SYM#/Y6D(<]O!?+]5$(5!:EZ3,>>@#[GAY"H7,8[FW"I@!`F0ZRV"C MH"+E'6M!RG+5[0A5QR8-?YBY#G@'Y=04&B$G0M#UI5T\;YEJ0S:@T<4#5)#! M>"T4OC1S@+3WU]FPH]-$E"B*(F"X\/H0@@VKJIG12Y6)/$A9&-8`HZY!)ZQ\ M\QM@\,9!K/!T\#7:Y&1YAUU?I#*A MYGA7)H>#W"0U52-:=6WZEOQM3UM&[9=(R&;*,I+;B$X@(F.@[F8ZLW1#0)W` M+["WC^`I$>WC7FX=VCF.;G*,Y=H_&8=[D#T,(Q'42S-246"$6"?J&AWHM]NR8K(##,T4#N6 ML=,9HQB$@<<,+2&SG5[/8K83:`KA*W<3N49`P!6%LR(24]D"W//:3@L(OR$" M(\$]<552W@K4%9?7`Q0X@#%;D+==W%J"WG(9>@8)8W$598D6MST;8;2X7M6WZ]ED%=#FECBC98$Q+H(+@B/[I M*Q!B-U8Y?"LC)XJ+1>Q$,A*.=?.+&97W^7%G!)*E^6X<%3<`;["B#@%^"A(V9-4=,*5_I%^1BEI69$F4UPOF(!.\ M@1+V=CE7;[2%OE2]_=FFVYQP1"C&PF"3CL!V@-LCXK8^BB4$;H(TB/"-_!` M<'H=@:6H1]]@#8-\CZBH36N&=DL0Y\/;L`$&I9W"]!M@(.,&W@48$1-Z`)'1"5-O0JP(.GI5Y)=V;F@<6]84]8B&@0>MS@+!R#8@HSQV'>'',/UC5L9 M2!(U87(N1#]B>/7-!*]("T6M;4U^/F+BW"I6N=:OT#M3@?]$\/7^V=MD=Z MG0(WD(K^,S4G85=;&PW/7O)0&D85ID86W?YIAR/K2;+ILGI![3#GRQ0@$7=; M)_OI]+]RK?J2WFDQC)5*F&2'KJY),@)Y%YXR(T"F`<0E@DV&5-B_!?3@PG-7 MAP#.#.>O>,G1I/)M01-T`DB;B0B[SA,I3@_%4KE$N[N7)-)4L+IY-(Z9S^@"-\@S^X`YRH9W?_Q$# M)IO)P5\\$$)%F MR;1U]+]JE99$.<%Y9^N].JIT/)LZZ]APGDN8Y,%]BZ41K0<\!TSCF*&L";,C MSN3LKI8_VQ20'NPS6J'8V]\_>F.3!9FV*5(N=D&#^+;,S@G7HT69%G=QAO6#D M!"($LR#1(X:5D+:%Z)6GAR]X`CK5/G%QAC`I!2=2C"$7>,L`H(OEK' M+ET2I85`C>30<-6.Z9/AI]OB>91O=^!E!]/_]>_`R]%):\JC>;-A/248749E M`<4A+-48+R!\KM:M4RJN<`NDC1A>**/(!G&XWR`^[!'#$J0BBQ*J,$6*BG*Z MQ)51F_81-,DAN)(L=710@Q&`#XLG:VF9.BM+\%>-Z=;)9Q43,K$DW[VNC09* MT%F?+<(:(=AHEH$K:1`;32S015]]Y)F,R(H#<4`A7HN<8+35&9F-"P';8MX2 M&&YX1%?=GN>F&(ONJ-MSB0H7Z`F1LW\46]]JN(O3D$44FSMZM`A?<)I[9+K MPW9JQ7)[)J_UN`-MPZ1G_3#\07;D-?Q<5\;LULG-SUOPFJX/_^O!\V*OWS\X[>>KGD*0(0CM+$%&V2@D.L9-0&0XUU&*1/'XT==`N!6MC'Z>CVF/3)/_0X M71%`-Z0L:P02DE/\VV'\^4(L?)WNNWC6;9H:43.(Z:/I0LP**4>@S4J[W=PW M+\E66R`A,M4:R/G&QC6]?_=R=-Z::/U2%U.X73I"O0&=41=[ZOV[4U(2N1)Z M22*5**V^KJ(K"+Q6!Q?ODK^PO;;KRJOS'XZ4B<#$6LZH(D*$VGJKE^E>!,V? M?%\`;'_L`.2'CWH;3Y_TGN[LYN=ZN-O;V=CN[;0_(_0:(?Y2/H0HTL?(7 M?;4-Y4L'G4[Q?'!R>%/H;!<-#^]WLG!_G" M&DHZ,&4B1615[R&/8NU+*#7WX167:>%\,@>NJ74@$N7#?\S05E@Q*<`P!21E M?46;,F1/G'NH6G-YF+9/N2!K`"D$CQF%SRDW7)3KO)YVFX)()"M[7\DWW:(QWW_6FG MP12`=K$Q.(D$!M'@.S%%=0S$KS*G>"0+SG9@QUB#85;Q@L)I5;HI)=K+P[VE?/!%[88'P$"Y./>%+D6*BV8PS9_-LVR\7P6X!@ M>V5+:6`0NB87N/+"U-$%H9XAH:JP3HDM-Y"%F+&\'"X<[#Y@SX\T__H\OS:ZSN+Y:_VGBF=+T(]XSG(M3C0T3]98T*6XB*[F"V>& M^>)97VRPYD+X0L"J@?9);/SHW/RY\&1Q@I\K^;N/)3!W>@,QPA^.RUO3TW<@ M[`FVS.G1_F_6&"B-!RGD@;F.:=+^I)Z>$A-'A\:KL82#,9E-J$6%N+[BVC@* M;1^6?XT-3M9NXPTIA8D5JG0Y<0HNA`&85"V_\%WM`/E]W`-I=M/VH/O09U[# MEK5!IM9C0SF?J]PMY&>#2[:M,[_J)_0I2>G`>JQ.^*-?6\07QHRKX@JEDM!B M?89Z;P<0DBQT*H4Z=JY'N,[[LCA]UE%6^Z;A;NY>.2.=`I[:YQ.%.O%N)W28 MBEW%4C314?19G,;JR32E;_GTV`]K=!7'$.5_"X8HG^)+>SK>A$=>"UXT^!$)+NY(1RXQT%7 MC.K8JVJ+V=GR=8.NP&27O`8NE&LZHU)ABY4A%:P-W6(O9H3O*,>%M M[4%/OC[TUE(W;Z[A?4`L$U<<_D)!2P/ZP[C:6R@P7[T@@' M!(C5?,H!+4V-#4MC^`H]UZ;;^@Q09B M*44YP'92P,_N%M4?2PF+`5:2JD8V/X)S???#=:/69H1U%DZH\SRW.'(;67?MC MIRAI`,]S8RAXX_QX9[+T?-&=[F@-TO)FFC!PT$Q7-FT?D.VH0G2G)0*BO=*I M0)RVA(H.^K@))ZL&6?%QD'D8&)`PD+2!-4A%*GQ]H-A.;4"?5S!]`!3J"KDVO`*B:[@%$*E?)RW= M6TY(@5%N8'&%JH6L)C\E5+S8[UK0UUK+]0BN)W9LN_ M MO4@-UZTYV+F;X>\U&*`8H?S<6P3\@RG\L8<@E@4J^%I#%6E/(8(5R1+`H5>N;;[]R@1JG]\`"O2=:QV+_#%W:?"3>UG\\ MJ>56KZB=`1W\\>-?@5K<.#U+`1NDY:PB'U&FN:2A7CNVV0W;/#*>QEJU*84M MIT+;T?E)+%K_Q2`4#-DW,?J?0L0@@73!WOV53Z4*:0* M=?],I#[>>FPVJ-&6S)"H&E_*Y/3UC"(A03N:W")0:]!LFLNA`"U%J*"GM9QT M;)XGF%*RNLUJRVRV];(]AV6EYG:T$NP!#AX& MI]1<%L@B(%('3=**BG3!XPW[5:'TQ6V+/2$*05=^YXS1(93?'Q#$$]*P*4/Z/:6#[*6-X MAN)%>R6/8Z0.4_C2>OX,H0`7C?S^Z.7S@Q-FA?^U./CMF\/3/^1/'L?<@*V; M_RQA%X!'X"MQ!H"@LPQ;GVD7T`%NFG+PK2(:;53+3O_M]QC8M7"FS2)P'V^S M(!D&8'??$02B`I@SU5U*%CA7RSXO[A66*:YFP,4L3%YC=A7L>AU50F%A/HXA^NT4>9%3V#/LF M/#F*GS=7YWZQ#P'0E_6W''Q6H\;A133-%186$(_Z[OZF64S1 MT[%\>4PT(<6GQ;^+46@H8*PT;P+)>E-2`3UFMN'XBC6&]=)15[*X*%0G*(TEKIU9],*PR]P/2 M[V`C[1X:)E7:%I8#$#@]B/;P,:Y$@;";Q>SU"2]4`\")CB?E^6!?PM:IN.0M M]F?1%`]03=.DWS$OID[<"@6\DW@L*X1!$X9*P+EA-$B1Y`1QI$.\Z$<[&SLM MN86\$-E_JBA_:OZ0U]:2W^60S"0<)UUX.^P!%+5I0_TOU=%E06SI/%@^T&^H>;-@0IA'9 MGV^+W_N_FIO*/:-.<).8=GK;.X2B=M*)CE8;F8HRT51B:W=MM/>AC1YI3&5O MDVQ`C>1\(\D7+\'F?SV(89\#1?YY8?*,!N6ZHEKB_.0+PR6Y-(B:I M7%Q,S).\2/+F%(#[G6N@M79.)TR:@$!IF(18Q/A8RLBSJYB)1S>(K![>G'BQN9B)-3R:TP)JY-`[0O; MH9&[/DX=:"IZW$;E)H/4T9J[*^5@C.R0M%R$OR%"Q7S;Y]">E@F0PQ8 M60NB4_JLR[A>B4)=-59?6.2@+K]PK%&?(5%,GC"]B$F4_,?K)U6`S0DR;;OP M1L;6I8BTG&#W=O4"Q/G4.JK:?+AHBGM-,(^\ZP4(5;YAA52](J7 M+_?%;F.D@//YM';VM7HQX*/US??O_-S;1"@F)^F0_(F`\Q9!7%EQ-4:H1RO9 M%6*8-QP.+_="@5Y0R(D'R'B\*372.HQD,U']!@$L%L33Z=3Z%"0(/T;=CXWB M8O/W'Z\_C5T)%+;T;S!KQ6'04RT]<>3([J6MZ3`H@U+HMZ/IH#ZFI M\M:IAD:J&\I,+?`NI_?Q^G9RU%..UB&R$X)Q,C9\.*8>5G[(^.XEC;A0$S25 M()&(;=/,`'K`/PP?O9N,0`$-U\PY_+C$J__6#3!3L+YAS:U6@<2AHD`[ MCWN[&YN]W:>6Z-C=ZFUN/.[M/-IM648OZD0:)/`B3ATXY#--,V9%(:/SJR6O M/$>.4Z*]Q*B[HSB0P>K%B[W#D^)W>R_?V"B6%X>O]U[O'^Z]I`>_?WKRIG,, M@NWCS`*";R%+*!D`L(B&#U2Y@AZ*10HQUVT@D+PR18E:M(XQB-<\%:D332=' M=&-!U'DXI`#R2NXV691&9"%8)3[I1K#(C08S!>:LJ31AZGSMWZO%+$3G3`.+ M..MLGC&3^T"GZMKMC$X?AB/A."'Z"#ZHZ)E3A8MK#"JQ#^YCTU%LO-B"KT5H MK)<_(G=Q)1;MJXH",OP28ER-*:O$]P)ME#?79>K(SG,*RS)8T!"8.2SI^\BZ'=3*C M7;;M,N.;7Q5'K<1UN.>?EU:N:/1H7HE-.`KUIG/_Y>9:/[LEM[YBQ(&.A@L$ M.0NUT-X'UI*8D-V%7Y0DTBNR`RS@YM9#N)"%.BEA!N95))\ISH^P_14IQF0= M#ZI(.5H5`-+DR8%D$+"N3+,>RSE?Y*X["R`J5T40C3%' M9C!02-+D5CV,Y@S/Z#&9V#%OP?9)EC?^R7=(=:>XE#A=36!\,& M!L\PB:2C_4#7CK3YW<<57FHSU&42?85M8%#+%$M8>I))#V$40HN-.D;D*D&S M0(>ZWH'=66./@GK55+20S0C&>M#!3F_=<5*HT7E@@J?I5Y?U@>5N9$[ROPDU MF&E4Y^!E&&B$F-A5]K4UWBJ+R@_=M;G"C2HG^8`*67LP)P'J(F1,M]"$9H?F M.TYL]=?0O8C9"D(A"3]\=W693)AZ4;/8'G)0?2%614ET0LS`_0ERIZ.6+)[H M`R+B%&U:0\HE@Z?C*9]2%.33?'U7@M^$7'!/4R;J(/>:+%03=8&X5"K;)QK# M19').E%-R7QI,8A9,,?/KSI:=AK#!IQ3"['>(63K1?C*#U\-)ONWS.P65LP;ZB`#_'E_.\';EAK*JK0)J+^ MP']OB[N%YV_SG=-9$:M7JN45KC>&F!]PY,<8Z>\HUYMO:#UO?/' M?IW8/E"/4?''5]457V3\E\XM-GP&*O^Q02`?+W56;B:1.R?IVMX'J-HG8FKZ MJI,02*W2BI`)FKRDQX&."@"H/4OV8QR/YKY&J@3(@(@_^LOW M0%`+U/SH:'ZX!P3G]7+^]UA'6Q1%'-9"0B0V!E!CY#XEBP))8QF!70-\? M*-_C@?_(9VOSA(P)!<=M\O=KF(3\,0EOY`S&?:/B2O9RT/7Y&K5*`74$$H&N M:GA0#]R`H\<0(\$,"W?_*Q9P:]=?.LR7"D+*59/9"<+%&D?)WT-%NV(>"W6I M%"V@?]6MLYWRXN5\@U6/6W)C@>N:O_!@Q9R-H)/!$XB5Z,=[TW?/6@ML6M=J M_F?/L@Y5`39X>=VHN?-I%S3,-VB",L5_K%%H:2OWP17+0E"*1.A-L891Z[&3 M].M=H9(O)ERH\QO,1B8(\C,]>&/%R[+O!6LCA MERA,Y5OY3,,S^F0@!W^I9X,`"-"B?*+;="?@L_W['_+!/@B\3O1U@+$>Q'28 M#&):":>#V/+_QJ8[8;FVASL]L$6+TP[E<,=;V40GG#4WT2D!X`I+[\&'9CN] M:,QV^I@%NZ<\!<,H4%KQWXM//W7'8GX4U2\][BL_\N%O59OC9^SR]XL`1#;*I4M?]IX?T"%%&F>C[-6?+U*[:?KCII/W/;%(]^BF1^PCH3'?C,;GK%6>)GT"UYP MTB)_P::4?+(:I8?\%?7XJV(2M"<1=?!#-_*=":7RHZ^)RG_TC$$2-WXS>Q4/ MY=(Y7RJ7N?GOWX<9&W=/2EG)BP;!NO;B3N/AI;H?5QB/&#_-62G"='[8F*&H MZ5OM7?EC#^+DE/P72W74+T>RXE#*+>2//WC1G*B2_XYC[M^42]]U%-D6ZCF[ MXTUDMJ:7Y$]$X2A?V;GZP9EL.-H?\HN]1%")AZ4K;UQ9>SK.;L76YN*;EZZ7 M\X>,^Y7[4]U?"%TD_=+Y\X=,K62D8CT[.+XK/[$+=OMU&N.\KD*I-VLYY$XS M*YW<3L34>;#\8!E1Y3^',$'!2`+'[%M/.Z-1#W:\.$.L^B1G=_`P5%99JOO:)VS\BJK1(8^A@Q90ZGJI)2`1&XO].2S,*= ME$4IL&8R@((-RH'FLF1S(">&82("FHT`^3O>!)U;J-0)S_R19@0M#49BI,5H MJKG%7ERVN#!B)FVOZ9*3R8.4;#(IMD.6XKB`>\#I>UVZGDG6<>*A%;P[7F(N M#)#&?C'8KG$=@_#<=WF;*`C5[;&F.@=4$`&Q5-XO;3)V-=K,J2=XF89\0^U[ M>J1\.QG7O_RM?E87OD#G4A8:AZ:T=DG2%`FV@YZ]Y&NC?!N6;%>/5)S':8!Q_?%DK[PU:<=QB#=BVTW\HJ M@FRQ?>1?<8(%K%;8M7T7QP;BL?-GOM#=8-]?Q"JQ=Q;=82(NQ6"[GVHJD5JZ MK/3^\:%BN0EE/03"9(>+:UD,478(9GE0NR35"%RGR3-(V/!,;,K.AM?1;5B? M:"P39OM;CFRB<*"'YE15'EXJ$SHAV!+)FQ1TBR-RSWE2EBNFVD%9I]-.G2Y0 M)U_1,[EV>F*.J%WE`OUH51$'^H%W)47:LR1@LXO>X:'>HJE`[-1@9R9T0D9R MPG!4>4552Z!Q,"D-+;>SR/^/2;$S-;TP-9R2IZ"V=E$N/DDN!;N*_*E6XM21 MON32>]+N@49<`&&+UZ%,.CN=%O`)\GOE:#IS6I;W[0L``/__`P!02P,$%``& M``@````A`)"[8+GX"P``L&L```T```!X;"]S='EL97,N>&ULU%UMC^+($?X> M*?_!\B;1G909P)@!YH8Y+JJZO;;?OF^Q??T[XX4>R&P43O779US0D6X=(-'B?Z M7Q^LBY&NQ8D=+&TO#)R)_NK$^O>WO_W-39R\>L[G)\=)-!`1Q!/]*4G6UYU. MO'AR?#N^#-=.`-^LPLBW$_@8/7;B=>38RQ@;^5['Z':O.K[M!GHJX=I?B`CQ M[>AYL[Y8A/[:3MRYZ[G)*Y.E:_[B^L-C$$;VW`.H+SW37N2RV8<=\;Z[B,(X M7"67(*X3KE;NPME%.>Z,.R#I]B;8^):?Q-HBW`3)1#>*0UKZS8?E1+_2M=3D M6;@$$'_XSR9,OOM=^N?=']^]Z_[KV^_^\9.S_.?/W^Q^]_.W>B=70V2"#^IE M7G9KQ<+7J>1.9L'MS2H,2D/ZX'5&T/5S$'X-+/P.@@',PY_=WL2_:%]L#X[T M$-XB],)(2\#+8!\[$MB^D_YB9GON/'+Q9RO;=[W7]+"!!UA@9+_S77`3'NRD M&LZK9XYHMTNTDH==B)EXUD7])U-V=7@;);UK;XUE&H9 M%XN[?D.%?4LFE0T*K??#N[/1*5]9E759&CY7#\`.)Y=%%[IN3?\>6O@Z1YR< M>4"3ZC$HX)+WGOL8I,-MO%E#1;>(W'6"S.VC]Z36,MNXH86?%S\(#TGBR'6F6/HY:[G%?.G MOHDS##AR>P-3N<2)`@L^:-G[A]NBDOVOX]6-DO_8,UH7%&L2A MYRX1Q>.,S6JRJG)V=6_-[IE>@DP41850RYH-3R#T?CJ>R4$D6 M^GZ`+\E"+?AO)HW3;*0U98$LY&F)BZL0W#P>]:Y&H]'8[/=,DY$\SR+: M#9;.BX,+$])HVD4P``3C_FA\90"0KCEBJLZ*H`\`AH/!:-`;&R;\S]+PZ1'( MYG2@J_8J0:#(JP2!(J^R2JTC(?-G/076!!7W58)`D5<)`D5>'4K.P$/E7B4( M%'F5(%#D55;)2^RKL-:NN*\2!(J\2A`H\JJTXC/+P&/E7B4(%'F5(#BW5_-I MU>S^WF*+>;N5675]S&9R,'>5P"PQ9@D<%KO]F;IVH]A8'OPMI.WR/_6M(03GW".[0'!A7Z21*DFK?6;H;?]>Z0O?>6`$:D=MFPPF'0:$D"X=R M;;>#7LC<)]B"N9IY6K`!Q$0>$H(M9-A8GN<0M9&T$+.1-!"TD;00M1&ZSK[. ME3.Y##=PSGW;P98UZG;93*QUO.P72(#OB9C&-KM\-C;9PVAC&U%.<_(@O^ST MC:F!+U:Q[K&TH<6NG0T-]EC9T$+41CYN]EI<+"=@>MZ#9(MO[N>'P0!%:<,< MSU82S/(3GNI*3W8)A^]^E.J'X!+6+S,><'M9 M%M3@`AK4=7AD(H`I?XX`G*`"`6Z'RSB`\%2!`*92.0((T!(!P*F)BF/Z08]D M,XB!4B7H/Y5*R#&YE9S*$UI9E7Y!?XV5%I=^CZ*9Y%L(]))F^%`#X"B552E6 M58HA;H>>5E(`'VHHLE3/D]:IROC)"2-(%#"4CD`;J&)$7E23G@LX20#TC M4XEU"`D*3$6J(0`<)1"((V`CC'H,BD9@&@V*AF`*@1N#S]@G:#1P(Z0B#(!' M2:\HZX0>-V*D)5BJ085.5( MX@I5*9)``$:49$CJ"54IDF)0E2-+5^`U9TI<02"HRI#$$_T3I\@.739-%U') M^BGL":Q>"@4'Y=/_;5^]K!H74GM5DR:0E3=/9T_IS!%\P>929"J-%R#:>%4# MKIUJ3V'D_@*33+P0<0$'G$C'"U<3=T&/?(WL]8/S`E/1]+S3R^HH`QLPE?IA M<5W7VBB7SL\16`0\W4!$H^5L4M^X,+\5&?SB=F.$-(+`Q1W5&)#K#(/T$)#4 M1;#GOB6:8,!L2D2M,DECG!`?G:%K2-76-@L@MV_(USAQ4N;K'E1%[937G$AL M+^S8%$OB2+IRFEEP/P(=>ML/?:UY;J"F;=`3I@RRX`^'N8KTZ#+E:*9^9=VA MP4UM\BXN';3KBS*5UYR!."@H6EE^CL)9"B`\$5!'QS0[_]!8N-'LDI?V;1#2 M=-??7O"I0VBQ4S2M\#7V:0VON,)S8 MP"S;M=9R$D5&DH,0@[%QW4!^'`0.<=Z MBP(Z13(]8FY)H4GGZH`AF.(Y!574E2D\**\Z=2OP%-&)&&H#X=2DB%=][/9Y MN]1A%L]K&G'NI)5];S5A-/G8./L*,ERD@A#0D$6UVX52];_>/@:U2"=MX!%N- MR(6;_&6;Q<8D#>\+"G=3[_Y>N]#>+Y#[8E4.PW&^<3VX)0ON.,)-8XM-#'<> MF*8'LU7V.EG%0A&>ZJ.RH$1K*ZM8HL!U*2H+TE5;6:`^'1+[8"V1!=>TMI8% M(V4F"]Y163"*M<4%33)9//<#0>[-?7YD&Z*)'\%D$5Q45NE'8([8"'=L;2VK M]",XCLH"D]OB*OT("(DL$Y2TE57Z$;Q`94&XM955^-'$OEYR/Q#D_FJO'_E8 MQ=V+(KBHK-*/?*SV!6.5RBK]R,@KD$8M,^$+!F"X4@OC_@,"HBZ/YE[=F!G831JX8[<@MQO-,' M@N+^%(8%1[P$G'2*`/H!GCT#C[71@)>4(3Z&<3=F&S%%7^#IZ0EZ+$<#K5,T M?/SAA51MT$#K5`R?5+%^$A'S(5AO"@_QN12';A$1']W@V5GRD<,SC"=61"1] M6<3'J M3D<79M\97(P'T[N+@3F;WMU9XZ[1G?T/*,-'65W#LY".>%04>Z057'70,Z]C M#QXH%67&9N`_E\:9F66%.B0-))?1O:XX`! MP[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7U MVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]= MQ9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK5 M9B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<) M=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[ MQR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF M9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F M8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8 M=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM M`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SV MN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5 M!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;U MKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C< MAT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\ M:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D M1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K. M.YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4 MALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q M/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY M2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-= M`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV M#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO M-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY( M%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4: M.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965T'3!@%6-D.TW[[W@A+>%:H479W3W[\>KC)*C&5=R5K5\9R^<$-O-A\_K/=*/YJ&6<=B>8MLZ#?-*(W1S997$(GF7[<]5>%DCU0;$4K[,M`2HDL M5E_K3FFV;<'W3+Z):=3^LQ;E-]%Q*#8L$R[`5JE'A'XM<0J"_5?1 M#\,"_-"DY!7;M?:GVG_AHFXLK'8"AM#7JGRYYZ:`@@*-%R;(5*@6!,"32($[ M`PK"GH?W7I2VR6F4>LER$04`)UMN[(-`2DJ*G;%*_G6@X$#E2,(#";P/)$'B MQ6&RS"Y@\9VBP>`]LVRSUFI/8--`3M,SW(+!"IC1V1(T.1VCUW-6P2.2W"(+ M!%("X0:6YVD31_':?X*:%@?,GQRE,P4.9T7L$Y_)] M!1ATJB!,Y]X=)AT4)$D69^F9ZL-NO=P[@N>9Y]X=QF6^"J+SWO%6F)RY]STC M^#1S'&6SJCN,JWH6IV]X=JW-G7S)=U?P[T[7H#&EY!:$+#]N%=CW1#:SJA[ZR519ZV?#9P-7%X70N/`!72MGC M`+ON>!EN_@$``/__`P!02P,$%``&``@````A`/L6[E>``P``NPL``!D```!X M;"]W;W)K&ULE)9=;YLP%(;O)^T_(.[+EX%\*&1J MTG6;M$G3M(]K!TQB%3"RG:;]]SO&"<&0,M:+-(37+X_?8YNS^O!2%M8SX8*R M*K%]Q[,M4J4LH]4^L7_]?+R;VY:0N,IPP2J2V*]$V!_6[]^M3HP_B0,AT@*' M2B3V0,EEG#)]ZZH.<%9,Z@LW,#S8K?$M+*UPY)/ M\6!Y3E/RP-)C22JI33@IL`1^<:"UN+B5Z12[$O.G8WV7LK(&BQTMJ'QM3&VK M3)=?]A7C>%?`O%_\$*<7[^9B8%_2E#/!N`L7G-:KC,(,5.P6 M)WEBW_O+K8]L=[UJ`OI-R4ETOEOBP$Z?.,V^THI`VE`G58$=8T]*^B53/\%@ M=S#ZL:G`=VYE),?'0OY@I\^$[@\2RAW!C-3$EMGK`Q$I)`HV3A`IIY05``"? M5DG5TH!$\$OS_T0S>4AL%#O1S$,^R*T=$?*1*DO;2H]"LO*/%OEG*VT2G$T0 MT.O[`7+"()K-)[BXFJB9X`.6>+WB[&3!JH%GBAJK->@OP5G-#$$^FJ.=ZUM3 MA3DJDWOEDM@SVX+A`NKSO`Z1MW*?(=/TK-EH#7RV&M]4;(<*%%\U+A"WV!!& M%_MV(2YT2JSH5&$4[D;_T$4)>B@W%+-68I!`:%T2%6#XYM*X$*E!$'0GBQ!= M9ZHAM2;L:**6H%%LQQ0&(YAT&?$_?CZ]\.6 MW.""G*9S*;')%:+>F'7V-?O@^Y)A.+8 M?/CF+.H27A^N]\JHQ.13QWZ';UJ9X1C\=YW/HE%.[7-;8G*JD[_#.;Y5H#/J M[Y4;E1Z^3-!\88:M>BSE-$:H>RC=8I2$[\F6%(6P4G94_9$/!W/[:]N[W0=- M]]7>@-:IQGOR#?,]K815D!R&>LX,#FNNFR]](5G=-#`[)J%I:KX>H$DF$KW M'!#GC,G+A6KOVK9[_1<``/__`P!02P,$%``&``@````A`$T4OD*0`P``60P` M`!@```!X;"]W;W)KWGD\]IC)^MM; M602O7&DAJX30240"7F4R%]4A(7_]^?SE*PFT857."EGQA+QS3;YM?OQA?9;J M11\Y-P$X5#HA1V/J51CJ[,A+IB>RYA4\V4M5,@.7ZA#J6G&6-R^511A'T2(L MF:B(=5BI,1YROQ<9?Y+9J>25L2:*%\P`OSZ*6E_<"1H!I#Q3?)^21KE(Z(^%FW23H;\'/NG<>Z*,\_Z1$_HNH.&0;YLFPW1^\ MX)GA.'HX%(T%FT^'^0T`ZJR=<3,VRS5O(=U$Z_`5=N":UBUE/,747ZD<(A!),^X<=D M*$X(C+Z;D84;=VL5?;*EJTB'BBN[0P8%,9X,Q2[95S?NUBKZ9`^N(ATJ[I`M M/D.&8I>,^@O=2N9-$=62WM#/3$4KME][<0ZBWW;:OI\\5>R:0W M-/?X<+,>SV>W]CY?[%<%M1J'SR^+&YI[?+A5C^>S&[O#YU<&'6[^L5\:-S3W M^&"/0DV@&BS:+;&>4RCY6QQU=@ZL8V;;41* MK@X\Y46A@TR>L!&C\&IWM^LLVY:O>P`]6LT._%>F#J+20<'W\&HT6<(G0=DN MSUX863=MSDX:Z,Z:TR.T\!S:AF@"XKV4YG*!34GWIV#S'P```/__`P!02P,$ M%``&``@````A`/G0&V*'`@``'@<``!D```!X;"]W;W)K&ULE)5+;^(P%(7W(\U_L+QOG(0F/$2H"HB92E-I-)K'VC@.L1K'D6T> M_?=S'0,E4%&Z(7'X?'+NN;8S?MC)"FVX-D+5&8Z"$"->,Y6+>I7A/[\7=P., MC*5U3BM5\PR_#"WDIF%9& M%38`.>*-7M8$$,"2I-Q+J`"%SO2O,CP8S2:I9A,QFT^?P7?FI-[9$JU_:9% M_D/4',*&-KD&+)5Z<>A3[A[!9'(Q>]$VX*=&.2_HNK*_U/8[%ZO20K<3*,C5 M-MR*W989[:9#TPUX$.%IR8Q?" M26+$UL8J^<]#T5[*B\1[$;CN1:+XTR*]O0A-H!,HNGAZ$_'X\D(N;\^@FM5.!-M#2S:07#<=D`WU@>V9Z MR<1=8O8.T3\B!/P=34)NIR:OFW,P%('1F[DX/.JV!4P](,7 MW>[-P1D&[1-O4??-4\\,VEB38;\7GKN?=0EH?_CFON,-"KS=FX//O9VU;.J9 M:[E=(SK>8/?<[LW!'_74,]>\72,ZWM+/>'/P>6[G/?7,OJ?W831(TV[7X0AT M*N\3WIL_XOSF;>B*/U.]$K5!%2]@-85!'\K3_H#S`ZN:=I,NE86#J;TMX3O$ M80>'`<"%4O8P<$?H\&ULK%I9C^)&$'Z/E/^` M>%_`)X<&5H//2(D419ODV0.>P1K`R/;L[/[[5+O/ZO("&6T>PL[75=7UU=%= MQCQ\_G8ZCKZ635O5Y_78F?/K+P_O=?/:'LJR&X&%<[L>'[KNLII.V]VA/!7MI+Z49UAYKIM3T<&? MS^53L>I.YN%TU-1GO9W*<\>--.6QZ,#_ M]E!=6FGMM+O'W*EH7M\NGW;UZ0(FGJICU7WOC8Y'I]WJMY=SW11/1^#]S?&+ MG;3=_T',GZI=4[?U-=7^]^I<0K0A3RP#3W7]RD1_VS,(E*=$.^TS\&BK;+JV8R?%H]]9V]>E?+N0(4]R()XS` MIS`"NE?D?2$/GW)34+VB`.9Z+^%3*+C.Q%T$3A`R-Z]HAD(3/J5K$]\-YHN> MWQ7%N5"$3Z'H^/=M":W5.PN?0G,Q M"M:"S@I,R<1REU6J?Y1I2#$S\LBLK,=``I+80GE^W;@+YV'Z%4IJ)V2V5,:2 MB*0$JQ]F-K:!Q`92&\AL(#>`*7!6Q*$4?P)Q9H41ERYO)6!$`LP9%:@98J-/L[@YG=OH02->W''%-OJZ_P$&)E)!4BPF2$"0E2$:0W$008SB#;<9. M,)F#_/!M)<\PIH<9@FIP(2UJ-S>PV$9"BDWI2FH@:-R6 M/^^I.9.YNT3_)9\LNXFV*QU**90)R&?]^W4#=JV8YE('M6'@J<#BD+'QYOZ0 M\6$(=I`>;AT.675FI3&24C?JC-L*9Z(:EIX?H)@I#OW!E6BKTIV40IF`1(TM MO8FO8]';R:62663N#R/&)J+[(R;F)S-B'+**S,IBY`C%&T7&I7SL>6C'2=G2 M<2)0)G84A15,/!(FH6,6EEGWN+#8W&2$Z:.//\Q,?[+I7G,7EF=;1TB9$Q,) MJ)*108BUFH02"J44RBB4(PA'`E)H1N+&J<2DK:.<0W@>#.8XR1$[CMC99=Q2 M%$HHE%(HHU".(,R/#5@DTW>,A0Z?S-!IPB%S,!12!A13**%02J&,0CF","\V M=$E>X->-O(D1S6QTA]:PG&@IY3FRA3TWIZ:;=>[2 MJ4E`R',N94"QD+(\MP;21$MISTU;V',V+QC5PN^8__GT`T\Y=D<(R/`^HE`L M(`]"ILN?C,9:2A/B.W+SF!"[80U"UX\<5]S'QI$C(.0YEP)(NTE[62B&(&R0 ML>[91$MI,LH\0)B,.0%`D#Z6'77_RQVW+H<01P+%0LK*CC67)EI*FD^1>4R( MW;#W9X??Q^;AQ(9D=D6;J7!#>U"14F9=#21,V,)2EJU$VN(/(=[,F3N^]=B1 M2ADX\U7JS?UP#&`_,P8LJ?Q;KQNURO2L`X]#(;2WVM<-K=DU>L_O;\/QC.>1#`"+$(?Q,%UH#1<26 M6?^;`],`1V$>5SSI;"XERGOAAT/E+2R9J3?W0Z$!2U=#\Z6^0/_>&H-[*[C/ M!60F6T/7DBVE]&":4"B5D)%L_K*5OXP[EX)V+B[ M@A=0`WM[\%9Z`'\$&O`H,K2QA96@?&.:!XU#1P;`,*T,%`5,GK/0>3%6MP.\! M+L5+^4?1O%3G=G0LGZ',9_TJ[K3OX!1*;JMR2;_P```/__`P!02P,$%``&``@````A`+&!80"R!@``M1L` M`!D```!X;"]W;W)K&ULK)E=C^(V%(;O*_4_H-PO MY!N(@&H@WVJEJMJVUYD0AFB`H"2SL_OO>QS;<>P#66:[>S$L#\=O[-?GV$ZR M^NWK^33Y4M1-65W6FC'5M4EQR:M]>7E9:W]_#C\MM$G39I=]=JHNQ5K[5C3: M;YM??UF]5_5KIP*//"K_*WJ^J5A"9[@J#Q#+4.NQGXLY[LBT/V=FK_ MJM[CHGPYMC#=#HR(#,S;?_.+)@='069J.D0IKT[0`?@[.94Y1A_HLNY=DD%U$Y8G(K#7P#/*H@P9OX*@A4$*H@4D&L@D0%Z0!(1D"Y_@PCB,Q:@[^#)%G*(]_2&)*)?9`C MA^SZD-X=1`)$0D0B1&)$$D32(9%,@J7I9YA$9*`8(2=[`W`IL:`QE_J0WB5$ M`D1"1")$8D021-(AD5R"]5ARZ?;>Q9<5$MV9P0>Q90363&'/4EB. M^$"9CVO+$+FI$U6R5*IDQZ-@61=1J.!$%)9'!`6MHZ;2BE_K7?%'% M(QXUVH581/&I3^0N&+;E6.JZDO)F][H@FTY.F1\PG80K"R1%2K*K-QP&BQI- M-%]$\1$''-%D-PW=GKNVLM:&/.@[R?Y('V*NY?;UG'#$^J"3?W*YI3SD7@]D MTV'>)=-_:$\GCZW4N:!(*0!7[NN.-QS-/E]$B;F@\JP`7$=W%!M"W@B<%A6( MTY_U?+0#L=#B'4@8LJ6&>-5A\O=1 MX@P68!1R).0C@4;D8QXEY!.,4HXZ>=D9.O-C64I/\-+V2)$-)HDD62H; MV,Z@41:LPR)*326?19FB6@..:+5:"]>%YZO*YAORH'OUVFT"T4-]B+F6Z$/" M$=NBW9OK-!V@>:\+\F1`U.AD?*ZND)8W;P.&FR:14=*7(BE]>S1J/8L:[I`( MA?`PGUQQ(!\)-"(?\R@AGV!$WA4(>>H8??9/G]">B_JEV!6G4S/)JS?R7!\6 MZLVJQ_2EP];VX&D+K#(J=SQX$G&#NQ[8^(K;"T/ MGMUA_F1[3S`1\,.LOP*\-+EF+\4?6?U27IK)J3B`^7IWVUK3UR[T2\OR]KEJ MX;5)E\)'>#U6P!VY3@[?AZIJ^1=R@?Z%V^8_````__\#`%!+`P04``8`"``` M`"$`].W7!#8)```;*P``&0```'AL+W=O?7A_[?__E M_F;W>V6U.>TVA^*4/?9_9&7_]Z=??WEX+RY?RWV653V(<"H?^_NJ.B^&PW*[ MSXZ;7KV_GW[;%\0PAGO-#7OVH M@_9[Q^TB>#T5E\WS`<;]W1AOMAB[_H.$/^;;2U$6+]4`P@UY1^F8Y\/Y$"(] M/>QR&`&3O7?)7A[[7XQ%:EK]X=-#+=`_>?9>MO[?*_?%NW?)=W%^RD!MR!/+ MP'-1?&6FP8XA0U=WJD)=`75'K3;5Y>K@4[SU8IF#,Y7G#%CUCP>)B+?&. M-]7U47%!5;$H7UB8QSY,%*B;$E:$;T_&S'@8?H,JW@J;Y14;U6*%%JQD6=BU M#AP=N#KP=.#K(-!!J(-(![$.$AVD+3`$:1M]85[\%_JR,$Q?5&:)0`IN:F*B M!;JL=>#HP-6!IP-?!X$.0AU$.HAUD.@@;0%%3"@4(J8%!7]]X<>YR;Q@B5?F MIB;6DMNP5:29P!--S\:D$900AQ"7$(\0GY"`D)"0B)"8D(20M$T4;:'VB;;L MH?K)A8"%@;4$RJ$1DJX$PJA+[<:D49L0AQ"7$(\0GY"`D)"0B)"8D(20M$T4 MM4%81>WN&(3XA`2$A(1$A,2$) M(6F;*!K"?D;1D#VZS,D`[#\Y9UD@55Y.S/8$-69C3=[&J)&7$(<0EQ"/$)^0 M@)"0D(B0F)"$D+1-%'GA8?[?R,L"J?)RHLFKK[>-42,O(0XA+B$>(3XA`2$A M(1$A,2$)(6F;*/*RPVA[X]6]`C!K54-.-`VGVA1MC!H-"7$(<0GQ"/$)"0@) M"8D(B0E)"$G;1-$0EC]%0[YY';"#5+>]U/M?+465A:LZ')3,-5VNHZTPA9=&1Z11Y$O'=OAM3U' M(*TP5DAC113%B&"#*GL_FZD+6H)6<$*05KH2J;2"3JA98T>+_S]K_(`"S>`@ ME^P"0,]:@SKZNA:.EEV?FLV1H6TS'&F`C;FT,8\B7SJR\SA$)KGB'82F,7)( MPT04Q8A@>RNS,+/U7-TS_O16+#5][/C23M^5XH)+K::ZQ&FGG2>!VHL61_`H M11G6[$J&95,BAR*7(H\BGZ*`HI"BB**8HH2B5$&J?NQ`\@G]Q/FEK1]'[.:P ME?JYFOH5NTEB^JE+$5FPKEII^T`'8\WJ`IF/)K:MS30736"C(#NEKPH>6DV; M//L2M1VU'@1H]7$/0C3I[$&$5K('L4!CY:AACU0]$^G8[J>F9WHKECH5V+GJ M$U.!F6O/?XY,V&)(U6VM4RMVA\`Q%:R?9B@<;P;)<=M;5G)M[5FR,H05?,@!ZEU?2RN99N'(B\L6,EL\^1*/+)R#9L0SO$NAB\L^@\M))%YU,4"-35 M7HANG>U%:"7;BP72BES3*I&.'962WHJE9A\FJI+]&]LB9JZMY1Q9\DF_,AK4 MT<\U6LG3BD.1BTB&]RCR$P&BCO9"M.EL+Z+MQ>@HQY=(JXZ^IXJCDBUV,Z9DZZ=6Q#J*6BH" M:=L>;<^X0BLX`WTL_1K#RT7$$6BL3`A;7Q/145FC9MJVT9.=:#*+CK+%X'J+ MVLD[1,?.%B/:8HR.LL5$6G6(DRJ.:F[9%`4FD%[)6L'][1[BX$ M&)YWP9K.1S-;VP>$:-/9A8AV(4;'UF(IK3I3W?2=I)K==W2E^J_B#*O@U6RX5#D(I+%X5'D(Y*Q`HI"1#)61%%,42)1 MQX#8&W'U%*_#\T+C;[CQ]W&.V>4U6V6'0]G;%F_L[35XMCT]-)B_6K><+>`G M)4B?SNT%_$QRA<\7\!,`Y7"YM&"W2?0;N%!:L!LD^@V\UO>E7JKTMN%UOWI0 M.C?A-<`K<9;0P-7X8XA_[8OE>`&_I-,.+2<+^'7X"I\NX&=-RN&&?,'NO^DW M<+F]8%?7]!NXGP6?:\.`^U7PN?;-"B1DEX,T&MP/+MA5'WPS;-2"5Q//F]\U/9.V0OD'QX[0T.4Q?^`DU@Q]>1NQ7[Y>B MJ/`/UD#S6NO3OP```/__`P!02P,$%``&``@````A`$/1+JY$!P``'1\``!@` M``!X;"]W;W)KEHX_WR)/DV=7M/FIVU^J$[%POE>-,[G^]]_ MNWNMZN=F7Q1M#R*?V6&-5N5VZ*=;5Y.1:GE@>IBT/>0O^;?7EN,-IQ M\Y9PQ[Q^?CE_VE3',X1X+`]E^[T+ZO2.FWGZ=*KJ_/$`>7]S1_D&8W=?2/AC MN:FKIMJU?0@WX!VE.<\&LP%$NK_;EI`!D[U7%[N%\^#.,\]U!O=WG4#_EL5K MH_W?:_;5:UR7VS_*4P%JPSBQ$7BLJF=FFFX9`NB5E$ M*VF$;FM"0D(B0F)"$D)20C*=&+G#=F3DSM9:;]P'^W>NMBR0*0LGGEX0[GAJ MR2*-I"R$A(1$A,2$)(2DA&0Z,62!7>-C9&&!3%DXL6296;)((RD+(2$A$2$Q M(0DA*2&93@Q9V-E=WYEOSQ1F;>;.B9E[,+1RET8R=T)"0B)"8D(20E)",IT8 MNVYQE) MW\ZT,S=31<1O`.P`M:)H35%(44113%%"44I19B`S9W;TTHM<&^AV7VZ>EQ6L MD6!T00L?CIGB\,D/<+!G8A4OV?X)A>!Y$JT4TK:.P#4GQ%I8^;!:J0TFL,YG MH;+"%B,5'E%,4:(<]?"^V8E466&LS(AE:LA.;?]?0W[V@V:PR:7+D:&A1'KW MB8;NL#)KBJAVTN5U5Z,5H$5OG\;9@RJV%O^D_*65DET@7FB@ M^BBPSFX1QKY69]T&$:.57NJDN12M1'->,/*MYC(TN=:<*3L[\;ZCK)FYI2]' MOJKTE2O1C3I;HY7:_D**(D0J?$Q1@DC%2BG*$'6Q3!G8"?<=,O`#L;$1":0> MH:Q<<6R&Y?[Z=%L+*Q@U55/<44SE\6SB#SUK&;M?:,^6$VC/D_+7)S*)8Q<:1-9GM.Z3+K7S8K&X)+V*I"1>B MHYFD-<$B8>6!OPH_L08HQEB^'-<$'56+*5K=;#%#QVLMFN*ST_L[:ID?]HU: M%N=_->=6KD1:SO1@*JS4-`S14:$(D0H?4Y0@4HXI11DB.J79I=*0X9=JL(MB MUB`B;:8+!*?06^J@(ZSJJFX":Z*%P@HG8S":TLF/D,DO1^=H7Z4IU!Y(M7*.UPVX6Q!H/?H?3=1U@!TF6VQ%FC ME5H&0XHB1%JI4I0@4K%2BMB[-[:<\:YR>?B[-/ZNXUC43\6J.!R:WJ9Z8>_) M8$NXOY.8O\1;CN?P[`[&T^;!'!Y>7>"3.3R]N<"GUZX%/-W^MWL(="7PN_0(O*1\N\26\O+S4QM*#EYH7VE[Z M6IZAV('@S+L'O#4_/4F M_]**XGVL6G@KV=7Q'EY#%_!L8\@>G.ZJJL4OK`'Y8OO^!P```/__`P!02P,$ M%``&``@````A`#<_\S)P`@``_`4``!@```!X;"]W;W)K$+\?GW',_F-\=5$-V8*S4;4[C:$0)M$(7LJUR^OO7P\TG2JSC M;<$;W4).G\#2N\7'#_.]-AM;`SB"#*W-:>UU[.P+FQ+7 MT"EN-MON1FC5(<5:-M(]]:24*)$]5JTV?-V@[T,\X>*%NS^<9FS%D6LP+B0Y\V8F!,J?+.%M-*5O,^_K\D;"W)^_$UGK_Q+H' M*["@2!,EJ6<2NL$$\$F4]).!!>&'G"8H+`M7YW0\C=+;T3A&.%F#=0_24U(B MMM9I]3>`XCZIP-6G=L\=7\R-WA-L-Z)MQ_WPQ!D27\X%D_#8I0?G])82E+%8 MO]TB3N,YVZ%I\8Q9!0P^CY@!P5!T4$:UZY4]V"O[JOA45B%P*I-FDJTE#91(.8IN M,2,3UC<\&`#^?<<[F7S?63JLDC&"MUD]%)%%,"C="Y;,J,_OIY=[6B MQ#K>Y+S6#63T&2R]WG[\L#EJ\V`K`$>0H;$9K9QK4\:LJ$!Q&^D6&OQ3:*.X MPZ4IF6T-\+P[I&J6Q/&"*2X;&AA2,X9#%X44<*O%04'C`HF!FCN,WU:RM2]L M2HRA4]P\'-HKH56+%'M92_?09>7PMN=HR/M* M\^=;L`(3BC11,O=,0M<8`(Y$25\9F!#^U'V/,G<5SM;1+)DO5Q/$DSU8=R<] M)R7B8)U6?WI4SQ58DIX%OSW+=!'-E_%T!`D+$74&;[GCVXW11X)%@Y*VY;X$ M)RD2O^$K7CLSH,SNJ0$8[5X"X_;R6RY88^8.M%C;@(&QU?,@&`H.BBCVGAE M#_;*/K<^E)NP<2J3O"\S_1\9#\XHCJ_!SU8#;U`.F-D)9CX@S@PB9+Q!#\8[ M.#5TF=L`&B&-135>VH,[Z2&Y_ M;7D)W[@I96-)#052QIT7$[H^+)QN,7)L7.VP6;MIA8\S8&'&$89?:.U>%BC, MAN=^^Q<``/__`P!02P,$%``&``@````A`,GYI/4S?=T:\B$-JG3C(2Q0?SHSFS)`\-+W\^EJU7EY M7OEL,/0]?L[*77X^K/Q__K[_,O.]NDG/N_14GOG*_\%K_^OZUU^6+V7U6!\Y M;SR(<*Y7_K%I+HL@J+,C+])Z4%[X&4;V956D#7RL#D%]J7BZ:YV*4Q`.AY.@ M2/.S+R(LJO?$*/?[/.-QF3T5_-R((!4_I0WD7Q_S2ZVB%=E[PA5I]?AT^9*5 MQ05"/.2GO/G1!O6](EM\.YS+*GTX`>]7-DHS%;O]X(0O\JPJZW+?#"!<(!)U M.<^#>0"1ULM=#@RP[%[%]RO_CBV2<.H'ZV5;H']S_E(;_WOUL7SYKRI;LKB/V'%9"P1)911X"FCL(D1Y8IG)#WA*3W#P90-YQ&^_8K? M2/K!\\8W0MR6,3RE9S09C*?#B$&!WB`PUQZ7K-PM`R>H?^9M-GTV%"+K;+` M9F/8V`82`PB`@&8![?L$%A@%6:CW;Q30T0JME)6%%'],<-\*&P0K5W;%,MMI$\W"0Q$0($YC)G\`$H\`DA`[K+-TY)(VN4=$F MFHJ#)"9"J,`*,*GT[T5JTJ-QF[%ZTT8B<$A0MNQU4;*+7:0Q$1(@A.:H%BN MT)D;URN&H:D+)#0KR\*IE;HVTJD[2&(B)'78'=Y?6S2F"0K$2G!F):B-=((. MDI@(21!/%L96>+WY:$P3%$@H]`6WKZV#Q`Z2F`C)!B:1F0UV>@R+XWI6Z$2S MDHA0T#8KB4"?C(4VIX6,I5&W%R9];M%0NY'<<:\QD[^>=&M-LY:064P7BETH M(1#-";7#:"\6-)KAV>*-FN*69!550495%72]K,K*J*N"B&/$?E)85!.#Q!N% M%=H#;U#+8<,$1`KK0+%KE1"(%A:%P/6RJ2XF*P$1/>N*-(M;@\[6^D(5JI;L0LE M!*(44#0L"KACW)J_U!XS?P%9^5OGNRT>WF&=D/P=*"%6-'_HL)T_&T,3;R6` M<:SM1$`6`?L0Q+15UP`'2H@5)8#*8C7@@W-(:!19N%JVS-ELGRV8MNHH.%!" MK"@%E*//H2"$C5"06D?.&)%]QF#:JJ/@0`FQHA10J"P*'YI&4O#,=2`@:QK9 M9Q"FK3H"#I00*T(`P]L$I%#=N!+:2'0E2,BB8.VFV\Y*4W"AA$"40H_6LLEX MT'TU?OS5+B'(8=4<1L9UV5AT'$0L<%900*\K!DMKVJ#T$\-8F"'DU M%T(H%9M")JZ2@ MK52^<>>HH(1`E(*ERM>/.Z&KO`J"]=>=`4:V\G96*J?8A1("T311YJQ*?VSC MQ].HI5T2LBIMBV]GU5%PQ9=840HH=!:%C^R:H1!,,MNUAIH]L,57.AIK,W:A MA$"4`,J<38"-/C3=A6(2#EI$30ZV^L)UJ7T"'?B6 MGTZUEY5/>`$*I-=+#8O;V4TX@NO9$6YDSL@81MH#M#,R@9%)K\]47?;:/FRV M0+'M>0^;P\B\;R0<0K1VD[6CA7BIW&XCSD@((V%OM`A&HKX1!N^!+WQ]N4$T M^,;2-P)U@S-TWPC4#4ZG?2-0-SCV]8U`W>`TY8[`[?E=__O!H<=^@_3[<"#? MQ_UN!/'[7KP!?KWT@%TO.>#62PV8]<:'^=!.AT!W$&[E+^F!_Y%6A_Q<>R>^ MATD[;%=>)>[UQ8>FO,!A!&ZJRP:NX]M_C_#["X>KDN$`-JM]63;J`U0TT+_H MK/\'``#__P,`4$L#!!0`!@`(````(0!]I`75,@<``/<=```8````>&PO=V]R M:W-H965T&ULK%E=;Z,X%'U?:?\#XCT!F^^JZ:@0S>Y(.])J MM1_/-"$-FB1$0*0 MSD.BTSEG7N9!IH?[?0TS$+([;778N(_L;ALDKO=P/PCT=UV]=N1OISLVK[^T M]?ZW^E*!VK!.8@6>FN:+@'[:BR$(]B;1'X<5^+UU]M6A?#GU?S2OOU;U\[&' MY8Y@1F)B=_OOVZK;@:*09LTCD6G7G(``_';.M2@-4*3\-GR^UOO^N'&#>!TE M?L``[CQ57?^Q%BE=9_?2],%FG413&:0*TIU?T<-J#BMNR+Q_NV^;5@=*$B7774A0ZNX-LHWR800GZ MGIX@I$CR*+)LW,1U0*H.BN#K0Q;=>U]AW782DD\AS$04(T(LDLBZ)0,>T%6< M0>;_@;/((CB/E\O'`3T);C$<$6/(%@>`IYIWHN=M<(85IIS?+L]13@&&0B1I ML]BDDB,$5DQ=65]X4*\8$8KL./!6B,$5LB[G*L`;%X101#)+MAPAZ5`7JR1+ M_3H&04"W&UHB)(\9BEB@)#+90[\O9"K"EK$X[Z)8C!*ZO)F0K.R*4LN/` M6R$&U_@6K@)L*9LJ"9`K0N)!V3B+4]\W`04"B*XT(LSB)`A4A,$4]O)R5078 M8IJIM,@4(>'`-)G0'/^K%,4!G%CHPX]*9[`4+DZZU_RN$F"3)2-YD29BYA9_ M1"BJ.(!461#H+3\`"IF%"DU#5CP+0]W+ MS<(`'6Z@*]`V76!$,K;"$J#D),[$Y.YL!O"_`?EC.9$&8>3:J8&MHH9L_RP8`B@=&D( MRY)4%Y1)5AC.)MQP7:*@QFW>CD$C1+&?-0RCBB;'*.LK"9Y931E$`1M:L8 MZ4%2Y='+-$@W56P5XBV/51?CR%M!ILC"8`CC93;-T9;,^K#]0X)0-\;"V$\F M-Q@20]6FCL>B)(RC4.]OD[MP&\)]WO(X>I/)V9(REZ#9`IFXG@S"B<;B28\\ MDYF,A>,0Q@O51I\RF=NW%WRTM[>67-;)"-$M&D=D:?,P"LB]E,E!VC^KO!6SR?WLY[B+*;B6V*$C1;WQ)#ZMN( MXBR"&\%(>X')W7+&9=423)\))[=NN00A=WBXRU)N3:^0$$J=/A3"@R2\K.6Z MPYK48(8OD866RX"@N4X9C!"U:]6(7AC=@4WFPL%N9XZ^9XJN[^HE\SESE`4T0C1S M',$7P.'[[YL"RT_G/6E`P['%<#XDV:'_D:%BBMH:0Z9PEBF*IB&>AV\\#8'S M+GLKVELHEQCQ]DCM,]*'I928"$!:2SJ$Y/%L#$]USE7[7!75Z=0YN^9%G'M% M\,I5C:HSN4RQ_E=\1;^,8CA<"]^*U.0C,=^GDH&QV[7\KGZ M7+;/]:5S3M4!Z/EK<6#5XL$=?NF;ZW`N]=3T<.`V_'F$`]8*CH3\-8`/3=./ M7V`2GCJR??@7``#__P,`4$L#!!0`!@`(````(0`[6DUG_`<``+&PO=V]R:W-H965T7S=`:38:#[+(K]OGE=3/\Y^_PRW(XJ.KTLD]/Q27;#']FU?"WYU]_ M>7HORF_5,[MW-VJ7F0,CNE-;2_.N;7JHUV MWGTDW#DMO[U=O^R*\Q5"O.2GO/[9!!T.SKMU_'HIRO3E!/W^84W371N[^4,+ M?\YW95$5AWH$X<:\H7J?5^/5&"(]/^USZ`%+^Z#,#IOA5VN=V//A^/FI2="_ M>?9>W?P^J([%>U3F^]_S2P;9!IV8`B]%\8VA\9Z9P'FL>8>-`G^6@WUV2-]. M]5_%^S;+7X\UR#V#'K&.K?<__:S:048AS,B>L4B[X@0-@)^#<\Z&!F0D_=%\ MON?[^K@9.O/1;#%Q+,`'+UE5ASD+.1SLWJJZ./_'(4N$XD%L$00^11#+'MG+ MF36;/Q#%$5'@LXLRM6>+Y2-MF8HH\-E&F8T>C@)];]("GR+*)](R%T'@4P29 MW63%D,^%<(1/X3@?+:S)REE`>PQ^,*F;5L.G\+,7(VLZ>42%E8AAL:'XZ(@8 M\]'5#%8_K=/GI[)X'\`*`..GNJ9L/;'6+'([3'EGY,"]-VYAP+(H7UF8S1#2 M`D.R@LGV_=E>3I_&WV&"[`3C]C$SE?%:ALT'%MCG!OAY$WBN.@4Z8ZE$B,-& MV+!M#;?/08V+6Z9M7,(-\+.W<6-(LJ7DG(UM!\:X.??,2\D]-GC8X&-#@`TA-D38L.4&-3]H&,=]C(/R8V:4_,!* MK.3'G!=&*WG!!@\;?&P(L"'$A@@;MMS`MS6V(L38D+2&F[FQZM8>I<>P2BL] M_MB(8%XP]XS&N4?;BLL94^XYL6R.!FA9\TGO@"1"DHA:0N:\-=S/ M.4DD)D+).2OK\#F+WHN8%\Y]M]DU)R27,Z;T6KNG0D:N2YG;G.O9=;3&919GR0"D@A)(FH) MF?O6<#_W))&8""7WK+90DO^QK;=QPRJ@(Z$KH%L94(H]&O%I)*"1D$8BB4@E MI.6^%#222*0IO^2Q4)6!E2QX';(6[!4$<2RVF*>JQ!QO`X(Q"L'#&!"?CA(( M9,ZW$UN;=*&,P7*!UKI(?`EC5QXG',1L98".06,JIAJ1&`!5%%;38%'HS<'B MI=#MJVGH0"R)BA`6FH:N9:HEA1`DXO=$<2Q4 M.@8]$-JC0AJ))-))0;8OEDZ=%.C1B1%196`EX`,R\(I1E4$KZ$QEI9"!1'R+ M(WS[LR_,8TD1D25H*^PIFLX6Z^J'0OM M3*Z`C%+09;6((DZ#,_T0$M#/"6DDDDBG!=FX6#K=E2LQ(JH6L+H\L"39#,?3 M`2V(KH",&O`X!L2GHP0"X3)]<9SE:C5%VU1(AXDDTJE`-B^63@853%%4%?K* M:&L%YV5B=>JIHRU<-]AD&>K1B$\C00_B6.CX'/9`:/Q$$NGT(+L02R>#'J8H MJAXP,!^9%0S'LP(?7&T.&8:\1R,^C00T$M)())%.!-X!7ILU:R*::['T,6A@ MRH*J`:L6/WY88F]E00-XL=LVV-5-GF[R=5.@FT+=%.FFK6Z*=5.BF-0^XWKU MDU>,X+*>-B"16*Y@V(M7^6IWAHH,KX/:K/JZ*=!-H6Z*=--6-\6ZB5T];*1M M+C;P?/&KA/QVUCDK7S,O.YVJP:YX8]<$H4_/3](L[C#:,[C$V-P>1-]`)MKK MC>@;N/?X=']AHNB8!]+#L`UR:OZ6OV1UJ^YI=J<,H.D*_)B-W)*_G% M2_Y'75R;"V\O10T7)IM?CW!!-H-;)9,1P(>BJ-L_V`/DE=OG_P$``/__`P!0 M2P,$%``&``@````A`,F,,V%X`@``+P8``!D```!X;"]W;W)K&ULE%1;;YLP&'V?M/]@^;T8R!444J6+LE7:I&G:Y=DQ!JQBC&SG MTG^_SYC2M(DF]F+LC^-SOJM7]V=9HR/71J@FPU$08L0;IG+1E!G^]7-WM\3( M6-KDM%8-S_`S-_A^_?'#ZJ3TDZDXMP@8&I/ARMHV)<2PBDMJ`M7R!OX42DMJ MX:A+8EK-:=Y=DC6)PW!.)!4-]@RI'L.ABD(POE7L('EC/8GF-;7@OZE$:U[8 M)!M#)ZE^.K1W3,D6*/:B%O:Y(\5(LO2Q;)2F^QKB/D=3REZXN\,5O11,*Z,* M&P`=\8Y>QYR0A`#3>I4+B,"E'6E>9'@3I0]S3-:K+C^_!3^9BSTRE3I]UB+_ M*AH.R88RN0+LE7IRT,?`RN;J]ZPKP7:.<%_10VQ_J](6+LK)0[1D$Y.)* M\^+901XM.?&[H3C MQ(@=C%7R3X_JN3Q+W+/`MV>9S(/9(IR,("'>HR[`+;5TO=+JA*!I0-*TU+5@ ME`+Q[8@@%(?=.'"&%QB!KP:J<%Q'R7)%CI`ZUF,>/`;65\R`("`Z*(/:>&4' M=LHNM\Z5!V^XE(EORTS^1\:!,PSKJ_-),O!Z98^97F!F`^)-@``9'Z`#0PTN M`[K.K0>-D(:F&B_MP)WTD-S>'!N1SE_*^5&(X$!^WA4WLFN:]?9INNO>"##]@7EM: M\F]4EZ(QJ.8%4(;!`CS2?N+]P:H6/(>A518&M=M6\#!S:,HP`'"AE'TY@#`9 MGOKU7P```/__`P!02P,$%``&``@````A`*K\YB/F`@``:`@``!D```!X;"]W M;W)K&ULE%;;CILP$'VOU']`?E\,A%P5LLIVM>U* MK515O3P[8(*U@)'M;';_OC.84)RD7?H"83ASSIRQ/61]^U*5WC-76L@Z(:$? M$(_7JM(%Y\8#AEHGI#"F M65&JTX)73/NRX36\R:6JF(%'M:>Z49QE;5)5TB@(9K1BHB:68:7&<,@\%RF_ ME^FAXK6Q)(J7S$#]NA"-/K%5Z1BZBJFG0W.3RJH!BITHA7EM28E7I:O'?2T5 MVY7@^R6,67KB;A\NZ"N1*JEE;GR@H[;02\]+NJ3`M%EG`AQ@VSW%\X1LP]5= M&!*Z6;<-^BGX40]^>[J0QX]*9)]%S:';L$ZX`CLIGQ#ZF&$(DNE%]D.[`E^5 ME_&<'4KS31X_<;$O#"SW%!RAL57V>L]U"AT%&C^:(E,J2R@`KEXE<&M`1]A+ M>S^*S!0)B6(_CJ;S10AX;\>U>1#(2;STH(VL?EE4:ZEGB3H6N'3 M$2345M0:O&>&;=9*'CW8-2"I&X9[,%P!\75'8`6Q6P0G9$X\J%7#,CQOHC!> MTV=H7=IA[BP&KCTF[!$41'ME4!NOC&!4QMYB*7(,(AC5P#%WTUH)&2,.F&B^-X%:Z;VX7TBD#EH__RZ+&S"H4.4G<1O:F*6J]E%7,W%=4T< MYZ//"H)=*1N)E^VH&9Z$IQ=6>?^!E MJ;U4'G!F1S#(^FC_/=E&N$SG\7BUM=\9VK^!.=^P/?_"U%[4VBMY#IR!/X>2 ME/U2V`G>OB4UB5-M8 M0)KVV]\LN[.P.S9-JE95[?SRWS_#[.RP0.\^?S\=>]_2HLSR\WW?&(SZO?2\ MR_?9^>6^_\\7_Y/;[Y55'])24@_R2GN$WSWEQ2BKXL7@9EI^'+.B^3I".?]W;"3'7K7/Q#[4[8K\C)_K@9@-^2!TG.> M#J=#<'JXVV=P!BSMO2)]ON\_&EYLC/O#A[LZ0?]FZ5O9^MXK#_G;JLCV479. M(=LP3VP&GO+\*Y.&>X9@\)",]NL9^*OH[=/GY/58_9V_!6GV_WYENVKPWW?&@^7\HH*S/!SZ%R?3=IS$68R=RK/'Q`.!P=0#P*0)P!Q-C-+4^P7+\]F)/IW?`; M++&=T,RHQE`5RF0TT%U@?,I&F.U)3.1.BKFQ+B2Y%.&Q!R)(0 MGY`5(0$A(2%K0C:$1(1L"8G;1,DA;#24'/)KV8#M$+K3R0:JZ>3$FLJ&.R=D M02#:2M(ST/9+M#9J:]N8C+4%XN,@*!VYC(CU"E6=`02-"@,($4WJ`.!I#OQ1 MRWB-DLX(-JCJC""ZKM+:RU:H++L.RC`&>@.*T>=63&H%L)N@]_=$MB?4UI%` MCBFFR9IJ29KCH.Z6V*AP`I9HS9;QMP?;,@U2`2*>=DN^4@%"U1E`0`,(!;)X M=8^GECDR]0IX3P2;QKNC4J/K*E(!_(@VSXHQ,'AEUN4)_VB7FAA-;Z5(+0=V M&_>!\`"%2(:@FTX$ZWUSX7B9PV!^X`*K9=H+1J"98^TS;*/ MUK=*O[X6K%#5N1R#1H4!A(AX0QB[SL2P23V(N#M#V*!39PC1=16I!WY$T1%& M\)Q.+=$8;6Z%I%8`N[EL5\`O76[9LS*]3W`D^\1XHL4YQT&=RW31J'!>E@(Y MV"<JU;OL`SHP1"3V8L;(GHQM M[5*W1M&M1E>O\LV[8HC0J[G^;"F*%:1.&K3VSDG[DE]@-J[>MK2WW,Q&FS6. ME%4D4>>L2176X1+>QXGEA\BG:-6@#OL`5>V^*.P;M$95>Q7)(#KL(SIP2Q%[ MP=B<$)\0_L*0OT$YI<5+.D^/Q[*WRU_9RT!C"IM+B?F;RIGCP1,KR(C.QQX\ MC:%\[7IPKT;YQO7@CHWRR/7@+HWRV/7@7HUR>'/Z6*]1/1[V1O6*?F9Z\#R> M^LPL#YX=4_YH>X^0./J+F>W!X\\KW/5FUP*=NQ[<15/]PO7@SIERW_7@_IGR ME>O!733E@>O!&PO=V]R:W-H965T;*OMLOJ0E:RF6_N=MO;7W<\_;6ZL>6G/E'86,-3MUCYWW25PG#8_ MTRIK9^Q":_CFR)HJZ^"Q.3GMI:'9H7>J2L=SW:53945M7!MU/- MFNRY!-UOQ,]RP=T_&/15D3>L9<=N!G0.#]34O';6#C#M-H<"%&#:K88>M_:> M!"GQ;6>WZ1/T3T%OK?*WU9[9[9>F./Q6U!2R#77""CPS]H*FWPX(@;-C>*=] M!?YHK`,]9M>R^Y/=?J7%Z=Q!N1>@"(4%A_>8MCED%&AFW@*97(0OT*=1*Y2UUP)(V$6VP@B8&D*J*I@2$P54,6LQ78/VX\]-.CY\A\+9=/ M9""Q@20&DJJ(%BK,&S74Q_&AL1[?@/`]`>=-9""Q@20&DJJ(%A^>,(S9VJ>R M.Q?Y2\CXMG(G[CG,4#Y9D4,/FR.>-Z95(N.Z(,O)<(VYT1R"E8N'+#V]EQ)I M)'HI51%-W/H'B$,.71Q'5'$24>.>BAN,?+[UN,2?Z)(D4M?48YR1FDHGCO9PB-A!2M26IF=-ECY^MB:S.EDY!)!I!\YZI)QV_R\9+[)PAO$ MVT+"(0\Z08KQW+7>.=%@A;N5M+HCF7/YJ[X!75CC"W>M_NBLR<@JPDD':*18 M/GDJPY@_/0VXYWX^#<,.K::!0WKEB:L'')'!ZH/*".XL_73ZH/+L*5C%RCY`\< MN61^Z^$G]HHV)QK1LFRMG%WQ1@/MO-M(F%^WPF4`.R:\9H+'3P$,@&<#/;\R3E_@ M!W`.,QW"10`G&L`=Z0!7O$MVHK]GS:FH6ZND1T@8KDS;:O@ED3]T[`*)A(L> MZ^!RU_]YALL\A?.`BX>X(V.=>,`7R'\/[/X#``#__P,`4$L#!!0`!@`(```` M(0![CN2@]00``"42```9````>&PO=V]R:W-H965TFTI M^[`>GZDZU*FJKJ)G]?6CR(UW4M49+=>F,[%-@Y0I/6;E>6W^_5?\96$:=9.4 MQR2G)5F;GZ0VOVY^_FEUI]5;?2&D,8"AK-?FI6FN@675Z84423VA5U+";TZT M*I(&OE9GJ[Y6)#FV3D5NN;8]LXHD*TW&$%3/<-#3*4O)GJ:W@I0-(ZE(GC00 M?WW)KG7/5J3/T!5)]7:[?DEI<06*0Y9GS6=+:AI%&GP[E[1*#CGH_G#\).VY MVR\:?9&E%:WIJ9D`G<4"U34OK:4%3)O5,0,%F':C(J>UN76"V)F9UF;5)NB? MC-QKX6>COM#[+U5V_"TK"60;ZH05.%#ZAJ;?C@B!LZ5YQVT%_JB,(SDEM[SY MD]Y_)=GYTD"YIZ`(A07'SSVI4\@HT$S<*3*E-(<`X'^CR+`U("/)1_MYSX[- M96UZL\ET;GL.F!L'4C=QAI2FD=[JAA;_,B.GHV(D;D<"GR,D#QR]SA$^.\?I MQ/'M&3[[@9O?N$^:9+-JJ)W`QH39-77!-O<"8"L3QYC MX.G\7C8AC4BR19:U.3<-2%0-+?"^<6UW9;U#V=+.)M1M'-EBUUM@C9!VKP*1 M"L0"8($B+@OJ\#_(0A:4U0<4]H"@4]'06_0N>Q6(5"`6`$D#M(2JP8/3,=[7 M?270"3I8JH0GQQ@R&P>X>+FFLLF.FW`=&A)I2"PBDA1H5U4*'M$7NPQ9H$^A MYCQNO`X?%D-\LAJ&**HF2G%X493,E!6W[ZP\*#Z? M8/]\H)&MDAAMO9/#''.@FQ)(X?$Z#6-G97?O0@X MRC"+=.:XA[C/L+-DL;@L!;$CA8,IQBO'5JNDJH.$GG,8!(>\U[[7H4B'8@F2 MP\1-^'R8W=X4D\\@G,B\3UQ[K@P>I[."PZW0[HQ2FG>,&.+%T'QA:X#/V&[B4;\?P$"_K(TPA M$(W:>P&\]>M/WOK!EEWZE6!#/X`W:=TAG`;PN@JXQ1W@DGY-SN3WI#IG96WD MY`0IQK-L&A6[YK,O#;VV2_Q`&[B>MS]>X,\Q!-XG;'P)/%':]%_P`?P//)O_ M````__\#`%!+`P04``8`"````"$`')^BZ(D&``!I&@``&0```'AL+W=O$-LG=7Y8:\^&EQAS;?:TZ@SZM\C?F\'?D^94O8=UL?^CN.3@ M-HP3&8&7JGHEH?&>(&@\0ZV#;@3^JB?[_)"^G=N_J_GM6:Y4V>N6P:$3U[R MI@T*(JE-LK>FK&OK0^N*7+&LY%PP=SA1G3W1$^^1T?S'7)6L(G;ZE/;=.9+SJ3 M1_PQH!ZZFY(_6-OQ=&=T?+MRV:5M^K2JJ_<)S$$8P>::DAEM>$2-%PJ]NRB= M>Y4#)4-4GHG,6@/SH"@:*/>O3^;<7LV^0HEF+&:#8PPY8LLC2#T2V9T*?!4$ M*@A5$*D@5D$R`#.P17@#Q?\KO"$RQ!O>JPT'`[,4(W@$;[)3@:^"0`6A"B(5 MQ"I(!D`R`B;PKS""R,!",B@28[&4>[ZA,:02124Y#A%8<(=3[Q_FTH,8>FF'-7*1X1Q)OM$/$1"1`)$8D0B1%) MAD2R!;8?9(OA3,FF=7O+Y@LO:2C;0(FU%.O-%I$=(CXB`2(A(A$B,2+)D$A] MAMU"ZO-X1TFTW%%&Z/&%;!=;1':(^(@$B(2(1(C$B"1#(G64'*KQ'ML-;GLJ MLM=-18]2-PRP8"^E.RP1D?M/B6GV`RU(OW88KK+)[FB0!=F*!<9P37F:^"*( M3Y,`D1"1")$8D802FK7D$AR#?MXE(B*[1,G0)4&&!J@NT2!K0<\RNJ$<9GQQ M71@D9#D)!1FY422$ND.3;ECR2,3B.I=-A"P0R4&R:TH6WB@H.+[SBNK"9;,X M&LPIAF!9Y0GL,/(Q"C`*,8HPBC%*)"3WF1S>U,E%-Y0/>D]/?;#1\GYMR*8+ MU4.>9^C>5=3ANW:YL*9R\,=\""8)O?50QXU MFD/$HQ:BBS%#-NS/O?Q2J;FD;SB(&G11'@%R:AR.P`>^TT,FW((;LS$H,J&P M!TDI,V[+HLA3;!\U2(H],3#YOH)]UM#2Z5Q>ZG-'?38)N+CDBRH>\JC1%*(^ MBOWZ*-YC MGR-:[*:AVW/75A;9@`=]4.R/Y!!Q+5?45QG(II-3[=!T M^K#\@QNY052499<+3Z=GU4/Q94GDT`U]$=Q8:`-X+`^W,KY%&C M"40\RAX,!$W`EAKB58=&D?8WDY#'`K2DL?A@U2'ABND46?VOFP1R/R$8_JM6*,$HXZ>=D9E+](WMP8L&$%"YX\&3]@WN>O`TBOENX<&#R@V^]."P:S MX<),W`%>]%_38_YG6A^+2S,YYP-36R1N;0U6U_`NY@?B1Z.E_````__\#`%!+`P04``8`"````"$`W4B1VJ<& M``!Q&P``&0```'AL+W=OQS[.+8/,+/;O5F69XY? MVZ_/L9WP\-O7TW'PI:B;LCJO+'LXM@;%.:]VY?EY9?W].?RTL`9-FYUWV;$Z M%ROK6]%8OZU__>7AK:I?FD-1M`-0.#\GSN:JSIR/,^ZL] MS7+4[KX0^5.9UU53[=LAR(WX0.F&N4_P^:0_46U>7N]_)<@-NP3FP%GJKJA84F.X:@\8BT#KL5^+,> M[(I]]GIL_ZK>XJ)\/K2PW#.8$9N8M_OF%TT.CH+,T)DQI;PZP@#@W\&I9*D! MCF1?N\^W5I:S&"YFLZF[F(/,4]&T890LMKN((%?A$ M%7!N2A:\=RQJQ>.\-<\37OTLG/VNS]4-=O0V@1F&! MFTO&*M[VF#(F$A^`3*U;F04IQ50>FL<4(EJ],UC=!8(+0!)$)8A,D)D@5,`);I#>0UC_#&R;#O,%9;1`H9AE& M8`0V\4T0F"`T062"V`2)"5(%:$9`A?X,(YC,RH)_99+8,U>?^8;'L$R403,] M9"M#I#N$!(2$A$2$Q(0DA*0JT4R"[>MGF,1DH!@A)Z4!SMPHE(T(NN>2#)$N M$1(0$A(2$1(3DA"2JD1S"?9GS:7K!Q9N*RRZ,P,GL>'$46=NN\9.LY5!V,PG M)"`D)"0B)"8D(215B39W.%:TN?.]=L@.W/LVL(:Z#9Q,EG)3V1+B$Q(0$A(2 M$1(3DA"2JD2;,QP)VISO3Y1%ZQ,5A-]AV)FP)<0G)"`D)"0B)"8D(215B391 M=K.F!VFWN.VAS%\V%=0S5/45`R9P8/)CE(GH\^?$-!DP>\P8WNJ3RR0?\>)A5(6241(+%MU-Z.Q;=HE_XX:J:JAV<6. M1LVO*PD%EV_,J"Y<=T8@=D-7DL.8Z!:C]!0R[;H>99S8`4;-.U=GT[&]<(V# M/\08R!-E5$9_$4:YLA[B'JD-C2$D&'5G""G&W!J"O@[LUJ@6_#OKP"^9<*[C M$F_8&0])Z\!2*S,V?-F**/9PIT09OOA]%,H'`DW&G>D3!Q[M#%-";`6G]6WM M"*/Z/3BF*#&[FR_'QK&<8JM;W>G^LLNHZJ]R6GY\0[7YE19Z1E\V`AGI/]?K M?(M1[Z0_EW?Z=`RP(4\T<'WJ+G7M$$-NY5EW%D08U6O'%"6(1'>..YT8W:48 MMQ758]9>C28^VMD1W\LS'J/ZL"R@*$?7R$44QHEXKH2A% MU&GI-K`+['?8(.Z[_:`VMD#]<]]6(#B3[MH@&O;E%HB&HI1GR_ED[!C%%6)_ MT/I>+7-QY5B,L6'?7V+V-W.=L;%WI-CL5G^ZG>Q.K-KY8\7,5(RSC".CF!=Z MP6W9Y@D-)Y"&M[WQ1916S**A/DFCP$)LJ!68^?HCZ@>!6U&,#?L23S#J;H\I M-KS5HVX^NYRKYK]3TBS<<)DCK:0ENFNIB.K+,+`)"A'UU1-1%"/JM1**4D17 M2II=W54;?BP'Q0-`/]:-+9!:Z1R]5^FB(229DI9&H05"'HO?G2ZN%+]0TK/& MN"1$0DDK_H\,(3&',+&O[`?O#$%/24C'M_7='M%O@P%%(:)^^2.*8D2]5D(1^WV@ZU%)5?Z^G[^@/17U<[$M MCL=FD%>O[%T^'.3K!XGY#PV;F0OVBA_G'J/8!S]PV;J MP5LGX"/9,_S@<BS^R^KD\-X-CL0<3Q]TC>7>` MG[8*>-LP'D)Q[JNJQ2^L`_ECV?H_````__\#`%!+`P04``8`"````"$`#ZU^ M;'P*``!F-```&0```'AL+W=OFPN="?I^?A^?54;A[K3H?]T!V-IL/#9G?LWCSNZ`R9[[U0^W?6_.(O"&_6'][>U0'_ORK=SX_?>^:5Z"T^[QVQW+$EM M&B=I6>PJ`_NT==BPU2)'-C_KGV^[Q\D*_S0?NS<293,F^ M]U">+\&.^>SWMM_.E^KPC[`2OK@75WBAG\*+-QU,9B//84XZ.GJB(_T4'6\: M5^_H.!8=R?UU5YR*CC/5\9-7I!E3*S57'3]YCPX-*M=8R_/):SI2'_:+N$]W M/'#&HWIT.O1QI$#LET]).^2942?:>G/9W-^>JK<>S5X:^O/KAJT%SH)YDRG& MKZZ2[KV(R=S<]>E?E:S.?&ZJ MM^0V;'8KHXEILE(F2F$@/I``2`@D`A(#28"D0#(@.9"B20RQ:3'X'6(S-[2X MT/Q00N+2((RZU%8F2FT@/I``2`@D`A(#28"D0#(@.9"B20RUZ5%GJ-W^B)?+ M+;.N195B+`6AYU=#9L_*6&4DNZV!^$`"("&0"$@,)`&2`LF`Y$"*)C$TI*?_ M%1HR:U-#3B;F4VQL::B,E(9`?"`!D!!(!"0&D@!)@61`U5TYEI#0$X@,)@(1`(B`QD`1("B0#D@,IFL30D!V_[#W5A!;` M*_=4S(TI+B>6N%,K0961$A>(#R0`$@*)@,1`$B`ID`Q(#J1H$D-<6N%^A[C, MC2DN)X:XM!6WQ%5&2EP@/I``2`@D`A(#28"D0#(@.9"B20QQV7['4+?[,52; MFRH*9"VB,TM&;:5T1.0C"A"%B")$,:($48HH0Y0C*@QD2LI.!LW5X`-)^4&" M]DM2F27;.U&N&IGINC>VI,I*=ESKCA+YB`)$(:((48PH090BRA#EB`H#F9*R M\T%34G9H=2<#VAASE1\[C.66(RM;K=+ARE%6.EL!^6@5 M(`H118AB1`FB%%&&*$=4&,A4FQTK;+4]*BE3PEW[=.,G%$-N=6AIU`D\NT[@ M*"LM-R`?K0)$(:((48PH090BRA#EB`H#F7*S@T93[@\6!WXN,2151Y6FI';9 MP%%66E)`/EH%B$)$$:(848(H190ARA$5!C(E9<>+IJ3\,X7!C#+X`W7YP<10 MER-OWEAZ`:T=0#ZB`%&(*$(4(TH0I8@R1#FBPD"&E&Q9-*3LUJ\V-\]C$O&/ M!]F'*BM$:T0^H@!1B"A"%"-*$*6(,D0YHL)`IG[7';YG9! M2UI1ABLK9VKMN=;2BIYCVYO.RV7Y<5 MR4E#US(Y//HLDG]"Z>)13R`:6QG%2B)]WVN!//WAFX\HP(XAHDAWU!JZ'HP' M#[5QQ01]I8@R[5[>4(ZH,#J:2K/S5G/E;E&4]B%*4GX\:R[7+D>34?T9L#>? M0P5-6+C-!('$76LK>2>^=.W4KL?.;&K-G$!VHN>JFE_@.I16G0%$VDH&$$LT MJP.@5V'H/[,(DTB3S@A2:=490=9N9:T\N;#RQG50CC.PUZ9"^GDO)C,#V('O MB@S@YT,C`SB:N&*8O+DETLH5G3Y8+)65'`!?=)RP2?W]?NRY#F2`Z$0_NC)` MN>ZPBG28,H!8('KEAP4PG7ONR#JI)+)79P2IM.J4(&NW@@S@=S/FJC@#AV=F MG9[TC_40*J33]P(TTX$"O"8=F+FU_^!(+`AC9S*SG@4K=K!A-8;.V;#65G(T M?('HDQ6>#N.1M>D.9*?W4K]^,H32JC.`2%O)`&*)^((PO9G,G#'D@[B[SA!2 MZ:DSA*S="O*!7U&L"*/!C6502#?OA61F`(5D9$!C,W_%PY=YL1*#([5.3&=6 MG"N6$:P3W<_[DWFMK>2X^`*I=6)B3X)`=GIO$HC$^$P`D?2EMPRQ0&*=<#QW M/J/_[6>%\-X90ZJ]=XB0M5M9@N;"2JP4H\',FB^%=/->2&9FL(K`%8\*7D`P M'A4<>;K2MG(5ZKC=M;;28ZXZ2A2@5:A1A_M(6KEJ7Q@C2B32T:<:=;C/M)4, M-4=4&,@4GB:N(?RO34GFQ9J2'(WU?:]-K;:5'3764*$"K4*,.]Y&T:JZ+ MPKU&B;32T:<:=;C/M)4,-4=4&,@8$%JO^O*7V#G[Q4?RM-SN2KW M^W-O6WUC+Z?3XG%_JS!_-NP6ZM+:@SJT MVI-DK8J18*UZD5RM:CFD%KVP@-I3V6?!2@W80M6?!:LX8`M5?!:LRH`M5-)9 ML&(#MM#W)KZT\24;K!;[)0U5JST-5-LX?1DOOE":XH67-'ZMPT>A+EM#75$+ MJPJA+RKG+5@E"%NH7K=@!2%LH;+=@M6%L(5*=0M6B&MK<:FE[C-4&43?\GC= M/)?YYO2\.YY[^_*))AKMZ&BO?.+?$^%_7,13Y:&ZT-<[Z@?,"WV?IZ0Z\(B] M+_%451?Y!UUZJ+XA=/]_````__\#`%!+`P04``8`"````"$`U/-HU)`)``"Y M*@``&0```'AL+W=ON:BJ1@5Y&VE&6JUZ=Y\IR"I0`XG(K*[NOU\[(R+##N<`->IY&+I..)P^ MML-V0#[\]N-X&'PO+_6^.CT.O=%D."A/FVJ[/[T]#O_S-?LR&P[J9GW:K@_5 MJ7P<_BSKX6]/__S'PT=U^5;ORK(9@(93_3C<-CZER>8.6U MNAS7#?QY>1O7YTNYWK:;CH>Q/YG$X^-Z?QHJ#8O+/3JJU]?]IDRJS?NQ/#5* MR:4\K!NPO][MS[71=MS/_PPO7&Z&[_$.J/^\VEJJO79@3JQLI0R7D^GH]!T]/#=@\,T.V#2_GZ M.'SV%D4P'XZ?'EH'_7=??M3DWX-Z5WWDE_WVC_VI!&]#G#`"+U7U#45_WR($ MF\=B=]9&X%^7P;9\7;\?FG]7'T6Y?]LU$.X(&"&QQ?9G4M8;\"BH&?D1:MI4 M!S``_C\X[C$UP"/K'^WGQW[;[!Z'@3_R9Y$7Q2`_>"GK)MNCSN%@\UXWU?%_ M2LK3NI067VN!3Z,E'D732>!]0DF@E<"G5A)>?2BLMJ;#IY;WIR,OG+2&7S$6 M:+7[X//O&QMK)?!IC"5NN_+TJ=X(GWJCYXVFWF0>3,&@*QOAQ+9FPZ?>2%PL M]XU5H-N\2=;-^NGA4GT,X#!").OS&H^VMP!=)F&4ABZ%_BJ#('50R3-J>1P" M"1A3FM!3BJS:-I74ED$0@J4`R@>0"*2C".."0Z;0:/QI!B*^SP6V< MC4;4`-.RT0BXKSN@GC_G84NTD"W6:<\V/PR[;@UE2@ MI:-A['09Q,++CZ_U#I.[BE)6"G'H\[2QI MQ\15:\+C$*2,.Q()I1+*))1+J&`0CQZV7<+]1M1TDZ;\%!3-.LM7GH`2":42 MRB242ZA@$">#S9:0P514]?F3714OG.Z14Y`3QYD;QT[*QE%`J59/HIU)*)=0 MP2!.'8Z(2]V+VAR^$5+@%()91+*)50PB//"7DQ">H., MZMRLJFB(5A4!)9Z`4@EE$LHE5#"(D\%N3%<0QSLQ&]EI.`H=E*>B+*6BN;MUQJ34>S9-A=S M+16$1K.=/%N!PJB!/.LUD#OM4V,1##]NX=*0#_'LGN9'#MN5V4A=V^,TI3Z< MMM3@&RU_SOY+OSAZ4ZO7>E';:%,RUU(A'NCO3Z#7\6EAU+`S&=D+''<9SCEW M'QHH$,)E"G+RS`GC2F_T;^29TA5/=#;,@S!B/N/-,K5:K<.T.7%7R7(MI7-L M'HS^AB47SGB<6SG#W)Q9*.P5,05@`R%ETYUZ_DS+4 M$@FE$LHDE$NH8!#GAU,9X4=:\8V,P(T.5071>0G/$T@1*)%0*J%,0KF$"@9Q M7CB5$5XWR*@9CG91/./(SV;62D*)A%()90SB9N*\=;^9>CHC(X^OH(B:V4$V MXVA^MZ<@T1MC*#0D+YTY/K52)B\S]D1.!J>H^\F@M)-`"F)D!)3X"G(L=X=43,-WNN92C*S6ZU.@=3+RI%SK#=F9DH+1U5M'G<1]@ M-W:">L_W]H'JXBQ7%13#:>B>Z\?.Q+8R&ZG/J'6J%5DI$\=40U`]\'801;-P M%CONRJ?_LH!\]%I61H*:23]V!WOM!3.`;VF:C\H]2!E M_:`@C'*WT8^=+IT9]2P)IK:O<$_0D0/4WS@(68_]VTO?S,51#`,ME!?&;3.P,%*M`2]&!J8>C5L\S MWDG=5.O2Z3T+X[[TUIIHZ.GSN&MP0+CBFJ_5&=K^S6"K,8/Y1D$LV!UT-=A: MR@ZF*=P"VL2Q4&8@$FSU1I1ZL^587M[*57DXU(--]8YO.T'-?WKH8/4JUM*/ M%G@5@'1T5SQX2TO1$2L!K`2]>T)8"7M7X#GJ0B"TQ;#2GEMWQ0=M^:4/BOIP(-+'XSET4MO*FR\2^()3KL#WI1"IOI4E,%WV,EW!RJIW!2YD"[QNR>?`A0=6 M^FR#"P6L]%D``SOXH/VZU_$U3+ZPHLY;MP0O#I[7;^6?Z\O;_E0/#N4K'+5) M^ZO)1;UZJ/YH=!EYJ1IX8["M*#MX1;2$UQ`F^//_:U4UY@\@,NY>.GWZ/P`` M`/__`P!02P,$%``&``@````A`%[(7&ULK)I9D^(V$(#?4Y7_0/$>L,UE7#.36O!]52JU29X] MX!E<"YBR/3N[_SXM2[(L-6N835Z6G8_NEM27)>&'W[^=CJ.O>547Y?EQK$^T M\2@_[\I]<7Y]'/_UV?W-'(_J)COOLV-YSA_'W_-Z_/O3K[\\O)?5E_J0Y\T( M+)SKQ_&A:2[6=%KO#ODIJR?E)3_#-R]E=78I?;Y>[ME)\;:J3*CUD#\Z\/Q:7FUDZ[>\R=LNK+V^6W M77FZ@(GGXE@TWUNCX]%I9P6OY[+*GH^P[F_Z/-MQV^T?R/RIV%5E7;XT$S`W MI1/%:UY/UU.P]/2P+V`%Q.VC*G]Y''_2K=30QM.GA]9!?Q?Y>]W[_Z@^E.]> M5>SCXIR#MR%.)`+/9?F%B`9[@D!YBK3=-@)_5*-]_I*]'9L_RW<_+UX/#81[ M`2LB"[/VW^V\WH%'P"I`9X)/O6?KX7^^;P.)XM)XN5 M-M-!?/2ZM;LK3/U1(9Z:H$8,9@4]A1)]KRP_8F#$;\\Z&/C$7 MB_G27-T_$9!L5P.?;"+F9&XL5N9'5K-D1N"3&8%UW>D)**MV`O#)=']B%6MF M!#Y_?A4ZI!*-+,DI&K7[UZ'SD)+_,.WU9*5KZ]D'PJ'SH)+__+P_=,@)NA21 M''=/9DH3OJT?.VNRIX>J?!]!4X*4KB\9:7&Z14;@E4/SO*NE'Y42U!"Q\HF8 M>1ROQB.HDAKJ_^N3L3(>IE^A9G=,9H-E=%EBRR5(@1*SM@H<%;@J\%3@JR!0 M0:B"2`6Q"A(5I#TP!==V_H7$^3_\2\P0_W+/;#CH.5QQ)I?@*K8*'!6X*O!4 MX*L@4$&H@D@%L0H2%:0](#D3Z@[FIH]RD,J1;=`F\ M4/S9B70.1<1!Q$7$0\1')$`D1"1")$8D023M$\FW4/O(M^01^L%&0,Q`+X%R MZ!QIK&:R*S=,:,C;G4CG;40<1%Q$/$1\1`)$0D0B1&)$$D32/I&\#8Z5O#V< MP42Z=2IWQH82V%()-^NKI>SF;2?$U6Q$'$1<1#Q$?$0"1$)$(D1B1!)$TCZ1 M?`@[$\F']-$U(4_F87<21=F=E,S677_=(F(CXB#B(N(AXB,2(!(B$B$2(Y(@ MDO:)Y#MX4DN^&W88D98=Q@C=2Y-']181&Q$'$1<1#Q$?D0"1$)$(D1B1!)&T M3R2'D9,BWB>UR=8E5]E+9*-E4 M:`;A[;JLOE3V6TXGQ,O?[6QSXB'B=UI]TTH##SHA;BA$AB)$8D;@$21FO5K) M32OIU'I"ZOK33@C&E\($AX7_'B9B1`X3)?TP=61@FC85FIET0ZSI7$0\3OM-IMMJ:KP>F^YS9"9"-")&8$GEB]X)CRA)-.K2>$@G/#DA0O MLN.2`G:E?N#XS`NH%9=#PU&O%3%$+QS808*,\SCN(0=+N1AY&/D8!1B%&$48 MQ1@E&*42DOU'SAW]OG3#?_28`MLSGAL;LE4CGH&G9B_P:SGP6RXE=QRU+5V7 M4C;2#I=:M66QUA:FJ>29RT6@SL6DU$3SN-2R6XTO4%]1F4'`I7X\@Y"+#,X@ MXE)B!C%#X#868'OGZ8*9(KWE2> M(EMR647ZPHV*[Z1$F!FBQ65HAF'.%.,N-SY871Z7$M7E8Q1P-#!>R&4&QXNX ME!@O9DBI9A3FS@N#8:92/[0EAYD<'?MA[IUN[M]PDAL]4JO]Z%,D%_E2V9EL MN>*-(F?F15TX3)$5^4(S=5-7SJ4N-P[:HL^H5>%Q*6'ZT1<"3-%,Q'Y+>G8(`5H8)XVEQ)' M$@IHL$W)>NYOD;[(B8SV,<\,05NW,?C!1P- MC!=RF<'Q(CQ>S!7%^A(A->"85%*4HT7.YOUH_5Q'9"=\D6P;G2*Y(YK*GG'+ MI6#W,Q37_@5">_1PF.)<2@@3]42F*/6HE;)M],0D1&31B,'U$96#=LBD2%\2 M"U)'C/"(,5<4C3(14CU;:D=/)44YMI!@4FQO5"(15RJ1(JG?=6A@4K;.I$0) M.QBY'(FT\3#R.1*V`HQ"CH2M"*,8HT2@@06E0@IR1/8R.9G_]PJBYWMI3T&1 MU`8INM4&J92RR51*S]&9%-OAK=<+8X%VE$P&HBFR6B.#R,?(Z$K0"CD"-A*\(HQB@1:&!!Y(46MI_J M"HV^H$)_8#_EU6N^S8_'>K0KW\C+)_!L>WKH,'TS!BZ%+'(+!":4;^`BR"(W M/_@;>)OF4]MB%(T-O&73KE7E!KQ]<\7.9F;![X%7[,_!_K6!-W,+?M+""IN% M!3_37.%+"WZ"P-PV+;B=QMPW+;A:QMQ>6W!7BKF_MH)K?`NN(Y=Y6`/N\RQR M-0??3#LOP9M`E^PU3[+JM3C7HV/^`L'2VKO]BKY+1/]H6,T\EPV\`]26SP'> M^&UL(*($`2B@``$````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````G)%!3\,@&(;O)OZ'AGM+V:91TK)$ MS4XN,7%&XPWA6TLLE`#:[=]+NZ[.Z,DC>5\>GN^C6.YTDWR"\ZHU)2)9CA(P MHI7*5"5ZVJS2*Y3XP(WD36N@1'OP:,G.SPIAJ6@=/+C6@@L*?!))QE-A2U2' M8"G&7M2@N<]BP\1PVSK-0SRZ"ELNWGD%>);GEUA#X)('CGM@:B)]7>#?62'%8$>% M`QY`)O$]>K`[)L_SV[O-"K%93A9I?I&2Q6:64[*@Y/JUP,?6>)]-0#T*_)MX M!+#!^^>?LR\```#__P,`4$L#!!0`!@`(````(0!.?E%_^P(``&P)```0``@! M9&]C4')O<',O87!P+GAM;""B!`$HH``!```````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````)Q674_;,!1]G[3_4.4=4BA"$TJ#2C\$$AO54MBC99S;QL*Q M,]OI6G[]KAVU3:G;:;PY]CG7YYY[;2>Y796BLP1MN)+]Z.*\&W5`,I5SN>A' MS[/)V;>H8RR5.15*0C]:@XENTZ]?DJE6%6C+P70PA#3]J+"VNHECPPHHJ3G' M98DK9%-MKMK*MSG<44$E`Y(= M)'<$0E`:-DH!%FN'A=K"G'&-C,Q2"ZZ;#%%S\H0MZ8N\9]T1\)":@DR$^A,& M/^D%E?S=A_-)WE'#_2Y3#6'*LP&G8FPLQYX_`OH)#.62`6.J1MOD@F"K2APS METY1(K2>-B"ZQ.^@IP,C/G0,]O$?X`EC\H8,@5-AJHLE<0JH+G!<`BH M-!0@#5^"YP5AF57L#4W!K1T#X=ZK('8$KS:XX(,42N1X!9'Q[QK;*(B;X+DB M+U34WN$)E]A)G`IL.3PR=9#2A#6-N\4[JB'GA0,?<2A4[L$_#@% M/VW+15#5Z<8.<]I>#O*NS/8/$]!RO%".IE!RN&)("UY0\_Z(T[@4I[ERUI>QN8$E&X5Q" M';9+)KA+B+(K:9!RNC$O/\'IM3E[S]J'A^R1RS?S7,W4"._@S4N]/YGXRR_' M-VRSOIM([O&1UL(%&194+B#?8`X7W'_%2_/SE%YYH$``!6$```&``````````````````Q#@``>&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`(9YIQT&`P``IP@` M`!D``````````````````1,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!@$8XO!`P``A0T``!D````````````` M````?!L``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`"1'JILK!```'`\``!D`````````````````V"@``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"55 MFX?R`P``-Q```!D`````````````````7D8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`')$LL]#!```#Q```!@`````````````````8U$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`$T4OD*0`P``60P``!@`````````````````EJH``'AL+W=O&UL4$L!`BT`%``& M``@````A``ALU%&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$/1+JY$ M!P``'1\``!@`````````````````W&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,GYI/4&PO=V]R:W-H965T`(``"\&```9`````````````````)GL``!X;"]W M;W)K&UL4$L!`BT`%``&``@````A`*K\YB/F`@`` M:`@``!D`````````````````2.\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'N.Y*#U!```)1(``!D````````` M`````````_\``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A``^M?FQ\"@``9C0``!D`````````````````S1$!`'AL M+W=O&PO=V]R:W-H965TR%W)?0@``(HF```9```````````````` M`$&UL4$L!`BT`%``&``@````A M`)?V\$`R`0``0`(``!$`````````````````^RX!`&1O8U!R;W!S+V-O&UL4$L!`BT`%``&``@````A`$Y^47_[`@``;`D``!`````````````````` J9#$!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````"T`+0`M#```E34!```` ` end XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Additional Information (Detail) (USD $)
3 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 3 Months Ended 0 Months Ended 3 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Oct. 29, 2013

Feb. 05, 2014

Common Stock Equivalents of Convertible Preferred Stock [Member]

Feb. 28, 2014

Common Stock Equivalents of Convertible Preferred Stock [Member]

Mar. 31, 2014

Securities Purchase Agreement [Member]

Feb. 12, 2013

Shelf Registration Statement [Member]

Apr. 03, 2014

Subsequent Event [Member]

Mar. 07, 2014

Series B Prefunded Warrants [Member]

Mar. 05, 2014

Series B Prefunded Warrants [Member]

Mar. 31, 2013

Series B Prefunded Warrants [Member]

Mar. 31, 2014

Minimum [Member]

Mar. 31, 2013

Minimum [Member]

ATM Program [Member]

Mar. 31, 2014

Maximum [Member]

Mar. 31, 2013

Maximum [Member]

ATM Program [Member]

Oct. 29, 2013

Series B Prefunded Warrants [Member]

Oct. 29, 2013

Series A Warrants [Member]

Mar. 31, 2014

Series A Warrants [Member]

Securities Financing Transaction [Line Items]

Preferred stock, shares authorized 10,000,000 10,000,000 ^[1]

Preferred stock, par value $ 0.10 $ 0.10 ^[1]

Preferred stock, shares issued 12,300 0 ^[1] 12,300 12,300

Preferred stock, par value $ 0.10

Preferred stock stated value, per share $ 1,000

Preferred stock converted to common stock, shares 14,642,857 14,642,857

Preferred stock converted to common stock, conversion price $ 0.84 $ 0.84

Warrants issued to purchase common stock 13,297,297 13,297,297

Proceeds from issuance of warrants $ 11,400,000 $ 11,400,000

Warrants issued to purchase common stock, exercise price 0.74 0.74 0.85

Warrants issued, exercisable term 5 years 5 years

Derivative fair value inception date Feb. 05, 2014

Liquidated damages paid (3,389,940)

Registration rights agreement description Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000

Additional liquidated damages payable 500,000

Common stock, shares authorized 95,000,000 95,000,000 ^[1]

Common stock, par value $ 0.001 $ 0.001 ^[1]

Common stock issued 52,107,465 47,501,596 ^[1] 4,228,181

Warrants issued to purchase common stock 4,343,247 6,857,142

Proceeds from issuance of common stock and warrants 6,000,000

Warrants exercisable date May 01, 2014

Warrants expiry date May 01, 2019

Offering closed date Oct. 31, 2013

Warrants exercised 2,343,247 2,000,000 0

Change in fair value of warrant liability 137,000

Public offering of common stock shares under underwriting agreement 6,100,000

Initial public offering price per share $ 1.30

Gross proceeds from sale of common stock 7,900,000

Net proceeds from sale of common stock 7,300,000

Sales agreement termination date Feb. 15, 2013

Number of common stock issued through company ATM program 4,700,000 6,600,000

Gross proceeds from sale of common stock 8,800,000 14,400,000

Net proceeds from sale of common stock $ 8,500,000 $ 13,800,000

Number of outstanding common stock shares increased 47,501,596 52,107,465

[1] Derived from the audited balance sheet as of December 31, 2013

X

- Definition

Additional Liquidation Damages Payable

+ References

No definition available.

+ Details

Name: mela_AdditionalLiquidationDamagesPayable

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate consideration receivable for warrants to be issued.

+ References

No definition available.

+ Details

Name: mela_AggregateConsiderationReceivableForWarrantsToBeIssued

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Class Of Warrant Or Right Exercisable Term

+ References

No definition available.

+ Details

Name: mela_ClassOfWarrantOrRightExercisableTerm

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Class Of Warrant Or Rights Number Of Warrants Or Rights Exercised

+ References

No definition available.

+ Details

Name: mela_ClassOfWarrantOrRightsNumberOfWarrantsOrRightsExercised

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Class Of Warrant Or Rights Warrants Or Rights Expiration Date

+ References

No definition available.

+ Details

Name: mela_ClassOfWarrantOrRightsWarrantsOrRightsExpirationDate

Namespace Prefix: mela_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Common Stock Issued

+ References

No definition available.

+ Details

Name: mela_CommonStockIssued

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Convertible Preferred Stock Initial Conversion Price

+ References

No definition available.

+ Details

Name: mela_ConvertiblePreferredStockInitialConversionPrice

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Gross Proceeds From Issuance Of Common Stock

+ References

No definition available.

+ Details

Name: mela_GrossProceedsFromIssuanceOfCommonStock

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net Proceeds From Issuance Of Common Stock

+ References

No definition available.

+ Details

Name: mela_NetProceedsFromIssuanceOfCommonStock

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net proceeds from sale of common stock.

+ References

No definition available.

+ Details

Name: mela_NetProceedsFromSaleOfCommonStock

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number Of Outstanding Common Stock Shares Increased

+ References

No definition available.

+ Details

Name: mela_NumberOfOutstandingCommonStockSharesIncreased

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Preferred Stock Par Value Per Share

+ References

No definition available.

+ Details

Name: mela_PreferredStockParValuePerShare

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Preferred Stock Stated Value Per Share

+ References

No definition available.

+ Details

Name: mela_PreferredStockStatedValuePerShare

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Price of public offering of common stock shares.

+ References

No definition available.

+ Details

Name: mela_PriceOfPublicOfferingOfCommonStockShares

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Proceeds from borrowings and warrant exercises.

+ References

No definition available.

+ Details

Name: mela_ProceedsFromBorrowingsAndWarrantExercises

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Proceeds from issuance or sale of equity maximum.

+ References

No definition available.

+ Details

Name: mela_ProceedsFromIssuanceOrSaleOfEquityMaximum

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Public offering of common stock shares.

+ References

No definition available.

+ Details

Name: mela_PublicOfferingOfCommonStockShares

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Public Offering Termination Date

+ References

No definition available.

+ Details

Name: mela_PublicOfferingTerminationDate

Namespace Prefix: mela_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Registration Rights Liquidating Damages

+ References

No definition available.

+ Details

Name: mela_RegistrationRightsLiquidatingDamages

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sale Agreement Termination Date

+ References

No definition available.

+ Details

Name: mela_SaleAgreementTerminationDate

Namespace Prefix: mela_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants Issued To Purchase Common Stock Shares

+ References

No definition available.

+ Details

Name: mela_WarrantsIssuedToPurchaseCommonStockShares

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Date the warrants or rights are exercisable, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(3))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 3

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Date the entity entered into the derivative contract, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: us-gaap_DerivativeInceptionDates

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Describes the event or circumstance that would trigger the transfer of consideration under the registration payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Name: us-gaap_RegistrationPaymentArrangementEventToTransferConsideration

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SecuritiesFinancingTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 14 0001193125-14-199057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-199057-xbrl.zip M4$L#!!0````(`%R!KD3W+I\3ZWZ)B%U)T-B0%W!W\O[Z/05V`C:V\07BC'J4 MQ!10SZESJU/G'/_TCZ?I9/!=IUF4Q!_/R#D^&^AXE(RC^/[CV2Q#83:*HK-! MEH?Q.)PDL?YX]JRSLW]\^O=_^^D_$!I<7P^\)([U9**?!W^.]$2G8:X'GV-S MQTC#Q=%LJN/\?P:W8:;'@R0>_.E>?QG0+BQ\_?IRGZ7CQF/-1 M,KT8(+1XQ>_E[#X,!M8YA1E6+ETGLWC\8<`K'PU3'>8P?#"&>7P84$PXP@(1 M_BM1'["$?_]7'9T\/J?1_4,^^*_1?\-@&`EWL,'U^?5Y!=A_#KXE<0:CIX]A M_#QP)I/!M;DK&USK3*??]?A\_M"GVW0R`)K&V<>S"CSS\7F2WE_`*]A%-*?. M63GR@[DZV3!^$L5_&_*]C#1=FM\5]\PL7AJH($\3(XI:Q?GU1 M,:-,C\[OD^\7<*%A^%1/PMK$S`?`G,"M.BM8QBPU9J]WP*OSYT>=-4ZJN-+P M&C.3<5Z?V!R_N"@OUH9&C4.M?!:FHS29Z'9"6MSQD.J[CV>&2]&",\^?LO$>,MQ>/5R4 ML,Q+/US-;B?1Z/+N#@@3WU_>@?*:)O&W/!G]_>TA3'4V&"5QKI_R:S-/G4QN MKGPB,;=:J].:W;][-HTYO5DGR M^9?@`)J0LT_DG+T0I"7("EU^T?E5FHRT'F=!FDR_A1-=NZ$[>AR-+]C9)\FJ M?+$-4XTM7L=]SK*9L6"7:7F'_\]9E#]_#9^BZ6SZ#NA`@0YV33[:@JL0I$*F MKU%L+KK1N."KG2F@*%#@8%FP'3(4?N`@V[<9XEPJI!0/4""4Y0^)[Q!XZZLL MO(!?#Z1$.W=#@$@:Y"35XXI\&&*!9[H;8(XI%F;)&;45?H+_N;(V:L,FN(2X MOO0#"Y$`+#)W/($4QQ(Q/E1,>BZSE;JAZY#YQ6Q^=5>]N(T8R[PP?]WQJ"///N%SR5^)LP_HBEPL M+I7T_#6YFJ6C!["PAQJ0OKE&`-?`JR3\FPM*:V0UM5GCM!PV5N/?P\E,7^FT M&-PQNQR;*J`Z255O;D&WEA)78?J>R4",T)!F,BQ#J]D,<._3/+J=Z/H]GV'B M43@IKYL=^SZ&Y*V)P@U1%'\Q*SMA;;:LI3PM!&T/0T-5S;*V@XPE9\0/`N0J MPA&GOH\0[K?8[9$3 MO+`;K3%UYTX8[`<:AE;(V<)[.F5W8B,Q]G0GVE/'>C_N1*]E1*Y'?!1(ZC`+R.P&WDVA4L1B8]X&084C@C`JW8U7$;N=1/=E'+\C MH'A?G&`SA,5>_<=-D]^TGI\!%G!>?@T.9^EU@K,U@@OA_>Z[[P(T\#S#5#P1 M;&/P:"HT>)RE>AN+"TH<%M@*$<<9(A[8%K(=5R+L.YY+W8"Z4MR\>(UL':EV%,(!Z1LG(C1J6P*9")B"3P[!^2:4DOU1BA:48IQ1+H]!J;&./OAQ'N7/*T[;Y2PO#O[!9N], M$\[P'KM6-72QH):-G"&87SYT/>0`59#E.,&0!E0J/[BA)JX%V@><,@O,4#L` M2Z8GS!Z<>&Q^F-CX]W`"!BIS7ER4PJ#OKE@8V<_U&%)'@%?M(2%H@+A-7/`L M*4<8=N6"N@Z&`>7:,[/XQ.(P#ZMB4]K`Z5TPY@3I2S"8$8RC*(]FQR;0>D_? MVR9X#Y.[RB:M+"XWT@%6:(,C_H*D'MI\#)_-UISPW'$IT(MX7D MAV\XVC'0:P1;'"UX]1;)920OC"+F17F`@K+"N7 M%B=;E-Q:S$T$-8RO%*SZ\XE+4J$=.MD#8)]SOE!+Q(SM@- M56?'T]W*/=W[.+H^;I^PS<:5W;P?;PF/VB6\=>@JT9G%`&1P(1#L M6AQ;8H$E43=%VIV%;657#\F.!7:%A":.DUV%SV:7P<"0`O_3`E;6/8KN&V\[^D4-I9Y]%V_`X@$%)CB%E=6[=1W/8*-3'JM"RD` M$W;2F$&(85$E70JC,:?XV'X&.4FFV7?2I+N<3)CA!7E##.[:JJV(EE"/IDD/TQI19"D M7C*[S>]FDP5?O$:+3I6IN0FJ8E7Q1';"LZ3"9OK7Y)T(LS1'IH16%/3ZV==1 M7NL\C&(]]L,TCN+[K&;'[Z)1='IH.6P>$)$6H8I7#>YV*,LVJG12K_5W'<]. MEJF),ID#1%F\:IR:IKX.7IP/X6>4_Y+$HQ,%28T'13"X4$T@5P&LC8R["S9H\KF6!RC9O8"*,.^G,,W)PGZ;,AR/R`HF@_ ML'OB<-=P85?(ELZ@U\]^[=*>'"QJ&6??-MM=WKB*:Z&8/.GT'NQ=:E)(K4D&W9NH;S=\I+Z`Y$E&*K3>`FPQ#E$^+;*%X/`1'1TV7O*H@]Q-/EXEJ@7G?M/H\G,G&#]G"3C']%D#,ID//EU! M(R8K1=6L6N/$FWCT],`T>B3E9+O/ENQ!*YK`-*425]#MD"BY'/5YW0T#-Y^J MP@%#P#BA9#5HU33]-=XE##@Y8";CUP+1HTT.)4QX^51H3?3\YS3)>I3$EN<% ML/FQLW:9Z"A!,M>GJ#:`6,.M/2^IP]3059@@?UAT*&$,V=P*D`N+ MRQ4UI]M>*8C"EJR97QN6L$A>C<;^TZ..,PWK7;$KIZIL)!A#"S9"]8/-;3!: M2NHI*B%3*6_;@@K60DY7E%(WB58O.9/48@"CL[RK@J7I70*2B,BG5,PTVCT.6O5'2(N1:=-;$2[7@]8FNJX(_ M!1"D8&B["<3K)/N7X=UK$=M"ID:&%[6([TN&CU"SVYY*_'@UN]V*L#H`9"G" M"F&.S-;][43X$!"%")LVHZL@WE"$!>U,A%DAPHO2A7_E16\C M32.FXPLQ/P!D*<3@AE+P1-]2B`\!018;@E40RT+G0H=R.U`Y MWMJQ(*4K?@`+(EAO=%BT,K).CA_ZID/)#V)O?G@9_E6'V2S5)EKX1Y0__!8G MMR8AQAS2?(X?9\6A31*/HDE9*V#^G*5&_;AA%F6+_(7G`X[?%KTY;&I;A,-? MMK2Q^4LQLM>!!QOZGN,RQ'UF(4X]#RDI!1HRC]C8\SS&^4M#:X9)?1O3"6%: MY-V_-]JQMNGXW9^*&=@P#Y!)@,_7-%H\QB'9'+?`ICN&M=\Y69<$,%;)7K/# M/0)^^A)UI52Q-N-G5'2&?U$9:F.AU)['I-W"5PIWM_Q\87^Q8I9%]L-_ MC"/3&QO8G$O3X$=:HL,3U`6_@YZKIJ=L.D,]*K[]]5DK?`L;*+C)7+?>`J`0 ME+?XEI(]`2Z:^#!8P6H8;A.^+O*,**&==F4K%;-]]DDJBP!%#\HU.F(+&;:" M^X@EV[1H(<.EP$38U3YT/;>0Z1JD;`6R^Q8R7>-D1>.\EG/OL)5*USA/J)5* MUU!/K97**MX.&VC0DVREM5/C>D8I.6JGTS0FGU4JE:[FG6U5Y MD[DZ5K^1C6M[A!P\6O8;X9RP=]-OY`":M`L-%,G1X-YS4N^N<:K]1GI@$A.B MY5+9=KT#2_?]1KK'9OJ-"$L0A2MGQSVV&^EA]>R&V/";MAOI`;,P6V4;OVV[ MD>YQFG8CBMJB%L/LO=U(]SB+=B/2'%?1:OW1*;4;Z6&Q38$`82?6;J0'898K M98)OUFZDAU4NVHU8RAA<60G-OTF[D1X6U[0;X1@[*0#H#7+J^J[+PAK.:UZZ7S1O?\*<\^*6E;]15\N\X;W0,V M)P*6C:7B+7BV%P'M,?&9GE;B\Q(!ND]\IJ>5^+R*O^/$9WI2B<\K\+M.?*9O MF_C\@K>WQ.>2WTUQ4Q^)S\OXND]\IOTF/J\`[#SQF9:)S])NC$=6\!65I;^$ MV3C\Y]@Z9"C\ MP$&V7^"0"BG%`Q0(9?E#XCO$0#!<>$44]N85L#O,LXIN_I7+PP3:X^/7*O\C4Z?]UU2WIY#I&4X67U7=#E5%@#:U/#`;;%.*?APB M[`U0@>"(OS9]\_K2?'?0?J\9$_OK0PF:9K\T.-@ M%H^SKV%NF/YY3_W.2+F.]2]=7X+9Z@O5BV8R5YQ^G:/<,,MJ&X<*%Y=W%"?] M\?BE@4696[RKF.[R-=I;Y+3MET*7S=$6&?.[H:M2I"#1Y=W/9L`.J-F<4:EJ M8%0L.2-^`)Z&(AQQ"OZR0UV%7#:T7`F>!B6\;#=^119R6)M(59]4TN!GZ>@A MS+1SG^J2=1??@EWX*`OX>Z/8W<-J"=1$QHFHK-3NH-[(0E<)=*");D>K>1WE M.S'1KS?67"&SX>-[49QK>ZT7J;7MX.AQGY9'3Z)JMEH@JHOOSV$49U]`.>KL,O:? MS*G\+,H>C/*\O#-]N7]:A'N1[OQM3,$K4P^#[U6J6;*?YB7ZGM;2O8>IUD M>TB_)Q-@!-,6Y7JG%EO+X%[6]'&6ZNIBKK8/:PGR\O&@RRWT'K$X?2]S"DLDNEF\-G$E#]<"(=N55&D3N/+&Q37BW?/`QE#SK0 MB\S$XO$Q->#F%,668LM7,A07Q1:+*N:CR\WV6NW5SIMMY<@"[L#GI+))W0*G MP[5O,K?SF-$&4%:^@Y4=&0$-U!A*6\-!'-L%B7Z7HD2E&F8>FPVT&8VL[R8 MS.7=\KHZT]V^IJB]5F_<)/M68/FPQ_`IQH@[L+E2V+%1$-BVZY``.[*4KD_$ M8H+5$A:/@;-OM@V?3HQM6)Y'M3(]XWP/U2TIQWC"(*-FV#WS@,/T*.P6AJWV/;.OD%D480'!&@` ME%K[]9N9A9N'2(H'=$3,(9)`56967I65E5E#PPJ*0++:2DLK'CCO@]M2QOX\ MY%-X#/@=!@QFF-!Y/1DZ/TY(!%G5^VJWVP-Y;8/]Z/8,J6N`O-IZJ]_O=NQ. MVY*%$UNN=;,.]$KT(PD+3W:Y6_ELG+:TB;BN;2H6]?GABWS"EFH^Z"O0UP8S"W:&D M,N[XVB_7O.U-44]>^-]]D'4/"SIA-.QRIVR9DRT[G=[HVJIXS[-0K4A#F8?J M28L6;HATRX#]8T$*EB%_RFPM)][7T$CAD4-;UUN;;-0R(I4M\0M2;^!`2JJI M%KWS+74;6*HZ6%X->K5215Y.LE)%LGXX@N:'-UK% MO>8&^+>YB"[2Y*HL43_,52P'H;4L>*I8YF@'G"H'M:$;\^O)!!T%P?SH,*1I M<;W@I(&7+6E@8JT(I7C+Z&DLME+Y(H#S$E6^0L7:*M[P\[!3T=GK;9:1+ MH;):7,<2R-7"BA%WPA$JOS[\[@6TN:LMDU+]/5,M%;#?B,)3?A=%UK/`8KVW M)XA\NU7N&K,U/NN%EWC\NEST_K`9$8<17KPO9LG&&LE=B47E,+[@TEQ/,L<= MI:.&RXTEZRM6>A,"3P<6A2Y/=O&G#;]MR^'@>K=T96,@?!F/-<<;B0*H89@8 MJQ>"!5+5]HJSC13LXMVI)!8U",(#728[FX$.^:*G M-TE;XH@U4PNW#,K@%B_#!/X(G,GS^8%;XF-003(Y;?"\&NPB7CP^EBN8MJYN M8Z^IK1H=/W&+8M#O:3VYVY5L>V!+>HM(H("`]ENZ90^TOFUKV:5'1;.*UT>V MP;-`EM*MNE=$&+HTIQ<)LQVFJZ]:[MHK9A\J+">_/8L`X&";9A'_)70*J.+I M47;CU4OPGZLVJ`#:VM#[3.HINP\<(4P"GHHF(< MN,[R7R7"0>6?FG?JK2WD?_G2TOC?"Y'=M,\=X"KFQ9;O^W@#V_9UU^E0O)R. MMA&E^B1`8RTN6;-`-^H6UG\X1CIT6M9(T8^?$5T/6F)7]^/04L]JVI5/Y@]( MRC%W/P]#!V\8W3S.;H,="CFWB^V"E^\D][JRH9JPX>NU6I+>Z_:ECF'9DMGI M#'KJ0&V!$A'W<[_:EYW__K0$2`Z?#>C&C]_X'9VZ^O&5,]O95W@FF(H`D]WT M+NRKGGW38!=7O2;[=/6[@'P5B#D"'5`(8U0*`\_9H:7K9LC;/:6+V9$2UL`# MR"U9LA2U+PU,3;'E#@S:LP3D$^!"+N`L05*E\,#U>-@#5^8N"'?H5'$0`L.F M\0:D!0!@W_@/\X.Q\Y:`TJUXZ1]E0!&.9>C$D9_MC_?QT)\)IBKH*0>/!`ZWH4_YC_^SD_-RGC7"OPBV1`ES->"E4.=U-W-.>7`Y-X2 M<,Q^DL#%2VF]#JQU8B?6Y!R"!]KC'\HJL2N`5$E.@)^]`//&R2G/4AB2UEL4 M05ZZ1Q0-`:6NM\:K1:=L?N"WG] MBQ=_&;OW?[F+OP`B^&G.HOC1X[]\^-KY]K>+*ZE[/1Q>?_W,Y'G\A0VNKX;2 MS<7_VI^9DG\QZ'R]N/S],QNZ,QZQ*_[`O@4SQ__"DB&&U[_!\]8\_E"8YQ;_ MMIKL9GC=^[O4[=S8?=:[_OJ;?773&5Y<7^$SG^@A^FM^`A#-'$*Q:73PAE<$ M3M@8#$@\Y:GI^(LSFW_Y\P]8@?:7"(#!9P,Z$V%SS_$C-G7N.;OEW(>A[M!R MP^;KP8VGC">15S;'RFT1#.K$#)L8^P'S>$1?^#35S`G_X#&[1_\?1@DF]&TR MEWADC,*<_$"S-%ER,I--FH$.0Z"7R1Q_#'_(!ON-`,6I[T02FO?(8J".1%?J M61"R.0\G03C#+:;X$L%(QL=ADM-Y`)'2J)W1*`C1T?(>$7)=SQG](=U,`UCX=+S[M%L4FP5C M[B&=800GOUL(?P.OT&2""28!-C6D,?&@YO/^1%+QBR(9Y(+$"H[OR,O22-.F M<^Q(].[UM[[]3>I=7UYV?KN!ET:`C3./^`*-]-7Z>.^-Q^OG! M'6/SNPF\R3<0$+T M+#81;2\DCP2HMLOJEB&:4HF47SY8ZQ5`_DC.?NIA'M^"\Y[6H*#K[F"F`)3= MGWL]VQX,UC!C',R+O\SWU->)=;BT!T-X@<^^L*']/T/IXJIO7\$W$GR53I-6 M+V&>.^%+1N.@,O`TQYA-(Q^#?(P#^SVE7G7O^6T324CR=; M\Y;9M+05T[UVF MD,`/'D)'$$IM*KJD-G5#+!V^#@XE:9J2$I3LYZ"\W7IE;0.%GMTN3<^ M+5,)ZO_R(5F%%8N7;Y+0?=I[ICT8Z4BPE9GG$VWSBE\D8:/"S9;G!;_6'.=> M^/-%'!4R;/^Q<##N2??D+GR*4.`L0U%<]\"1M*[:[QD]M2/IJC60=,TTI;;6 M5:6^8K7[>F_0LK7.J2-IA6UYAT6+VJ" M88,LT`"CS'@\#<9@4NX>*;`3`?^X$W=$X0H_N,6^U;3)=VDMV`(#1#!\$M]8 M&11[$,?4X/WEJ=Y9L&LD3EJP>`8!YR(4EYA4SK0TH%6(N4Q='N*N[A&#'_#S M\A8/8UMZ$BSI\Q''8H=+#V@8GX$11,0D>H^4[!8I,5N[1TH4]7"ADGW&>H^M M/'N/O2*>DGVH5Z"@L.7>A-!*_5#":6-,87>0AM\%K!`YA%X#H/1]O,SMB?.Z-B'Y%I?*\?YL2!C38=^;-TTV#*EF MV"/['3Q^,S7'UU6EX2GOW<\?V%XYV= MU=I:4S=KS&L(GU9C9JL+:^&[N$-,.ZZQGS%!)SHQ?ST=T,`7MXF4Z4W+D(RF M;-&\QPWH'8)/C::V-YL>*:KSS$!,]1K\75+C*/#3*LIYC64;Z]D-@R%\$4UX MB*U/W7%2YN%@26O;-#6B_-;O6>H*<-TL2N,21108-7>*6'9YIU',$F(3U^-C MYK"P^$H$!*-G,4&$-E=,L40`H\$>IBY\?G`BS//VG!!>YY,)'U%(Y_:11K^Q M>_AJ9QZZ'M/$FTUV,PT6WA@><*-U\XVH4@Q(=\AGCNL71L98SBP(>9)]Q(G: M:=M9-L(J+6-P4V\WAM105&D&:SC%O"(W&)=) M]4#0WW(6+6[_G82IG*R1%/.23E)`C['H)(6S)3E$\WD8_*"D&^^1_63(TJ9H&'M`IPC(^\>-5 M$//T8DK2\NP(68UFIS48&%W)MKI8AULQI*[2[TF]7E8DP#&+'HT\A^Y1,G1JU-T4(^TP97AK:>X;\%:6I[1UY?8LQ?_V3:G[* MS@5?DD"GD%LOC;6?B[C9UAJJO-5Q6YW0WE>BF\J147WM)EN1/VG*RY3Q#/2W M)^0-RV@U%/VMB+G_??0'.]=PS8*YJLR0H0Z'X/"+S(XG(K!"27?7242?< M78CKO^;G<5UW@;>8R5".9&\F[\[Y#&=\[F0X/M?T*@U9;S5,73F+"7I5W/!N M>\YO>S0P!>-@<>OQ4QF?_6=\_=9GBWRKO=,LMND"MF=#^_.EN0PZ\+_6P)!D M`RMU&5U%ZO8';:EOVW)/[BNRT=-$NA:XTH;Q9"^Q@Q)@J=?'ZA:>!T^$Z:N: M;+24CB1W-5W2L1."U;,[4K]O&VW#:.EVMW?.1)B4$G29D*=D:#`'JZ)&\$>2 M!Q.]^428MOJ\1!ACCT08[7S9*"]KZH,-]7;O%6Y..%A3JNG8R14GQ'#U7<-S M(;EF\[,R!20M8T<#[9OY<5`$WJ7HB;2=H]S&K8TH%=$\\`7=TZ*Y`;7O$9\L MO'SBR[1TUG$$L`XH'.5R]+K;SH=Y_+T`W%:G;Y=XW02WK\R=SSG@]CY, MNL+F^_R32_BS3YT;LJ4U3/,\$?]W='>2.$TRV+X%/(\X]VLWYM>3B3OB;+(( M?3=>A+P^;%T7D7]!Z+XUD:^+@'_EGC-P?8KW1(N5%^N, MCU_8/^UOPXM>YU+J7%[\[>HSR](=$D+;@M`P`G[+;AZCF,].[_0_5V`,L)%* MPU+,^@O,&T-WE8R>3SL\1S?4)?.AJF/>>`9;'9!XI]JAJ%93P7C/23R4Z6HW MY+;>4-KGB6+M1*AW\AR>/'7DZ%>^4^B,1HO9PA/%F/@\Y"-75)K"D(`SPR:K M_R=*2>REL%^0[OG9!.FR&FU][UM9?ZVE4#V7+$9#E[6&OG\=@7J2I8X<_+[S M>/>AWZEV2.D]:#;YNY__S"-JM=%N&PW5.$_D^N@V94^J:`VS+3=:UGD*];Q; MVE=I:=_43:%:8/%ZZ58':[O%7:NGK^R4K_CT^6V<=SD[^+T>S33[IM(WI('1 MZDOZH*-(766@2YIM#08PH&EH@Y/?Z[%6%,!L-UG?[@Z)J+?96IRB,[M9*+?K M5QN!*8;H\U4N+`R&^96'HP5V8!_RT=073=#^ M%@8/\93UG+D;.QZ[\$?-!G,8EHI>4/LR\3T6NN9A`P9YF/*0)_6YTWEO@Q"& M@7E_,MG,]3P,D?R,#R0``Z2]+Y<`4_ZY_^6OS3^)EO/X`W-&HW!!K=Z3;IK8 M/XU::E*Q;1E;53;I<2Q1GMZFPE<1)B=BNLJHYK;`-A]GGC3?8X'O/:9%NNDF MEAO"SXH*[XL7FTCG&SZ/*_<8%'DEK3W1^34.V#SD,`N,$V?8^&.8V!WG)*^4 M[C:;>DJI!L`Z\A9X7RH9`AL_(H*(Z(03`7[250/K]C5POHC'L4.?>R6CYP93^DCT'>IF&W2%?"2.!IX+&W?1^2; M+V!PK!T?X87)[-;>RKY_I<+7"P2=%AGT-PQ4EI#RBU'AMBO.X,!R!/,@`CE# M*/U1*,K7KV\YZ"^01>G=13Q-V@OF()<@`T%RXPA&(BJ)+BKL*^=$8GBX>/=6 M2%@^>C(D=C.$`49IY7IG!-8#*_8OD@4+1V[$4V*E!$4A('9.?D?R8H55K(HO M1F8/(*/@M,<@C#]@N/6KVV"WBS@KG0\CC3F*A^MC6\4I]TL3HSJ@M89G\=54>'"MJ$%F]0$S MEZY5]"T)4ZZ?D=TJW$!+G2TS_C).E'M&HH)I^=-_I0(:\A%W[ZFY1"ZIN9PF MU0^74(8!,O9W"CPJ.!`%IZR0L:Y@SICI\J0SH.?J`/@8A`86QP6=`28#3SQ05!8AJ"L>"8M8,/J3!:S9F%77 M<(/61EX"0Q:,2$D+FYPP5=X6->>FW-X5%'K.96E;D1CK6R//%!<9S9MA:L*, MILKIUO$$[SG83&2\&"$4BQ!^"E,=+I`HB2@I0[S5C<.`B09*`'LL/**.2\U" M7-^-D6HC@.P1OR9,4CP\X;@L\Z'1U%)J"G%*#1IUHG6RUK%('!A`##JC9FRB M]0F0)=.-Q M,*8Q:)TL52[Y@5AT@/TS6=:O`O*HZ!B"QYU[:4*ILDD8S')_`-0@IVH%I$-0 MDP,$7DG=%!@%EW:R\"9`521ALO`%908#"'76V#1$R">)RX6%9[_B?A(-H1-Z`6EG_&46C+DGFB@3W]\[P`4+Y+ZL3H7X-47K M5JOL'N\P9S9$1;K8_`!$EKL%G:&@SP2G)C M&Q5+4IZ('.BF8J13F>*@F(5N]`>C3HK9MB3=V804$)BUV$&Y&N6B$H+;5%NY[$[)>Z M8-&&+N2IQQN1^^$430-0M+)-0W*/)2.)B2G#%.JEG`@=)5P"\&IGY1( M,TC43MXG*N,D\$VXC][W?<(VGCM)B8>Z":?)Y2U[371";[).1$`L(K(OMS!* MH^3!5LF1+H>`+G/HUOB-C62(%8LXX;!_%2W1:6`@Q)S@7F52R%4N&A40LJ+^ M[(.9N*?V;,(F_\K'*)5%Y5E6N)V;'HP)PY3U:[(,H.M%XZ^URLP10(K]!"YW M1%N,%(JUUJ)@*S*C5:!/P;5>3]2"G[UL$&A+EKG4?D!3DQ^=<'`!2">G-"D1 MEE%E!2'6^A($],@#W0SKP[$O?;*JI7T,I[).Y]$IG8C@%E+[6Y7EG1L:>N1,E03[WP,TSAU';U*`B=Z_G[:CY`FE4JQ(#Q:'+7J@V?LE1,4`X+:* MP%3JTB(\&84S:HFDLDG7JPC8`7/M'H?G`Y+NHPP@2 M\AO)]0;:B#4CESFQ(E2[*HF_40Q+;$9E^JJZNJJ[XO7_XF\RA*!RM*YD>%$BVKRA#C M;^_@=X\"M]1^+CP M61^5;Q6A$FX)T)O8#*TJ:+0#8PR&B?VAWTB@?>);V`AMDF MWE'VF6!UB.TB#)A#J;=#PC.X(DN&[Q@B(N(JE'SXB#(#9GN/]#\9*3D93-2GP0W1:RDX(L]SQ#8<9G40$1EG M:*#*UR-%I)WY'/E!WM$%Q/IZ)%H)(XS_'D>@=.AR)REZ!C1D!8%2,@5/C'"^ MM.HX11`-I"E!($DO70.A:\#N#&9=8U2D7O+8S`;YOK@B%=I:[F_OUWD MU6G(AR(25@%>+&+2=2"QUHVK6HU5+(]IS;"KM4!_+@G..0OZ\]#QO#"_31'< MWIO"5:@0P%_UAKL0@^-J2F)E9C9W!YC9]J-;?ZA.XUY9/D^ZM7$_^M_H%;G=UFB!G44YI1N_6 M1:UI-6QWAV4-^K=R:>4&A&U71.N&)3]]Y8DKIW]"XM.&Y6MB#6887X(A3CAM9AKTWC5GR?I'@G MP4L[HI'RCXC8R-FSF!<6+]ZH4?,*%]U2=<-3#7NAX,';\=.MN9)P)I7>\1LS M>A$BW8D-)G;7?D$W.[ZM^N[*/O0FI6*;&F.^G$A%.N+J5MP][9U8G!K6JW3% M7$BZ0X.".1SXL'U3WO./\3#M3YSA,ZY\5]N>@YV'`_-5V]T1Y;Y/^_F0((J6 M!OF96\!109I^^S)G^.TRG.%`"F:LJU!D03YT_=VG2_=/]^L$'7HM0YN80D%? M7\FN'CX^#8;/<8P7D)<,L`#PEW[GB3?2>VY@<==>;!.&;EO7`UOSVXZMV;X> M:H'1L33';'I^I^U:'4O?)GWZS51=61SU'GB^7`2SJ-R#X0Z%"')F'4U<(RUP M$`G\EE3GV!I$O7]IUP]#0,!A[8DT-UI?3).%Y`2W*(*X41=E8/XV&Z6A&P_)?ZN=A MZ94.%!T!\.@S)"YN5JA>3O813A*83YN,KM?4MZ5#.S4&&R:!G_G=V!E'6>L0 M-9.O*R01A*'=;H5MK=/R#N/`:!(,3N=@#P.LN&67N803TPSL&Z8RV.U6E;CN=K@=GQ-=MH>UI+UUVM MU76\L.VT3:]IOAAK>8RR^R35R/[_B/N;_4ZED?X)-)*6)_^)/QKB][OH,1D\ M?YRC7="*MQK*5=@FFU\)VNV+;^IWLWIK3>?1H6:B@MJ?[R M9$8Q&T<2R^+O">DXS4S+8WBI>(\*B!PQU+>19HJ2R-&0XZY!["K#XMD2Z-K\ M2ML30+8C#V+ZSR)8/TM)?WGCG*4`_#W,GFN$?K?;MNZ[?J!91CO0;&)C:2V3 M_-KJZ*;AF&;;,^V=``"R&\K9^>]D3UQ,,8&(&SW*>9#VD MUCDEM6:14HK20`03P&0`Y&/8'_=$]769]\I@A'4WD)N'NDG&Z88#)\P`==&X?4X`@_")1/- MTUNNB'E]@?JSM"BJK<#"IWB4?<0WN(48/%D\%F,7-<)U2BB%^01,;]@9T4"C M)?4,1G0(D)?1(,[E/X.XX6&14:PD!B690,T[*G5X@,-NRH,E*K3`NIM&[[7) MXQP-N?9MR3"\GABW!V[$F!-[@)LX%,(&N["R[O&$(L-O2ZYX]Y@NR]]\TO>K M+UWLC5RZ+/OWK;WZ[=Y"S$\\GG&7LXVBF)I&6%WFO88N'T7JA0+[6BZY=D:N MY&'6#!1P:$'L>NRA:VH/;31J"1^NF-H'I-&&ZKON*A'(U_;YT$9Y6&%XV!\, M\0R80_K[5Y1@F;;J^C5GK>Y*L:YE>FI3U_=!PG?W3`A$L&?OI-VT7=5VFV]# MVDV3#-:J>;"'EI!^.`4FZQ+#MS5KF[!/%EZKP099Q%]=W-CT+%4W:SYQU5-?0?*@_;9]KB2+FB&MT0!Q*-8Q,Q7,T?V:).=6I2O:E4AFELJNJ]; MJ]9).9HWNWI0'\V;HWE3>U6OH[JV?[A6S>JS8AF[8B/.D%:;^3#,:0 M[;5JFN`X3>A#E,K]G=*/>\EC-,@Q.6(BB=#0;;=IA:[6?;+]INK;>%%.PVL`FBK\E;LL0J2W/AZ.XSK3)CJD' M>JNI.4;7T,B@#,WW#5=S/,^V?<=N!KJU$VF3AMY0KF\NVO_\?/&%;(1K.:U5 M"?_GV]G-GRB9XLY4EO__TC3EYVTV4&^'_6=%TS8P"K=B$/!#`C]<%@0KN.+8 MWZ3H>?48-M!1.>$0*"W&HP=&I@$Y7Y`;35I'IGM0/W1'0695P1=SPOFR,>\M M`@I#483_J]XP=$&33;^#)&_]&)A!*&L\:0*/<)H`2EN.4^#LBH`;\1D2-"7. M;TKASM!E\?];Y(^*@`9]RG)"'IT" MKN.P-^6<1,R#9;0NO/@C@TS&TT3R1H'C\YZ\Z9YA)ABF:I6DXSK&C-N`M$M. MB6R44!JEB3V@2L)")86RG+-L7R%%!@H?$2,0-LJWWA,-T_Q$,A+7-E7?\:1^ MR#Q&D+<8`3D,S\"G3>2<4(D+K&]34JG31!YR@?LV&M*%H/,]?H+9,BS5;'KP M;]:[(2R4`I-I-NS%,=)0X\",AEVP[^)>+-Y#,_W3"9IXUD?/+L\&[*WD\3'N M)S1_E#U$64[3/B\;0$XJTL(=`-9AE2OCQLHG7YP.4XU7(S"":,H%"VFK`Z3! M&F*:[-V8?.<1`6 M#2/QU\DOG!@)>B$SG(XH&DD^OLW)E,#@.1Q5_A#'C+^VDB1L5%X;TNM9A$7` MG2V8S$`?#J?8MN>IEXE93H=L77##E!B4R(MN@9RWF`"6FDW^05$I$?K1`^E+ MVL?#849_MY9]3F0LI;4K(E-;4&F7M2'2WG+8F(+%7NA%6&\RW>2_^R0?L6(! M=I15$645R@&D7E8/2)H^>.:8,X7ZG%"8?(U.?A$B(9\)(YG-/5*NY&Y=T6X% M_(#@K'C2:"AW./!^#>AX&<H82)32/0WFS.N M"_-EY[*823XA?/%A0XU35*&DWX^P3WODQ(E@-R2,ZKH_-0ZF\QX%FR`KWP#" M>.3#KIC,*M%BQ1KBG(T>H1@+I[A<*V!)9\@)`#1SUNI"%."7N<)0$GM00LD` M:^)F3#Q70\1NY]J#T5XCTU\?"AM@HL4*WC[3Q0C;\'!`SK*!8G%-4"B'ZP?* MF4V+)V:M>@P'+THG"(STDCLDYT8^/R(^HSC%;9:"G82?]T`UDA.-S/MSKI2^ M/&71.,6W\60@W^]3YFH0#=F4ZVHGL+$8O0M)OP#V6(M/`0Z9*[2HAXES\3'O\V:IJ^:OB&-.5SJF++A*-WXP&1?M26 MX`V"1N\7>AJ<$?%P^S>FX%L*`T#/Q8>=W]XC)7W96K=5RR8&N^V),X-T#DK. MRNX"*&^Q:XL#M^KE`6EJT=>[X*,`K&[ER[E`4F^@.+QXXVC]RM;];8%2CL]^ MC::QR='Q*;LXCN23XRGV\PD,]5E--$N]:2#P"E"F8ZE2<3:K#XKJZ2- M%D(#\2ZLG@:9GQ1X3KNYG2T(_60ANL(?ZRMFH55@"DTN515&.K.QF9DS\:'' MCU#A/`R>57YL3\TY,U,@F!)3.YT3G_">%;;#79+E(Z!RS4;4'MON#$X+\[Z[ MF@VZ$O!===)5P[&5_23F@9(F"K^PY(,6'NA,\2]YH&@B3?B@U1YH/L<%124H MG-"@J,*%6:+]O(U'/^A`&"J(I6_J^`<[ZDF;4WM,X754Z_ M83(6X]GF0TH=J1]@02#W^(3AT![^B.G>8\^KRI)>P M#MR&(3K#+8F2H3#/3.!GI"J?;*77T>!:PY)CSP/JH,FCPG@LY7KGK.?$8A0" M>)\-\[R(V0DWC<\8C42#8P]1`-'QPD@FCQ!MA7&07[U&^'2Z")K847$65O MV&YX,Y7&N`AZD''C30.=%C!!Z2Z&;I1D?#J0XC=\[M:PA29_4)8 M7)V]G[]=+=]*L3%1G3#]>K?ASAH>LZ5%A&+A(1FV"`[Q,9'5]&<,:CL.KK@I M+WM@A2VU.S1^FXJ[[!",A&^_!"/!K]N1,4M!3#CE<` M4ZSK[V_QU?6C$52EW$WNK&7>5L@WWX?9_>TI\.L<_/YHV(Y M#:LBO'F&0<(.AT"MCF1N`#6AJN\K(PJ$$-'!DU7TI6*(=9<';GT>;N"PQ=\$ M$6(1J7MCFSH.JXZ(UE:1U>"5"S@?O@ZGK MS7IU2QTE8MAQ!L2RO>+DS9[LZ(:Q%SR_NWMD&_H'R]C//5YT_>UMT5[-SM8^ M5;!N[7LU5=V68CH;*M]?QSN7W\J[O_+;,6"7Z>_&$&"V^+U]0;DQ#56W/=6U MC:T<1`1GS,W\F9U9"=\O M2L%(,T,IS6/A5"F6"9*DO2QFM#V8=$>TL*,;JM-T(?W*,55#]U3;=1:AM5H8 M<:$,U'`>C]I1_G"9#8'@L-]Z_D;Z\#37`))HL-RB/032K#'YF\AH?3V: M19(/;=/P_OIVW9D/:=$V`\-EM:R3%O3/=URS%:@DR\`I(7_ M[I/F&:;N^YZ8G->-<@+:HJ`:++!"VI1RJLP;N"YDB["C=ZV6U]5,UVMK=M!T MM:;E=[26'YI&Z.I!N_DR(9A$24>3A-;#2?:M"Q6TCPDS.\),LY&!ULU-,Q4^ M65+:#'VFN,VZ7F!GYB"^&^$0UOW(3 M@O4V9ZY^.V7AU1J4+\NF7=.=N56<3U!3MX)=9IZV-#MS^&F.]L>"]L<&^&EV M>(O-96)90(;60$^S MTA;=TC17:$-J9"WOW`$-?+!SMS13S:)Y*+.R5SH%X-\7AC:7Q'DPZD9)]CM@ MTM63S>)9ENZ;EJ]9@=?2[-#H:$TOZ&A^QS";0:O=\6QSXSPMS9+GR.Z[\$GU,HZ?+.X]DNS>6S70QS_Z%B7JU!YS];#;DS>0NZ9$--?')MY1X[L2+1X57 MM'&6/HTIEHGTU=,O\?=X(&6%O%_'&71<]>I59X`RDDJ<6`[IW-C0.NQUV76K M`+7F/"G1:)K!B&4:KV3#;"$APE)U8P-ER?M6JVO-E03`YHH8LT@!!XCXD16$ M/_MXM^JHCF^KOKL7%=S;U!CSY:2-4-&(?"[@;P5J]-Z)Q2E`4K]"5QRIP^LH M83H($NS-'>,A+?:1SO`9Q4*K;<_!SI-T^ZKM[HARWZ?]_*9IE5<-.Y6#5\67 M`F)`/2*[1'Z5Y/_J9G%\AFCG^>@*D*1?79;V1+Q:N1[-G@YD!8;O=TQ;<^RV MH=E.R],"L^-JH>>%7C<(7#_H0#W:NT]Z@YC(EIB+14(\.>.M9?.4R>H8_!<2X[%>]+OP)Z-AQOY-`/5S:7^>D_U]%T1W=@V@RMU>DVM4X8ZFV]8^A.&WB:R7Q_*(\?1IW% M#V3@1'3.TM[P,88"Q[4'*)M!2[<"P]%,)[`UN]VR-#]T`LT..IX-M8>AWEJJ MW,Y?7[D=^M_PL]=0VA=?+Z_"S^'Y]=GOH?+EXOH:=]YMH?(J@Y%2Q]SU]:L+ M,.Z#04&@0A8JASC"!(?<0]1'!DYY):$(EBPE:22!.@#*3]6#)&IRR`Z>*6T- M4*"1!_O)'>-0+LA;H'E*X()5M(`;/^`@\A(9U"-EEWAB:/K7@O/O3N)G@:=. M?IGH7ZE)2MU3T?0B%;HO27!9WL,H@UA!?AEG?%^OET=>JKS]BXSGKVE>>7-E M7GGWW2=-;QBN&/P+PZE1UU6IUJ])FCR.'S=Q3BRH\$P\)TS#EL[,#`4*]^O%N7+].;@*%U&U]9%#XMX1B@F4$<<5>*#<=;W!N!\#,3O97$"X M`?EQ3T37I$`1CK0W]".BWR2^=>0T08R")U0QM\_D:\1``'>'JL#1*$MNQVCN MG2`7LXQGP+GD&`?/CQ@\!N#.^DX4[+T$FR`1QC#$!`E$H2]P&>AQTE"XRJL8 M,6]#N2=CR1EK*G2L&-^0RK\J`FT%IQ!YN)B4T@PNTR/22/4J),A<#:QNE,/I M=M:J%6/($W0HX2`5:U6]4LAP.$HT_N$)Y5)!-C1V-SEU&#>4RZG1PKJ19P7% M=GGH$=;SSR+GIL?E#(H<^:JTA'I1>A?EC!:D]T\%G3'CPJ+/%(M8:HE34)[\ M4EY([=RY'PPS0@MM%5W(-$<9#7X#Y)!E;J.O?^H!KKN\O-_:`ULY_ MO_-G*T;Q%3$(>SU?W_^+L/DQ]_9L`V*>^;!:!'Z+%V2&K;JV"4C?]<;6USOR M%_JQ0@O3,R/,*5!E=77US5QBE384LZ[W;K>8:E/W5*=N5.G=&[BAVI:C6G5S M%[VI4X4[DX4KN7_;8;LXOML<^28HK0[K`+B:B)$HT8^]Q*QQ'55W]HK,[&@M M[6'RQN$D8QWG;Q>2V78WY[2@EMWIU+77'AN6K[JNI1KF=NBT]FBF#-7=%5]C MGPZ,0\KV.\[@>@^-!?(E9V9AE),U@G24\"O@Z^)Z.*3W__UN-GQLXV4^9HY< MW$VV&F#RTNNS8*93A\[.NU.)'WKH=MVP:VLA\=#IM;M-INMP.CJ M@4=3_SY9/E'.1#>+^5C+0,MS=Y'=1VGR'WRB/4S16*`9-FG_DMZ9L]:Z21JE MO20:%'EC>06OPMH2$,U6UPQL2VM9W5"S.[ZK!4[7T%S3"0V]906NO?'\&+E" M&MZ#ERI&0[FX^GMP?O:_P45G!]=JU<=)7+J_":V!;X"8IX=;8, M$+\O,T&ZNT45?H&$FF^AE\"Y?K_VWNRW<:1)-\;J'\@:GN`'D!T\199T]T` M;4D]QE:5O>6JG9U]:=!2VN8416I(RK;VZSQ8B5#2Q%+A,\B6<; M89XI-U%PF]V%(W@Y&8S[.=54OEO8C[GJ2V!#YO_N?OUV?N9_4OU/YW]\^:@\ MW9%9R:@?"VD(ZHA;#@&3MS"]F]8D(-60K0%RAW@4+UCT8`8,(F17K1[8+Q,B=#' MP^WQNEJL]WD(@+`LOL5!.'D":_2#$2X'C]R&.6(CR`,^JZ8?A3$B*)HH03X9 M$:Y&X>V02HV4[$>(2(R`9T"U7\3A4K7 ML&-@:I;EI=3-'=(#@@:"RO(@G="FKS$M3*5*DI"\SNB:Q2@1-2`W2EQ$'.QB MQ,?8`+<-@UM1MY=<_XOUJ4R,T)S(TNB(7R8=A%E2L7?(WS?`('SK=>BS/`4M M,TX%HQ+C\P2QO#"4$(##'TSCN27BC4?[ACI+MC6 M=9B,,EZ9R%>;+=G>AO7\QE4]%\9B6LXFN08^RK'&7E_FYKRNRFU;[DB#2NMT M3?O+RXKI]+^$$Y'DLLWC;**#[MK5I+_SK$ZM![] M4=1BPJIL.(J22:;<@1G"P@TALF1WN4X;CJ,\5$FWI*`3PB@:#\$5%R+_"_UY MA/.>,)-&LL1-6JDD8A:DJ"G20$W9X*\OC\R.`G(4D+4+R#S_HI00[FDL,H#7 M+`K!^QZ026/`%@<<'=%+7@\(7")!<>#%;%!]0?EU[[?D6.T5$DCB*Q M(Y$H!()S=^'O@S\Y8S`P<(!E:R$".)+`R.@#HLLX'1ZP1[`:_5R(C@R,R!LJ M/$$SZ_>3J1.DER8#`[J3C6\4?@$4%A,HD1S6]T>OXM=0&>>B;S#UGR\]2>`,ZH"!`Q8Q`K5VR4EWB"I0KDG"5$^A"48'<,2AAB MQYC5/W#6K:^/^RF0>0)4>"=NO.#B1IT(80P!4A2Q`>\-&*997DGK;#AED[5$ MF`M;[3.&0VRIHU`]MP3&8ASS.T(;V0P/@@N$8!JBSYM21C0C%!-8=+%(N4RR M7"V(?)6/!Y,I4OM7-5*@RXAM;VA@*X&5X55:&MPZ(=K?!!&8.6D&E12-'0!: M1J*8%+G)@3'&F5QCL_$ZW?P*4QXDD];!&U[AIE)F#P'>DT;I">Z#,$(MM9LH M%Y05BD=-.MA]$J$0DD+"25D9(SF:3BB*7.D[NE\85'F7ROS!<\H89[,-\S+J M$H*BS(5B#H3]>RRV.96O#8HAPO#<".^D2R83&QV$=$<]R94A8_GB_!-H9,JR MW";`T/7L3G:B?`5:!K[0&E4%@_H/P6OL4>\=8P[UJ*0XVY MURBG3B."[])D?'N7C/,2T#"&9_#VQ,XXAX_D#M.!\N]QD.;\RBCN"'/SF(,6 M?20!+%"P$->A3@'\@RJY30/,=Z`"+-5U5<*&55VBXP,^,<[*GS6-.;F M?C!N+<)\+"XV)B.@>H*.?D"7:+DNG\HN/]R!0@'BY9A"FQ07/6%92B9A3A2# M:9"0'\@+E83EB>(#2@";_*4P*[:'.34%NQHHH M/EF6*<-DP"+I%FPXKTU:@XQY#$96Q8AFP#5$%H#C)GY!.ZH;H3M@!F(2)L\3 MD&_07`X&]`;=F,;;LM19`B4$8"QSE$K.@J$TKBD3:52!"OHV3U80!Y!M*_4` M!6DYLK#0""1T"PY[-HU#0DN%I'C2$64)F%'V@]OD?B*N:@\8[%GF6@H74CDC M#9R]XY>-/],95UIIVDK_A_^(OX4#<,92/#3)N+C=@%^"J1SX1MR?D)^.QDHX MHH#&$H_2I%1[T4#0,N0:6!@^DST@7`&.F11^9GW%2 M1Z4S#&ZG-+P11JU<^>-Z'`H4QF!$!VL1H6BC`Y,PKMRC<>?0.61KP)"D'N=#C MB#:L[V&#$Z&X@(TJC<>-JK#@FN/1@#)2%)92+"N00Z?HUPS#+*FX%4*OD%;EG0`F:)I7!-^'K M[9TY_%(;S5%`61(-I!W%N6Y9CB<]5 M*3PIK_S6]E%K=(+U)G$1%O(E,A[RA+R+],_:B6M))_67L`ITT1H%8R%YR8U[ M)Z!H#*^-_Y3?KNOUNN!5-\7M+;:S$0DG>IEX]Y$Z%5.1T\^Z?F*!/HXB/'$G MOBWV0_4;`!=[1%<8,S<5:-H66HEWHC5.B^I&PB&65='2\B7*VW,[@HLIZ%+A M"CS=CJO9(1!$0?1153Z7?$,U7C#E& M3[C02N,N''7,[8752.:&%TW&MXL5.3IB8)3[)-.2-;FK4Y520S-:;E+52KF[7]%/9=95'JW]G@ULXS%2ZG=M.3(7P0JYY.Q>FEV\3,WY(`&22LKO]SFP-\&G,>+Y(./<0 M!L_G51X=2Q'B3A4J@U+0@!TA_D??M#Q"$:(VSR%;J-_',6`FFLAT86&#YND= MOHE"VX#8X"R!XANH`+DF5KY6M_65;\L',2`O6*K%"C243<3^8'G$X15Q&,0N MX#QS_V80\)(STIE\*TF?>R!<^H**HB6-EXDB-(0M`4Q'A&;>J`T6%P$9SZ"` M081_*!<1EX_4\9L5O3LIDA8X>U?TDGLA+@M,2H14`YIQ3"H<]DT)VSX8;@Q" M.!#<"DS!48DSLAG_>80)D3G(G,=:0NA+O<4;C<[86.5GLV)@\9`/X:^S`O[P M)#/4V!ZS.V$D,IYS$0\_\",P&:#),UHN^`/6!Q/%*LB1WO=5]PQ?)F=:,?F[ M)Z6G)@PD,H2("F(DLD*0^Q:E#*@"KH@L`8Y(2.(.X@? MBCSB=9+\D*WZL-5OP:5%PJO4:B*V3,E>\2%O-;#LOO(L]74X($' M0M/AQ]FR;QT^!X3 MU>C"2E8'_0_?OYP^6"T]QI+.Z/(-L9A@4#,RV1@$O:`&EU-)#^Z)4EP=#N># MF=U)^4A9@,!R(?W7.*X99=!W@O'FKB+1GG%GA+BDBNR%J0,_CK$EYU<>"0LR M@YBH_UFI;D`O%PPAKB7/1$I.D/TM=R>4$Y)B,L/VF3,95''(J1)@G MN80V>'>0],?D(2S^F*#P(E;&"*C0''CRQOF!6T'/J3Y^D%,Y"X),@*C!Q`'B'3&6KAS!7,<1-0`#M]8%H1Z2]$>%>>2MN3GP"GF8B)>%7S5W M+R(CQ,>S3(KX9SXS80CX%#M5A*95E<="2XM3X%Q.>JC"C->QORF2`B,]DIHY"BDQ>P)3GB>A^Q3'X7'WRA^NU M)_+\01P'"U^.PA0L/5#N@Y3.)`O]1(E<+.I`T9+&"+`5Y7=8DU,G#VF3&'@= M5!BB1@G**0`4RM`)<:M^+TNRQ`.('"J=F%<%5MJ9CT<@6?@#A3.9#..02?`, M6^P!O5T*Y\%6Y).6^*\*,?`/[B8.&-"HR*&^1$W=_S%T$B!U(V6-NQ*.^*U:Y`EY%<2RW'*B2S/ MG,M`6Y)`I&B(7^JA=L&3$N.%(:_3NNJ3BFDT10&E0I5]A'SZ$$^JI)1TCJ(R M(5KN&M^6^^;;7H*]>&%+)J%"'WU\`Y(>,AYV/5TQ6`**TH-*E_(X<[\YA4:$ M7%35U)#$:UG(L2U'$,R?^-"2ET3IM+(\IL-8#F6&9YMH)`_9=KINC]6[89(N M&B+!GZ95A5,FN_J3VP=.2,P=`(2'E]U$(-F+<83H*.T9E>C(?%YQCO(]CH05 MJ!5)<0:#!7@.MBONJ^3O##-1H&`" M\'VX8R?RI,"98)+NN=DO:LY:I)'#K"@]668TT;I[86Q[G$_PV+!Q/B8?YV/9 MVQSGP[%0Q_VYJ/;M,/[?\_@2G9-PT!%>=I<7"0.A+U"/P3<8CY37-EVJBM#9 M=B=GAF^W#:^CXFPUU?+T4_74-"Q5:VNF;9SZVAF-`]*-][^KEF[9MENB]'7` M/3]7CN47-]^"QRUB`5BE8YR>GJE=PW-5Z_3,5D]MWU.[5KO3.?6[ON=JO.F+ M]O1`,;'U.HQ_X)GG99K<#HK`UHP*:$]#,"V\:$I1$?"'I+0W#T[O_>^.7I/,^3M?,,^S M,@KT,P@R:.'!1?Q59GYPWE7&9V&?Q]]C$/4("[#_`!OX*:B8PV*NZV:1A5;,S9^7-V2Y0]9%_I5)J5F%`[XXRB@XD?";%"*JB@9O(%7!XU!US]`U?1D=]!1PBX9O%R=J%S?_D(GX M[>'!,LR.U>F9:L_3SE3+X;ZX9`K!-`S!A5L:L/P/$C"DZ M"[*[2YYQ&IQ.OD,0?A[W9%[-+_(K9SRO`K^K#(YN'",8X'7INN5H[:IZ7PW* M925$:-CF(87&4K<=QWE2,TZ!L4PJJWF@(OD="ZS[<_FG.G@=1HVX9.K/'V(] MU/\U%$8P=([GN%4-_\3^I[(^(`;P`/ZG6XZ3NZ1ZOFF6:![DAOO^=\LT/=>H MT/,:S2=:]FU&I;KL-S*:H0L"WT.=[RB/OLXH9/>^+%O\VC MJ#E/7S\+R'0J,P.'9OOJ=UDJ@D.NN[9A5C.8E1W7@?DJ^H,`2W?*[B"-95&( M@\$)=8U*%/PD!,\94TH3%EF29CN=F`-P0#Z?LJH+X5F0T>I6>Y MKIMV>TXZ2VZ;0X7=-SZ>!D#^ZQUP[I+D(\X%&SIGLQ4HKL2]VHL;4CP7_!@* M6%O&3]\PC%Q[,WQ+,S1#]WKJJ8[!7KO753W;M57#A0C7ZQ@],(/;;H9?*5R\ M3'(6BTN9BR;4CG-LFTR'[P'5%,T.PW['KSS3H??L7ZGN9OGT];>I:;B\ M`&K1/%QYVU`,_)PJK),W\*K7BWC-:GU47*4CGY*-A]C0'MNA!'A-$"^79Z_O M,XRU(*]I&KG;_HUMYR_3LZA?U,VQ;2\>4+^SF?8[_/1QFOM[Y\GAYK,Z8JI^ M>\VCSM\@`9Z=+F^M%^7-!]C<+(_5%[MC6#3VVWMWL6(L'RF!L-;S^/[/^'O! MX..Z`_&4^S!;2-;PX;!E;XVEWC\.B&W6@-C]F:9<$RCA7>^=M!@M3VNW[/:& M)STV#W"]935EQ.7!6)6BTY`,)?=/'/269K7!@.AO31X,WG9@'Z2A*;S_=2I' MHN``P<'^,;UCMS1[PY0_>DMO?CKRX8R#/^)OG9.1]]$I,I\T#-^2/(A>9P:B M_1D2;[HMQS%;NF'LQ'3L$:;TEM.46&.?#,8A#8,_8G"]1F-F'%=YO_4U1]>5 M0^_O&;S4S7)J89*M_7#;U7L]1]<[>(W4Q0]] M?L.TV=YJ/8.#"BU[C%^$'HI_A$_V_9!_,>7LJ[K;7 MI@GQ!B+O?JJ\1CBE2D/>8V6(W5&J?5Q*/%$W4'&?GD)E,;FE7ZVGK;8W:`-CL7TQ84J<9(A?MI#<>-\!5I&0%5/OBZ:V$J78F*6? M8^KV;0?W+XUCTU(IE9UB^>##`SMN\7[@0D&<7?*JIP5.JNZ+< M>^$C&_`;X7,Z&*Q-QY\Z6J]K.:K5<4'1^Z>VZG6=GJH[/==R#=WJV<_K^&VT M@K-/E-[Y_W0[BG]UU?VVE([?3D,X/IHAXYV"(CX7ABL][`J"S:S"E'3LPQVH M\GL21\%?.(&%KM)RBQ"F_?$PRV73(&H\R,J.*'T0^@G7;-7.0/QKE0XQU+04 MA_C@>#W%EP^$U?Z"[WX2G=[X_G`8HVQ0!N(G53+V9,F*+MES9\1((K@.6*NP2\ M1"RL@8W)6CBW$`C20DB'XN8R5GV1H1$JH8]M1/,')F!%8+#9*RR!HQL7;5:( MZ8#W8*0G=]8@?'8*V@MFH+W;[(S/%TY!.Y_M)$L=/OF`.SZZC!Z=&;\D!_$. M9CH2E\VF>;7A1D>:2ON"`[-9*J9\HA?&)T72_(Q07%"=H,_S1+M6H57DRC4@ MIQ9*F6@#2OV,N.G"N7^(-/[ZB7(EUB'M4;;/C1@WXT43[AJA"-E$O:'HMS0? MLMTP_^7$9AKKB#> M+IA/@/8]8S?CRG3`3^$-VZ``-@&$)E=O+WC<6,_C^W]@_70ETR>,8+`+*V8` M<`XEI51GTVT;-BD_O\04EL>KGF:W7-==ZN7-%3`=85RD<(B[RE6^L72X:6YZ M[2X.JT#Q4P`!:L#S)/Q.)]U-+^/\K4OXZI44FFNV'&?7Y;E'<)>0.%.U^3C6 M'4C[$]\^=&-^@6W*L:-[&H=\I$3*Z.^VPBF[8IZK9P[DFL"Z1.V)M+[#6 M4,'83;BP--*B_;D&X;4TSVKIWFZR6"]"U!$]ZT=/$SGZP",%O]\?#W%0-XZ` MK+3)E9,0BT:YKU/8>Z1[?G%`NMR69]FOE:Z_-E*H5D6+W;(TLV6]_FI:,]'2 M1`X^1AY''_J(M75*[XK^SM'/7^L1M='R/+MEV+O)7&_&NFM7WN-O_3US:K'>M?.V^9_M5]'(7\DCF?H++J MB.FI:Z%=3?:UJJ9UM>M]?U#=_M\&NAE[KV3]G(8!,0 M53#VE=V**5E)_)6&MG\*_SVF2>#Q;2<8!K=-G,>`DZ%-T_4\2PXQ6`:.J!>LF`5WD>);6=X)YELPC^QSSK/K*T'V8KS"']TS/,MJ<_ZKKE MV>W94>,F,(C?U1S5U%Q/M7JVJ?H=IZ.V3;-C^X"9GJ,!DC03QY_ALJIFJ]6I M?ZM!56&,>0OEV>R[DL'P$SM'BD-(\2127@W(HBF(Y3WZKKBABW6$KP?;,3WG M43=LVS3T&;`[NG4*"[D`35=7+=VU<&;V&0B$8YW:/;?GV#H'VP258?]SWM## M^1M>'KS_3B)`"G9#^+H2?>N`%GIA!'J\JA",%9``*D$[:;>7PT(=KN?Q\37, M?O125LRTW@HV9B5A>6S8B`U-GX"R";7.MMM75'<>PX!.&4'XU"[`$`+N&V'6U M5T)L(<3ZJA!O6K!-P[/-UPFV@8)M`8#6/W7ML[,'HBV`W81H4T1DM6U-IYGL M>R#:A(PUB;9!HFTV7+2G(%Y)M`T2[94@+J3D,V]9@\_^(\SO9DQ]]I4!Y'UP M!'G@R/KC%!N=030=9G)@X62M(V(!2VU@>\"2Y^@6XJSM:?B3:^JOFOAGGG4[ M_JFI6EW3`;1V.JK;;MOJF=G1/:W3Z9B6Q3T%`^>$FVW=,N;HDTUB:J/$P1FI MKTY1K$:,>2IM>7(`E]NV:[F.O3%R<-S4T>_'>3@(HS&VB;O"UZAY8/<1N\VQ M`28),-$TSFG=BYMND,:P+LX4)K7J\V91KT:W:VJ@(5P-X'ZYN>@Z/:?;L]0N M*$;5\KO@]6N^I_9ZGG?JZSW-;YL9+AH8S]P0 M,LD1P9G;H*BU-X!)R_7L-X!(UZF9P:0EK!BZBU78L?:/( M7.A\%'U7I!=ROXH9(L])-\``6NV,[;=7T+,1*SU#=;L=43=_L0.#@ M@!?=XXH/9%7<=%C"?9H'P19=QR=!7LI;E"!OR#_>`(471`-+$=@0;%]<=-LL MB3<#O6G8KX/>%':=[O$K&.NN!#Y/!RYZ+UL;?R\`>2GVG@?RTOO>)97GQG]+ M4=D29G(]/([M';/\XSG]AWQI<>JSIF,KT]0,4&$:6#ST&Z;;`&N^@V"IFN'Y MJM4Q.^II5_.`VO:I?N;8?L^B8RL*\6%95]4LU7!^_;#DMBN,C//;S^,L3\?X M.(_"+F[.P?:&021S^^)T>$/0VH;NFSW/577?/U.MGN>HGG_:5K6NWSDU3GO& M:=O^TT!MW0O3+%=T0QG"1NXRP=,O`6'A,65QG(>1#W9`;01Y32*O2>2UYYY* MSMUW!4K_-F5LP-V3;\D_`F#Q2VR)/^&XBH,HGUS$J"$^)4&\+H!?$_\NR08. M!&@N5L@(=+P,0(X9`27MX/50TEJP&GP'(F;Q$^J.`?[F)F2IDO7O(!+_[?U= MGH\^?OCP\/!PDK'^R6UR_^'L_#_?_PX?TC5;MW5PZ\O7RJ4R=DM<^^OC=1H- MPH_L<12%_3#_S)L.#T+X:P9"_=O[XA2?^D.GHP#TW9=@R/S','O_.V'J[RSM MCR-L;]Z_BY,HN9W\D28/^=U9,`ISE)0^7_;7#W._]ONO'^1V!.`?:I#_REOZ M5S:?PR:('7FY@4XGZ^5OBP=9/*@\!GI=QZ4'E8=^_5!9_-_$0+R:@)\QG*+ST M9J[DH$'TP_(),F828PAT-.M/E$LUDJ\VDKM8^NM?L4"[_HW/88P7F(Y,\S9# MZR/KK%"=VTAF.1+JN1+Y1I*M>8:!WVP],LW1,!Q9YX4WLAK)+$="S;DCV4A* MU2LW*BD%>>7Z.@IO@[>7":S=:6\DY>9>C9_-"18&@1_=$'`L#4+S+5N>^UF*M^K\77& M_CW&,_9[^->LYSSUP&8C=VNYV!3#TXU0SQ#D,PR7D\]SM497\Q05$B(!0_%- M8VIQ#%5SEB"GH1KNYLG9+%75!.QP(Z<9WC')^&)#`Y@TEC`T^)BW0>II8%J. M-]%6=<>!3M92#J=N;XZ6H*9TKY%J2G^6T?EC&V1T0(YF'TWR6DSRLZS.']L@ MJYN::QA-8W40<%OQQ?PQ/?J?]Q MB(T2,41(TLG412EL,98.SH)TL&:C',;8M#&O1;SR=QNG2Y/OL2U'EXU=8-LE M732O[=@-374N01>_WV=9EJ"-.`":O-'ZPWTBS?&J_'Z0Z2T68^X/@9KM#C3C M6OL.R+/S$&.;,!O-@]G8-,QE+Z9CM/0"NA0%?ENC2Y/58W.BI:W3Y1@M-8@F MQVBI\:0Y1DO[0:9CM-1D`C7;'6AQGNY+=<$OU5L$^%*>O[8Y! MX[H2-(C^#2XU;P;]-W'Y>#?TIYL&NFYJFMM0=VOITO_RP9W](\ MW@]9@2W%7='-D:B6>FVTKG@FP;EE?;%IR]H\;V+C,%N:93;A5G?=@[)4P82(UB3&W`?/Q\O(Z&'.S1JT9=Y+K&I-?-=X7T`D'8A.1,ARJE14X'[(@&Z?L=_YK'&G- M?^9+X%M3[U<&:O\)G_MS:KU!>`_X+W>-[WT9#QF@)BGI4?FP6.\CK%?_.H=H M_ONT;(?%R1!HLV#A>1"5:\Z^_.N'RMZ?`WT&?PO!6`J)PD5O(!:KQ2KKQ.4( MEIE!(OYR">QA77X&'YMYGS8K_[IX(93'Z.--DN1QDK-/8?Q#>8S@WQ_3)*KK M&'SR)$EO/QB:9G[`/W_`!]^+Y_/)")X'&6/Q@`V*[?#UHZ0O'KM+<1+]?U1& MS7M6V[=\NZ>V/=-6+;-GJ>ZIVU9/_9[1T6?>L]Z?QIZ[)+T7!-8MJT^I? MO`3?+.P*Z?3^P_HWJZ^^67UKFS56WZRQMV66_US7K;VNSJFFMKBLM8W7X96[-?QNKVR]B:_3+, MU3=K;FVSJ]LO8VOVRUC=?AE;LU_&ZO;+V)K],E:W7\;6[-?J\K4U\3)7U[+F MUK2LN;J6-;>F9SJYL$;V3,+J(8VYM9#&7#VD,;<6TJRN#+:F"ZS5C:VU-6-KK6YLK:T96VMU M8VMMS=BN;A&V9A!6MP=;,P>K6X.M&8/5;<'63,'JEF`Y0R`/5.I?D[\%0]VV M;-/5"FY:YK1%OEW?0,JR9)SV\;=#0%$0W_[VGL7J]ZOWOW=8&MZS@7*3)D,E MOV-*,!Z$.?SB.H#G^DS)[AC+E2!3DANEP_K\_-?46PJ>J_*SVA*4^0#ZJ:0) M?F7%4YGD*10%:?\9+(DG/MP$_5PML96D`Y;^]EX_F;(U\/@BLJT!*OT@H3(. M$BKK(*&R#Q(JYR"A:A\D5.Y!0N4=(E0'J=B-@W0MC(-T+2I'<(<$U4&Z%L9! MNA;&0;H6QD&Z%@>I+,R#-%?F09HK\R`=)O,PY>H@C;!YD$;8/$@C;!ZF$3[( M^-X\R/C^(%6@=9`.DW60#I-UD`[30=K@@S3!!VF!#](`[][^3A]]?X*'X`_\ MU_`__P]02P,$%`````@`7(&N1'+V9"6<#0``#;0``!4`'`!M96QA+3(P,30P M,S,Q7V-A;"YX;6Q55`D``]#-H/^#S@4.=\`YCI/M8X--"^>U-9`F@9.TQ7TI&(F.B-Q M[_ZV/[H]'8][/_WX]5>?_M'O.Y.)8\Q+N]QS MZ7S@]/OI<+_&C!TYW^T=`&^Y_YG0,/".G`^Y1Z<,QP-[P-*1<[`__-#?_[8_ M_'`W_.%H_WOX\]\\-5TL&7F<">=?[K^!&"BAQ:$SV9OLY3#^T[FE`0?J^0(% M2V?D^\Y$MN+.!'/,GK"WEW3J)W`=D&C`CWLYA"\/S-^C['$`PQP.4L+>UU\Y M,?'1"R>%!L^'*?EP\/LOE[?N#,]1GP1KFD;B0E#08=)87\K9^2]>6C_O"@?SC<>^%>[T->\FS&\/2X-\<^DI+_L'\8M__FC+KA'`<`U3L/!!'+<3"E;!YQW7-D MO_>3<8%]V0=W"2@NYI$*B40?!Y)Z4-GA8%=V)]#RCUL!.B?'N)Y>D`!>$D'^ M#>5$#G$*S'$R)=A[%?>:7;\ECAO$\.M>Q1;]BQD6Q$5^\\C&L,#-\:[\)[TT MSMTIXK,+GS[S<>`1AEVQ*Z.;'>[,\QGAKD]YR/`U>T0!^3N:2Z/`.T&<\.OI M#8/%$29<]-3SHM>+_)WG\4\QO,P*>:T^!V!HM]IAG)0T'=/^7P3\B'\;E\#BK#!'GP,4SS M*68,>Q%5]-?U0KX!GFM\$S)W!L[);X@Q!#T`''#8!".N2!KN*+ONX&CPY4@W ME^$9#CAYPA)>&Q-)EIAJC MM`HL4X_K4,C(5B8=C8#5H'/&.)Y%D6FO&2J_$PP0[#X M[^J`[3*R"0&<80;F4H!M2-[#)4$/Q`?MQ+NJ0C,\-!/Q75&!^1U=\;$*V'@^ MN`%W@5.?>&FDDP]QE82#D"C9#P2.6'N(Y8Q3<4B:#?>E/MH5YN[';EL0JJ&Q_#E0.91+G M'8+`XG7+Y$X#MHTY%ZFV_W9K!C.+M94WK#5DV[C/$0M@*9$A=11,M_5ZU>,8 M0]C*2ZT;K6VTA3@_SI9+XK9>:^UP;>/-I:>G^3!X`AT)&1ES<#'EBX@"Y1NT MC%JU)8Y=N>FXM%J9,RRC2=MP^C1$3U&Y6V"/K>@KHH04./)E$CI_*41NKSXB' M'ZR-WSY3FF47$2/`"DBL,+PORVPH*ZI$,GI42S-%_"$JJ`EY_Q&AQ4!6'PVP M+WCZ)*I'ZN\/D[J:;Y+'?R11-P?[(U_1:MR7-C&$@878RZ4#:P$HZ(UPOTKRWR#BC8-3M"`"^;G4MPI&?4,C M>**(5<5S_)_F^*K1C`*-"2YE7=`H\.0_N2WJD3A%C"TA<(PL@X)[O;9&4&4Z M60E@GWZ.LA(G70C#MYR^N'\K=V,^4>L_$]Q58M)J:P92DRH$C M)>\Y$A,\%O932UG1AEV\'A(BY1(=%H:`*/ MMJVJLDZYM-:(%5E'S$T[A!\W\XSEJ?AHM_AMP4CE`&6X]Y!SPDY,$<7<=Z@J^BJ)U$& M]KOW`%;/X\Y`?_\>0"M<@PSE#[:A7#-7>;":.9T,_/`=@:].,&>8#]X1YF+` MF6$\?$<8M5RW#/H'>Z"7A.)YX&6AP0KG\%WB+%VBAQ89(MW;K0MR@^\`GC9CFV&W:)T@9ZQ+DWX9G@M M,EUZ>#?+"#+7Q"*+I0=6IRXH@V^1]=*#KY.$SN"_QH9UMGZQ>--2!WA-;E4R M4CC$8?S$HBFKAO(T)C885B6[.9/U"T:R=->[#B98VB+0X>A&I/A0YCBX#QA& M/OD;>Y]!S^6-&PIX#75N0BZ?<8`9\B'X''ES$A`N6.2/)DDC!>"Z5D:0,'FM M#*-3Y=Y7GL)0X0YFF(MJV:Y3F2K'X4*N+/&ZDO)449I32FZ"]RN<<%$Q88LT M1KB$97PA+P&%=2%FI5HKU/1&"C!25A(F5'+>I#/*;:U>E%$:*W#95D5J&FV' M8_,4CGP"+M]CLMC3(+[/]9*`?^A%XYVA.7K%)/D[[4.;56;G&UVR6913=.=M\@^&% M>:`$8+PY/L/QOZI<_S9=F#D#NH"72M*[-T=SRD1R+Z<"4E6++YL9W=G,6%>O M<;!6/"9?WD9ME3*I_:K.NH4[*^G>&F6N:3NH$P.>Z03HS28P_: M8+4Z,[2]*5TKB"N>"+B[)\M[CL&O2FI5@L>1"P%67%-)Y173(3Q+7AH-*O9# M=^FT0W*(DY`-RT&WTP[)835/FY2#;J?O<=M?$=7),E:05'5I1Q5E(URD5ZI> M4'9"&://43E>X"5?83A_P*"O@OTBKNKEM:-?\&8M+;W%:4 MTG^1GV8AF)573;V%^"JJ1ZPLVW\+F976J]EY#.P-I;5Y&M*F"SO?QF)NUMCM M=GN8@7+[W"=CV2,*DOP`+,N1XWD]!7O'Y:<-HZ>K:Y:Z\('#C/.*HDYE`Z/+ M9IFP2V_K3I3&RBRB-LB2MZE($7;X/%6V!EV0%^S%$4I7E\DDV+[N,UT;+4_9ZDKZ:?KC6*0>W^=EF_AZF![.,VTX#H4 M7*!`?N`KMVZDZT4'F,^IZ>J:XG$`:U@85?&4Z///!#-Y"`L``00E#@``!#D! M``#M7>N/VS:V_[[`_@^^L\#%7N#.,TEW&S2[F&<[P"0>>"9-L5\"6:)MW?_NOX>#29C&ZB,`1!`-:CWUP0 M`.C$8/3LO$9AM%R/;L#,#_T8#S9Z\,/?IPX"_SLB__1&^*??KB8/HXN3\]%H M$<>K]Z>GW[Y].X'0RT<\<:/EZ>CX.)_MUY2N]Z,?3BXP::6_3*(D]-Z/WI9^ MNH;`H1-[F*+WHXNS\[?'9^^.S]\^G__S_=D_\/_^4VX=K=;0GR_BT=_=_\&- M<4OKERPO7H,@A&$](+C28``?@"O)-LT""#.\(, M#=&'HQ+"URD,3B(X/\73O#G-&Q[]]2^CM/'[5^17.GQ[DS<_/_WMX\.3NP!+ MY]@/4>R$;J4C&8S5]?S''W\\I7\MM\9T>/&F>9FL=Z?I']/6R'^/Z)P/D4MY M*@%GQ&U!_NLX;W9,?CH^OSA^GOV)NW_MYO(398@Q(SQ;L/8C]?WX2R"2TKUT8B, M^WER7R&?C(%<'TLY0%3@XDQX3TGK4^&`I[N2.\$]OS[%6$+)'./9G1_B)?6= MX#%"]+.YQL0A?^8#KQ/UDD/O$\>C`T&WI6@Q?KP`L>\Z@7ID]W@W7()=Z<]& M44[=M8,6=T'T#=V'G@^!&^]*:'W`G6F^\9$;1"B!8`SG3NC_2;^ER]"[*X(^0'T@;!R^'RCD7/*2`!#Q M3G]X"*R=?'`@=/`*&@]6[&/ING'7`A33>.3[\ MU0D2_*^WCKM(Q>SRFP.]GXE4==1,5BM+6EV]YRK%*3ZSR1"^^@(WA/Y/7-S\^('#LH M]O&FAIOTQ!;>+'VCNW3=*`ECLH,MG'`.B(9X"V&$U5)(C'VB3_:%N=W;0A[6=2FV?I&6['S4V\Y:=S7LC9.US?>DGMZ5C:#)WB@F%C& M"*N89"&HH?SHK&FOOMBQ*S6&]DSQ7%J1]J/V2HO#8`S,G">)VU-6[[X?6 M:.GX86=2T]Y]4DIG.%Z"Y13`EF16NO9(XP(/`=UD"HXWG&E'*6N`C%YODS]' MTNB;ZDOY*AE"4VI;.?5J?OG23);"63B:MF'VFG-,LSTDY'/8U( M#TF[9P%1$C&1^)2K4!:0U,@(-AWCY)>OQ<@//M:24@_XC;-TY@!APX"TK0\=QQ5JH%#2VC]^M%2XHY$I"-G`6(QI`F$=^^XF/`1V0=GP%< MLD1`JI]&GC()`X_0=\'FCRC[*Q)SO=U0:E:E".-^Q#O0,EE>^1Z=D;D6_-:J MJ2[G$-`=]7*._VV.M]>?(>CU0/KO70.5VZYZI MH?\IL\;\?EJ^MP@?@R&F@^7,=-),,'QZ@GO\&_=#:S6&HG7@9+#=DP/?"=*_ M$PU8L"3MAE!"]R<'>;:"] M8-B1?X,\.8[#*"DC5X M`O1*"O<$_YBY^>JK(-E3RSKDG"I;BY>O/N]CY[?70SW1G.A^>9-`+-+I$9#N MHX4J5;E[\(0/3YBE5'(@[C2H%CXD4X1UF7PK8DJBN*T!5#_C^422QVEM".5" M5PR_O=74J_(GY;I"^M$]1[GF6+-?69NK?.<-K86+]A)6J7:@F\^1Q3?:AFJR MWC.L#`E=A_FT4;LS8A1!K%F0V@879V=G1Z,5WIKPQK/^<'1Q-$H0)C=:I198 M7W!IZ)()LHM13_!WT@ER/IR=G9Q13J2!K??$00Z\#T@0 M'XX0F*=W"/?//AEIZLI4+\;'FH9'T[!@!^&RX!=C:J"2?\8'I.ZQ0$*EOQSH"QI MH<(7S/AQ>,R0]:1NF'"N28W?!Q.ZA=4+U@Q6`Y7*GRCX,%1=="NB4P`>JK8I M2BLHT`]5I91+8RCX,$`ELW-J3,&5`6J>+4)'(FKL:; M)HW56#4$L#=56:X32"XLB=*$V&UUA-TWE%#5OHG5W MJHW3@'.FM,WW,$,18U635W*SU\5$(#H%_]"M-]*JI!Q40*M50,7T?@+;-X.8 M3;322,K.9+6UZ*-+C;RM=[!/S1;0,`$NWH:O'>@UT%!O:)*:?%#U#ZK^0=6W M6-4W-^S>$AGC@+$A<[,E2GK4ZT_(/!AJ>S;4S$T*ZXB6H?_8<`VA`UJ&?=GV MAH%&`[SQ%;1!&I0F&`_*BAO0Y]T>`R>,RV^\-1FY$AU-4N(/AHB^J[4]XFE] MV59UH0;N9R!7I:&A^[ZM*/G=@'U%M8D;`S:TNK'.Y!B+*)%GF+J[)K/%EB0? M?1$F$Y(PY7;Z_GQI9BCYXG>!-1S%V'Q*E@E]C^,&K"!P_33U&:P"0*4E]"Z7 M$8RSNL#<5>0F;A?KF#TDJ8V"ZD6]="! MX*/S2F[+"VFNMOE>3RBIN8K;P:4B_&, M62Q7JI]17&[V$$GT'!PB34XO+F5_-UR>M46\5.FK<`_6X?.9]7;RPPPO=U\(>;X@]OTH-M**/5#;DZ/Y8-=;44 M2\=6VI.Y);04XV;;P#:4T6K'B!9FCPV%LA1+`1N^P4E2\L91&;_01ZP_<-H; M[IH/4GOTK#^L'*^K#25W6R*6"X_J2K^6L@IJYG.E7%/9>M6NX4NL'\/<+N/9 MBEK8D#O>A*@:L=*>-;Z7F'Q)9K4+Y7Z2$&1,][8EH33F(F!5_X$4`20UWFC% M0%(EL5PJ:U-&D"!]<0*B)53*,F_5LB;_&*?EU1@U"/-*K)AS$X!BZ+MQUE%+ MLD,8^YX?T/<+BNK2MZ]ND&#FDK*ZY!F#)'WL>#R[=6#HAW/"+,HF;$`F_$P' M)6/K<$/N2/G5FCV`P#'@VA^VH;+8E& MRU40K0$H;:;BE"-N>ST/(U8V=G'(A=E6;_`EW5-(R6"RZV!%(GWKOBB.BJ[6 M19N\=BH5&JGHS*[C'QX:Y*YA$V=YC*TYBK87;_>!C>0'5]**/3#TB*K;N-_W M,M6!9ZVGTG2N9GJ]<*^OMM$;A-Z#CEN)1C4J4=JM9SD?E6%\,R+<+>$ZDE6B MN[_4J,UW+?F]L?3N2I"_EVU7OVS(?54ZN&/$M]/!9Z=(/6_>9A3M:@<>LV1< M>]5\;I*2.B."G<2T,V\'G.74#^\5N7EMB(GW:;U4@NA\#Y4-P>5]L6G++-(? MB#:'-1PO8=M`L,;0&>$/!`MRHKX`$D035.S12"9E;WU!+:*U.#OO'!^2RG.` M[-+N(MUXJ-S1Y_TP";H1W(!IK*!R$Z]X=N-T&4N)YIL_0>>FA^AQ]%L9\J,3$U5GG;\G7F>DJ+D.KG5[RY7) MW$Y#*5F#ZLR;P?,'>F_P1\=:"YEN6M:$?&4`KAP8K\F)+@B<,IOJH)ELPO!JWN<6TMX[G<4ZEZOCYH]CW1!\F M:FHJLIDUQSJ>6O77SV]1)@:KI7Z*/X=.>A\->,2:D-X[6?UTH-F89I?>_R4H M)J05V@P'B;B/7A18[UJF::P5K;$1":^?.6A6@'A=B'G4"DRIFVE8?HT"AY:% M6T_JVG6'`4S!-_'1[W?8UBVK%"W0,;LK.4U*?IC@C;Z^#V MS_AH1<1G!]`XO'TES[\G/EJD.Q#98#EL;NZGA+^_D(!=`-`SD(C!??@YC*;DB1"B9]V'JX2I M7LIU5%3N*7<5CF<\#V.MS:&E)4=[?I5=C:SMUJ@!KM>XE&6,OT%JM;[&\:P6T02A;;8+9!72K]2_YG(0"L-5*5XN4 MD@+Q('0L^52&`KC5>E6;V.<&\H75JE6+)+8"L=6Z58O4D0*Q+3J6H!0%-^94 MH-2D;DA?;!?DAE9L0V:(1KM+7C7,>LU6?;?P56-C16`RD&],"!Z)@F0VU7]6 M6M#:B,!7?R6M+\PU63J6M+XPUQ)IG7*R.>?D-WCY>3-R`\^GLK+_(E+K!&C1V?-N)$AW4W1Q>,!7)Z.EX\PFD.'G=K);J/Q M*B^5/V&.%Z.A*5>/44R%[RZV/&.IE MQ(_9PWH$JBX/BH)F1%(9=XGD^QG#9;L+#>1C?TK(GE^?,R>)>:)U':I''/5) M!1=&NH^C!D'QT`5?:Z@WTE/.H7B3PX%CF"9F46]M7N^,)^@2/34CHD2@RR1> M8(7\S]HRR/0P`@%3B)I:*Y)D3L'9+,YEL#V<(^_T'5QL+;D`>(@HY7E: M2.7I(Y:82_8\7%$T[(KB)Q!W6F^I?GU0^.0$K:FK]U%#6:80CI,8Q4[H^>&\ M?AJ%+B0OBS)UH'8#Z)#*ZI'54D62[*SJ&FMU+A&!,CWTB66=90T*64,GY3S?S`'3`RU59S/5I8GGXLYJ:.TDPGN2 MWKLR@MU%W6\;U]((D7TC']`,_+\:RF6 MQ0/4?4`E,EV>/_7F;4*&X3P+&;)$6ZJ?$@K)5K,)/$M\=,+V6DH:;-Y'N,.D MA"[9"LB".BX-XO,_1HF.YN%Y:'KW3[*W>_)R>;/]Q.IQ&]#-K421%M1CU=*J8R5XX;B=IJJ)"&*UD:MANJH6$!@EGY`*9V M98,@-?71\@7G-)0S5D0'(K>]5NJW0@*B9]G%??2@V$1/;Q)BIJ0E"%*[J0@L M$:-J\XD7NQ(7YDZ#:N%#,D7@CR17NH56"+NM`5234TLD?9S6AE`N/JZY[566 M`WGEK M+R+.[9VWNFIAR!V$\A[(2K$(:?^*?EF5^OCZ98,1AR;_">9V3ML6#!A\+4C&%#L4IE\/F9/S84KE0L!?5:<.:64^H`72J?RH9BEFJP-TB]N;>9=SDV M=G0LVE`DLZMTM+X38$/5S*[,:.%ZLZ%RYDX'A3B#S(::F3O`W[&0J,&%-3OO M$U*W1&VHM+F#6/!O%ME0>+/KTLLE9ME0C7.'I=\EWM-=G[7<#D2V&;W#Y M135?`_/>F0VU&KL?HK(72`LN#$JK;'M1LF##\)3,YFH)!?KAZ9/B^V9%GM&@ M5$A>S:T"[O!40ME"-04/AJ<$RI5N*3@P/%VP90&6@A6F5^AO<9FQ,0AC6]G^ MCM@G-I;Q[XBUX?:2]@K_O>/GW9S)D+\=+G*)-,B,">^&RP3^U<,,^P\F9UZW MO?M<.)!KU%6X@*_+I267N]UT59BAPU3N MNFE77EKB%%TJ+F/EW)JQ!:[X_FK#@6T.6(E/N.F^JP!K?:N6\T`:]4K*D[L` M7D)<26Q3:^-G-J5X_>&)AL/C`?O&7/-3R*`K.AF#H_2)MT%2[F8,%E'=)T$' MU<\@Y$+[Q8\7%7F^#0`^)!XC?"@]X\'`G?_"+J*G8L2]H1J'@!*`___Y6[0; M'N98>T/R'P`C.OTM$8[=5X<[WOX1/1$YN8L2J`C1]G@J2WLTOW;";JB^O$C# M_*5&@Z@F88=^WJ;(PJZ[L@TWOU3S@[V?VW#)2S4G^.>!#;>\>N-&[2S1?MF+ M>YE>3G5OW!Z'?W5>GE&\4]*&&_+=4')S30V^!*](\"O6H0TWX!7AEK_+J.M& MO'38K=E2[BFI0*-/.YYE81CRXC/"^S/9@E'AX-PT_,4'$+-VL=;AU"RR M>1$",;D1\>`[4S^@<:2/P"&0O#&Y/))`DNZ)&WR*0IC_YY6#?$3ZTSV*/N'M M_Y$`U.2BZGU:O6^M*04E*]T M-].P_!H%6(*PU*TG=;=%AP%,P3?QT>]WV"Z_Q_HT!"ANB8[9_?`RH:Z7"0^O MXVRWV+=-O"]M@WU?J8]3>[%XAS_-IB"IK".?7YI-R`MXB!/P['!.V\: M#[<*$>GRYDN[+_9ASXEO%IB>F5?3A;['2M4&.YV;$'$J54LZEVWPLA5UP3*_ M8ND3UN%O*^@I$\+6U-EM=5@5PJK[6U2SVUI)=>M7WE M/X`7$`B,=,G.6G'=AZLD1I28-T*+7M1#*P*Q2%$9^AQ&4P0@K4M%R<=_CO!V M'OA.[6H6#[:J:;3R*J.<'E]UD13N7>W&^"Y0ZMZY2S229)::^*&J_$VV]M54 MGMH-53;&/RB%P>4]E2H7J,<0YN? MHAB@YV@3S-Q`1V,X=T+_3_J%DP<=HB![R@4K(8\0(-R&_FCV%^2!YO,I?/2=:,D)"\K72](7)VHB;<01O`Z@E@5I":= MN=3?AZ1(4`37-HB$B%AZRB'C2+[S7X&7F@\V<%A,KJ$\OG5@2-YMR9\O,I>] M7$H-Y2PY,B%8D#.9OJ`7+0%I;"Z#"Z&E9:A7F/+,.1&05ZZN(Q0CRODK4I(Y M>Q;.X.UY1SR&BM4-F,8V[(;U0G2D[:`H-U1"-F990;+!7ZF0V@8._W1*B)GB MSQ?_Q_\#4$L#!!0````(`%R!KD003]FC[TP``'T&UL550)``/0S7-3T,US4W5X"P`!!"4.```$.0$``-1=>6_C M.);_?X#Y#MQT8]$-.(DDRU=M=P^HPJ0*F)RZ;?)?>[ST>C]0O?WO?..`5^H'MN;\>J2?*$8"NZ5FV^_SK MT9?'X^7C^=75T=]^^^M??OFOXV/P\``N/->%C@,_P!\F=*!OA!"LC'?/]38? MX-IX@DX`KFWWSRSK4^`3WWU;D/C1"U!A:2YA/0%%4_5B;' MJKY2YY^4&?K?/_.MO>V';S^_A.`G\V?4&+5$/<;@X>3A)*?>?X-'SPU0Z\W6 M<#_`TG'``^X5@`<80/\56B-/[X%=Z/`V3IJKIW_<7#^:+W!C'-MN$!JN6>B(B=&ZJHO%XI3\&K4. M[$\!H7+MF<1*'`("9@O\K^.DV3'^ZEC5CL?JR7M@'?V&&?[B>PY\@&M`9/@4 M?FSAKT>!O=DZ\"C^[L6':[H4CN^?XOZG+GQ&S]+"'!:8@SK%''Z(OR9^=@1P MRR\/5TR%%@5:4:=384*ND`O#5I+F>L;B.O@?&%8%@>%["%T+6HG(F$;%TR4L MB&,0HIBL9Q8(.MA%/+]H@@UT#(P071E'S_D'_,VWI6G"(/!\&P8W#M?!,V4XQ:GIHQNFCR<\ MO4J53QNA,!:3B+@V@BTT_#11BX^EUMH MDXFJI^")J8.8/$#T`6$` M'A-B`\JHG?0KYT]._<1CC.5\=$!1;2(1/<&]\6$\.?!\AY#MUB"GW%@\:DH2 M<'K4>#R;30J("4!,",24I&*EBU9:0:MMK-5/MFLZ.PO!Q4$Y6/+M>(1(!EN< M!5ZA\_'S`$#(\&$*`&F&'@#X'J)G=!\]HD90I'>5!TRJ/+P.K4\6"@.F,5T0 M$QX4;+OK3`7QJ(S=`4&MTF,K@,`>V:GJ.$4F)@5RM*2C ML@?=M+QN\'T+W0`I5CUJU<8C55O$N)R/%.7[Q66U2Y=`66%N28C<;7;D\5S` M+8JF-ME,1)\=B#\L76NY\=!C^P_Y_M[WMM`//^Z15X1X'>G?.WN[J01P/^3% MXKT7F;DAI,\6:7A(.(,\:Y#R)@NT>>X@80\(_V@!-Y&@WYA"*R@8D@7UL@FM MO`EQ'#%R3"7'C%Y!5PHQ_=F^641BU4I8EHU9&3WZ!?NWYX"UFA='Q!(%-N)T( MGMLLHE2:VOV%.-\"/%"S\X-5][OAOT*[WV(9IPX5-Q#-)8, M/^[<%?0WUY[!"!N-*(B/:DW$XY^[*XJ:Q#/,`$0-L*HPPMVAC5`7O`YG"1*V>+NG<+US]O>T:[:/&]$0.1EL(ACWZL=\D<`VK8#``XR$`:#5A\(`Q8@:RJB\B\4B$';_Q<+*9)M5*^SN!N M#5)Z@!"4E#/Z4E';4]%;`PNN(8J3%EBGNIHL784E"`Y_+.2#.@M)`94;VI;M M['#%UB-$:99U>GTV3Q/\<69'Q!PAA@SB#'&H,^88YF>CX@[./IH"3X"S==-/WS M0I26;,,IK%$!^.\=&ETYTH^(]@FN0BCIS=K?88<*` M+;DP?RZX0,%K,\WD^69=S5VQD7!?;7S5B)Y>]T?ZRR]*:Z]&%+`?'R]7C_(= MN++8:U]'>0Y=LQ]8:"/_I* M]VJN:%UN*\O+FP:]J:I/:-X^D!C>12L2RHNN+[<,N,JIF!@X0"%NN+GWO6?? MV%3`^\M="&ZM MA<:MA;`,0W.70F;94[:7C')F6!?P*;R,KB"A19!2"]'9I,B>\RG/%[.%%N42 MU!]@`B"F(#:/=)!>%29]=0;IH(*6J&!A%2!;!2&Y@^[J:>:@Z"DC;YQYON^] M0>OSSK58>:/81F#>*##FG=).IUKBS7%W0/K+21KM52#>C"N\9=Y#4.DF^7RQ MKV<_^2)/]L8(\=[!QSWT;8]ZX*^JN?!,PI:%TP]F"T6?QVDE<>4UI@8V,3FP M)?0$'\_K2S,*2$%"#D3T9"2@GK0C^+TI/BA
@P#N"(24KU>,HR5(TA9*0K M?"9YZ5KXSV56VK4,SPW?_[#=YW\8SJX\K&S65V!ZXQ*(>VM-F\=5P>1:`'S- M&/F0HPR6(4AH`T+\(/"*7/W2K;R!K'_=]51W?).8B3_DJO^`@4:$+@'@]G"1 M)2+]&!I^*%;Y2:WR3_#9=G$-S(%-4#LBZE]YK5)YF<.F1N$J/YSB-])PHG"4 M&JY1%S!(2(_)=+FXG72:7/S,#LT1!Y"P``D/.7N)![,"V6K$ M5]G8B:+DXJ?O!KK5/EZ/X`H3R@+R9\=[NT7V0!^OW%<8D-M=7"L]EI+=]')A M!Z;C!3L?UFQT=B8K&/!=9.5_2YVBYX(`9@EBGB!E2F)#=HHK=WM3QECZ?JM0 MBY'<_KC;;AWRHB_#`?BEP];.(9?'[QO08!A0ZGYN7S`KQY?.3T%*S'&,(+A; MDWOQ*NN:*0U%QH4][KR)3ILDM3Q*"0,6TQW*J"% MKKQ$_X\O%[KS\6O;@_#"""$^M?#[BVV^)!4[]$T[H%S$W!-1\;AJ M*2FORRIJLKZ88C"F"NY\$/$$F&ET.(FPS2[ZBIN$^`Q3REHJ:D68JWC[%\RH M`'PM\@`PWA$RE'C0Q:Q#B1UA1<4'N[UDQ(=-:BC&L^3>'!:80ZF%(?TH6$RP MB8)>O8(R41BRZD>J;3(8[/`,0*D]9..GV0FS^6*JU")H"*/3SDK6H6@X(]8J M1ZQ%4NLQ+&.?G^;<+T MQW0,WB1YU)&2G<%KY.->G%E,RJM-+,#B>V$1KUR3W%3W,/OA7F#C4]^-,W^? MQAE70AN"+>8QH%%/G[H3U2_?3Z(G?Q`E7Z'_Y$E64VUTI)-QWE^EIP19[3H:I`D)V2/.R=KK63T4:#0=G=+@Q"P[5LMWSK+W&O[\7MC0^H9W59TAA'AJH7D?EN6/AW71C!FF#&8;?!3(56#>NIX@ZRIS^K M!H4]VGRLUTY\OA**0UI?:*YBW=H"6T6I,Z!5D_JDG%D.,!I((8O?=(A?5L27 M_.G=Y.9ZJDR<0U!E,5;GLWQN1_[TED1OY%!^E+CLF#2)Y(+/7_>N+35`Y--T M0GH82;H'C?-)N?@L!Y*5*^'(2,)LNTC)N=YF8T?OF,;GH#P7GTZ`KFE#Y@I_ M10^169P'.[VY7 M5[=_O[P]O[J4>B\NA_L5$FZ-4?K)N&03DAQ"8+^T?+^1\&Q:EH!W^491U7&2 M.Z/]UNBV:V]VFS/;(KOH-0^HW%HB=$NB\%;# M3<835:5@."8'$+T#%I/PP+F38ONX%J,8-\0[:1?=.10K](04DE;?P@DC&IAI M%I`U@(U%NC?\._\1P0Y:Y.:-Y#5"%2.LNIZ"![0UXG`7)?'/'VGT_NX((^\Y!ZG MLN4S^O2,F/_=]X+@WO=,"/=NHFQ+16+ZY121-[Z/]L@9+93%X#Y./DT/$>4!&I$#&3WI(X-."E)&!$&D MH5&IH821`&PQ".1S%*Y7=9$9`UK4<(\G\SD[$,@O5>]+ M139ZO&H=I4&HKFB]SC)]3Z@C+LEHN&Y'J=Q:X@2Y)`KO_KVRF$YH>TPQ-.ZK MICE"9KN=]&)"_K!Z<4]=.RFWG__326D"^R%,3AF(HDU":>8X,,#)/WFVHMC] MA@/Z3"A>3YIKVE3A@'_TA>2=JIZTK0\*!]>V;8!HJW)]J!C.UE8M0#DB1\E. MDD?3,[)N]):`R70^H:#H<*_`:#*`;J[)/CB.P8_*B:*HV9;4_^06 MH`%C=01PHB)] M]-EHHJBCR6**&UQ`D[S],FDS'LB(G?UZ!9KY^T[<257F[W;X4KB)X=*!K]"] M]VPW7"%B\+/]"MDOV.U(46*R;R$N[Y['=+S0:;.`M'89\RS?>Q.Q!80O((P! MYBSIG;\B#;4?^X9G*.XAQL&M5;PT!_P(5/5D/)'_-N)^8@MM--+6I,)"YIT+ MB1#H[^K-ZQ8LJ;2&&"9I@C;QY'G3`(D8Q:#'GQ#/`8?&[L9I&!0%&Z=[..QN MH?U`>*)JWT<\1$2[QX9[N@T4FO2'&0):P#1QYHC6- M@YAIC'7"=NC#Q'Z,U#`>2C!2]YC8CZ7VXJ)R,O].QH=UP:11;*RTIOCX^(C' MJI^15_44'\OT!AT?2\(V<6B]0WPD;`'F^SW$QTY&:A\?11FIQ_C8R5*4^#C3 MO[/XR`@F[>(CS9J2UOBW/GR!;H!B]95K>AMX"\.[]ZUEM748,1-0`?BGIW1H@@M)V!'K14-O7T(XT_,GQ@N!GR4OS=>Y76J6O M-,E0$.2%<`7?PS/$]L\&3[?033*6\K+POV\EMZM&`12B";YBJH"0E77!4)_: M4L!UC4`U-$S1'+(.6'LVD8,NUT)2P>05IH9#SJ61:QG.C2T>*`?7=?>$-Z(A M%'<-!.,N0E;T%(0Q>9#2!QD#D'`8PIWB!S.$5F^($;\EQ$&XA=<7\=S4H#U- MSMU7Z(?VDX.&NW`-?1]:T74,KATB(:+?`\2]HEZM&0GQ4_!&\O%.DS1M,DNW MKU,.(&617#D2,0$9%SD%;0>T@3HH&]1-H`]HB/C\9J)\5-=C1ARC=YGDCW.. MXI^(/617PK6*`KF)='.KRAF;!&CN\8!G\A7%=M*8ZB?-_MF,58<"P0'LT!-`\>?9>3RUH M1T!`'\K^C[[Z=KY#><8-/]N!:3C_"PW_TK4H-]Y6-A7@_U7\>6=&B$.R>1%1 M`A$I@&D!1$S"K:Z]Z:6UT>O0..!Q,(R#6BO(R`H7\"F\0-(X7K#SX?(I"'W# M#!DQC-%88&:@2\"]JI?>9X7I@(P0BJ(Q*4G9H0>]M.9ZB@*`R#2E_;[4"W%R'#04+ET7Z6S+#Q?V[X_H?M/B\W M>%[#]>1*7:0AHB@'?\'!7*5C(Z$'(H)#`$D'%0E!>O%QH,SI^$*D!0:>=8M$K:*&_ M`6LH=3FVQJW8L"CJ+1\15WBU#`;A@Q'"Z,+>>XB>O!L:SZP=B08$I.&F2BK> M88T^3DXPE*&44`>8?')%=<9@"/CJS0`$T#-;>B=F0K#65 M?)1>UQ0HL5I+P]]UTUH;?:$QQGWRBXOZ4(T^/:I130Z:]IR-#9WK#A5`A\`) MWO&Y\#:&7:Z\J6TN#2F9#-SO#M`TA0Z5:*\NHC8(K+14C@:64;UV#W`J:[*%C8(\%8`L&(RP&"N MXLK!4X5SLM'%LH\RX$7H@(R@+5SVIJ!549"DD#D/U3E>$3XT9Y"*'U)V?PR8@!1`WDRZ0_5I0] MJ.3H'`0FT<[*I6OQ0:6M6CJY'S!ZX\B3@3J8U*LC(GOCWI"'),O&=D\"):7T,#BZ5<_\:4T@!3WJJZFZ- M+TB#;D#&AP_0P66&^,J&@+RFZPF_L"O>C@WJSL=V(RH2@)TDY7]QNIH,`+.3 MA'=KD.<(8I:`\`3_W]VW-<=M).G^E7K8B/5$T#,-]'WVB10EK\ZA1:Y,>Q[F M80/L1I,XTP1HH)L2Y]>?NN`.5"$!%"J+VHCU6#(J*[_L_++NF46GV;6&!/]Q MKCECN35C12IC70AK_=S+7,:BA!:"5>+(^)_!ZDAS55:[\ZWQ2*DVQIIV5<$5 MIIW5:DBP(5K;P, MZ>KK1*=SG\-#%#^+_:KV*0:\G?%[H`"E@"ZY=-Q9FB@QD\JW(7TNEP2%8--W M/75C="H8V5:RD$M*@M'F/=-`=L=#-G.YLP<#SHUG!@F&@6CF@!F6>`0W':O?_J@7, M>?]=MM,O27K8_IUASZ]T#G>133W^I_$1+]7A>$!N7T`F/;[5F>K^WL1NSMOO MJ5C%S\+_LV'?9GWV\(!Z*&?-\?RXM_(N2'F3/EMVB;JKYO!0=@?/_GV4;D#< M>3'@"$_>P.2>GE0+\.$6G>*F7G[VR7V4;\VEXI"/[_3@JV3H\+^S'2<_N2!Q M"O5%2$;=9NOTO\H.FMHL&`3ZZ,5A$#XF=,#A>W<=1W32SPV21Z8#-,9N-TZ: MXCR3Q*8(Z6XV]F&9%G#N('"F.-/EKA9Q<^`>L>O!Q1K%"LJPH),>7 ME8NVC3_*4U&U,5`X\_QRC-Y\GQ]+W_)[R*TUWKN_-\D9F1+@Y`V;;?K,)!.5 MUD03PI!JB>N%EU54+8JJWV;5&1'+A8/]KD(;I4&FW^P2QXP?Z-(K9FEC]O[W M_^N_M6SBM']G:/NKM7/X5M(V/2A/#XI3.80+(E22^2VQ\8#@$$:Y`^`.^L<:G+2*:(]2DX^O$'[^0_1K%\$*E^990ZE:[A\7:Y MK'"%2R&9&"QJ#,?B]L)BSO-;W:?JZDW0IGS[J_\8L#TWD>)3^JO4/C/JW=6^ MX2XQK\Z/"C$\(2N6?X]`X_9#8\[#VYVHZN(MN%%6SW^>@Q=VKJE>,]>^,KE2 MKG8-+G*WF64SGTP`]IIX!!#NZ51X%#,_>.-[LE_]Q.>/8F$`C2V+VQVJLAAN ML026[Y_>NHX`JQ\9]ORB9^AFHSO/A`OD%R)(Q&^^K'#Y$IO$X)<")%C'I_ M#,2_].>^5?E=7@5WKP4TF@ M&=.M&O,BLZ8GLV94MJ8WQ)KF0Y`^[K9'+$V_V7L-<#<=I>[T]O'.0MQ-W]IS M&V?E3!/C;K"K\N'9ENT.L.ZD#!VO/'^_?^[BD,_CS[ M1J*?LMMW%A!56,!Y5MW--#$R5XX4VOT@@5.;W6NQ-#,P3XISH8B:%\.L^YZB M*"0\Z`ZLG;_K#Q1K507G)NWR_V08EJK,N##XL5\TQ:8,J$D MDTJX6/R0,AZM.!K,8+VP]M,M`H=`'G,UVOMATQ0P@E3*I-(6,@5DZK7[W3.6;7"40U M![LBQM`?L:C^?8K(LV5#.R%/+)5^.YQR8V`"=ET=[&2#/FYZW!(S]=AN'9 M.UH;;MH9"@T\+9:R)01]#9)_?8I]_W-(/=U/3CT#4&MSY/#3IA/X7&NY4`4Y/#/#"8008SIH+81:C8IS.$:0HP#@Q(XW_P'///'+/L M%\6,1"JB=L4AJ8%0H]#56_ZO_QWX,7N,\7;COU(S?P\ZS_W4C3$BD%(C?>`;EPH*O'*DQHD)\MU66G9;"I641=D. M\!7+MB88!&S1`WQ6L)DU=T!+\NRYRC@69/U`!`[2.,<4KMC*+)EI;.%35S8R M=1MD1O4N>+1R6Y;Q%6]#STRF#V>=572:_"D(O7`7$0SU!EY\F,['@^H7+*+ M6/CYRG*M/H`<^96V+I#B$"MX M#(-#L&,/C7X/HX?$CU_9L7$&^:<4\U^L>+D-<,Q6=DDL90.WBH/^_SE[+.U" M6J\\K[;$3_'!X]I`J8@<[:DJ_-QE)N=QZ190N=-*Y2[>K4TCJ`%[B9"P>_+W MYZ,885O6Q#8%@('L406)(?9%#23JNT+\\8_-O?_^(%(4OS MVN5TXX1CA)51&H.+(6R6S?=\W9<+Q5W"],'OYY`4"A"F`4^\BQQES)D/\_'S M5I@E]!]9Y0?+#.,L1EO&>#S6$H1:P_)XN]L>G.-!N\$ M=6-IQ(;H#GX^3-<_@V-WGZ;'R#DB;+!G\,=79DF_K4O_M>,ETOZ?K\AL1T0E,;. MBQX+6;S M-'2QORG4RQ.ZWCX<@T>N0LW#NK_7'$+VT8[?=QND#,QE'7>Y9%LQ\UH\*!(P MDT+D)(1NBY.:P=6#G3EPTFBE&6&QD]8X0XR4"*<.-V".L9`!,XH>V@??_;U( MQ5)ELA&6R<59`>B%*XI>L6KI44A\+SZ^$;\* ME@ZV>PE84[-YL)N69^8P.Z&PS@_]V#M>AOO+_7,0\@IU;-^=)0((I5NK7:U, M,DZM"KB@QB)[3Y<*Y*D+JR))*A.):QJ!BIO)_O'($P<^IHA92D&O(AN5:##/ MK-`,8"(M<]I?8LKENSC:^?X^^435SHZR;@^EHKUM,Q!@2]-S7)A:P`G2;$W_ MUQ%S72Z89)()$TWRG8_LY>WN*8R.T>,;[>;; MZ>F#]Q)0FW\.=ZV/7_NU-3U`0A6#QLWM+-\+SD230C81PDDJG1V!_W7:=[+2 M87(:X`X<.-+[X`G!N[I^=2.C9E\ZY^-F+^-AC)Q4@^C9_XV2GA^5=62/D7UM M<$25J`!^5K!9IJF:A""22T+/%J,#F3L`F:EQN,/5RF.RRA1(+*G<>_D<7NYV MT3D$7?>&SM29LOMW2X^^^4\^_+?>8@PLQP;H"%TAKBB(T!.P>JM-O:"->N* MI'V)32C16_G]#QI)IS8-YW!NA9?4"GQC*K6"+_9R4"\#CZ-$C>Q#36I7+/CJ M[_S@5?&V$M34"IX7^D!==[G(ZN2H65U(QGI_K1_UHL+86(D0GY]--X6QL68= M.[AW[1_\.!XV[+:U165?BT+@(PUGZRCHETFV<0`=BYJ/ESG`F,X7[>*=PD75 MQ),9QB[F??5?_5!Z>;J[G16,2Y6!^MW&<=80MJ5B;6/:$+1UEDF!X1.MYI$P MDI5M8@?!LKS?Z2SXBZ_8E>ENBDJSICY`WUO,5FO5M#)/YY\M%JEH6]@V$G1Z M$RA\_)F*>2XR^J<+0KNH)_=5-?LD-K*%@#0DT-[ZS"G+;9`IERL"7LRL2WNC M;5S+)=JS=!L,`26*86=`39KM:JY1^77^*QA7LN>DS`&2S0LL>3?BF' M)'*JD@'>W,%7I<'L(.Q=[+]XP3Y;T:8W?B_#/5=>O'8!>PA(&"J-(1J";ZVY MSDK!Z+2K8F,G[8R?30H"R-\_X4R,]5N'SY@S2V1'D'R0CBHAP$-["::'&NI` M`+8K3DPXT1\R8&>F7!&ZGO[X?7<\[VG,^B6*]M^"H]R#`$V-\KU;'_`QP7*Y MS-B=29E*Y)!=,,LE8X[1FS'R`OJ/!(TRGTW2.N?>?O?A?R04)V[?*S)$4 M[JM52@*-A$1`OI^E?CI6_\HLKA.Q"A<>;(7;"5/Q*S6,*BKD)ERB:X/.I?EG*[41()O728-I`5+J%O%G8[ M70=Q\%/'Y$KQ]XQ=/Y_X"(,=O&?P+O-\OJCS@0M`]O[^(.H3+BD*XTY?\9=6 M-R_0HCKV31#ZGT_^.]0_W'6QMLZ<_)],"N%BL"/],#QN/SS& MO;[A3*V>7\6.ZOVJZW^E3S`\'GZS;;Y9.XV`CGAE;R"`FG/_%/H\+1=5TH]? M>:Z/_YB[RXO9;$:\A/WQ5U9ZA:GJ+C_O/S2QR]BIJ1K9G)("T,#D$*-<#^ M1I=H@EFY,%*6AI1S2S="=R!"4Z,3P`7+`U2765!8U'DU'NGJ^Y`,-$Y6RGSR M6^M=.Q-#M><;$_=,>M?->V,^KKYM;L-M\I(.E^&>9W-E+*-1ZN.?Y^#TUOT; MM3?#\?967>#O`]>;!@7X3>^R3"*$HE-C/-1VOO!-RK+D_U0@1B"2TDLE[)+; M"IERZ0VF[E\[^Q"'5FGO\"K',Z=)I%0(.G&&@"E1);LQ9]\04W,F"1?*\.WP M_H[K\W2ZGY@KZ[;B22E\H7.B@ M4?H6ARF%`N")O)LOSDLD*>2@CQX#(97G6E'X2.Y9:A?[AI"F=TF843.#-:2` MCR4M;;!)TC/BSNFB=Z8BBTV#RDB4>5*D!G-L&5GD/MA)(?3QY5?O>_!\?E9N M`%>_,4B52L?@+5`G.VI,FR/OZ@X'X4)!F/+Y5FK$2%E$P.282@OYHM@:(!AI/!(!Q'*@FS MM(D&4&[EMX%@,E*P1$F2O#J)'+\VIG[U=U&\_^#%^PZF-C_$8&I#"WAA='>Q M+9A*A"#")2%5+=*`QT'`TTW9D:#<_J",<59*EPIGVPV`,F,,PNX98^4;DS/& M'B$LCPL#;9`6J&[ MB$`L'(4G?T\>WLB7R]^N+_^'G"(2^X]>$+)RW2_'@-6XMC90C0E/XX*2GM7# M%__TP4N>[N+H-=C[^ZNWWQ-__SG\%(34[$'X>+D[!:_B!#8*3T%XIG^7YF"- M0ME=RY%"#:Y/QFD*3@2X6:7W#5BJ0]8AR7HD5V^$]=.OEF;[`@WYT+E%?O/S2 M/)6!"L4/.$!-P7DG-LX2$&CR7M_75&8*8U6G,F=F(+JT"7(#63V-Z4D>0#3I M8^+W%T6&36/Z"G\W4:7WQ>6-`UDHP:.+K=.8*>W7.HUIBSO$;B&$9V'W>-ZR[=8O.P[:FR6V1N\&C]M&#U'PG)KL'YBDOY"+D^G M.'@XGUC9'79OXLX#/#9$(4C'2"@H&T,WXQ"Z`4]$K.W-ENY^F-+.I:F5S"!)-,,KD]$"%;I*(Q M?!5+.US'`K@=EZ^T8\ZCQTN&F4^F$^_(,Z7O!-Y$AM?,1:L>+"UN6$%--44@ M^8V:KV\0:;9!#B`-A:"7BYWEUET7P:/;LPR_EM2+4Q(UF%3[(L9(K.\P6DBI M*(L4[2;2$R6HZG3=KBY#J_K2>$1H50/J,PO'F2_3.$#=@N\.![6RKJ:IKP&0 MDP+B>*8MN`NCN`9,;HKIY]8?"8_+2L(4#)9;`&5='87Y9J18O:@+3LN_-[F^ MEBD!WX)Q5SDWBLW8=%4Z*3TZMY2T8%ME@:P`)\H'\&2<%I2I[O2[RLI::1.K M:-.U-=79S@8:]=W;6=-_[:03_O:55KA\%+H]/?EQQJR?4EHE?\$]RH&Z)HAA M$^QCG=F;;#9KI>)WYU/PZE^=DR#TD^3:>TN^1*DIYNM-MB7&^Q.KN[Q'DG5)6)^$=IH^4O/WA'6;/^MC M#_IXSX:GON:,Y/0QT@<$(W5,J,U9RBU9BB^@"TL]9);:TSXO2,@FY_FC1_;Q MFM"GPVY-''8^&]9B5O&A_Q-U+ M`%;,!&D'=>I5Z=@@IW^IA\IN&!&=D+P7G'@X@0$U)";!(4CV?Y*NK,BNTW:_,XD-^J=`SUH,5ME M:^GB.G@F`VZR#949O3V>J]__UT=6S>89RL&Y.DTZP[N%K.9IF^ M`BQK0"HJ\)JF9278AD&N!BGT((4BY)],%<)UP1H),4WJ-DS*EEI77A+P78ER M_ZC!9")F5B+1%+\#2AAC]P$ND\0_=9?5:__69$!I4P"C2FTKT.C\M!)9_*GRH,DN)&HP&X*+'L:]-4&%[1=^5N-V4R&"M2#*+# M2%PE0F15`(]VE)GL<+,&/RRJ6)L08QS,%[Z/+'2^(SZ'AZNZ._Y8EJFI\^2H:8 M'@(,CN]PK@VGN3FT#3N#LSD9Z`25%S]_F MJ'";FAOT=^OR/*&GY?3,&6@D8,/O(WL/^T1_!O]S^'L8/21^_,K2BGP.7\YU M#O9H:'RV`-$*^FQRO5VLTK>MA5Q^V9U+9CG]E\M7PHDRWLZNZ_)[ZG1??QOP@:/^'=SRS&F3\ZKIL0@=K;'*: M#=((7*IWF=,CO]$LWFY0R>0V%L>P>\*%LZ)\XDT'SM;:!-#=*G1^F?N"O%#L MKTPFZGRZE]]6YM)P.^D9]>K]J9@%:6%\7%2J`TXAM-[,M^E`V4(F$Q22#YX: M$4K#!6J0T`[3PM#0@VW%(-QM$OQ16;P>NSR?GJ(X^'?CN2FP$=HH7-<$7+-D MN9BUTRE].5F(M&'$'06SG4[IVTA/B1-GQ)7YI'RD;;6/+>1B"2)[$2MM@$PJ MH05X3K>=+Y2$$N+L(=,`>$HB!5)\F"2J^EX7@4HVL84\I3?//7[<#@W05G MMEYM%T[[8M#@E@IP/3@:9WN8L&#K:`JP;:&"_I.#Y4M#NDJD:!,96H158L?& M40\KX8_(7"?0B""^1!MY>??0J=U\MERVT^@/V6Z#Z0&V/YY6IOQ,_F/V5V=6 M[*3\5VGY1YS9Q6S&_S\=?/^>SFGY18?20/QWXK@7<_J9=R*_4E8\D;ES0=C` MQ+_D?W_M[_C[_>P_S>T9O2M>+!^Q"YLC$>_%"_996L=P7WHRH+Z?#VEIEIA= MZD`=>[O<%D1E0O-P&4N5A"^HU?MV0W3+D[.6V(&7EGC_^`Y@>7ELC'LA@ MNJ;++^+&T^WA)O)D<]'J-PB3X8H"0'^A_^?.\JEO*H&=NS,9QJ>YPQ$X!A%T M3F"'PW!K,*(#.4I@F)J9MKI^>2+:1*N)=0&KD'-W?C@&N]L#'6=9XI3#%H*=?L[5;'&,&XC+X"Q=._TU(K]="2:=JIM\)3`+<*8#S!'8< M>":]7O`FW0I#"0E3@.>QXG,8G-@+_/J/SG/P6K&T[HN]/_ M61*XL?F0`]0,.%"MELM5'G+*A9=L>YDT"6ZG@IL7US+[-@D8<*;`[C9_\_(C MI,H@8T6.S=Z,+D6?/@;$6>[W*Q4*;V=TJ:^E?N1VOMEN%VWS1X>OO5^\Y*:'3- M:M2-,>?82LW`A1#G;K$MU^YJ<5[IU.<]D&?1!>(T6R-T932)\X*VH@>2=H$\ MT]8(GP>97^(H26RN;MN;S:WSZVZS80_L7[,]SN3V<.T_R,_1%$V0!O6Z'N"G M[.NUVT;"0AZC'Y.(/Z"/PBB911^C\)%0+9[)7H(18S"7.:)L*&^U##:;^(3] M]H6-I4FVCI;?=>YJA\2K5F7`\\A5EDZN5J:=;YVD4O,-)+0;T#K1MLR:LXU! M-IR)3:-(]&`+VY2.*J.J96!7A[>;%;%+I$T'PUZ M_GZ]>-TRWHL4L-<#L$'JP7RU1CV`K:RBWM7;/>W[\GN@V![J;&D#_0IUP(_+ M-GG>%A4!K]X(DTS]DLJVC80#47?3\*(+-#H1FYX+HF+-8E:1\6-R"I[9[>G? M$_]P/MX$K]*Z3?UDV$#0-L7`-6#6FQF`JGD71/1!>">647:T'3AY6Z`>D)-. M#'!J$&.E!K.*NWQ_K*\OB$8VL)-K`C[QVRPA(R>7:1G[^N,L=C^MI%?%[T!\ M*DQ@%8%N@M#_?/*?>Y.H:&@#D7)MH#%].5]O(>M`)IAPR;9-0H=!ABP%.S"C MDZ_ALR`"5NUE%0F_^+TW85@3&XA']0#7W-RL'`#EOK2GS$=D6E^,%8Y5$_Y* M*P*,A]=5`$\;O%5Z7&)E;"A1"105,O"ZKC:T]Y)DD^B#Y%T]H!W"A89.I:`/ ML3?K[39_72_G?M*UK)KT#H-FM)V1;GJTG?<6-$/F@0]Y9=R;B.4+"3![6#5W MZ"J'"6AHPSRB;WU%=TG_%S*!1R]`J1DRY]AOY^=G+WX3-21+\PQE007TL5E9 M'Q)H)KNX1WN^CIZ]H#Z`]FEI!?MR=:";-+/%`K(9)8XSA&CK^#<,-/P41P$; MGXL-UX61L6HSJ]@HG6/W:6D#&_M.O[;N9@&ZU8`VWYP*L@T3S@%^":+:J$FG M;($ZZ"6]?4_H-;VBGLT7JZV;KDNM?#*O%ZA3`FKA$WF]8%WXKRIJZ(A_?HL# M7IO4>XQ]'VLJW8^LQ0K6X$OY2E?W?OPS-LNV.4^'NRE\!"8+Z$7!+6 MMYD"99K.M?K]E!;C_AR^4CY&\9OJTJ.JB>R\T5,^7G82R8;M)+^(Z MNVS84P*[)H1E%NPH?65U)A7C4O'?#3(G[Q2<%G\Q3T<D2AHQD)NPT*B/&^Q M]T?V?K*+@Q>9*8R1>313*MP?9UXM^X=E';YRJ]\$?YZ#O<">E+N:;S<+L:E8<4TAEY0$DU2RV;U%_5B;@N:DZ`="-+,8>&^#1MEO[Q*)\UQ5L*YR9 MU4M:>_XR&\H^1.>0#KPO7GQZ^^(]JS>1X.V-SIN`2H$G`;/L@*,037+9I"R< M,.G(.TO3X.>3H'Y0SGIQ=9+3QUHX)$U\5@CI,MQ?^Z_^,1+O;D4]$ZD/ MJ-H8):-"$7!:H,4LV[)*Q?$+2R6!6;$>+,;I`NE60++;@OM"("['`$Y8Y567 M39"X=(J#W2DMPZ7>&&O]UBQWF@I`@_9\.U_EG$G%I#=WD/?-1J-R6U%=?O/B M?:($9Y`LG'(<]COZ'KV?&1S[VO_$.P"V>M30$.C MM.G2!AJ2EXNEDW%(R"294%*22E*Q6'S2"I>3JPQN+P=GCD]0QZR2"V08+=M4 M+!UM/G\$W')3?F]Z6TJE#'09OUC-G70[BB=<+I9'N%?<]&%SL+"I+[CI`^AF M`,L;VZ<20M2[;A"&Y9LNG4;!&%ZY:;_2N7!X]N69'.I?&1PX:UV#`E:!B#(\_Q'(OVJ&F%)!Y3'N3:L*(X]^[)WY^/O-1*N&=KO/TG2KIP M%WA'7G.1=( M:[:IC)!N*@X%;HR'_9V[PM&>UL/E[[7/JT(%K_Y-X#VDU_`N3Y^$.95R[F> M7=D$!HM#878_'>'I()UMD^9%7Z34&;D\$=8=X?T1WJ$%.0F,F,BMF"BJF"BK MD%CJU(Y`,(PE[5%A@&UQ0T1^*3>MG]XS)'0T1PD!:IW`_KQ<;IJ4+ZYEI\(M MY+=&_`T^Y[+MH"[,>]NI"C`3+C7E&1E`4^^.YBC45.L$?H/D+&9-:G;D!+)B MRJT1/R2KITW3;9@WMU,58#970U\B)[9L2C?HBK=L$RNWHIOL@N8 M[)0+QN6Q\E'(/E)I\.ISN6X9J+E@PB63L6* MQ6*VI!$8D^3\+*I?]5Q`Z.\1.=9I@@%^1;?,2J#+HE^5C9E*Z4V+3"D^?R"Y M6J2DEX4K'%QK-X)D:;>'_NFCMWM*J_FE-O^%[7NT%_3#C(":*=X5$W7^5,A1 MDFG]%!WWU&-%V=HOT(\8V%,>3H3KIR3X0O(VJSA;B5^ESK)J MSZR[O)X\JP:=/AFQ*C!-:*1&V+D]GY(37?&QMS*5=%[_L*`8_6BV2,+)``/K MN15452$M]4G7HEG?RGG/(!'&[P[UTP_HO.QX,+M-5'+>2NE7OF_Q+>W%<+Z] M*5&WQ[6\U"_;HLH#&O8L:W)C-.)7)68Q,K]Z1[Z`'0IDL^;MSS`^_TN/Q$&_ M+O9V?'(G3[P":&AR^M.I#7@(=^?9"7(ND^1"24DJ:A87S8#=D8"-S5;`[EJ9 MEL",91__;CHJP$%;6\/$F[Z%T=;SY0)*QQOL>G!38`+4^BF/AP`MK6%HK[,(=^6X4':B'M)HA@PDI04'*G"GA7,1^1!$K5M7#DYP M8+>#S-S^M#[N! MC8QOH75I!$U3/I_--FF5BI*WY9L;Q;.U21^`RS?-].*LQQ33.#LVQ?2"K8>0 MGF#-;%-!Z5AL3(&,I"E6Q.Q2=6F+,-\AE&>"Z-/2?-2`J`4V>(J7V( M%%&J6D"'J<5VN5[4(DA^FH(:+L;@<1#P@&+!&%!N?U`F6=U.ESJ)6PR@D;-7 M4,[6/\3A[-4@=YBY"\=Q*IR]LH.SH_`X"'@@G!T%RJV`8L,6*T*WMXZ]$N+4 MV-MF"I3MN]:[U[*MH?:/36[-M6H`W8K:+-89.23/')"VW,:C$NQ@4[CT,<&N M`Y6Q_32E@U5VS^16T#.N=3TSD+TR$%=OO[\$:1YX2N!H_ZOW/7@^/[<&NTDZ M,CZN3H$"FHYI/G.=;!^/4[7IU,0KU69X>!/U2=/O7M*[^QZ_1R[^Z><:D1>N M$GD6.IF^.(=O5V4(K-2\4#[T2E]&%'85*I%4)XQI!KYM>2#FDMXR/XL.Z85- M\D(EX$U/IHQ_Q?1FLI_`GND1`$V>N:+T((-E_F5W*:^#UV#OA_NOSF'LGT(U^-)T6TT^X\,.96>0O\(^[++E/, M[I[BZOY%T`+E0S>RAS[(6-I*1^7(@AD)\.V>30V&08W!`229KCK.-V#?=3_##S`[_B(X>+_W[9GI^6.OY MO<\0JW"@/%W.5AU[A/KFB(6&/]HL<83MJS'R-1>$'BG-$'WRZ6++3_/N8^?7 M(/G7I]CW/[.B57YR8LC:-VB-=_]>HZ@"$_AN_CJ_7C15*&5:$J8FR?3DD11G M"]+JWT%4#*+"?CXPBFZ\66.%6:/JCAML!OT-7N)4;[,<)M]6(8#;F(\7 M_!Y"Y$W?Q]FKQ5;;T8X%+]?-VLW-[=:1LK0C8VF'W:R/;`WR:8E9-_AOY0Y1GL+(<^25TKMA=%:L0T;-GPZGA"AO8*8D/-CQ;6[N)@ISPE$1^8#B&\5[AC5N^E M\,:(_.RO?'']F+RPQK@Y-!M^T:!`@5#3U6+_>/CJ/P;)2=Q>RVN:*5[/=+4Q M?^%7K1#0(19+=[G-KNY2B:0LLJAJA_6Z1B=(!Q=DUUU8C4C=44@-76^%<;!T M4Q5@()1Q+=/CP]%+DC1EI2KWH_1[DZ.>3`GP*<5VDU4GRIV*RRH2P*)F>-2" M3SPZYZBB;E3&!LPNAZN,GTI#H/)%3.O9S#8*V5P6PIG6-AB\:5,$7G1NZ]:Y MDZYQ"H%VT&_C@)4^?CM&WY/*!C9$[:<%V M51,,+K7H`3\L7Z[J5&*EJ:D\P@523TM%8E-I+$JWBC+J@=(XIQ3.V$HIF6V0 M&947O;Z+DH!OO8"9)6^*PS"I/N!,UZOMO(5I107T3+!-C-.#NLF\WJ@1&-CI MO!(FJFV&P\AZ.13I+]_XT"C;ZKU#X_MBE:<';)8$FH9$T0W4ELJ9>$/,UKPN75\ M&4?^;A=)U*.'TA1VD(:5T+H.DMTQ2LYQ=^U.<'M42DF4`B_1'7C.VXI&@R!XKRO?MA%CZYU/$,S(5P#OER]E"P@U1K`7S4$T#M':"=$!#XDC=V10LJ=C" M$IZH+TY+O\?E2K\KMMO->JYD"^[E8RWP5(RQX2IQE^-UL`;Y4F^^D.S8DFQ^ M9Y`GC<[AQ;!FZ;Y\L?.!ON\X#HW;"XTI%DC=J.S][<"'>WWB[_[Z&+W^;>\' MPN'IO]3]G/[5_]['WIXN@WY[>WZ(ZC]*\[\;\.M&I]"`Z&RS[;ZT.1'MS3KR M./5=F/I3>Z[4,9C'MB/4H#KB2V6 M\S2Y-)7$3M_]3);A7-!:@#@9D-L#R64A;JWK0^:6?J)<%MH%\PZBY/?*5="U M,#8M'5'D2KYN)HI3?&B:K:U:0&M_S)>;V4QP-9533CA^/576-"EC-8!Q3(-1 M,U4#HB+GN1J)$9HJV9&35(X:8]&3:J/<8JY^8W"Q4^D8O%)>.8NJI^/N)`\' MX99`).3:CX-7ZC"O/KD)O`>61X\5)+)A0[G5BQN%R!^`R.5C)N%,?KEJM MH)/$"3^F[9A/ECY"(FZA`71!X:Y62[="V41<7L";0PX%X9@$`2+G4"2`K!9U_DUZF,41N;;A;.(^#NT<\T`:^.@,/!/A31%XR\.4K5'8$$0B/ MVX-+I]50UJ=^\/AT\O>7KW[L/?I?SFSR<7O@6MV>3\G)"]G6])67!+O+<'\= M',_T:]E2;)@PDRO>01K";PAG-TJR?DC:$1$]\80'/!%0J3/">^.YO-+^D!;2 MT]N&\UW`I<+(7H@@WS)K>:FU0F&MZ)`'`''Q-"K40%V/CR)-9>$^W.8HT2(. M3O[MX7![N$[OO5[[#R<6W3QJM`]1(CO3!S0T&04ZM0%7Z%UEMZ:Y3,KO`^-X M)I8PN2033)AD)&[K1>SFB'^.*&+*TW/H/4?Q*?@W!7T0KT)I9-M1P:A7GN$. M6V$ES%K"8U-X-U0(_3/]$_T7ED.5_N'_`U!+`P04````"`!<@:Y$A6L"&W`L``00E#@``!#D!``#M76EOXSB:_C[`_(=L#;#8!;8J=Y9.%>-L:ER M-DE-S\Z7AB+1-J=ER4U*J;A__9(Z+,GB)8HR9=I`HZHZ(:GW?7B]-W_X[Y=5 M>/8,$(9Q]..K=V_>OCH#D1\',%K\^.KKP^O)P^5T^NJ___K[W_WP;Z]?G]W? MGUW%403"$&S._N&#$"`O`6>/WDLO7_S[NQLF23K[\_/OWW[]@:AH!SSC1^OSL]>ORZ_]_>]G#W&$2>O5VHLV9Y,P M/+NGO?#9/6$5/8/@33%H6+![1B"-$^O:AR^/*'P38P6Y^0S'\[+AJ]^_[NS MO/'W+Q@V.GS[4#9_=_Z/S[?;;O#6& MW^-LE-O8SU!2(/",VX+^W^NRV6OZH]?OWK_^\.[-"PY>_95^\`<4A^`>S,\R M&KY/-FOPXRL,5^L0O"I^MD1@_N.K%0@]BOS'MQ_R_G^XBOUT15=1%%Q'"4PV MTV@>HU5&]:LS.N[7^VF#?#H&]B%9N0!G2R@I%N0Y;7TN'/"\+[GWI.?/#V3- M`_J-V?P&1F22H!?>Q1C23UP2XC"<0Q!H4:\X]#[YN/,0T)N*#N,G2Y!`WPO- M7MZ$\3<\C0*(@)_T);0]8&^:KR#VPQBG",S0PHO@ M;]E>FD3!A8^[CW5PTR/HV>R;=B!`$>@D/I\,.P0F^: M(`T!7=[Y#S?F&&$-;I"-&_@"@@G&(!ED1J3##\/*0[I:>6A#5W>\!BC9D/5^ M_6L*UW1SFV-)_!F#K'T!R6V,\1U`1*9:Q='#DASVU2+Z/ MZ<_)DD$)?`H!V>9S@!`(LE;9'[,UG0%:6/Z[IF5S& M84`T7WIPD(-XJ&6J$5!&:N6QRQ-J&9+K0ZUHZ\\\HSSJOQADS=ZM0.VBL^4 MZ/,HTTPQ8ZO\#0+DD<._KP#6Y\LV`+@"B%R7";D;BGFXA=X3#,GJ!'V7@AD: MS&A\7^($X,=X2\=68<-UY8:("S@.85!J.G45I\9$U;EB]A&\)!>AKJ"S1_*& MQO,KIM<.3B`YU$B3@6#A?65H[B:^'Z=10D^PI1.[V[:&1V"J5P^\!X:=L\OGH$<5"[YCL]<&A>:YIJL//KN1C=GD=9(:5/CDT MW]<>BLA10E7J3)D>:GKYW['&X2"3*OO:T-PV]/S<6DX;#S6MTL\-S6_-/#VO MJ\'W9*"$:L:8B)AT(C)%^<[;9+V&@J,O-2-':Y`=8X:FP9$#3\GPER#O*T-S MUU;7:=OA^57_[F@0&&0/=/WZX-)0J;-7)`QV9HJ_99738<0^A2\67*]KFCT- M[&FP3[J`**!6Y/RG]+/&`C2R[Q,*"$V-CX8TD"5&3="+;V;1*ACX;Q;Q\WD` MX#D-[:'_R&)\7K]]5\2J_('\Z.<)^71`/W\3>HMRN-![`N&/K]J_/Q^GII\U5^2#R)J8`[`R_^`#8,L=KN]T5=Y/#*A%M>\(7QB19WV1?D-#`&Z M)"MKD<6G<$AMMMH7;?=@`>D1%R5?O!5K+3*;#4_=(_+H'#UL5D]QR""K^?LM M/?5[?X*:M'G(+PT)8T0H^/'5^U=G*2;,Q>O< M17I8\.S(-Q4^[T_X".ZV"JL&/=2A<^?3OCP MI8H*IC^?8!*(W!5.?SGA)#8N5%!]=X**JVML42+"Y0DE15VR`FUHD?R'\UU# MY1[,EXH96MHJWMS#3QDH*7Z]\+QUKN>!,,'E3W85ON+'/Q^\V`P MC2Z]-4R\L+;/>6S(.UKA)PMNX=&<_](>71QK.J>1/3HE*[C1QCJ52J#NMK5! M-4W0)%$(B[MM28V:&RDYC!);"?.6*.0W"GMX"8YV>QNEGD1[\^1[,HV M&1*13-#!,OW2,YW==C14JP//Z&.#BUFR!*@XD678L]M:HUIYF_):VZ"\68Q` M).ZR6EJB>.W!X/J%AFD#=CC*2V_K-`N?)V(O]"&/$X6.-O@1V78EAZI25SL\*4I!(Y%[&-4* M9,AS.]CPK8AM?=21(K%?;?TG[]WR]JH#(SX:*WS<\O*JXZ.F`%7B5<>) M(U9N@?G@EE>WZ\E31T+'51LG7G@(2'#4T3H@BD;YRK7M5C1E9[S$+ML*)K>" M*3O#U+3J5;"X%3G9&18E9:Y"RZW8R>Y[C8>+3LSD^,]LN1V1=1#MQKRXFA>@ MC1(O.L75!`$]H'A.25?3`W11$CD174T0T,.*:R1V-3=`#R8Q0L[?='S?C>!T M8NJT[YW?=%VQ8H7(5'`YO_G4X.)X/RN:F'=<`9JR]6\'FIEG7`&SU!5R.BKU(6Q1F1][QR3:CLAQ->]7#Z)V@+ZK^;YZ^*@D<;F:]JN'F$KX MDJLIP'J("0]RK7S?+@?YB/-]FX\8VD_^+8K8$K*45GI8YRNL#3-)D2;;V M;]4NY'/2ZC$*#J88I^K4%ZU'03F_SI]2%RM):BEXC+N<8((.5I.YZ%8L:HIG MST?S\J8$'>RG!W0\E!0[V^=+\6B2=!H+'\(#2M!A+/3+CRE9+Z<3!@[(]--1 M:G,]4D<71M$EXGK0CO;24U*"7`_FT45/)':Y'M2CBYFJJ.1ZM(\9_-HBF:L5 M0H?`K10!W7<;F,.,7;G067^"OM=8:J%RW[70&SS!\>:L=\$0:*VS3:99`T-;@.73R`"R`O)[$R"%8RR4O(T6:/(M^,P+.MEA1-$,+Q#\9Q; M2*3>PHZIGYXVV^-'8O/CM;9410^0(SD1KXK=5K;<*3@+6LSQ*VD2.%.8S6W0 M_@445`B.FF8;*U22JW0-Z'Z/%CDIXE7!;S\JZB6[4=[/2E6QDJ2"&-ZJ:;<; M!;42S/GMK5(OW:.LEM9JSG7=KI).1IX/+=^LR1P5<+%,\"W\-85!]KTK;^4M M6BM9O9^=VF88$*V-E@6Y(N)Z&&<5B,1`B_M8<5!Z(??=$!%X$(X[IY5@>ENJBTO]#OT>.CH(2X7CVL"UI-M;A? MP3"GUI'4/.MZ%;$.6.F*C*Z7%E,VB.S&F[&M;*Y'Z&G"M6,^U8O)^RY'*0(+ MZE)W$"=33AK7@_8Z@=O!XJ(7N-=RWVI5]3%B-?JPB.'\Q/'J\-J<7HQ]F"X M^OG]B/BZ`^1@);O2)YH-!E<@_[L3>YPA;/%(#V%:GX[\,S<=T*,F"K:[M#IV MKB#VPYAJ?)*SKO>P=EY4)5>?#W-I@0@PM3.+PZ:HQRF.'_ND,-BZ^J_3=SES6NHZ#I[)`L,[4L?J.BRMQ%+J\WSBX*8VLQ181 MO8VLT'4L/.5YW5W66[W/.+C8:A=%E3EYX+/J`"/ACYH&MS3JG!'\$<;!8?$( M3[GQF8_Q*#.K-)BE^&N6'@][ZZ#JXB_D]'+OEUD(BRN$2 MM31"!9&M,\/T38PN8H3B;UD1W2CXR4/(H[XN@'S8SF#IUM=*@;*"N,=XXO^: M0@2X+Q)SIKS#`);>GOBCD MT"`SG:ZN5S/<"Z@\B=#UN,E]'0LJQZKK11+WA35/?'`]'G-?^)J/R>X2PWA( M(>^F`AT:16J%@5"NE]'K[DIJ9EVHN*;UGD@\I'5I&L6&4U+O\<1CAD_-EZ;W MON(QXZH6;^/Z&XRF417XMOL]RGA\4#*#B%Q_BWTH$-M%.QQ]G=W\[=T.D^KW M%V0_X+9]-?WJB1PCKAW]L'HE2`Y)!-W/TN6XZ/K5 M,3G&]6LJ3J]?593QIQZ;C<]J+.L.L0YZ=>8<.#X,X-PWTK!?);N#7>&:$69* MQ:;J3K%10&/3YZA0#OKS:#]0=KN$%3YO!DK.CW M;JYH0[AV%ETJ7-TLF6L(U\Y*3X6KFY[=KKAV*Y2P1>^#CLG-O5-4L7Q&!9N& M16V=S06A#"5'"-[/[^OP:;@6<_BNHY&KO#K@]8N)J5`=VDQFI5I5Q?(,+;RH M"/4A\&0!5;/Y77V.@P#F%$^C>8Q6>:2;C?),N:N=S-U='$)?H3`5OX.1Y*(* MF6U9RS@JREH6CBY67I%*-RLE<\B2(7.?&8ZOXI4'>>D0C(9&\"S&+7P",Y25 M#"ULUQ251X!6+$"5^EE$E$D8N$.0>NV*7^+BM[P,/:VAS,Q*Y5;\#".X2E<7 M,,B^R)P+?FO3U-RER%\2R6NR0"`OQ+T@_Z(6W/(=BDK4>F)KL?U7FF-_/RGZ+R:48$3JVS])N)0=\Z>6^,'*7@BGY&7>C=1K# MT#P0`04ED!Q5S0?`IQ&Y*+PP_STF7Q9,2;CCP?BVV>38NV>OW('/1 M9#MI>]%](IW>$&`3"@&?DI+T%ZDF*Q'C*^\#?X2 M)S0A(80@^`DF2X4#N]^`1GDJCQ'$/+,9KS,YM_HG9N>WMT,]E9RR\_(JI7EF^160GZ.5*)4MD1+Z M!YJ3)JJ_UG-0*SBD3YC(,N51Q%R)XK8CH/J1?$^T\CBM1T*YT!##;V_D9"KO MVGS1/L:EY-72_UB'DWIGJ_FL4IMB(^NWR^U214.Y&8'--Q=NHWY5KS:]=+X# M@DK'+E'53>BG\KE>$*0?N"+KINM5/WHNRRZ6$]=K?`P+)<>0YGHQ#S/'9MVJ MY'IY#FW$5"Q-_=Y..P+P^JJ->KD+1P"PGI>D7SJ"ZW!V4.Y<+_ABX-04V[== M3\;M#:!>H$2O7-QUC"%5I1Q%MD-`C5[&[1&L3I9[T/7\66/:="N^I5_^Z_$B M5X_%<3TQT!B&RK%AKJ?V]4.TXP/NG1+W#BGGNK>`TR=RH%]VGNM+5"D(6Z_< MXN%`J!'VT#1<<+WU)7)O775C]86.YVPN@7/6_]<3N(Z[?KL.W5V(LI`9AL+< M<+ZZ[G"6Q'5(=N41H]3VSDL"?/3*P!Y@]ENMJ/!HTMQ*FC:7*:*3+0I69+>U M\WIG08GR4^JB'E8YR#1$&=%Y(ZMTMF1B'JVW9M-5/I,_R*4=/&PP'90?G\IN M:"4`/7T*H?\U*0K@;I$1Q`4*NXR)!VF4H$)'NZ5F!>==P\LBG$3G%15EG%@' MA/OBL\(%Q`2IB:;KTB'_\F""4UR%KH<0JEP/*B?1,>D9ZM?1UE3'$1SV%V8Y M'FVC,IYL@>NF:_!*4OB$")Q]@B^7M1M9E6-/>LY)S[&JYQBF-WO<0$PI;6*5 M1EH^*O?JD9,//7.3U@0=#D^7%-!`2\6BX-)#@82&=L,QZ8(G??:DSQZ*`'G2 M9T_ZK'5]ULU0M(ZH,(0!O4290PKIZ8A1\\4JK0R8\5=X/=E!QF$'.2XKFP0I MAFCN>F*N!E(,P\_^R^T]I:0YF:;8U76BRIE8J0:;6Q0.9O/ MH0_4=A"[[:A,!VX90BXVDIJ\*CU'Q=$U3N"*WC)?,9BGX2WD1]1T&V-47(I, MF9).H^+C4`UQ/++X`6?"+F9>S^!]`9?+>,Y\=D2IWZA0EML*%7J.BB/N#'7I M:>4=#EHX0W!_5+^W1IU0XJBW.)F/3^;C$=I?.@AO2J:7HS*0:IG>96*7Z]5A M]5`S9T#2*Q=[2"%OAM?E3DB<3F6E`PB),XL96U%TO3YL-Q`[Z!6]*L`Z!UPG M@=_UJJ\=]+@Z=D)3MO/><#W,6F96U_VZFCAQC-*NOXW2$2VU@`$W$S=:AHU& M#=&Z7<%U'8IA1*ECL>.%^EZP^U](D-J>VP4PR-3@Q-W?YS1#5. M3U%(V4_UHY"^@.265EZGY:VS,NVTK'V]ANRV=CL%ZMD+J>#=>"KIKODV%?UC MEM>)911^+U\+(<#?`YP@Z"=%1RMA3E$"`QAF;S=6+SY=O_AA2L"ES\;0)QS3 M?!)F\VL/13!:4+`RF"8K^D@I+\;)R-@VW!`]*;_8L`<0.(:&_.)X$/SBK<2> M2FDW*[Q\\U`@"0QIMK%!976@96?6&D2X2)W.;-"7,4YPME:>Z-L=1:G_UJ/" M.VSU'-1*<.)J'<8;`&K'L#A,D=O>BHNV>26(G;7,MG;=MOEI1!=#?;G47I3` M%YNJ3?G@1+9YE/RZ?<5.90ARP.V9?'=G;S^`X\2#^Y* MJ^Z"**`RMO36&^13-C`K9%OAJ=5L8U.'VH.4UW`(2T4BUTUGJD+AUMBJ>M"Z M;M9G2J"-\*!!#BO7UZ,9D9D=IM5;$'(=?.,RH_RL-72T'Y%Y=HBI:9YE1V2I M'0!,$T*[^Q4+S:DV!L^8TG3J>NC&D'I4(]:#;_=Q/8YA7Q#OJ'>NQSSL"U:. MS6]_H0.6'7`47026!&#ZZGV,QU,KK4'9-"),4&_A;/[HO7"L&Z(>-BPRY.,Y M%1FN8F,_NZW-'2BDOOEFIV"B]G?#6MY(V?'1/K#&LIL.WT/%\P?HRI?9']*-<^W]N+?SNH$XW251RZ1O0"H2'H%GV%`5M<]X=JT@T_YN];0?))S M]=2%JT>`5N]$,`[S06=6X]]CLOMHX;G-OM?CSI>S]\VYBF^<%6,.V^+P;LMX^SFC7[;(#S<;0)[[KKOZ13XOP:'/=SGZ( M<]-68=TTUH]\;MCJU-&8^*_`4V+`#LE[6WBQ0%F9DTN"-($7%3/O`_A,/>OZ0UDQ(8X(5\&0>X4?HQ_\N`SC75;Y\OJ#A#4DLTL MHK+);>SM!I+JC&!#RKZ($8J_@>`FC0)>N'"SC1%L&T-^]A+JJM_D)CX6D*+F M-E"[))L,S^;%RINA>[A8)M_Y8&K-921.6A^>3LXW4(> M.3ZNVNJ\7'P3F-;=$]C0@!:7;% M\I%F-+1/[R59NAL8+82IDL(N]GFX`>),3UYK^Y379>&'A$J"Y"#WJ<2SX)D/ M.PQ@G[]6A)J0F5NK&35-6J19,=SF1NZCYNCY[3Z;3R,BHE(!-9_T0JIG74R= M^MM'6Y1=QVIIG^*OD9>71Z1*$_:53Q]6/QO<5%I@\*\4)Y2T2H[A<"+N8Y>+ MNBY;DQ>EG/#ZC8>;RNS;B9E:M['QHN0F&[FW2]7"U8$[9G!MJ?R,6*:90=P+/H^B4ATF<*\3(_@>@!RX%9WL\(OG\C)T<: M`OP(_&44A_&"/@/X+5E>>FN8T/O6Y^=<*_?5QQT#_\TB?CZ'T3-95CGJ^;]W M\E>Q1XQ5&'57BX^4&2(RH$?!^(]0K'5%6;SRR4U'$^CKU'\ MA`'*#(K3:)TRQ4NUCH8>RBB-A+,YS[;8:G-Z7.'P'E>X!^NB!E5F*LXL#3NV M*:%"IM[?6@2'2"2M-3"R;UH7-_\*XC6UZ3`363";V2G*J\;UE&6Q`;4.&E/Y M/@9XV'9:/C3'MGP$EKLZ2#N.,N=CD=21Z6+>=3Y62`Z;W/_I?-".(DC=#,+. MA],HHM96'ERO>*U]5M6<:*[7P59=/5V#7EQ_:4H=-ZV`)[V'I)R"KU],3:\W MI9X!>HH=@%#9A.GZXU&JNU4I],GU!Z-4P1)[4EQ_&TI;N-B-,JJ`.EJI7M$1 M7R&E(/=RB`NMH!?H.D3856D'ZW0WB$>L4+K:*7V#A%$%5K'(+T+ZIIS7<<50L=@5N:6 MM67[IIVONZR(#N.EP"/QF7(A8;F>2VS>G[!AG^'N%WX^O5HKB$Y3>;7VO9NJ MO^:KM>_=U.@[QP5NY1CUL.P*PZ'MD6.HH+B,0$NIN^%)IL!ZQYL1[Z%Y%-! MX7M9$1T/WWD;1LJ7.W:!D-QU+5 M`"?4&4:?3OAI"?WEKL>L,(<)4AE[#CH6'$1)[OSVHZ%>9?DQ>PQ0::+IVJ>S MS$CT4^\W&HP/N_Y'.?:7E)Z7[6^6)#%O`]VA!N2C_5%!-I?^.&8XJ-XDY]^X M[49VJJQ4SZ=[:(;R$-_,[E\^H\-;Z`H]+7.4$8$G:;(D`NUOK6E0Z3$*#IB+ M2-;:T$KFO`M91.WFO\=D][#R@K2&L%,7`1$Q-\E?M@#K\C3@E_S@-+?R&G>N M`HEK#>TTLD1Q[N-H"-5=F\6CN*7"-[\E(E"EAWVT%<5,2:>Q\"$4-@4=!E@= M\A6LV,D0;9GR?I<^A="?S*LX-4Q]!71" M/3]S\_,WHT+'\?%S*ZE)J]I[?)R)JJBJ]!PA1^3S0F.7R1!MB'QBPK48BPA4ZFF2RE)\E!*UT]`@#1>J-.PV-$/#$H3S^A65:5Z2 MA23K8V7_EC34XS9$5P:WO57J=XSF6(4#9A\[7&S]H%3S\C"Y9E&YB*C: ML=WBU:G$9;/7H%9P2)\P^#4MQ5*AG,YN.P*JZ9TE6GVX_*Z5=+0U3M;K8K(C:*KWAA7E`.V(:\?W`RBE@:N2>NM'$OA/X4@N9W5 MU9*=JL7D9J)T=XA:(NX6HH]NYF*R0RD:U1M4E%?7-YLPDD-]F[F987]*B!(8 MFE42HCX>)QJ M%=GPZFL7SSS&0X$FU+(E.N5DLW@)MFI;EH0>NS4OA99URLPZZ[*SBD5KI=D MU@6R@ZW4];+,O2YD<4!=KX+,;D/7L\*U3LWF@ZB&JGTR*J45NU[&N<>"Y*>Q MN5[567?)J47FZ95Z_BY'+\K*:@3.X6"N MEX\V@YN"=IWTL(^KI>TUM[KXD2Y_96#/"S8M*MDN5XXO,>!J?K^CZ.U;LWL8&8: MKNN%H5A"?EI0ZAO.!-A=Q)3ZDC)TXWKD)$3ZI) MTW/<*BM90752->I0J=9'J_`[*1>"HTV*WDG':*#7K=Y8!>,Q:A;\)XKXV4_. MOU.D"=DQO5ND"9$D7=KY)XUT8>-E^):`?3@!UB%7H8G=QQ-V[#W:+LA00O;' M$V0=EEM-5''_2;*NY7@J9V3K(9I*,CM&_5T`E4(5H2J%[1A5*Q%VTKHY%72. M*@2R@CL,-:!1+\+Y]#Z5FCYUD#@IV<[C)*X[(Q%@CQBE]M$D*4!4W81#.Z)& M][K@@[\$04IM^VQ[SM;1.9:'JTY/FYT>#MLWSRUCJ`IW5:?1\%';XETXJ7<; M#2^B6JJ"#J:?0"L7[4\P63;6\W4(R!5S%T-R)Y'!P`U\9A>F-C'BWKB:12`C M@/S]^"WNQP]SK+UQ\D^`XNSSUW1Q])\=[GC[Y^B!KI.;.$6&.-H=S\V'P,1% M"^4O,K(;FB^<*/E^K='H"K*=JONI(L6QKO2]>%RO"&$:2_9UYWKQ!],H\J]: MUZL_#(9DZXIWO0B$FE[&+I^Q$WCG:.DO/82X"2F.5O=21TE=DW:]M):%6]L+IQ$!+:7N2%SY M0K8-_P8!(M.PW-CP?U299QB#A&8ZWT+O"8:97_XS\"A+P8PFE*>(I@B1!E_B M")7_>^%AB&G_#-9'X"\C^&L*L,R:/?AG[3YU;I0ID15ZT$_:QC!=93L;-RYU M!2#8_<;#S1KX"0CR8EP=F*EU&QLO?X]#LH+(JMO&<2W6QCAQD+#J)"YEB`9U\0O8P,)_P[+7RV`-++"76:`8T9V*DM MJ^.V.F;VP^\A]\V"*JK%'C`_DI?C6H+[Z7&T;H^C.>J8E:'! M>1QM<`?LH1CCJ\+OA?>B=BC9,,M7]-0)82O#[+;V`B@Y[UHRXRAWV]HV_.G> M2*K&-!.?.%2,]N$3&HD#Z&+3]N[=@F<0"FQNBIVM\C6-UFF",V(^"`UTHAY6 M.1`OJ6P-?8WB)PQ05CX[(Y_\.B971PB]5@4!'MNF/F,5JX+R[*IL+TGAZ=YM MC+%P26,A6]."F_-ROW/>Y/.\R8(`I5O;Z+<<0"U_$:^LY'4%\K_W@R+GVX>$ M*N:PEHUE&$7QMVR@II3CO\.]N(\-+@I]0WB;-MO8#P(3O%S/8#SQ#$]]O+L MKK/)NHY&_HAC-_N-;'$+=.:CN7P-FUN8D$LFZWB\Y@."K5CT][2@32QH,R?[ M$84>=#%4,A%GV;5==QD?7HE$*\[D+W$"\&.\=1]O8<,SM/`B^%OV6?KZ9AP6 M[PR3C7E7(ZGF>ZXZ5S[J1T+A14B?@[!@?9KX?IQ&]*WN.T(^04'FR11TL&$] M,SX';*Z-?\;FQI?/>7W7FT=X?P?KR`Z,KY@^#883N/)H$YO[?OMQR79OMS-2 M;(J'1),(85.;.XB+WK;R!9?!HUW\U:ESN:3!:E2^O48H1IMC8 MIT)$E5D8QRY4F(WZIA.S?MIC#%@RBY*5,.7#WVE5"/B6LLL4T36=H2K;=3^;^TF9JZTZ*)O,TT9B`F/O8MO#PAT#-[+K3:'CP6S$+F`<[7Z\ M]E!$]%U\!U#VRK)5/6Z7&%EE?EYS*ZEP7"#5B!_'!I/-0,,]R.?XM)UV,;%W ML]G95!PAMU(ULIKDL[RD"#F4R\*]0B5,:XBQ;R<]7(YVA]%P!`26(,+P&4PC MTA70QE;O+2E-[*TF[79P;^*,LTJQ=':.=C-5*MAL3F$B&!4AV"%I$ES&.,'9 MP77A81#<>9NLE]6]IDSR4YUDR7KN.:B-?=IWZGH"P1G5YDE@9F4T(N/[8GPZ M6/20LR._Y8OVU,*R+=55*QG8T;-B_HMN M'4N#SLWQ'EG@*1E)/$.3%-GAPFYL12;A0*A"^$@VJQ#Y9M8CW4#M=^!I MVY%LJ>&?>C55XT(51,XMJMQ_W$I[!QQ.&TZ&D47C\Z%LNZ;]M07J[KMR'839 MCN.-?%OJXW2TVY15,-GJ7>C"XS!B4-69&,?&TZZIS>;^M-58N-B[!9W:<$7J M=)6I_K\I.?%ADE40F4;S&*VJM'?E+:DYJEU9@5DY99)LF>IH]^HXW$$>6+JK MQ_7D_*Z`ZB]"R[7@?SBGO%!;)_F?_P=02P,$%`````@`7(&N1!P.>09:#@`` M38\``!$`'`!M96QA+3(P,30P,S,Q+GAS9%54"0`#T,US4]#-`L``00E M#@``!#D!``#M75N/V[82?B_0_\#CAW-2(%ZOLTG:++(M]IHNL(D->],6?2EH MB;:)RJ1#4MGU^?5G2%U,61(MV;N-C",@V-CBS)##;WB9(35^_\OC(D!?B9"4 ML[-._^BX@PCSN$_9[*SS>=P]'U_>WG9^^?G[[][_J]M%HQ&ZXHR1("`K](=' M`B*P(N@>/W+&%RLT]N9D@5^B"9;$1YRA/RY&=^C541^AN5++TU[OX>'A2`@_ M$7+D\44/=;M)!;]%33E%;X]>06NLDA$/F7^*7EN/+@7!"JB1#XTX1:^.^Z^[ MQV^Z_=?W_9].CW^$?W_:U'RY$G0V5^B%]P,0`R5PG*#1T>C(TNK?:,R9!.K% M$K,5.@\"--)<$HV().(K\8]BH=(HBZ`'F3SK6/H]G!QQ,>M!%?W>'Q_OHD[I M?/\=BFA/'RE1)A5F'K%8`LK^=G#H8MWG=B4YEKA9_7?OWO5, MJ44=RNX,XV5*/\5R8JCC@I[NJNYQOWO2SW*IU9+(0C934LRW(`'.-$T_D!X% MTR/2F(3&\O@DP\0`HG!1W`F^$CU=7P^(ND!%!/5LUNU\.1Y-XZN4S>[O-[VH MT*+VP#J56&7))?&.9OQK+RXL[@LO%`+T+F.-2S7OJQRO3V@Q&Q04UT8>O7DQ MBRXIYJ'L*Y&JF"LJ*^:3:BF*N72)YNE;/`J+&5&?$+()?9(#?.`66A!F+KA M8G%%IC@,H*U?0AS0*25^!V&E!)V$BF0(0K8F^5E+>8\9X\K,)^:[?K)<4C;E M\5=XH`?-J>`!N0>;0?K#Y]&MNZ4JGAI[FKIWQ;U0MQ4S_YHIJE:W(%\L3*T= M1/VSCI,B;4G2%I],*:.FS?WC/NJBA-W^"*)0)`M9PM[W-B5L"@]A#A^PG\UG M#P=>&!C&._@>,\<4+L:E@%F3J1TXURTKYXN?)I`\(5)C:+(QJ\'TAC*8C2D. MAER:]EP"IXRM2V,V`H:_*C*X(3P!W%)!\/D"!WHA0.,Y(4JVD#T!9$,,$ZJ: M$T6A@VKC9[BW@/C:"2)ZD6G!#RVH54&]A8WI@A1#%I>Y@7FS`4SZ62(^18.E MWLP"93O.*D-RB>7$N`/\I;Y5!!/%:.3)W,#]=8)E):&C+@6*"=0G[@B\IZG MT]FZ&P=BAAG]K]'H$BR>!]0W7\Z9/[2TM>;"-?,5E5[`92C(/7E4%P'W_K9@ M_PBT5A?TED-0RC3)> M-$_;2(,8C2,STK9['*.V8Q(&*+70G!QR86>O_4J60_A>A+= MN+_;Q'U$/+U0K.N`$0UZAJ"WJ;RU@QWMX!;<>Z:X6.TZYSL%.%'N'V^BG,BB M[<#>&=`;^DC\+UI'6,%3%TC"]G5M3:RJXV0B=IUK2[C=6/Z9A-3+:;%;T?\S("8\\`G M0EY_":E::=I=$:TNS8WQV$Q&PO^#XI$MYCONLW&5/R&@]`"IN:L[9;@QC87 M^=+"D)&FPR-I;>!1227"UD5^+A?Y'D\"(O=VE&,Q;M!SP3#+748O(A'M8=/S M^,TU<*XDR(UT+OQE^]`MU,_F3-=`>9L,)\"OZ1?L;>V`U;.)I:G); M3BZ\5N:-M8;SCVWK:YA(79EN8\C%YXJV^*TA/.M>O\[.H((<-^"Y2%V%?7^+ M?\6;F^O9V[I&<,Y\B]79;E^+ZC.@JE_G\,.`Z$N'L<_NP+2( MVHUH+C*71301J(=P*K(%M"Z@EA]>:9ANI7>#F@_)V3Y[.TZ?`=9QN%A@L=)K M*E\2H5;ZQA'L>9=ZW^.`U\WGACD7A-N`.98=+;^1].CUC$1^BWA=Q#\1I4,C M0R*BP(AQH=>S;OQ0>SZZD[_BP%Q%A>\+&Z$I$8+XALK\&2RU8M)B M'H;"FX,;_3L6`NO[;,P?$=A%4T_%C)LFU9R&N6TV%TXLCS9E5Y^D2->!+!VB MLE0+E*H1D;Z,.6)57F;E).J@1!\S/M8:Q63M,*DY3#*7-C2ZE5:]BEQ.`SO) MA3/S%TC:%?#)@#;CPP3\['A?);3KL+HAKQZ';(%_7N#7"TX:7QI,K[$WCZ;? M\P9GQ*@6XC*8Y/%AN)O>YDHUJZZG@M0:9R%-?>6E!="]+7?"I- M%.6$;L1S`4HMJ)T"GG8*R)P?5)_W*["YP2V^";AYW-""_7Q@KZ?F0:AT"A&= MQL5R%9(M]7;\*TMRFT0N.%EB$O;L;E68]0Q2AZ"UE+I!D?5"G9X!64=`!2OZ MKY0(#(Y8+K*YCRBWK>3"GE4.KTHW!FFMK;4\F[5<$0$NOP(?+AZ:=Q1/:``J MD-P4\S1"W1:TR[7'#0M:UYY,-\BJ___)EO0?G5%J1*;()(LZU7F2SCJ2+I8! MZ<3/8(AI?G>:J=XR"G5"#_82L8F`''%`M-TB10,I757S&9Q]VJTEKM2(>P"CG]3%95N606=SBOB2+_LUI"!G8;66V(SIM^Y: M3/VV;"1"K-2,A$=_V*LC-E,J5JH]93*?]JH_GYRQ4@LLMOCS7JW83/98J0TI MD_G47;/;]<>)'TT#SCKG'G@VTER3^4@6$R(B'T0OG'\5E$7+?914]-3G"TS9 MK2(+O17N(#P!#P%[ZJP#CH)>S'7&UE-8Y"GW[PVC'XHXEL9H$.@KE`FM#(&9 MJE"7?A`\7)YU(G8*XDN:GH;$[NB7,,Z*=(47>$;D$*^T=%N9*M21>E'%"\[` M;Q&K(OVF.)!;%(S*)E$6.R@@$ZJ>1NW93)`95D1G@Z)^G'Y-)W,!)PQ$WW"1 M!'WN^06YE3),3BFBCMB-W^X:J<^U9:V.B;8P3]4#@A#_?*%GW7O^.P;'$S9Q MR^CN_Y``Q&HU8/=$+.XX9AG5ZS$^GSEX@OA/90]J,11\)O`B/X!S14T:OQ?8 MUR<9UX_ZR,H>JIL%AS`J+[@0_('X-R'SY4>L0D'5:FC:8&OFHK+53%J\HYI/ MH)#)WCF8QE/!0)ATWM>/1'A4:M%ZE%B:52,_`!4E;'!AJ*2/9?(\5B8SE^XL MH4&S:;$.^;8OJ8C73$6V=L$V]HPAP).F&$':8+WLZ3G"J6T)=8.46Q\^Y?8! M!65[6N5S-?TC9701+BZH/P3/DQ3KD".*ESI8YY;Q^Z3?;HCE+QZ:K8@F2;=C M($M*6*X]V*+(8ATK,Q_"BFGI9="1B78E1IHC:M(<6MI,\]5AM@[R9AIP,O7] M3M4\6=!,@Z\#\I6P(:>PMYZ#?=[`[CJW(]U74)/VKU5T&3!B%('_[Q_X3MU1 M+.+0.N)/(KA1XUHOF#O;1KF8@^V0L;;V&QZ*_3HD)Z99'5)R/?]6G[#A("K7 MOV&4GRIK^_-4A-]OIA2 ME82WD:I;"#.3D$J>?SL+S>R3;P1?))Y;YM4B2\&J#(>PX_X5UHTPT/D1O#GC M`9^M@/%!S2_QDBH]M7BY):@Z2Y.6FX_0]!O*_/%*`DW^8*.DO&DJC(C'A7^) MA5^L0D%YDU3XA*6/O\1^N5F=P3D?D2\A%9'SFI[(?(!6D5RP=$?^9L48MRFQ MF^I-5IBH.O-K-?)#F%TW-!GCH*K2!:3/MDEX0GTY\["<)QO2_#%.&<%!@!F' M\/49*?%"?;?U(I24$2FO\$I^XDJ_:A50XFN/K#Q`N:>A*@$[)`+[O0;CQXY61&Q+=K?9(.[X:+Z.119U<$;ROV M2I)`@JU3=9:#.!R'-5+_R`V>Z0G6_(3.+?O,^$3_)K$6?V25J3/!!DT MPS?$.(X/F/([,H/IQHV:?-$![%RBL#I,VY.`>H,I(`&37&8#%JU)&3VKLC0*M_4>L_+\ M7YWG$/9QA;Z%B#;*UN^=VMFUUFN$O(]N_.6/"VIS M-NW\8`Q.O#"OM>;NXN1"M!5HFQ2N'1.33;7TP+5`OVH,#50R,;0WRX<>STDP MM=?(-"EZWB2VDC;).CZ[?A+;Z%-*T;3E(G6:2BY/EY0W9L>6N[Z0,ZU2BB99 M5#(7FGO.Q1#894WK_JAM_CU/]A$N%Z<&S[=S==[WHM<9X>/_`%!+`0(>`Q0` M```(`%R!KD3W+I\3`Q0````( M`%R!KD1R]F0EG`T```VT```5`!@```````$```"D@;UT``!M96QA+3(P,30P M,S,Q7V-A;"YX;6Q55`4``]#-`L``00E#@``!#D!``!02P$"'@,4```` M"`!<@:Y$N=@/^;P:``#.L@$`%0`8```````!````I(&H@@``;65L82TR,#$T M,#,S,5]D968N>&UL550%``/0S7-3=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`7(&N1!!/V:/O3```?1P$`!4`&````````0```*2!LYT``&UE;&$M,C`Q M-#`S,S%?;&%B+GAM;%54!0`#T,US4W5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`%R!KD2%:P(;=R@``,+X`@`5`!@```````$```"D@?'J``!M96QA+3(P M,30P,S,Q7W!R92YX;6Q55`4``]#-`L``00E#@``!#D!``!02P$"'@,4 M````"`!<@:Y$'`YY!EH.``!-CP``$0`8```````!````I(&W$P$`;65L82TR M,#$T,#,S,2YX`L``00E#@``!#D!``!02P4&``````8` ,!@`:`@``7"(!```` ` end XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventories - Schedule of Inventory (Detail) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Inventory [Line Items]

Inventory, Gross $ 5,973,020 $ 5,956,205

Reserve for obsolete inventory (325,000) (325,000) ^[1]

Inventory, Net 5,648,020 5,631,205 ^[1]

MelaFind Systems [Member]

Inventory [Line Items]

Inventory, Gross 5,401,866 5,401,866

Mela Record Cards [Member]

Inventory [Line Items]

Inventory, Gross 324,685 327,900

Accessories [Member]

Inventory [Line Items]

Inventory, Gross $ 246,469 $ 226,439

[1] Derived from the audited balance sheet as of December 31, 2013

X

- Definition

Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of valuation reserve for inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 09

-Article 12

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventories
3 Months Ended

Mar. 31, 2014

Inventory Disclosure [Abstract]

Inventories

4. INVENTORIES

Inventories currently consist of MelaFind^® systems and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind^® systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices.

In December 2013, the Company changed its business model for the MelaFind^® system from a rental-based model to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind^® systems from property and equipment into inventory at December 31, 2013.

Inventory consists of the following:

 March 31, December 31,

 2014 2013

MelaFind^® Systems
 $ 5,401,866 $ 5,401,866

Mela record cards
 324,685 327,900

Accessories
 246,469 226,439



 5,973,020 5,956,205

Reserve for obsolete inventory
 (325,000 ) (325,000 )



 $ 5,648,020 $ 5,631,205



X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C7S1F9&-?.#9D,U\R-C(W M,S9D8V)D93(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T:6]N7V%N9%]"87-I#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E M8V5N=%]!8V-O=6YT:6YG7U!R;VYO=6YC96UE;CPO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN=F5N=&]R:65S/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;7!R96AE;G-I=F5?3&]S#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]486)L97,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7V%N9%]"87-I#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5N=&]R:65S7U-C:&5D=6QE7V]F7TEN=F5N=#PO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9I>&5D7T%S#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;7!R96AE;G-I=F5?3&]S#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D1E8G1?061D:71I;VYA;%]);F9O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-T;V-K:&]L9&5R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-T;V-K:&]L9&5R#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D9A:7)?5F%L=65?;V9?1FEN M86YC:6%L7TEN#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP M/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^36%R(#,Q+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$Q/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO6UB;VP\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M'0^)TU%3$$@4T-)14Y#15,L($E.0RX@+TY9/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3QS<&%N/CPO2!#;VUM;VX@4W1O M8VLL(%-H87)E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2D\+W1D/@T*("`@("`@("`\=&0@8VQA M2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(#$P+#`P,"PP,#`@'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2!R97-E'!E;G-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO'!E;G-E3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#(T."PS-30I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'!E;G-E&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N M9"!"87-I&)R;"QB;V1Y("TM/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`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`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+51/4#H@,3)P="<^#0H@5&AE(&-O;7!O;F5N=',@;V8@=&AE($UE M;&%&:6YD/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM M04Q)1TXZ('1O<"<^)B-X044[/"]S=7`^('-Y6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M)SX-"B`\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W M:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$ M,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@ M86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P M('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L M:6=N/3-$;&5F=#YA(#QI/FAA;F0M:&5L9"!C;VUP;VYE;G0\+VD^+"!W:&EC M:`T*(&5M<&QO>7,@:&EG:"!P'1R86-T(&QE#(P,4,[1D1!)B-X,C`Q1#LI(&9O M$%%.SPO#(P,4,[4$U!)B-X,C`Q1#LI(&%P<&QI8V%T:6]N M(&%N9"!I;B!397!T96UB97(@,C`Q,0T*(')E8V5I=F5D($-O;F9O#(P,40[*2!-87)K(&%P<')O=F%L M+B!);@T*($UA$%%.SPO#(P,4,[4$%3)B-X,C`Q1#LI#0H@979A;'5A=&EN9R!T M:&4@$%% M.SPO7-T96T@=&\@=&AE:7(-"B!P97)F;W)M86YC92!I9B!-96QA M1FEN9#QS=7`@$%%.SPO0T*('1O(&$@ M8V]M;65R8VEA;"!E;G1E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T)SX-"B!);B!T:&4@=&AI#(P,40[('-T$%%.SPO7-T96T@9G)O;2!A#0H@ M6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U! M3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X@$$P.R9A;7`[($UE9&EC M86ED(%-E65A2!P87EE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M,G!T)SX-"B!/;B!!=6=U2!W87,@;F]T(&EN(&-O;7!L:6%N M8V4@=VET:"!T:&4@;6EN:6UU;2!B:60@<')I8V4-"B!R97%U:7)E;65N="!O M9B`D,2XP,"!P97(@2!.05-$ M05$@:6X@=VAI8V@@=&\@#(P,3D[$$P.S$W+"`R,#$S+"!T:&4@1D1!(&YO=&EF:65D('1H M92!#;VUP86YY('1H870@:71S#0H@0T* M(#(P,30L('1H92!#;VUP86YY)B-X,C`Q.3MS(')E=FES960@96YR;VQL;65N M="!P;&%N(&%N9"!S8VAE9'5L92!W87,-"B!A<'!R;W9E9"!B>2!T:&4@1D1! M(&%N9"!T:&4@:6YT97)A8W1I=F4@$$P.S(L(#(P,30L('1H92!&1$$@=7!D871E9"!T M:&4@#(P,40[(&%N9"!A<'!R;W9E9"!O=7(@;F5W('-T=61Y#0H@=&EM96QI M;F4N(%1H92!#;VUP86YY(&-U2!T87)G971S('-U8FUI6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T)SX-"B!);B!&96)R=6%R>2`R,#$T+"!T:&4@0V]M<&%N M>2!S;VQD('1O('1W;R!I;G9E#(P,4,[4'5R8VAA M#(P,40[*2`H:2DF(WA!,#MA;B!A9V=R96=A=&4@;V8@,3(L,S`P M('-H87)E$$P.W=A&EM871E;'D-"B`D,3$N-"!M:6QL:6]N+B!4:&4@=V%R&5R8VES92!P65A#(P M,4,[1&5R:79A=&EV97,@86YD($AE9&=I;F2!A;'-O(&=R86YT960@=&\@=&AE#0H@4'5R M8VAA0T*(&9I;&5D(&$@7,@;W(@;6]R92!T:&%N(&%N(&%G9W)E9V%T92!O9B`Q M-2!C86QE;F1A<@T*(&1A>7,@9'5R:6YG(&%N>2`Q,BUM;VYT:"!P97)I;V0L M('1H92!#;VUP86YY('=O=6QD(&)E('-U8FIE8W0@=&\-"B!A9&1I=&EO;F%L M(&QI<75I9&%T960@9&%M86=E#(P,40[*2!F;W(@2!I;F-L=61E9"!I;B!C;VUP;&5T90T*(&9I M;F%N8VEA;"!S=&%T96UE;G1S('!R97!A#(P,4,[1T%!4"8C>#(P,40[*0T* M(&AA=F4@8F5E;B!C;VYD96YS960@;W(@;VUI='1E9"!P=7)S=6%N="!T;R!S M=6-H(')U;&5S(&%N9`T*(')E9W5L871I;VYS+B!4:&4@:6YT97)I;2!F:6YA M;F-I86P@28C>#(P M,3D[65A M$$P.S,Q+"`R,#$S+CPO<#X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P="<^ M#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@;6%N86=E;65N="!I2!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(N#0H@2&]W M979E2!H87,@97AP97)I96YC960@2!C;W5R2!A;FYO=6YC960@8V]S="!R961U8W1I;VX@<&QA;B!A;F0@ M:7,-"B!P2!T86ME#0H@=&AE(&9O2!M87D-"B!R97%U:7)E('=I;&P@8F4@ M869F96-T960@8GD@;G5M97)O=7,@9F%C=&]R2!O9B!W:&EC:"!A M$%%.SPO7-T96TN/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&5R M92!C86X@8F4@;F\@87-S=7)A;F-E2!A9&1I=&EO;F%L M(&9U;F1I;F<@=&AE($-O;7!A;GD@;V)T86EN2!T;R!T86ME(&-E2!V:71A;"!A M8W1I=FET:65S+"!O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAAF4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXR+B!54T4@3T8@ M15-424U!5$53/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P M=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M3I4:6UE'!E;G-E M2X@06-T=6%L(')E'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA3I4:6UE3I4:6UE28C>#(P,3D['0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQD:78^#0H@/'`@$%%.SPO7-T96US(&%N9`T* M(&]T:&5R(&9I;FES:&5D('!R;V1U8W1S(&%N9"!A8V-E2!A8V-E6QE/3-$)T9/3E0M4TE:13H@.#4E.R!6 M15)424-!3"U!3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X-"B!S>7-T96US+B!4 M:&4@0V]M<&%N>2!M86EN=&%I;G,@82!R97-E$%%.SPO7-T96T@ M9G)O;2!A#0H@2!R96-L87-S:69I960@87!P2`D M-2XT#0H@;6EL;&EO;B!O9B!-96QA1FEN9#QS=7`@$%%.SPO7-T96US(&9R;VT-"B!P2!A;F0@97%U:7!M96YT(&EN=&\@:6YV M96YT;W)Y(&%T($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,RX\+W`^#0H@/'`@ M2!C;VYS:7-T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($UE;&%&:6YD/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E# M04PM04Q)1TXZ('1O<"<^)B-X044[/"]S=7`^(%-Y$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`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`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#8T M."PP,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!0;&%N="!!;F0@17%U:7!M96YT M(%M!8G-T&5D($%S'0^)SQD:78^#0H@/'`@&-E961S(&ET6EN9R!A;6]U;G0N(%1H92!A;6]U;G0@ M;V8@:6UP86ER;65N=`T*(&QO2P@:7,@;65A$%%.SPO7-T96T@9G)O;2!A#0H@2!R96-L87-S:69I M960@87!P2`D-2XT(&UI;&QI;VX@;V8-"B!-96QA1FEN9#QS M=7`@$%%.SPO7-T96US(&9R;VT-"B!P2!A;F0@ M97%U:7!M96YT(&EN=&\@:6YV96YT;W)Y(&%T($1E8V5M8F5R)B-X03`[,S$L M(#(P,3,N#0H@5&AE('-Y6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)' M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/DUA$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/D1E8V5M8F5R)B-X M03`[,S$L/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^17-T:6UA=&5D/"]B/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.TQI9F4\+V(^/"]T9#X-"B`\+W1R/@T*(#QT2!A;F0@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$L,#@S+#8V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1&-E;G1E65A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($]F9FEC92!F=7)N:71U$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#(R+#@S,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`R,BPX,S,\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^,RTU('EE87)S M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E65A M6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$%%.SPO7-T96US/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,#@Q+#@Q M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CDL,#DT+#$Y.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CDL,#DT+#$Y.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-2PT,#,L-#$T/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/"]T$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-CDP+#6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA0T*(&1I;'5T:79E('-E8W5R:71I97,@86YD(&ES(&-O;7!U=&5D(&)Y(&1I M=FED:6YG(&QO2!T:&4@=V5I9VAT960@879E$$P.S,Q+"`R,#$T(&%N9`T* M($UA6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W M:61T:#TS1#6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T* M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(L.3`W+#4W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ+#0S-2PS,30\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;6UO;B!S=&]C:R!P=7)C:&%S M92!W87)R86YT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q M+#`T-RPV-#$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV-2PP-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS."PV-C,L,3(R M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXW+B!#3TU04D5(14Y3259% M($Q/4U,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6UE;G1S M(%M!8G-T'0^)SQD:78^#0H@/'`@2!T:6UE+6)A65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P M.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S(&%L:6=N/3-$8V5N=&5R/CQB M/DUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^,C`Q-#PO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($5X<&5C=&5D(&QI9F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M'!E8W1E9"!V;VQA=&EL:71Y/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^-S4N-3$E/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C(N,30M,BXT-24\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($1I=FED96YD('EI96QD/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1C96YT97(^#0H@)B-X,C`Q-#LF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA#(P,4,[3&]A;B8C>#(P,40[*2X-"B!4:&4@3&]A;B!A8V-R=65D(&EN M=&5R97-T(&%T(&$@6UE;G1S(&]N M;'D@9'5R:6YG('1H92!F:7)S="`Q,@T*(&UO;G1H2`D M-BXT(&UI;&QI;VXL(&EN8VQU9&EN9PT*('1H92!E;F0@;V8@=&5R;2!F964@ M;V8@)#0R-2PP,#`L('1O('-E='1L92!A;&P@;V)L:6=A=&EO;G,@=&\-"B!( M97)C=6QE$$P M.S$U+"`R,#$S('1H90T*($-O;7!A;GD@8F5C86UE(&]B;&EG871E9"!T;R!I M28C>#(P,3D[&5R8VES90T*('!R:6-E('!E$$P.S$U+"`R,#$S+"!B=70@=V]U;&0@8F4-"B!D971E$$P.S(U+"`R,#$S M(&%N9"!O;@T*($%P&5R M8VES92!P'!I6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U3 M25I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@ M,'!T)SX-"B!&;W(@9FEN86YC:6%L(')E<&]R=&EN9R!P=7)P;W-E$$P.S$U+"`R,#$S('=A2!O9@T*(#2!O9B`U('EE87)S+"!E>&5R8VES92!P6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B!4:&4@=F%L=64@;V8@=&AE('=A2!O9B!T:&4@ M3&]A;BX@5&AE(&QO86X@9&ES8V]U;G0@86YD('1H92!F964@=V5R90T*(&)E M:6YG(&%M;W)T:7IE9"!A#(P,40[("@F(W@R,#%#.T%30PT*(#@Q-28C>#(P,40[*2!A;F0@=&AE2!U;G1I;"!T:&4-"B!W87)R86YT('=A6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!!2!T M:&4@;&]A;B!O;@T*(%-E<'1E;6)E$$P.S$P+"`R,#$S+"!T:&4@=6YA M;6]R=&EZ960@;&]A;B!D:7-C;W5N="P@9F5E(&%N9`T*(&1E9F5R3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M9#DY,3`Q,%]E93)C7S1F9&-?.#9D,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-? M,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@8VAA#(P,3D[($5154E463PO8CX\+W`^ M#0H@/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@0T*('1H92!#;VUP86YY)B-X,C`Q.3MS($)O87)D(&]F($1I28C>$$P.S4L(#(P,30L#0H@<'5R$$P M.W=A&5R8VES92!P28C>$$P.S4L M(#(P,30L(&%N9"!T:&5R969O6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!);B!C M;VYN96-T:6]N('=I=&@@=&AI6EN9R!T:&4@ M4V5R:65S($$@4')E9F5R&EM871E;'D@ M)#,N-"!M:6QL:6]N+@T*(%5N9&5R('1H92!T97)M$$P.U-H;W5L9"!T:&ES#0H@&EM871E;'D@)#4P,"PP,#`N/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX- M"B`\8CX\:3Y#;VUM;VX@4W1O8VL\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T)SX-"B!4 M:&4@0V]M<&%N>2!IF5D('1O(&ES2!P86ED('!R969U;F1E9"!W87)R86YT&5R8VES86)L92!I;6UE9&EA=&5L>0T*(&9O6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@:&]L9&5R&5R8VES960@,BPP,#`L,#`P(&%N9"`R+#,T,RPR-#<@;VX@36%R8V@F(WA! M,#LU+"`R,#$T#0H@86YD($UA2!C:&%N M9V4@:6X@=F%L=64@8F5T=V5E;B!R97!O2!E;G1E$$P.VUI M;&QI;VX@'!E;G-E6%B;&4@ M8GD@=&AE($-O;7!A;GDL(&YE="!P&EM871E M;'D-"B`D-RXS)B-X03`[;6EL;&EO;BX@5&AE(&]F9F5R:6YG(&-L;W-E9"!O M;B!&96)R=6%R>28C>$$P.S$U+`T*(#(P,3,N/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!) M;B!*=6YE(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A('-A;&5S M(&%G#(P,40[*2P@=VAI8V@@=V%S('1E28C>$$P.S$U+"`R,#$S+B!$=7)I;F<@=&AE('1H2`T+C2X@1'5R:6YG('1H92!T97)M(&]F('1H92!!5$T@ M4')O9W)A;2P-"B!T:&4@0V]M<&%N>2!S;VQD(&$@=&]T86P@;V8@87!P2`V+C8F(WA!,#MM:6QL:6]N('-H87)E6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\+W`^ M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T M)2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P="!S;VQI9#L@5TE$5$@Z(#,U+C-P="<^#0H@/&(^27-S M=64@1&%T93PO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.T1A M=&4\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/E1O=&%L/&)R("\^#0H@5V%R$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D5X+B8C>$$P.U!R:6-E/"]B M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE M($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4O-R\R,#$T/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P,"PP,#`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C,U/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XT+S(V+S(P,3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$P+S,Q+S(P,3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(O-2\R,#$Y/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#(Y-RPR.3<\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-S0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#`T M-RPV-#$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@ M0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!$=7)I;F<@=&AE('1H$$P.S,Q+"`R,#$T+"!T:&4@;G5M8F5R M(&]F#0H@;W5T3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C7S1F9&-?.#9D M,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@8VAA M'0^)SQD:78^#0H@/'`@0T*('1R86YS M86-T:6]N(&)E='=E96X@;6%R:V5T('!A6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@ M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E M(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O M<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A M;&EG;CTS1&QE9G0^3&5V96P@,3H@3V)S97)V86)L92!I;G!U=',@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI M9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I M9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N M/3-$;&5F=#Y,979E;"`R.B!);G!U=',L(&]T:&5R('1H86X@<75O=&5D#0H@ M<')I8V5S(&EN(&%C=&EV92!M87)K971S+"!T:&%T(&%R92!O8G-E2!O<@T*(&EN9&ER96-T;'D[(&%N9#PO=&0^#0H@ M/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X M03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E(&%L M:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W M:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG M;CTS1&QE9G0^3&5V96P@,SH@56YO8G-E6%B;&4L(&%N9"!D97)I=F%T:79E('=A'!E8W1E9"!L:69E+"!R:7-K M+69R964-"B!I;G1E2!R96-U6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C M>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+51/4#H@,'!T)SX-"B!!('-U;6UAF5D('=I=&AI;@T*($QE=F5L M(#,@;V8@=&AE(&9A:7(@=F%L=64@:&EE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$8V5N=&5R/CQB/DUA6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-T;V-K M(%!R:6-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C M96YT97(^)#`N-C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C8T/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-S4\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,RXT,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%1I;64@=&\@36%T=7)I='D@*%EE87)S M*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU M+C,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P M="<^#0H@1&5R:79A=&EV92!W87)R86YT(&QI86)I;&ET:65S(&-O;G-I6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/D9A:7(@5F%L=64\8G(@+SX-"B!- M96%S=7)E;65N=',F(WA!,#M56QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($ES$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-3@T M+#@V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,S6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C@L-#8T+#@V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\ M+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUA3I4:6UE M2!C;VYS:7-T$$P.SPO<#X-"B`\ M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ, M05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O M$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A M;&EG;CTS1&-E;G1E6QE/3-$)V)O$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[ M(&9O;G0M3I4:6UE'0M:6YD96YT.BTQ+C`P96T[ M(&9O;G0M3I4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS,C6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B!!8V-E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(T-BPT-CD\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]TF4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4Z.'!T/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!297-E6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S,C4L,#`P M/"]T9#X-"B`\=&0@;F]W6QE M/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@S,C4L,#`P/"]T9#X-"B`\=&0@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O M$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)V)O$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]TF4Z.'!T/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-C0X+#`R M,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XU+#8S,2PR,#4\+W1D/@T*(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/"]TF4Z,7!X.SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C7S1F9&-?.#9D,U\R-C(W M,S9D8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F0Y.3$P M,3!?964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R&5D($%S'0^)SQS<&%N/CPO2!O9B!02!A;F0@17%U M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/ M4#H@,3)P="<^#0H@4')O<&5R='D@86YD(&5Q=6EP;65N="P@870@8V]S="P@ M8V]N$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQB/E5S969U;"8C>$$P.TQI9F4\+V(^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^57-E9G5L M)B-X03`[3&EF93PO8CX\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D M/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\ M+W1D/@T*(#QT9"!C;VQS<&%N/3-$,CX\+W1D/@T*(#QT9"!C;VQS<&%N/3-$ M,CX\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP-2PX.#@\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^3&5A$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.U1E6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ+#`X,RPV-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#(R+#@S,SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E65A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($UE;&%&:6YD/'-U<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^)B-X044[/"]S=7`^(%-Y M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#`X,2PX M,38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$65A M65A M6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@ M86UOF%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-BPP.3@L M.30U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U+#0P,RPT,30\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#DY-2PR M-3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@$$P.S,Q+`T*(#(P,30@86YD($UA6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(L.3`W+#4W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ+#0S-2PS,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($-O;6UO;B!S=&]C:R!P=7)C:&%S92!W87)R86YT$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#`T-RPV-#$\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-2PP-3`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS."PV-C,L,3(R/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.WEE87)S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D('9O;&%T:6QI='D\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)I6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C$N M,C4M,2XS."4\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6EE M;&0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1C96YT97(^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`H5&%B;&5S*3QB2!;06)S=')A8W1=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!/ M=71S=&%N9&EN9R!C;VUM;VX@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W M:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#4O M-R\R,#`Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(#0O,C8O,C`Q,SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0O,C8O,C`Q.#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XV.3,L,C`R/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ+C$R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(#(O-2\R,#$T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P M<'0G/@T*($$@2!O9B!Q=6%N=&ET871I=F4@:6YF;W)M871I;VX@ M=VET:"!R97-P96-T('1O('1H92!V86QU871I;VX-"B!M971H;V1O;&]G>2!A M;F0@$$P.S,Q+"`R,#$S(&ES(&%S(&9O;&QO=W,Z/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^ M/&(^36%R8V@F(WA!,#LS,2PF(WA!,#LR,#$T/"]B/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X03`[ M,S$L)B-X03`[,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%)I2!9:65L9"D\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%9O;&%T:6QI='D@*$%N;G5A;"D\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDS+C0S/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT2`H665A6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C0N.#4M M-2XP.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,S,\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/D9A:7(@5F%L=64\8G(@+SX-"B!-96%S=7)E;65N=',F M(WA!,#M56QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($ES$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-3@T+#@V-3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@Q,S6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L M-#8T+#@V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)S$X M,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)S$X,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`Q,%]E93)C7S1F9&-?.#9D,U\R-C(W,S9D M8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F0Y.3$P,3!? M964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!;3&EN92!)=&5M7-T96US(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!;3&EN92!)=&5M2P@3F5T M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8T."PP,C`\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@1W)O2!;3&EN92!)=&5M2!;3&EN92!)=&5M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9#DY,3`Q M,%]E93)C7S1F9&-?.#9D,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-?,C8R-S,V M9&-B9&4R+U=O'0O:'1M;#L@8VAA2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M7-T96US(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M M3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C7S1F9&-?.#9D M,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M'0^)TQE87-E(%1E'0^)TQE87-E(%1E'0^)SQS<&%N M/CPO'0^)S,M-2!Y96%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)S,@>65A M'0^)S,@>65A2!A;F0@4F5S96%R8V@@17%U:7!M96YT(%M-96UB97)= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2P@4&QA;G0@ M86YD($5Q=6EP;65N="!;3&EN92!)=&5M'0^)S,@>65A'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M'0^)S,@>65A2!A;F0@4F5S96%R8V@@17%U:7!M96YT(%M-96UB97)=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q M=6EP;65N="!;3&EN92!)=&5M'0^)S4@>65A'0^ M)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M'0^)S4@>65A7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO2!3 M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C7S1F9&-? M.#9D,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C7S1F9&-? M.#9D,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO M'0^)S8@>65A&EM=6T\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!D871E(&9O'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6EN9R!V86QU92!O9B!T:&4@;&]A M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7,\'0^)S4@>65A'0^)S0@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M9#DY,3`Q,%]E93)C7S1F9&-?.#9D,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-? M,C8R-S,V9&-B9&4R+U=O'0O:'1M;#L@8VAA&EM=6T@6TUE;6)E'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)U5N9&5R('1H92!T97)M2!T:&4@4T5#(&]N($%P'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO6%B;&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^36%Y(#$L#0H)"3(P,3D\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO2!!5$T@<')O9W)A;3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C M7S1F9&-?.#9D,U\R-C(W,S9D8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,F0Y.3$P,3!?964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R M+U=O'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO"X@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^1F5B(#4L#0H) M"3(P,30\'0^1F5B(#4L#0H)"3(P,3D\"X@4')I M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2`H665A'0^)S4@ M>65A'0^)SQS<&%N/CPO7,\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)S4@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R9#DY,3`Q,%]E93)C7S1F9&-?.#9D,U\R-C(W,S9D M8V)D93(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F0Y.3$P,3!? M964R8U\T9F1C7S@V9#-?,C8R-S,V9&-B9&4R+U=O&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U'1087)T7S)D.3DQ,#$P7V5E,F-?-&9D8U\X-F0S7S(V,C XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Comprehensive Loss - Additional Information (Detail) (USD $)
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Net Income Loss [Abstract]

Comprehensive income (loss) $ 0 $ 0

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NetIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock (Detail)
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Potential common stock equivalents 38,663,122 1,635,314

Common Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Potential common stock equivalents 2,907,574 1,435,314

Warrants Derivative Liabilities [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Potential common stock equivalents 21,047,641 200,000

Restricted Stock Awards [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Potential common stock equivalents 65,050

Common Stock Equivalents of Convertible Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Potential common stock equivalents 14,642,857

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Additional Information (Detail)
3 Months Ended

Mar. 31, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Expiry period of option plan 10 years

X

- Definition

Share based compensation arrangement by share based payment award award expiration period maximum.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodMaximum

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail)
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Expected life 6 years 6 months 6 years 6 months

Expected volatility 75.51% 76.83%

Risk-free interest rate - Minimum 2.14% 1.25%

Risk-free interest rate - Maximum 2.45% 1.38%

Dividend yield

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Recent Accounting Pronouncements
3 Months Ended

Mar. 31, 2014

Accounting Changes And Error Corrections [Abstract]

Recent Accounting Pronouncements

3. RECENT ACCOUNTING PRONOUNCEMENTS

The Financial Accounting Standards Board has issued a number of new accounting standards that require future adoption. Based on the Company’s initial review of these new standards, none are expected to have a material impact on the Company’s financial statements.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22644-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 45

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=6368906&loc=d3e21914-107793

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22595-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 1.N.Q3)

-URI http://asc.fasb.org/extlink&oid=26874127&loc=d3e30840-122693

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 1

-Section N

+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Debt - Additional Information (Detail) (USD $)
0 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 3 Months Ended 0 Months Ended 3 Months Ended

Sep. 10, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 15, 2013

Mar. 31, 2014

Warrant Obligation [Member]

Mar. 31, 2013

Warrant Obligation [Member]

Mar. 31, 2014

Minimum [Member]

Mar. 31, 2014

Minimum [Member]

Warrant Obligation [Member]

Mar. 31, 2014

Maximum [Member]

Mar. 31, 2014

Maximum [Member]

Warrant Obligation [Member]

Mar. 15, 2013

Hercules Technology Growth Capital Inc. [Member]

Mar. 31, 2014

Hercules Technology Growth Capital Inc. [Member]

Sep. 10, 2013

Hercules Technology Growth Capital Inc. [Member]

Debt Instrument [Line Items]

Loan payable $ 6,000,000

Accrued interest rate 10.45%

Maturity period of loan 42 months

Time period of interest payment First 12 months

Prepayment of loan 6,400,000

Term fee 425,000

Prepayment penalty 180,000

Warrants issued to purchase common stock 693,202

Warrants issued to purchase common stock, exercise price 1.12

Expiry date for warrant outstanding Apr. 26, 2018

Warrant issuance date Apr. 25, 2013

Fair value of warrant obligation 563,000

Initial carrying value of the loan 5,300,000

Changes in fair value of warrants 137,000 15,000

Stock prices $ 1.16 $ 1.18

Volatility 93.46% 93.43% 77.00%

Maturity period 5 years 3 months 29 days 5 years 4 years 10 months 6 days 5 years 29 days

Exercise prices $ 0.62 $ 0.64 $ 1.15 $ 1.16

Risk free interest rate of return 1.73% 1.75% 0.84%

Change in underlying unobservable inputs 10.00%

Initial loan discount amount 727,000

Loss on early extinguishment of debt $ 1,000,000

X

- Definition

Expiration date of warrants held.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExpirationDate

Namespace Prefix: invest_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate consideration receivable for warrants to be issued.

+ References

No definition available.

+ Details

Name: mela_AggregateConsiderationReceivableForWarrantsToBeIssued

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Agreed Amount to Waive Prepayment Penalty on Term Loan

+ References

No definition available.

+ Details

Name: mela_AgreedAmountToWaivePrepaymentPenaltyOnTermLoan

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Borrowed funds maturity period.

+ References

No definition available.

+ Details

Name: mela_BorrowedFundsMaturityPeriod

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Class of warrants or rights issuance date.

+ References

No definition available.

+ Details

Name: mela_ClassOfWarrantsOrRightsIssuanceDate

Namespace Prefix: mela_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Debt instrument period of initial interest payment.

+ References

No definition available.

+ Details

Name: mela_DebtInstrumentPeriodOfInitialInterestPayment

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair Value Of Warrant Obligation

+ References

No definition available.

+ Details

Name: mela_FairValueOfWarrantObligation

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Percentage Of Change In Unobservable Input

+ References

No definition available.

+ Details

Name: mela_PercentageOfChangeInUnobservableInput

Namespace Prefix: mela_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Prepayment Of Loan

+ References

No definition available.

+ Details

Name: mela_PrepaymentOfLoan

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, collateralized financings, and capital lease obligations.

+ References

No definition available.

+ Details

Name: us-gaap_BorrowedFunds

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the fee that accompanies borrowing money under the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Agreed upon price for the exchange of the underlying asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets (USD $)

Mar. 31, 2014

Dec. 31, 2013

Current Assets:

Cash and cash equivalents $ 8,122,709 $ 3,782,881 ^[1]

Accounts receivable (net of allowance of $43,080 and $46,130 as of March 31, 2014 and December 31, 2013, respectively) 34,121 57,151 ^[1]

Inventory (net of reserve of $325,000 as of March 31, 2014 and December 31, 2013) 5,648,020 5,631,205 ^[1]

Prepaid expenses and other current assets 465,140 879,698 ^[1]

Total Current Assets 14,269,990 10,350,935 ^[1]

Property and equipment, net 2,995,253 3,690,784 ^[1]

Patents and trademarks, net 40,526 41,795 ^[1]

Other assets 48,000 48,000 ^[1]

Total Assets 17,353,769 14,131,514 ^[1]

Current Liabilities:

Accounts payable (includes related parties of $85,972 and $32,902 as of March 31, 2014 and December 31, 2013, respectively) 1,311,174 1,478,995 ^[1]

Accrued expenses (includes related parties of $23,129 and $48,000 as of March 31, 2014 and December 31, 2013, respectively) 819,851 844,131 ^[1]

Deferred placement revenue 201,864 243,605 ^[1]

Warrant liability 8,464,865 3,017,142 ^[1]

Other current liabilities 61,815 67,934 ^[1]

Total Current Liabilities 10,859,569 5,651,807 ^[1]

Long Term Liabilities:

Deferred placement revenue 28,834 63,754 ^[1]

Deferred rent 110,111 120,120 ^[1]

Total Long Term Liabilities 138,945 183,874 ^[1]

Total Liabilities 10,998,514 5,835,681 ^[1]

COMMITMENTS AND CONTINGENCIES ^[1]

Stockholders' Equity:

Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 12,300 at March 31, 2014 and 0 at December 31, 2013 1,230

Common stock - $0.001 par value; authorized 95,000,000 shares: Issued and outstanding 52,107,465 shares at March 31, 2014 and 47,501,596 at December 31, 2013 52,108 47,502 ^[1]

Additional paid-in capital 182,430,391 176,396,209 ^[1]

Accumulated deficit (176,128,474) (168,147,878) ^[1]

Total Stockholders' Equity 6,355,255 8,295,833 ^[1]

Total Liabilities and Stockholders' Equity $ 17,353,769 $ 14,131,514 ^[1]

[1] Derived from the audited balance sheet as of December 31, 2013

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13495-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=20225523&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization and Basis of Presentation
3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Organization and Basis of Presentation

1. ORGANIZATION AND BASIS OF PRESENTATION

MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company primarily focused on the commercialization of its flagship product, the MelaFind^® system, and the further design and development of MelaFind^® and its technology. The MelaFind^® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. The MelaFind^® system features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been ‘trained’ and blind tested on the Company’s proprietary database of melanomas and benign lesions. The MelaFind^® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.

The components of the MelaFind^® system include:

• a hand-held component, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);

• a proprietary database of pigmented skin lesions, believed to be the largest positive prospective database to date in the US; and

• lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.

In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind^® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, the Company installed the first commercial MelaFind^® systems, and proceeded with the commercial launch of MelaFind^®. The Company is currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using the MelaFind^® system to their performance if MelaFind^® was not available.

In 2012 the Company evolved from a research and development company to a commercial enterprise. The launch of MelaFind^® in 2012 and the subsequent commercialization activities supporting the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013.

In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, the Company appointed a new CEO and adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. As part of this strategy, in late December 2013, the Company changed its business model for the MelaFind^® system from a rental-based to a sales-based model. The Company has reduced its costs, added more experience to its management team, and reorganized its sales and marketing activities to better support the commercialization of the MelaFind^® system. The Company is also seeking a coverage determination from the Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, as a prerequisite to obtain reimbursement by Medicare for use of the MelaFind^® system. This process could take up to two years. Once a coverage determination has been made, the Company plans to seek reimbursement by Medicaid, Medicare and other third-party payers.

On August 22, 2013, the Company received a notice from The NASDAQ Stock Market that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. The Company was granted an automatic 180 grace period by NASDAQ in which to regain compliance. On February 19, 2014, the Company was notified by NASDAQ that the Company was eligible for an additional 180 day grace period and has until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement or risk delisting.

On October 17, 2013, the FDA notified the Company that its report with respect to the PAS was inadequate to allow the agency to complete its review, and as a result revised the PAS status on the FDA website to “Progress Inadequate.” In January 2014, the Company’s revised enrollment plan and schedule was approved by the FDA and the interactive review process was closed. On April 2, 2014, the FDA updated the study status to “Progress Adequate” and approved our new study timeline. The Company currently targets submission of the PAS report the FDA by year-end 2017.

In February 2014, the Company sold to two investors (the “Purchasers”) (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, (the “Series A Preferred Stock”), convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of the Company’s common stock, for net proceeds of approximately $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. The number of shares issuable upon conversion of the Series A Preferred Stock and exercise of the warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions. The Purchasers have been granted rights of participation in future offerings of our securities for one year. In addition, as a condition of the financing, the Company’s directors purchased an aggregate of 202,703 shares of common stock at a price of $0.74 per share, for aggregate gross proceeds of $150,000.

The warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative.

In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature.

Liquidity

The Company has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. In February 2014, as noted above, the Company raised net proceeds of approximately $11.5 million from the sale of Series A Preferred Stock, common stock and warrants to strengthen the Company’s financial position.

The Company’s net losses have had a significant negative impact on working capital and its financial position and may impact the Company’s future ability to meet its obligations in the ordinary course of business. As a result, management believes that there is significant doubt about the Company’s ability to continue as a going concern. The Company continues to assess the effects of its previously announced cost reduction plan and is prepared to reduce various operational costs as necessary. Although the Company has no specific arrangements or plans, additional capital will be needed during the upcoming months, which may take the form of equity, equity-linked or debt financing. In addition, the Company anticipates that long-term it will need to raise funds to support further advances in the technology and clinical trials. The timing and amount of any additional funding the Company may require will be affected by numerous factors, many of which are not in the control of the Company including the market acceptance of the MelaFind^® system.

There can be no assurances that the Company will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms or at all and there can be no assurance that any additional funding the Company obtains will be sufficient to meet the Company’s financing needs. Any additional funding that the Company may obtain in the future could be dilutive to common stockholders, provide new investors with rights and preferences senior to common stockholders and provide for restrictive covenants that could limit the Company’s ability to take certain actions. Unless the Company is able to generate sufficient revenues or to raise additional capital near-term, the Company’s operations will be scaled back to maintain only vital activities, or discontinued.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) (USD $)
3 Months Ended 12 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Stock Price $ 0.62 $ 0.64

Risk-free Rate 1.73% 1.75%

Volatility (Annual) 93.46% 93.43%

Time to maturity (Years) 5 years 3 months 29 days

Minimum [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Time to maturity (Years) 4 years 10 months 6 days

Maximum [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Time to maturity (Years) 5 years 29 days

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Agreed upon price for the exchange of the underlying asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments (Tables)
3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value Hierarchy

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2014 and December 31, 2013 is as follows:

 March 31, 2014 December 31, 2013

Stock Price
 $0.62 $ 0.64

Risk-free Rate (5-year U.S. Treasury Yield)
 1.73% 1.75 %

Volatility (Annual)
 93.46% 93.43 %

Time to Maturity (Years)
 4.85-5.08 5.33

Schedule of Derivative Warrant Liabilities

Derivative warrant liabilities consist of the following:

 Fair Value
Measurements Using
Significant
Unobservable Inputs
(Level 3)

 Warrant Derivative
Liabilities

Beginning balance at January 1, 2014
 $ 3,017,142

Issuance of warrants with derivative liabilities
 5,584,865

Changes in estimated fair value
 (137,142 )



Ending balance at March 31, 2014
 $ 8,464,865



X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) (Significant Unobservable Inputs (Level 3) [Member], Warrants Derivative Liabilities [Member], USD $)
3 Months Ended

Mar. 31, 2014

Significant Unobservable Inputs (Level 3) [Member] | Warrants Derivative Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Beginning balance at January 1, 2014 $ 3,017,142

Issuance of warrants with derivative liabilities 5,584,865

Changes in estimated fair value (137,142)

Ending balance at March 31, 2014 $ 8,464,865

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13495-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=20225523&loc=SL20225862-175312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=28370219&loc=SL20226008-175313

+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 29 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventories - Additional Information (Detail) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Inventory [Line Items]

Inventory, Gross $ 5,973,020 $ 5,956,205

MelaFind Systems [Member]

Inventory [Line Items]

Inventory, Gross $ 5,401,866 $ 5,401,866

X

- Definition

Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 31 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Use of Estimates
3 Months Ended

Mar. 31, 2014

Text Block [Abstract]

Use of Estimates

2. USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements, the use of estimates to determine the elements of our revenue and deferred revenue, accrued expenses, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates.

X

- Definition

Use of estimates.

+ References

No definition available.

+ Details

Name: mela_UseOfEstimatesTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets (Parenthetical) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Statement Of Financial Position [Abstract]

Allowance for accounts receivable, current $ 43,080 $ 46,130 ^[1]

Inventory reserves 325,000 325,000 ^[1]

Accounts payable, related parties 85,972 32,902 ^[1]

Accrued expenses, related parties $ 23,129 $ 48,000 ^[1]

Preferred stock, par value $ 0.10 $ 0.10 ^[1]

Preferred stock, shares authorized 10,000,000 10,000,000 ^[1]

Preferred stock, shares issued 12,300 0 ^[1]

Preferred stock, shares outstanding 12,300 0 ^[1]

Common stock, par value $ 0.001 $ 0.001 ^[1]

Common stock, shares authorized 95,000,000 95,000,000 ^[1]

Common stock, shares issued 52,107,465 47,501,596 ^[1]

Common stock, shares outstanding 52,107,465 47,501,596 ^[1]

[1] Derived from the audited balance sheet as of December 31, 2013

X

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28368275&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of valuation reserve for inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 09

-Article 12

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventories (Tables)
3 Months Ended

Mar. 31, 2014

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following:

 March 31, December 31,

 2014 2013

MelaFind^® Systems
 $ 5,401,866 $ 5,401,866

Mela record cards
 324,685 327,900

Accessories
 246,469 226,439



 5,973,020 5,956,205

Reserve for obsolete inventory
 (325,000 ) (325,000 )



 $ 5,648,020 $ 5,631,205



X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
3 Months Ended

Mar. 31, 2014

Apr. 30, 2014

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q1

Trading Symbol MELA

Entity Registrant Name MELA SCIENCES, INC. /NY

Entity Central Index Key 0001051514

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 52,107,465

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: mela_DocumentAndEntityInformationAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fixed Assets (Tables)
3 Months Ended

Mar. 31, 2014

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment, at cost, consists of the following:

 March 31, December 31, Estimated

 2014 2013 Useful Life Useful Life

Leasehold improvements
 $ 905,888 $ 905,888 Lease Term Lease Term

Laboratory and research equipment
 1,083,661 1,083,661 3-5 years 3-5 years

Office furniture and equipment
 2,022,833 2,022,833 3-5 years 3-5 years

MelaFind^® Systems
 5,081,816 5,081,816 3 years 3 years





 9,094,198 9,094,198

Accumulated depreciation and amortization
 (6,098,945 ) (5,403,414 )





 $ 2,995,253 $ 3,690,784





X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Operations (USD $)
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Income Statement [Abstract]

Net revenues $ 97,638 $ 144,100

Cost of revenue 918,523 1,080,263

Gross profit (820,885) (936,163)

Operating expenses:

Research and development 707,824 1,262,001

Selling, general and administrative 3,203,533 4,287,228

Total operating expenses 3,911,357 5,549,229

Operating loss (4,732,242) (6,485,392)

Other income (expenses):

Interest income 618 2,105

Interest expense (1,199) (48,763)

Change in fair value of warrant liability 137,142 15,433

Registration rights liquidated damages (3,389,940)

Other income, net 5,025 5,000

Non operating income and expense (3,248,354) (26,225)

Net loss $ (7,980,596) $ (6,511,617)

Basic and diluted net loss per common share $ (0.16) $ (0.17)

Basic and diluted weighted average number of common shares outstanding 48,926,409 39,233,943

X

- Definition

Registration Rights Liquidating Damages

+ References

No definition available.

+ Details

Name: mela_RegistrationRightsLiquidatingDamages

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those liabilities still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Comprehensive Loss
3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Comprehensive Loss

7. COMPREHENSIVE LOSS

For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts.

X

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e689-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669619-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e640-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e716-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e709-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Common Share
3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Net Loss Per Common Share

6. NET LOSS PER COMMON SHARE

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of March 31, 2014 and March 31, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:

 March 31,

 2014 2013

Common stock equivalents of convertible preferred stock
 14,642,857 —

Common stock options
 2,907,574 1,435,314

Common stock purchase warrants
 21,047,641 200,000

Restricted stock awards
 65,050 —





Total
 38,663,122 1,635,314





X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization and Basis of Presentation - Additional Information (Detail) (USD $)
0 Months Ended 1 Months Ended 3 Months Ended 0 Months Ended 1 Months Ended

Feb. 19, 2014

Aug. 22, 2013

Feb. 28, 2014

Mar. 31, 2014

Dec. 31, 2013

Apr. 03, 2014

Subsequent Event [Member]

Feb. 05, 2014

Common Stock Equivalents of Convertible Preferred Stock [Member]

Feb. 28, 2014

Common Stock Equivalents of Convertible Preferred Stock [Member]

Investor

Condensed Financial Statements, Captions [Line Items]

Number of consecutive business days, non-compliance of minimum bid price 30 days

Minimum bid price $ 1.00

Grace period granted by NASDAQ to regain compliance 180 days

Additional grace period 180 days

Number of purchasers of preferred stock and warrants 2

Preferred stock, shares issued 12,300 0 ^[1] 12,300 12,300

Preferred stock converted to common stock, shares 14,642,857 14,642,857

Preferred stock converted to common stock, conversion price $ 0.84 $ 0.84

Warrants issued to purchase common stock 13,297,297 13,297,297

Proceeds from issuance of warrants $ 11,400,000 $ 11,400,000

Warrants issued, exercise price 0.74 0.74

Warrants issued, exercisable term 5 years 5 years

Purchasers granted rights 1 year

Common stock purchased, shares 202,703

Common stock purchased, share price $ 0.74

Proceeds from common stock purchased 150,000

Liquidated damages paid (3,389,940)

Registration rights agreement description Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000

Additional liquidated damages payable $ 500,000

[1] Derived from the audited balance sheet as of December 31, 2013

X

- Definition

Additional Liquidation Damages Payable

+ References

No definition available.

+ Details

Name: mela_AdditionalLiquidationDamagesPayable

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Class Of Warrant Or Right Exercisable Term

+ References

No definition available.

+ Details

Name: mela_ClassOfWarrantOrRightExercisableTerm

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Common Stock Minimum Bid Price

+ References

No definition available.

+ Details

Name: mela_CommonStockMinimumBidPrice

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Common Stock Purchase Agreement Aggregate Gross Proceeds

+ References

No definition available.

+ Details

Name: mela_CommonStockPurchaseAgreementAggregateGrossProceeds

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Common Stock Shares Purchased

+ References

No definition available.

+ Details

Name: mela_CommonStockSharesPurchased

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Common Stock Shares Purchased Share Price

+ References

No definition available.

+ Details

Name: mela_CommonStockSharesPurchasedSharePrice

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Convertible Preferred Stock Initial Conversion Price

+ References

No definition available.

+ Details

Name: mela_ConvertiblePreferredStockInitialConversionPrice

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Nasdaq Minimum Price Bid Requirement Additional Grace Period

+ References

No definition available.

+ Details

Name: mela_NasdaqMinimumPriceBidRequirementAdditionalGracePeriod

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Nasdaq Minimum Price Bid Requirement Grace Period

+ References

No definition available.

+ Details

Name: mela_NasdaqMinimumPriceBidRequirementGracePeriod

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number Of Consecutive Business Days Not complied With Minimum Bid Price

+ References

No definition available.

+ Details

Name: mela_NumberOfConsecutiveBusinessDaysNotCompliedWithMinimumBidPrice

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number Of Purchasers

+ References

No definition available.

+ Details

Name: mela_NumberOfPurchasers

Namespace Prefix: mela_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Period Of Grant

+ References

No definition available.

+ Details

Name: mela_PeriodOfGrant

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Registration Rights Liquidating Damages

+ References

No definition available.

+ Details

Name: mela_RegistrationRightsLiquidatingDamages

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Warrants Issued To Purchase Common Stock Shares

+ References

No definition available.

+ Details

Name: mela_WarrantsIssuedToPurchaseCommonStockShares

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_CondensedFinancialStatementsCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Describes the event or circumstance that would trigger the transfer of consideration under the registration payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Name: us-gaap_RegistrationPaymentArrangementEventToTransferConsideration

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Common Share (Tables)
3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock

Potential common stock equivalents outstanding as of March 31, 2014 and March 31, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:

 March 31,

 2014 2013

Common stock equivalents of convertible preferred stock
 14,642,857 —

Common stock options
 2,907,574 1,435,314

Common stock purchase warrants
 21,047,641 200,000

Restricted stock awards
 65,050 —





Total
 38,663,122 1,635,314





X

- Definition

Schedule of stock options and warrants.

+ References

No definition available.

+ Details

Name: mela_ScheduleOfStockOptionsAndWarrantsTableTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Stockholders' Equity

10. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors.

As discussed in detail in Note 1, on February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share, convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of common stock for net proceeds of $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014, and will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on March 31, 2014 was equivalent to the fair value on February 5, 2014, and therefore no change in fair value has been recorded for the three months ended March 31, 2014.

In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

Common Stock

The Company is authorized to issue 95,000,000 shares of common stock with a par value of $0.001 per share.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6.0 million registered offering of 4,228,181 shares of the Company’s common stock, fully paid prefunded warrants (“Series B Warrants”) to purchase up to 4,343,247 shares of its common stock and additional warrants (“Series A Warrants”) to purchase up to 6,857,142 shares of its common stock. The Series A Warrants are exercisable beginning on May 1, 2014 at a price of $0.85 per share and expire on May 1, 2019. The Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013.

The holders exercised 2,000,000 and 2,343,247 on March 5, 2014 and March 7, 2014, respectively, of the Series B Warrants. There were no warrant exercises in the first quarter of 2013.

The Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The change in fair value of the warrant liability for the three months ended March 31, 2014, was $137,000.

On February 12, 2013 the Company entered into an underwriting agreement with Cowen and Company, LLC, relating to the public offering of 6.1 million shares of the Company’s common stock, at a price to the public of $1.30 per share less underwriting discounts and commissions. The gross proceeds to the Company from the sale of the Common Stock totaled $7.9 million. After deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by the Company, net proceeds were approximately $7.3 million. The offering closed on February 15, 2013.

In June 2012, the Company entered into a sales agreement with Cowen and Company, LLC, to sell shares of the Company’s common stock through an “at-the-market” equity offering program (the “ATM Program”), which was terminated on February 15, 2013. During the three months ended March 31, 2013, and in connection with its termination, the Company sold approximately 4.7 million shares under the ATM Program for gross and net proceeds of approximately $8.8 million and $8.5 million, respectively. During the term of the ATM Program, the Company sold a total of approximately 6.6 million shares for aggregate gross and net proceeds of approximately $14.4 million and $13.8 million, respectively.

Outstanding common stock warrants consist of the following:

Issue Date
 Expiration Date Total
Warrants Ex. Price

5/7/2009
 5/7/2014 200,000 $ 11.35

4/26/2013
 4/26/2018 693,202 $ 1.12

10/31/2013
 10/31/2018 6,857,142 $ 0.85

2/5/2014
 2/5/2019 13,297,297 $ 0.74





 21,047,641





During the three months ended March 31, 2014, the number of outstanding shares of the Company’s common stock increased from 47,501,596 to 52,107,465.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation
3 Months Ended

Mar. 31, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8. STOCK-BASED COMPENSATION

Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.

The fair value of each option award granted is estimated on the date of grant using the Black-Sholes option valuation model and assumptions as noted in the following table:

 March 31,

 2014 2013

Expected life
 6.5 years 6.5 years

Expected volatility
 75.51% 76.83%

Risk-free interest rate
 2.14-2.45% 1.25-1.38%

Dividend yield
 — —

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Debt
3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Debt

9. DEBT

On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc., a venture capital lender, whereby the Company borrowed $6 million (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6.4 million, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000.

Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 693,202 shares of common stock at an exercise price of approximately $1.12 per share. The warrant expires on April 26, 2018.

For financial reporting purposes, the $6 million funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5.3 million. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of approximately $15,000 are included in operating results for the three months ended March 31, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $1.16 to $1.18 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $1.15 to $1.16 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value.

The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders equity.

As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were approximately $1.0 million.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments
3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

11. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

• Level 1: Observable inputs such as quoted prices in active markets;

• Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

• Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2014 and December 31, 2013 is as follows:

 March 31, 2014 December 31, 2013

Stock Price
 $0.62 $ 0.64

Risk-free Rate (5-year U.S. Treasury Yield)
 1.73% 1.75 %

Volatility (Annual)
 93.46% 93.43 %

Time to Maturity (Years)
 4.85-5.08 5.33

Derivative warrant liabilities consist of the following:

 Fair Value
Measurements Using
Significant
Unobservable Inputs
(Level 3)

 Warrant Derivative
Liabilities

Beginning balance at January 1, 2014
 $ 3,017,142

Issuance of warrants with derivative liabilities
 5,584,865

Changes in estimated fair value
 (137,142 )



Ending balance at March 31, 2014
 $ 8,464,865



X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail)

Mar. 31, 2014

Class of Warrant or Right [Line Items]

Total Warrants 21,047,641

Ex. Price $ 11.35 [Member]

Class of Warrant or Right [Line Items]

Issue Date May 07, 2009

Expiration Date May 07, 2014

Total Warrants 200,000

Ex. Price 11.35

Ex. Price $ 1.12 [Member]

Class of Warrant or Right [Line Items]

Issue Date Apr. 26, 2013

Expiration Date Apr. 26, 2018

Total Warrants 693,202

Ex. Price 1.12

Ex. Price $ 0.85 [Member]

Class of Warrant or Right [Line Items]

Issue Date Oct. 31, 2013

Expiration Date Oct. 31, 2018

Total Warrants 6,857,142

Ex. Price 0.85

Ex. Price $ 0.74 [Member]

Class of Warrant or Right [Line Items]

Issue Date Feb. 05, 2014

Expiration Date Feb. 05, 2019

Total Warrants 13,297,297

Ex. Price 0.74

X

- Definition

Warrant Expiration Date

+ References

No definition available.

+ Details

Name: mela_WarrantExpirationDate

Namespace Prefix: mela_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Warrants Issue Date

+ References

No definition available.

+ Details

Name: mela_WarrantsIssueDate

Namespace Prefix: mela_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 46 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity (Tables)
3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Schedule of Outstanding Common Stock Warrants

Outstanding common stock warrants consist of the following:

Issue Date
 Expiration Date Total
Warrants Ex. Price

5/7/2009
 5/7/2014 200,000 $ 11.35

4/26/2013
 4/26/2018 693,202 $ 1.12

10/31/2013
 10/31/2018 6,857,142 $ 0.85

2/5/2014
 2/5/2019 13,297,297 $ 0.74





 21,047,641





X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fixed Assets - Additional Information (Detail) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Property, Plant and Equipment [Line Items]

Inventory, Gross $ 5,973,020 $ 5,956,205

MelaFind Systems [Member]

Property, Plant and Equipment [Line Items]

Inventory, Gross $ 5,401,866 $ 5,401,866

X

- Definition

Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Cash Flows (USD $)
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Cash flows from operating activities:

Net loss $ (7,980,596) $ (6,511,617)

Adjustments to reconcile net loss:

Depreciation and amortization 696,800 496,733

Bad debt expense 700 40,000

Non-cash interest expense 14,101

Write-off of unamortized financing costs 41,166

Stock-based compensation 164,168 268,381

Change in fair value of warrant liability (137,142) (15,433)

Changes in operating assets and liabilities:

Accounts receivable 22,330 (29,447)

Inventory (16,815) 238,642

Prepaid expenses and other current assets 414,558 89,173

Accounts payable and accrued expenses (192,101) (834,292)

Other current liabilities (6,119) 19,785

Deferred rent (10,009) (5,913)

Deferred revenue (76,661) 88,873

Long-term interest payable 7,417

Net cash used in operating activities (7,120,887) (6,092,431)

Cash flows from investing activities:

Purchases of property and equipment (1,641,297)

Net cash used in investing activities (1,641,297)

Cash flows from financing activities:

Net proceeds from private placements/public offerings 11,460,715 15,746,549

Net proceeds from long term debt 6,000,000

Expenses related to borrowings and issuance of warrant (245,358)

Proceeds from exercise of stock options 18,059

Net cash provided by financing activities 11,460,715 21,519,250

Net increase in cash and cash equivalents 4,339,828 13,785,522

Cash and cash equivalents at beginning of period 3,782,881 ^[1] 7,861,524

Cash and cash equivalents at end of period 8,122,709 21,647,046

Supplemental Schedule of Noncash Investing and Financing Activities:

Amortization of deferred financing costs $ 41,166

[1] Derived from the audited balance sheet as of December 31, 2013

X

- Definition

Bad Debt Expense

+ References

No definition available.

+ Details

Name: mela_BadDebtExpense

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Non cash interest expense.

+ References

No definition available.

+ Details

Name: mela_NoncashInterestExpense

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Payments for borrowings and warrant exercises.

+ References

No definition available.

+ Details

Name: mela_PaymentsForBorrowingsAndWarrantExercises

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those liabilities still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_WriteOffOfDeferredDebtIssuanceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 49 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fixed Assets
3 Months Ended

Mar. 31, 2014

Property Plant And Equipment [Abstract]

Fixed Assets

5. FIXED ASSETS

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition exceeds its carrying amount. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value.

In December 2013, the Company changed its business model for the MelaFind^® system from a rental-based to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind^® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent new and unused systems. Systems that have been leased under the rental-based model remain in property and equipment.

Property and equipment, at cost, consists of the following:

 March 31, December 31, Estimated

 2014 2013 Useful Life Useful Life

Leasehold improvements
 $ 905,888 $ 905,888 Lease Term Lease Term

Laboratory and research equipment
 1,083,661 1,083,661 3-5 years 3-5 years

Office furniture and equipment
 2,022,833 2,022,833 3-5 years 3-5 years

MelaFind^® Systems
 5,081,816 5,081,816 3 years 3 years





 9,094,198 9,094,198

Accumulated depreciation and amortization
 (6,098,945 ) (5,403,414 )





 $ 2,995,253 $ 3,690,784





X

- Definition

Fixed Assets Disclosure [Text Block]

+ References

No definition available.

+ Details

Name: mela_FixedAssetsDisclosureTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fixed Assets - Summary of Property and Equipment (Detail) (USD $)
3 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Property, Plant and Equipment [Line Items]

Gross $ 9,094,198 $ 9,094,198

Accumulated depreciation and amortization (6,098,945) (5,403,414)

Net 2,995,253 3,690,784 ^[1]

Leasehold Improvements [Member]

Property, Plant and Equipment [Line Items]

Gross 905,888 905,888

Estimated Useful Life Lease Term

Useful Life Lease Term

Laboratory and Research Equipment [Member]

Property, Plant and Equipment [Line Items]

Gross 1,083,661 1,083,661

Estimated Useful Life 3-5 years

Office Furniture and Equipment [Member]

Property, Plant and Equipment [Line Items]

Gross 2,022,833 2,022,833

Estimated Useful Life 3-5 years

MelaFind Systems [Member]

Property, Plant and Equipment [Line Items]

Gross $ 5,081,816 $ 5,081,816

Estimated Useful Life 3 years

Useful Life 3 years

Minimum [Member] | Laboratory and Research Equipment [Member]

Property, Plant and Equipment [Line Items]

Useful Life 3 years

Minimum [Member] | Office Furniture and Equipment [Member]

Property, Plant and Equipment [Line Items]

Useful Life 3 years

Maximum [Member] | Laboratory and Research Equipment [Member]

Property, Plant and Equipment [Line Items]

Useful Life 5 years

Maximum [Member] | Office Furniture and Equipment [Member]

Property, Plant and Equipment [Line Items]

Useful Life 5 years

[1] Derived from the audited balance sheet as of December 31, 2013

X

- Definition

Property Plant And Equipments Useful Life

+ References

No definition available.

+ Details

Name: mela_PropertyPlantAndEquipmentsUsefulLife

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155824

+ Details

Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 76 182 1 true 29 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.melasciences.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Balance Sheets Sheet http://www.melasciences.com/taxonomy/role/StatementOfFinancialPositionClassified Balance Sheets false false R3.htm 104 - Statement - Balance Sheets (Parenthetical) Sheet http://www.melasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Statements of Operations Sheet http://www.melasciences.com/taxonomy/role/StatementOfIncome Statements of Operations false false R5.htm 106 - Statement - Statements of Cash Flows Sheet http://www.melasciences.com/taxonomy/role/StatementOfCashFlowsIndirect Statements of Cash Flows false false R6.htm 107 - Disclosure - Organization and Basis of Presentation Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization and Basis of Presentation false false R7.htm 108 - Disclosure - Use of Estimates Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsUseOfEstimatesTextBlock Use of Estimates false false R8.htm 109 - Disclosure - Recent Accounting Pronouncements Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsAccountingChangesAndErrorCorrectionsTextBlock Recent Accounting Pronouncements false false R9.htm 110 - Disclosure - Inventories Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories false false R10.htm 111 - Disclosure - Fixed Assets Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsFixedAssetsDisclosureTextBlock Fixed Assets false false R11.htm 112 - Disclosure - Net Loss Per Common Share Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Common Share false false R12.htm 113 - Disclosure - Comprehensive Loss Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlock Comprehensive Loss false false R13.htm 114 - Disclosure - Stock-Based Compensation Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R14.htm 115 - Disclosure - Debt Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Debt false false R15.htm 116 - Disclosure - Stockholders' Equity Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R16.htm 117 - Disclosure - Fair Value of Financial Instruments Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments false false R17.htm 118 - Disclosure - Inventories (Tables) Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) false false R18.htm 119 - Disclosure - Fixed Assets (Tables) Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsFixedAssetsDisclosureTextBlockTables Fixed Assets (Tables) false false R19.htm 120 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss Per Common Share (Tables) false false R20.htm 121 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R21.htm 122 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) false false R22.htm 123 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.melasciences.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value of Financial Instruments (Tables) false false R23.htm 124 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation Organization and Basis of Presentation - Additional Information (Detail) false false R24.htm 125 - Disclosure - Inventories - Additional Information (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureInventoriesAdditionalInformation Inventories - Additional Information (Detail) false false R25.htm 126 - Disclosure - Inventories - Schedule of Inventory (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureInventoriesScheduleOfInventory Inventories - Schedule of Inventory (Detail) false false R26.htm 127 - Disclosure - Fixed Assets - Additional Information (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureFixedAssetsAdditionalInformation Fixed Assets - Additional Information (Detail) false false R27.htm 128 - Disclosure - Fixed Assets - Summary of Property and Equipment (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureFixedAssetsSummaryOfPropertyAndEquipment Fixed Assets - Summary of Property and Equipment (Detail) false false R28.htm 129 - Disclosure - Net Loss Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOfConvertiblePreferredStockStockOptionsCommonStockPurchaseWarrantsAndRestrictedStock Net Loss Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock (Detail) false false R29.htm 130 - Disclosure - Comprehensive Loss - Additional Information (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureComprehensiveLossAdditionalInformation Comprehensive Loss - Additional Information (Detail) false false R30.htm 131 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R31.htm 132 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionAwardGranted Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail) false false R32.htm 133 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureDebtAdditionalInformation Debt - Additional Information (Detail) false false R33.htm 134 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R34.htm 135 - Disclosure - Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingCommonStockWarrants Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail) false false R35.htm 136 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueHierarchy Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) false false R36.htm 137 - Disclosure - Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) Sheet http://www.melasciences.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfDerivativeWarrantLiabilities Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) false false All Reports Book All Reports Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 4. 'Monetary' elements on report '124 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '133 - Disclosure - Debt - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '134 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 104 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Oct. 29, 2013' Process Flow-Through: 105 - Statement - Statements of Operations Process Flow-Through: 106 - Statement - Statements of Cash Flows mela-20140331.xml mela-20140331.xsd mela-20140331_cal.xml mela-20140331_def.xml mela-20140331_lab.xml mela-20140331_pre.xml true true XML 52 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation (Tables)
3 Months Ended

Mar. 31, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Fair Value of Each Option Award Granted

The fair value of each option award granted is estimated on the date of grant using the Black-Sholes option valuation model and assumptions as noted in the following table:

 March 31,

 2014 2013

Expected life
 6.5 years 6.5 years

Expected volatility
 75.51% 76.83%

Risk-free interest rate
 2.14-2.45% 1.25-1.38%

Dividend yield
 — —

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Comprehensive Loss - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net Income Loss [Abstract]
Comprehensive income (loss)	$ 0	$ 0

Net Loss Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	38,663,122	1,635,314
Common Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	2,907,574	1,435,314
Warrants Derivative Liabilities [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	21,047,641	200,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	65,050
Common Stock Equivalents of Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	14,642,857

Stock-Based Compensation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expiry period of option plan	10 years

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Mar. 31, 2014
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	3. RECENT ACCOUNTING PRONOUNCEMENTS The Financial Accounting Standards Board has issued a number of new accounting standards that require future adoption. Based on the Company’s initial review of these new standards, none are expected to have a material impact on the Company’s financial statements.

Debt - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended		3 Months Ended				3 Months Ended		0 Months Ended	3 Months Ended
Debt - Additional Information (Detail) (USD $)	Sep. 10, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 15, 2013	Mar. 31, 2014 Warrant Obligation [Member]	Mar. 31, 2013 Warrant Obligation [Member]	Mar. 31, 2014 Minimum [Member]	Mar. 31, 2014 Minimum [Member] Warrant Obligation [Member]	Mar. 31, 2014 Maximum [Member]	Mar. 31, 2014 Maximum [Member] Warrant Obligation [Member]	Mar. 15, 2013 Hercules Technology Growth Capital Inc. [Member]	Mar. 31, 2014 Hercules Technology Growth Capital Inc. [Member]	Sep. 10, 2013 Hercules Technology Growth Capital Inc. [Member]
Debt Instrument [Line Items]
Loan payable											$ 6,000,000
Accrued interest rate											10.45%
Maturity period of loan											42 months
Time period of interest payment												First 12 months
Prepayment of loan													6,400,000
Term fee													425,000
Prepayment penalty												180,000
Warrants issued to purchase common stock											693,202
Warrants issued to purchase common stock, exercise price											1.12
Expiry date for warrant outstanding												Apr. 26, 2018
Warrant issuance date												Apr. 25, 2013
Fair value of warrant obligation				563,000
Initial carrying value of the loan				5,300,000
Changes in fair value of warrants		137,000				15,000
Stock prices								$ 1.16		$ 1.18
Volatility		93.46%	93.43%		77.00%
Maturity period			5 years 3 months 29 days		5 years		4 years 10 months 6 days		5 years 29 days
Exercise prices		$ 0.62	$ 0.64					$ 1.15		$ 1.16
Risk free interest rate of return		1.73%	1.75%		0.84%
Change in underlying unobservable inputs					10.00%
Initial loan discount amount		727,000
Loss on early extinguishment of debt	$ 1,000,000

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock Price	$ 0.62	$ 0.64
Risk-free Rate	1.73%	1.75%
Volatility (Annual)	93.46%	93.43%
Time to maturity (Years)		5 years 3 months 29 days
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Time to maturity (Years)	4 years 10 months 6 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Time to maturity (Years)	5 years 29 days

Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) (Significant Unobservable Inputs (Level 3) [Member], Warrants Derivative Liabilities [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Derivative Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance at January 1, 2014	$ 3,017,142
Issuance of warrants with derivative liabilities	5,584,865
Changes in estimated fair value	(137,142)
Ending balance at March 31, 2014	$ 8,464,865

Inventories - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Inventory, Gross	$ 5,973,020	$ 5,956,205
MelaFind Systems [Member]
Inventory [Line Items]
Inventory, Gross	$ 5,401,866	$ 5,401,866

Use of Estimates	3 Months Ended
Use of Estimates	Mar. 31, 2014
Text Block [Abstract]
Use of Estimates	2. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements, the use of estimates to determine the elements of our revenue and deferred revenue, accrued expenses, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates.

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Trading Symbol	MELA
Entity Registrant Name	MELA SCIENCES, INC. /NY
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		52,107,465

Statements of Operations (USD $)	3 Months Ended
Statements of Operations (USD $)	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]
Net revenues	$ 97,638	$ 144,100
Cost of revenue	918,523	1,080,263
Gross profit	(820,885)	(936,163)
Operating expenses:
Research and development	707,824	1,262,001
Selling, general and administrative	3,203,533	4,287,228
Total operating expenses	3,911,357	5,549,229
Operating loss	(4,732,242)	(6,485,392)
Other income (expenses):
Interest income	618	2,105
Interest expense	(1,199)	(48,763)
Change in fair value of warrant liability	137,142	15,433
Registration rights liquidated damages	(3,389,940)
Other income, net	5,025	5,000
Non operating income and expense	(3,248,354)	(26,225)
Net loss	$ (7,980,596)	$ (6,511,617)
Basic and diluted net loss per common share	$ (0.16)	$ (0.17)
Basic and diluted weighted average number of common shares outstanding	48,926,409	39,233,943

Comprehensive Loss	3 Months Ended
Comprehensive Loss	Mar. 31, 2014
Equity [Abstract]
Comprehensive Loss	7. COMPREHENSIVE LOSS For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts.

Debt	3 Months Ended
Debt	Mar. 31, 2014
Debt Disclosure [Abstract]
Debt	9. DEBT On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc., a venture capital lender, whereby the Company borrowed $6 million (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6.4 million, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000. Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 693,202 shares of common stock at an exercise price of approximately $1.12 per share. The warrant expires on April 26, 2018. For financial reporting purposes, the $6 million funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5.3 million. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of approximately $15,000 are included in operating results for the three months ended March 31, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $1.16 to $1.18 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $1.15 to $1.16 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value. The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders equity. As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were approximately $1.0 million.

Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail)	Mar. 31, 2014
Class of Warrant or Right [Line Items]
Total Warrants	21,047,641
Ex. Price $ 11.35 [Member]
Class of Warrant or Right [Line Items]
Issue Date	May 07, 2009
Expiration Date	May 07, 2014
Total Warrants	200,000
Ex. Price	11.35
Ex. Price $ 1.12 [Member]
Class of Warrant or Right [Line Items]
Issue Date	Apr. 26, 2013
Expiration Date	Apr. 26, 2018
Total Warrants	693,202
Ex. Price	1.12
Ex. Price $ 0.85 [Member]
Class of Warrant or Right [Line Items]
Issue Date	Oct. 31, 2013
Expiration Date	Oct. 31, 2018
Total Warrants	6,857,142
Ex. Price	0.85
Ex. Price $ 0.74 [Member]
Class of Warrant or Right [Line Items]
Issue Date	Feb. 05, 2014
Expiration Date	Feb. 05, 2019
Total Warrants	13,297,297
Ex. Price	0.74

Fixed Assets - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Inventory, Gross	$ 5,973,020	$ 5,956,205
MelaFind Systems [Member]
Property, Plant and Equipment [Line Items]
Inventory, Gross	$ 5,401,866	$ 5,401,866